{"PMC7239118": [["IntroductionOn December 2019, several cases of pneumonia with unknown etiology occurred in Wuhan, Hubei, China (1), and the disease quickly spread to the whole country and all over the world.", [["pneumonia", "DISEASE", 47, 56], ["pneumonia", "PROBLEM", 47, 56], ["the disease", "PROBLEM", 120, 131], ["pneumonia", "OBSERVATION", 47, 56], ["disease", "OBSERVATION", 124, 131]]], ["As of 20 March 2020, the Chinese government officially announced a total of 81 307 cases had been confirmed of COVID-19 in China, killing 3253 people.", [["people", "ORGANISM", 143, 149], ["people", "SPECIES", 143, 149], ["COVID", "TEST", 111, 116]]], ["The pathogen was identified as a novel coronavirus (2019 novel coronavirus); full-length genome sequencing showed that the sequence of this virus was 79.6% consistent with that of SARS (severe acute respiratory syndrome) coronavirus (2, 3).", [["SARS", "DISEASE", 180, 184], ["acute respiratory syndrome) coronavirus", "DISEASE", 193, 232], ["coronavirus", "SPECIES", 39, 50], ["coronavirus", "SPECIES", 63, 74], ["SARS (severe acute respiratory syndrome) coronavirus", "SPECIES", 180, 232], ["a novel coronavirus", "PROBLEM", 31, 50], ["novel coronavirus", "TEST", 57, 74], ["full-length genome sequencing", "TEST", 77, 106], ["this virus", "PROBLEM", 135, 145], ["SARS (severe acute respiratory syndrome) coronavirus", "PROBLEM", 180, 232], ["severe", "OBSERVATION_MODIFIER", 186, 192], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["respiratory syndrome", "OBSERVATION", 199, 219]]], ["The World Health Organization (WHO) named the virus SARS-COV-2 and declared the disease (coronavirus disease 2019, COVID-19) a public health emergency of international concern (4).IntroductionAs the effective reproductive number (R0) is estimated to be higher than the reported effective reproductive number of SARS at the early stage, SARS-COV-2 has higher levels of transmissibility and pandemic risk than SARS-COV (5).", [["SARS", "DISEASE", 52, 56], ["coronavirus disease", "DISEASE", 89, 108], ["SARS", "DISEASE", 311, 315], ["SARS", "DISEASE", 336, 340], ["pandemic", "DISEASE", 389, 397], ["SARS", "DISEASE", 408, 412], ["SARS-COV", "SPECIES", 408, 416], ["the virus SARS", "TEST", 42, 56], ["COV", "TEST", 57, 60], ["the disease (coronavirus disease", "PROBLEM", 76, 108], ["COVID", "TEST", 115, 120], ["SARS", "PROBLEM", 311, 315], ["SARS", "TEST", 336, 340], ["COV", "TEST", 341, 344], ["pandemic risk", "PROBLEM", 389, 402], ["disease", "OBSERVATION", 80, 87], ["coronavirus disease", "OBSERVATION", 89, 108], ["effective", "OBSERVATION_MODIFIER", 199, 208], ["reproductive", "OBSERVATION_MODIFIER", 209, 221], ["higher", "OBSERVATION_MODIFIER", 253, 259]]], ["The primary patients with COVID-19 remain the main source of infection.", [["infection", "DISEASE", 61, 70], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["COVID", "TEST", 26, 31], ["infection", "PROBLEM", 61, 70], ["infection", "OBSERVATION", 61, 70]]], ["However, asymptomatic carriers and those in the incubation period may also be infectious (7).", [["asymptomatic carriers", "PROBLEM", 9, 30], ["may also be", "UNCERTAINTY", 66, 77], ["infectious", "OBSERVATION", 78, 88]]], ["Clusters of infected family members and medical workers confirmed the presence of human-to-human transmission by respiratory droplets, contact and fomite (3, 7).", [["respiratory droplets", "ANATOMY", 113, 133], ["human", "ORGANISM", 82, 87], ["human", "ORGANISM", 91, 96], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 91, 96], ["infected", "OBSERVATION", 12, 20], ["respiratory droplets", "OBSERVATION", 113, 133]]], ["Besides, it can also transmit through aerosols when exposing to high concentrations of aerosols for a long time in a relatively closed environment (6).IntroductionIn the early stage of the epidemic, the number of infected people doubles every 7.4 days (7).", [["people", "ORGANISM", 222, 228], ["people", "SPECIES", 222, 228], ["IntroductionIn", "TREATMENT", 151, 165], ["early stage", "OBSERVATION_MODIFIER", 170, 181], ["epidemic", "OBSERVATION_MODIFIER", 189, 197], ["infected", "OBSERVATION_MODIFIER", 213, 221]]], ["In addition to confirmed infections, there were hundreds of thousands of suspected patients in Wuhan, Hubei.", [["infections", "DISEASE", 25, 35], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["infections", "PROBLEM", 25, 35], ["infections", "OBSERVATION", 25, 35]]], ["Admission to hospital of so many patients at the same period put a lot of pressure on hospitals and caused potential cross-infection among individuals including patients and medical workers.", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 161, 169]]], ["Wang et al. showed 41.3% of confirmed cases were presumed to have been infected by hospital-associated transmission at Zhongnan Hospital affiliated to Wuhan University, including 40 health professionals (8).", [["infected", "OBSERVATION", 71, 79]]], ["Statistic data have shown a total of 3387 medical workers were infected with COVID-19, 90% of them was from Hubei (9).", [["COVID-19", "SPECIES", 77, 85], ["Statistic data", "TEST", 0, 14], ["COVID", "TEST", 77, 82]]], ["Among them, patients with malignant tumors have high risk in COVID-19 epidemic due to their immunosuppression status and requirement of frequent access to hospital.", [["malignant tumors", "ANATOMY", 26, 42], ["malignant tumors", "DISEASE", 26, 42], ["patients", "ORGANISM", 12, 20], ["malignant tumors", "CANCER", 26, 42], ["patients", "SPECIES", 12, 20], ["malignant tumors", "PROBLEM", 26, 42], ["high risk in COVID", "PROBLEM", 48, 66], ["malignant", "OBSERVATION_MODIFIER", 26, 35], ["tumors", "OBSERVATION", 36, 42]]], ["The outbreak of COVID-19 makes the medical treatment of cancers difficult.", [["cancers", "ANATOMY", 56, 63], ["COVID-19", "CHEMICAL", 16, 24], ["cancers", "DISEASE", 56, 63], ["COVID-19", "CHEMICAL", 16, 24], ["cancers", "CANCER", 56, 63], ["COVID", "TREATMENT", 16, 21], ["the medical treatment", "TREATMENT", 31, 52], ["cancers", "PROBLEM", 56, 63], ["cancers", "OBSERVATION", 56, 63]]], ["For example, maintenance chemotherapy and/or immunotherapy treatment for patients with advanced cancer is often suspended.", [["cancer", "ANATOMY", 96, 102], ["cancer", "DISEASE", 96, 102], ["patients", "ORGANISM", 73, 81], ["advanced cancer", "CANCER", 87, 102], ["patients", "SPECIES", 73, 81], ["maintenance chemotherapy", "TREATMENT", 13, 37], ["immunotherapy treatment", "TREATMENT", 45, 68], ["advanced cancer", "PROBLEM", 87, 102], ["cancer", "OBSERVATION", 96, 102]]], ["Here we share the experience of the medical management of cancer patients from China.", [["cancer", "ANATOMY", 58, 64], ["cancer", "DISEASE", 58, 64], ["cancer", "CANCER", 58, 64], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["the medical management", "TREATMENT", 32, 54], ["cancer", "PROBLEM", 58, 64], ["cancer", "OBSERVATION", 58, 64]]], ["However, clinicians should make individual clinical decisions based on the specific state of each patient and the local epidemic situation.Threat of COVID-19 for patients with cancerIn general, the cases with cancer are usually old people with systemic immunosuppressive state caused by malignancy and anticancer therapies, who are more susceptible to viral infection compared with those without cancer.", [["cancer", "ANATOMY", 176, 182], ["cancer", "ANATOMY", 209, 215], ["anticancer", "ANATOMY", 302, 312], ["cancer", "ANATOMY", 396, 402], ["cancer", "DISEASE", 176, 182], ["cancer", "DISEASE", 209, 215], ["malignancy", "DISEASE", 287, 297], ["viral infection", "DISEASE", 352, 367], ["cancer", "DISEASE", 396, 402], ["patient", "ORGANISM", 98, 105], ["patients", "ORGANISM", 162, 170], ["cancer", "CANCER", 176, 182], ["cancer", "CANCER", 209, 215], ["people", "ORGANISM", 232, 238], ["anticancer", "CANCER", 302, 312], ["cancer", "CANCER", 396, 402], ["patient", "SPECIES", 98, 105], ["patients", "SPECIES", 162, 170], ["people", "SPECIES", 232, 238], ["COVID", "TEST", 149, 154], ["cancer", "PROBLEM", 176, 182], ["cancer", "PROBLEM", 209, 215], ["systemic immunosuppressive state", "TREATMENT", 244, 276], ["malignancy", "PROBLEM", 287, 297], ["anticancer therapies", "TREATMENT", 302, 322], ["viral infection", "PROBLEM", 352, 367], ["cancer", "PROBLEM", 396, 402], ["cancer", "OBSERVATION", 176, 182], ["cancer", "OBSERVATION", 209, 215], ["malignancy", "OBSERVATION", 287, 297], ["viral", "OBSERVATION_MODIFIER", 352, 357], ["infection", "OBSERVATION", 358, 367], ["cancer", "OBSERVATION", 396, 402]]], ["It was reported that the mortality of viral pneumonia in patients with tumors was significantly higher than that of patients without tumors, with the mortality of coronavirus pneumonia being 24.4 and 3.0% in the two groups, respectively (P < 0.01) (10).", [["tumors", "ANATOMY", 71, 77], ["tumors", "ANATOMY", 133, 139], ["viral pneumonia", "DISEASE", 38, 53], ["tumors", "DISEASE", 71, 77], ["tumors", "DISEASE", 133, 139], ["coronavirus pneumonia", "DISEASE", 163, 184], ["patients", "ORGANISM", 57, 65], ["tumors", "CANCER", 71, 77], ["patients", "ORGANISM", 116, 124], ["tumors", "CANCER", 133, 139], ["coronavirus", "ORGANISM", 163, 174], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 116, 124], ["viral pneumonia", "PROBLEM", 38, 53], ["tumors", "PROBLEM", 71, 77], ["tumors", "PROBLEM", 133, 139], ["coronavirus pneumonia", "PROBLEM", 163, 184], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["pneumonia", "OBSERVATION", 44, 53], ["tumors", "OBSERVATION", 71, 77], ["without", "UNCERTAINTY", 125, 132], ["tumors", "OBSERVATION", 133, 139], ["coronavirus", "OBSERVATION_MODIFIER", 163, 174], ["pneumonia", "OBSERVATION", 175, 184]]], ["Of the 138 hospitalized patients with COVID-19 in Zhongnan Hospital, there are 10 (7.2%) patients with cancer (8).", [["cancer", "ANATOMY", 103, 109], ["cancer", "DISEASE", 103, 109], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 89, 97], ["cancer", "CANCER", 103, 109], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 89, 97], ["COVID", "TEST", 38, 43], ["cancer", "PROBLEM", 103, 109], ["cancer", "OBSERVATION", 103, 109]]], ["Among the 72 314 COVID-19 cases reported by the Chinese Center for Disease Control and Prevention (CDC) in mainland China as of 11 February 2020, 107 (0.5%) patients have the co-exist disease of tumor, among which 6 person died; the crude mortality rate in patients with cancer (5.6%) is higher than that of the general population (2.3%) (11).", [["tumor", "ANATOMY", 195, 200], ["cancer", "ANATOMY", 271, 277], ["tumor", "DISEASE", 195, 200], ["cancer", "DISEASE", 271, 277], ["patients", "ORGANISM", 157, 165], ["tumor", "CANCER", 195, 200], ["patients", "ORGANISM", 257, 265], ["cancer", "CANCER", 271, 277], ["patients", "SPECIES", 157, 165], ["person", "SPECIES", 216, 222], ["patients", "SPECIES", 257, 265], ["COVID", "TEST", 17, 22], ["Disease Control", "TREATMENT", 67, 82], ["the co-exist disease of tumor", "PROBLEM", 171, 200], ["the crude mortality rate", "TEST", 229, 253], ["cancer", "PROBLEM", 271, 277], ["disease", "OBSERVATION", 184, 191], ["tumor", "OBSERVATION", 195, 200], ["cancer", "OBSERVATION", 271, 277]]], ["Moreover, in the study by Liang and his colleagues, the incidence of cancer in COVID-19 cases was higher than that in the overall Chinese population (1.3 vs. 0.29%).", [["cancer", "ANATOMY", 69, 75], ["cancer", "DISEASE", 69, 75], ["cancer", "CANCER", 69, 75], ["the study", "TEST", 13, 22], ["cancer", "PROBLEM", 69, 75], ["COVID", "TEST", 79, 84], ["cancer", "OBSERVATION", 69, 75]]], ["In addition, compared with cases without cancer, cases with cancer had a higher risk of severe events (39 vs. 8%) and deteriorated more rapidly (median time to severe events 13 vs. 43 days).", [["cancer", "ANATOMY", 41, 47], ["cancer", "ANATOMY", 60, 66], ["cancer", "DISEASE", 41, 47], ["cancer", "DISEASE", 60, 66], ["cancer", "CANCER", 41, 47], ["cancer", "CANCER", 60, 66], ["cancer", "PROBLEM", 41, 47], ["cancer", "PROBLEM", 60, 66], ["severe events", "PROBLEM", 88, 101], ["severe events", "PROBLEM", 160, 173], ["cancer", "OBSERVATION", 41, 47], ["cancer", "OBSERVATION", 60, 66], ["severe", "OBSERVATION_MODIFIER", 88, 94]]], ["Moreover, cases who received chemotherapy or surgery in the past month had a higher risk of severe events compared with those who did not (75 vs. 43%) (12).", [["chemotherapy", "TREATMENT", 29, 41], ["surgery", "TREATMENT", 45, 52], ["severe events", "PROBLEM", 92, 105], ["severe", "OBSERVATION_MODIFIER", 92, 98]]], ["These data show that COVID-19 infection may pose a greater threat to patients with cancer than those without cancer.Threat of COVID-19 for patients with cancerAlthough the percentage of cases with cancer in the COVID-19 cohort was higher than that of the overall population, it is not sufficient to conclude that case with cancer had a higher risk of COVID-19 (13).", [["cancer", "ANATOMY", 83, 89], ["cancer", "ANATOMY", 109, 115], ["cancer", "ANATOMY", 197, 203], ["cancer", "ANATOMY", 323, 329], ["COVID-19", "CHEMICAL", 21, 29], ["infection", "DISEASE", 30, 39], ["cancer", "DISEASE", 83, 89], ["cancer", "DISEASE", 109, 115], ["cancer", "DISEASE", 197, 203], ["cancer", "DISEASE", 323, 329], ["COVID-19", "CHEMICAL", 351, 359], ["COVID-19", "ORGANISM", 21, 29], ["patients", "ORGANISM", 69, 77], ["cancer", "CANCER", 83, 89], ["cancer", "CANCER", 109, 115], ["patients", "ORGANISM", 139, 147], ["cancerAlthough", "CANCER", 153, 167], ["cancer", "CANCER", 197, 203], ["cancer", "CANCER", 323, 329], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 139, 147], ["COVID-19", "SPECIES", 21, 29], ["These data", "TEST", 0, 10], ["COVID-19 infection", "PROBLEM", 21, 39], ["cancer", "PROBLEM", 83, 89], ["cancer", "PROBLEM", 109, 115], ["COVID", "TEST", 126, 131], ["cancer", "PROBLEM", 197, 203], ["the COVID", "TEST", 207, 216], ["cancer", "PROBLEM", 323, 329], ["COVID", "TEST", 351, 356], ["infection", "OBSERVATION", 30, 39], ["cancer", "OBSERVATION", 109, 115], ["cancer", "OBSERVATION", 197, 203]]], ["And according to Wang et al., all the people are susceptible to COVID-19, and the existing data could not demonstrate that tumor is the susceptibility factor of COVID-19.", [["tumor", "ANATOMY", 123, 128], ["tumor", "DISEASE", 123, 128], ["COVID-19", "CHEMICAL", 161, 169], ["people", "ORGANISM", 38, 44], ["tumor", "CANCER", 123, 128], ["people", "SPECIES", 38, 44], ["COVID", "TEST", 64, 69], ["tumor", "PROBLEM", 123, 128], ["COVID", "TEST", 161, 166], ["tumor", "OBSERVATION", 123, 128]]], ["Meanwhile, since the average age of tumor patients (63.1 years old) was significantly greater than that of non-tumor patients (48.7 years old), old age may be the factor influencing the poor prognosis of COVID-19.", [["tumor", "ANATOMY", 36, 41], ["non-tumor", "ANATOMY", 107, 116], ["tumor", "DISEASE", 36, 41], ["tumor", "CANCER", 36, 41], ["patients", "ORGANISM", 42, 50], ["non-tumor", "CANCER", 107, 116], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 117, 125], ["COVID", "TEST", 204, 209], ["tumor", "OBSERVATION", 36, 41]]], ["In addition, Wang et al. believe that the greatest risk for patients with cancer during the COVID-19 epidemic is that they cannot receive the necessary treatment due to the impact of the epidemic (14).Threat of COVID-19 for patients with cancerIn conclusion, although it is unclear whether cancer directly increases the incidence and risk of COVID-19 infection, it is certain that the prevalence of COVID-19 will have a significant impact on cancer patients both in terms of infection and receiving treatment for cancer.", [["cancer", "ANATOMY", 74, 80], ["cancer", "ANATOMY", 238, 244], ["cancer", "ANATOMY", 290, 296], ["cancer", "ANATOMY", 442, 448], ["cancer", "ANATOMY", 513, 519], ["cancer", "DISEASE", 74, 80], ["cancer", "DISEASE", 238, 244], ["cancer", "DISEASE", 290, 296], ["infection", "DISEASE", 351, 360], ["cancer", "DISEASE", 442, 448], ["infection", "DISEASE", 475, 484], ["cancer", "DISEASE", 513, 519], ["COVID-19", "CHEMICAL", 399, 407], ["patients", "ORGANISM", 60, 68], ["cancer", "CANCER", 74, 80], ["patients", "ORGANISM", 224, 232], ["cancer", "CANCER", 238, 244], ["cancer", "CANCER", 290, 296], ["COVID-19", "GENE_OR_GENE_PRODUCT", 342, 350], ["cancer", "CANCER", 442, 448], ["patients", "ORGANISM", 449, 457], ["cancer", "CANCER", 513, 519], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 224, 232], ["patients", "SPECIES", 449, 457], ["COVID-19", "SPECIES", 342, 350], ["cancer", "PROBLEM", 74, 80], ["the COVID", "TEST", 88, 97], ["the necessary treatment", "TREATMENT", 138, 161], ["COVID", "TEST", 211, 216], ["cancer", "PROBLEM", 238, 244], ["cancer", "PROBLEM", 290, 296], ["COVID-19 infection", "PROBLEM", 342, 360], ["COVID", "TEST", 399, 404], ["cancer", "PROBLEM", 442, 448], ["infection", "PROBLEM", 475, 484], ["treatment", "TREATMENT", 499, 508], ["cancer", "PROBLEM", 513, 519], ["greatest", "OBSERVATION_MODIFIER", 42, 50], ["cancer", "OBSERVATION", 74, 80], ["cancer", "OBSERVATION", 238, 244], ["cancer", "OBSERVATION", 290, 296], ["infection", "OBSERVATION", 351, 360], ["significant", "OBSERVATION_MODIFIER", 420, 431], ["cancer", "OBSERVATION", 442, 448], ["infection", "OBSERVATION", 475, 484], ["cancer", "OBSERVATION", 513, 519]]], ["Therefore, the admission and treatment of patients with cancer need to be adjusted according to the local epidemic situation.Bronchoscopy ::: Lung cancer ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)Lung cancer is the leading cause of worldwide cancer mortality.", [["cancer", "ANATOMY", 56, 62], ["Lung cancer", "ANATOMY", 142, 153], ["cancers", "ANATOMY", 187, 194], ["Lung cancer", "ANATOMY", 231, 242], ["cancer", "ANATOMY", 277, 283], ["cancer", "DISEASE", 56, 62], ["Lung cancer", "DISEASE", 142, 153], ["cancers", "DISEASE", 187, 194], ["Lung cancer", "DISEASE", 231, 242], ["cancer", "DISEASE", 277, 283], ["patients", "ORGANISM", 42, 50], ["cancer", "CANCER", 56, 62], ["Lung cancer", "CANCER", 142, 153], ["cancers", "CANCER", 187, 194], ["Lung cancer", "CANCER", 231, 242], ["cancer", "CANCER", 277, 283], ["patients", "SPECIES", 42, 50], ["treatment", "TREATMENT", 29, 38], ["cancer", "PROBLEM", 56, 62], ["Bronchoscopy", "TREATMENT", 125, 137], ["Lung cancer", "PROBLEM", 142, 153], ["cancers", "PROBLEM", 187, 194], ["COVID", "TEST", 198, 203], ["Lung cancer", "PROBLEM", 231, 242], ["worldwide cancer mortality", "PROBLEM", 267, 293], ["cancer", "OBSERVATION", 56, 62], ["cancer", "OBSERVATION", 147, 153], ["cancers", "OBSERVATION", 187, 194], ["cancer", "OBSERVATION", 236, 242], ["worldwide", "OBSERVATION_MODIFIER", 267, 276], ["cancer", "OBSERVATION", 277, 283]]], ["COVID-19 epidemic seems to make the effective diagnostic and therapeutic management for lung cancer more difficult because of the high risk of interference of COVID-19, which needs to be highly concerned by clinicians (15).", [["lung cancer", "ANATOMY", 88, 99], ["lung cancer", "DISEASE", 88, 99], ["lung cancer", "CANCER", 88, 99], ["COVID", "TEST", 0, 5], ["therapeutic management", "TREATMENT", 61, 83], ["lung cancer", "PROBLEM", 88, 99], ["COVID", "TEST", 159, 164], ["lung", "ANATOMY", 88, 92], ["cancer", "OBSERVATION", 93, 99]]], ["Bronchoscopy remains an important diagnostic tool in patients with lung cancer.", [["lung cancer", "ANATOMY", 67, 78], ["lung cancer", "DISEASE", 67, 78], ["patients", "ORGANISM", 53, 61], ["lung cancer", "CANCER", 67, 78], ["patients", "SPECIES", 53, 61], ["Bronchoscopy", "TREATMENT", 0, 12], ["lung cancer", "PROBLEM", 67, 78], ["lung", "ANATOMY", 67, 71], ["cancer", "OBSERVATION", 72, 78]]], ["However, as an aerosol-generating procedure, it could pose a high risk of infection to proximate healthcare staff.", [["infection", "DISEASE", 74, 83], ["an aerosol-generating procedure", "TREATMENT", 12, 43], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["Thus, careful preparation and precautions are necessary, such as elective bronchoscopy should be postponed, measure the temperature and ask the history of travel and COVID-19 patient contact before the procedure, and perform the RT-PCR for SARS-CoV-2 before the procedure as much as possible (16).", [["SARS", "DISEASE", 240, 244], ["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 175, 182], ["SARS-CoV", "SPECIES", 240, 248], ["precautions", "TREATMENT", 30, 41], ["elective bronchoscopy", "TREATMENT", 65, 86], ["the temperature", "TEST", 116, 131], ["the procedure", "TREATMENT", 198, 211], ["the RT-PCR", "TEST", 225, 235], ["SARS", "PROBLEM", 240, 244], ["CoV", "TEST", 245, 248], ["the procedure", "TREATMENT", 258, 271]]], ["Lung cancer is associated with high COVID-19 prevalence, morbidity and mortality due to specific conditions that represent cumulative risk factors for COVID-19 complications, including old age, severe cardiovascular and respiratory complications, smoking and related lung injury (17).Early stage ::: Non-small cell lung cancer ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)Surgery is a definitive treatment for early stage non-small cell lung cancer (NSCLC).", [["Lung cancer", "ANATOMY", 0, 11], ["cardiovascular", "ANATOMY", 201, 215], ["respiratory", "ANATOMY", 220, 231], ["lung", "ANATOMY", 267, 271], ["Non-small cell lung cancer", "ANATOMY", 300, 326], ["cancers", "ANATOMY", 360, 367], ["early stage non-small cell lung cancer", "ANATOMY", 442, 480], ["NSCLC", "ANATOMY", 482, 487], ["Lung cancer", "DISEASE", 0, 11], ["cardiovascular and respiratory complications", "DISEASE", 201, 245], ["smoking", "CHEMICAL", 247, 254], ["lung injury", "DISEASE", 267, 278], ["Non-small cell lung cancer", "DISEASE", 300, 326], ["cancers", "DISEASE", 360, 367], ["non-small cell lung cancer", "DISEASE", 454, 480], ["NSCLC", "DISEASE", 482, 487], ["Lung cancer", "CANCER", 0, 11], ["lung", "ORGAN", 267, 271], ["Non-small cell lung cancer", "CANCER", 300, 326], ["cancers", "CANCER", 360, 367], ["early stage non-small cell lung cancer", "CANCER", 442, 480], ["NSCLC", "CANCER", 482, 487], ["Lung cancer", "PROBLEM", 0, 11], ["morbidity", "PROBLEM", 57, 66], ["specific conditions", "PROBLEM", 88, 107], ["cumulative risk factors", "PROBLEM", 123, 146], ["COVID-19 complications", "PROBLEM", 151, 173], ["severe cardiovascular and respiratory complications", "PROBLEM", 194, 245], ["related lung injury", "PROBLEM", 259, 278], ["Non-small cell lung cancer", "PROBLEM", 300, 326], ["cancers", "PROBLEM", 360, 367], ["COVID", "TEST", 371, 376], ["Surgery", "TREATMENT", 404, 411], ["a definitive treatment", "TREATMENT", 415, 437], ["early stage non-small cell lung cancer", "PROBLEM", 442, 480], ["cancer", "OBSERVATION", 5, 11], ["severe", "OBSERVATION_MODIFIER", 194, 200], ["cardiovascular", "ANATOMY", 201, 215], ["respiratory", "ANATOMY", 220, 231], ["complications", "OBSERVATION", 232, 245], ["lung", "ANATOMY", 267, 271], ["injury", "OBSERVATION", 272, 278], ["cell", "OBSERVATION", 310, 314], ["lung", "ANATOMY", 315, 319], ["cancer", "OBSERVATION", 320, 326], ["cancers", "OBSERVATION", 360, 367], ["non-small cell", "OBSERVATION", 454, 468], ["lung", "ANATOMY", 469, 473], ["cancer", "OBSERVATION", 474, 480], ["NSCLC", "OBSERVATION", 482, 487]]], ["The delay of surgery because of COVID-19 epidemic may significantly affect the prognosis of patients with early stage lung cancer.", [["lung cancer", "ANATOMY", 118, 129], ["lung cancer", "DISEASE", 118, 129], ["patients", "ORGANISM", 92, 100], ["early stage lung cancer", "CANCER", 106, 129], ["patients", "SPECIES", 92, 100], ["surgery", "TREATMENT", 13, 20], ["COVID", "TEST", 32, 37], ["early stage lung cancer", "PROBLEM", 106, 129], ["lung", "ANATOMY", 118, 122], ["cancer", "OBSERVATION", 123, 129]]], ["Therefore, experts of thoracic surgery department suggest that surgery for patients with early lung cancer should be carried out as early as possible once they are completely ruled out of infection of COVID-19.", [["thoracic", "ANATOMY", 22, 30], ["lung cancer", "ANATOMY", 95, 106], ["lung cancer", "DISEASE", 95, 106], ["infection", "DISEASE", 188, 197], ["patients", "ORGANISM", 75, 83], ["lung cancer", "CANCER", 95, 106], ["patients", "SPECIES", 75, 83], ["thoracic surgery", "TREATMENT", 22, 38], ["surgery", "TREATMENT", 63, 70], ["early lung cancer", "PROBLEM", 89, 106], ["infection", "PROBLEM", 188, 197], ["COVID", "TEST", 201, 206], ["thoracic", "ANATOMY", 22, 30], ["lung", "ANATOMY", 95, 99], ["cancer", "OBSERVATION", 100, 106], ["infection", "OBSERVATION", 188, 197]]], ["If there are any suspected symptoms of COVID-19 of the patients, SARS-COV-2 nucleic acid detection should be done to rule out infection before surgery (18).", [["SARS", "DISEASE", 65, 69], ["COV-2 nucleic acid", "CHEMICAL", 70, 88], ["infection", "DISEASE", 126, 135], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["any suspected symptoms", "PROBLEM", 13, 35], ["COVID", "TEST", 39, 44], ["SARS", "TEST", 65, 69], ["COV", "TEST", 70, 73], ["nucleic acid detection", "TEST", 76, 98], ["infection", "PROBLEM", 126, 135], ["surgery", "TREATMENT", 143, 150], ["infection", "OBSERVATION", 126, 135]]], ["For patients requiring adjuvant therapy after lung cancer surgery, studies have shown that the interval between adjuvant therapy and surgery is not related to the therapeutic effect, and even starting adjuvant chemotherapy 4 months after the surgery can still benefit from it (19).", [["lung cancer", "ANATOMY", 46, 57], ["lung cancer", "DISEASE", 46, 57], ["patients", "ORGANISM", 4, 12], ["lung cancer", "CANCER", 46, 57], ["patients", "SPECIES", 4, 12], ["adjuvant therapy", "TREATMENT", 23, 39], ["lung cancer surgery", "TREATMENT", 46, 65], ["studies", "TEST", 67, 74], ["adjuvant therapy", "TREATMENT", 112, 128], ["surgery", "TREATMENT", 133, 140], ["adjuvant chemotherapy", "TREATMENT", 201, 222], ["the surgery", "TREATMENT", 238, 249], ["lung", "ANATOMY", 46, 50], ["cancer", "OBSERVATION", 51, 57]]], ["Therefore, it is recommended to appropriately extend the interval between adjuvant therapy and surgery during the outbreak of COVID-19 (19, 20).", [["adjuvant therapy", "TREATMENT", 74, 90], ["surgery", "TREATMENT", 95, 102], ["COVID", "TEST", 126, 131]]], ["For patients with postoperative N2 lymph node metastasis of EGFR-mutated lung cancer, targeted therapy may also be one of the adjuvant treatment options.", [["lymph node", "ANATOMY", 35, 45], ["EGFR-mutated lung cancer", "ANATOMY", 60, 84], ["lung cancer", "DISEASE", 73, 84], ["patients", "ORGANISM", 4, 12], ["lymph node", "MULTI-TISSUE_STRUCTURE", 35, 45], ["EGFR", "GENE_OR_GENE_PRODUCT", 60, 64], ["lung cancer", "CANCER", 73, 84], ["EGFR", "PROTEIN", 60, 64], ["patients", "SPECIES", 4, 12], ["postoperative N2 lymph node metastasis", "PROBLEM", 18, 56], ["EGFR", "PROBLEM", 60, 64], ["mutated lung cancer", "PROBLEM", 65, 84], ["targeted therapy", "TREATMENT", 86, 102], ["the adjuvant treatment options", "TREATMENT", 122, 152], ["postoperative", "OBSERVATION_MODIFIER", 18, 31], ["N2", "OBSERVATION_MODIFIER", 32, 34], ["lymph node metastasis", "OBSERVATION", 35, 56], ["lung", "ANATOMY", 73, 77], ["cancer", "OBSERVATION", 78, 84]]], ["According to ADJUVANT/CTONG1104 trial, adjuvant gefitinib led to longer disease-free survival with reduced myelosuppression risk compared with that for vinorelbine plus cisplatin in patients with completely resected stage II\u2013IIIA EGFR-mutant NSCLC.", [["NSCLC", "ANATOMY", 242, 247], ["gefitinib", "CHEMICAL", 48, 57], ["myelosuppression", "DISEASE", 107, 123], ["vinorelbine", "CHEMICAL", 152, 163], ["cisplatin", "CHEMICAL", 169, 178], ["NSCLC", "DISEASE", 242, 247], ["gefitinib", "CHEMICAL", 48, 57], ["vinorelbine", "CHEMICAL", 152, 163], ["cisplatin", "CHEMICAL", 169, 178], ["gefitinib", "SIMPLE_CHEMICAL", 48, 57], ["vinorelbine", "SIMPLE_CHEMICAL", 152, 163], ["cisplatin", "SIMPLE_CHEMICAL", 169, 178], ["patients", "ORGANISM", 182, 190], ["stage II\u2013IIIA", "CANCER", 216, 229], ["EGFR", "GENE_OR_GENE_PRODUCT", 230, 234], ["NSCLC", "CANCER", 242, 247], ["EGFR", "PROTEIN", 230, 234], ["patients", "SPECIES", 182, 190], ["ADJUVANT/CTONG1104 trial", "TREATMENT", 13, 37], ["adjuvant gefitinib", "TREATMENT", 39, 57], ["longer disease", "PROBLEM", 65, 79], ["reduced myelosuppression risk", "PROBLEM", 99, 128], ["vinorelbine plus cisplatin", "TREATMENT", 152, 178], ["completely resected stage II\u2013IIIA EGFR", "PROBLEM", 196, 234], ["mutant NSCLC", "PROBLEM", 235, 247], ["resected", "OBSERVATION", 207, 215], ["IIIA EGFR", "OBSERVATION", 225, 234], ["mutant NSCLC", "OBSERVATION", 235, 247]]], ["Meanwhile, the orally administered EGFR-TKI drugs could be taken by patients at home, thereby reducing the risk of cross-infection caused by repeated hospital visits (20, 21).Advanced stage ::: Non-small cell lung cancer ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)A questionnaire survey was conducted among lung cancer experts from all over the country by the Lung Cancer Committee, Respiratory Society, Chinese Medical Association and Chinese Respiratory Tumor Cooperative Group to establish the guidelines for patients with advanced NSCLC during the epidemic (22).", [["Non-small cell lung cancer", "ANATOMY", 194, 220], ["cancers", "ANATOMY", 254, 261], ["lung cancer", "ANATOMY", 341, 352], ["Lung", "ANATOMY", 394, 398], ["NSCLC", "ANATOMY", 569, 574], ["Non-small cell lung cancer", "DISEASE", 194, 220], ["cancers", "DISEASE", 254, 261], ["lung cancer", "DISEASE", 341, 352], ["Lung Cancer", "DISEASE", 394, 405], ["Respiratory Tumor", "DISEASE", 478, 495], ["NSCLC", "DISEASE", 569, 574], ["EGFR", "GENE_OR_GENE_PRODUCT", 35, 39], ["patients", "ORGANISM", 68, 76], ["Non-small cell lung cancer", "CANCER", 194, 220], ["cancers", "CANCER", 254, 261], ["lung cancer", "CANCER", 341, 352], ["patients", "ORGANISM", 546, 554], ["NSCLC", "CANCER", 569, 574], ["EGFR", "PROTEIN", 35, 39], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 546, 554], ["EGFR-TKI drugs", "TREATMENT", 35, 49], ["cross-infection", "PROBLEM", 115, 130], ["Non-small cell lung cancer", "PROBLEM", 194, 220], ["cancers", "PROBLEM", 254, 261], ["COVID", "TEST", 265, 270], ["A questionnaire survey", "TEST", 298, 320], ["lung cancer", "PROBLEM", 341, 352], ["the Lung Cancer", "PROBLEM", 390, 405], ["advanced NSCLC", "PROBLEM", 560, 574], ["cell", "OBSERVATION", 204, 208], ["lung", "ANATOMY", 209, 213], ["cancer", "OBSERVATION", 214, 220], ["cancers", "OBSERVATION", 254, 261], ["lung", "ANATOMY", 341, 345], ["cancer", "OBSERVATION", 346, 352], ["Lung", "ANATOMY", 394, 398], ["Cancer", "OBSERVATION", 399, 405], ["Tumor", "OBSERVATION", 490, 495], ["NSCLC", "OBSERVATION", 569, 574]]], ["The guidelines suggested that (i) the infection should be treated first for patients who are infected with COVID-19 and all anticancer therapy should be discontinued for severe patients.", [["anticancer", "ANATOMY", 124, 134], ["infection", "DISEASE", 38, 47], ["COVID-19", "CHEMICAL", 107, 115], ["COVID-19", "CHEMICAL", 107, 115], ["patients", "ORGANISM", 76, 84], ["anticancer", "CANCER", 124, 134], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 177, 185], ["the infection", "PROBLEM", 34, 47], ["COVID", "TREATMENT", 107, 112], ["all anticancer therapy", "TREATMENT", 120, 142], ["infection", "OBSERVATION", 38, 47]]], ["For mild and moderate patients, continuing or suspending targeted therapy could both be considered; chemotherapy and immunotherapy is not recommended. (ii) For patients cured from COVID-19 treatment, targeted therapy is recommended to be started 2 weeks after pneumonia cure; chemotherapy, immunotherapy and intravenous anti-angiogenesis therapy are recommended to be started more than 4 weeks after pneumonia cure. (iii) For advanced NSCLC patients without COVID-19 infection, routine antitumor therapy is recommended.Advanced stage ::: Non-small cell lung cancer ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)It should be noted that the symptoms and imaging features of interstitial pneumonia caused by immunotherapy are quite similar to those of COVID-19 pneumonia and it\u2019s rather important to distinguish immunotherapy-induced interstitial pneumonia from COVID-19.", [["intravenous", "ANATOMY", 308, 319], ["NSCLC", "ANATOMY", 435, 440], ["antitumor", "ANATOMY", 486, 495], ["Non-small cell lung cancer", "ANATOMY", 538, 564], ["cancers", "ANATOMY", 598, 605], ["interstitial", "ANATOMY", 703, 715], ["interstitial", "ANATOMY", 862, 874], ["COVID-19", "CHEMICAL", 180, 188], ["pneumonia", "DISEASE", 260, 269], ["pneumonia", "DISEASE", 400, 409], ["NSCLC", "DISEASE", 435, 440], ["infection", "DISEASE", 467, 476], ["Non-small cell lung cancer", "DISEASE", 538, 564], ["cancers", "DISEASE", 598, 605], ["interstitial pneumonia", "DISEASE", 703, 725], ["pneumonia", "DISEASE", 789, 798], ["interstitial pneumonia", "DISEASE", 862, 884], ["COVID-19", "CHEMICAL", 180, 188], ["COVID-19", "CHEMICAL", 890, 898], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 160, 168], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 308, 319], ["NSCLC", "CANCER", 435, 440], ["patients", "ORGANISM", 441, 449], ["antitumor", "CANCER", 486, 495], ["Non-small cell lung cancer", "CANCER", 538, 564], ["cancers", "CANCER", 598, 605], ["COVID-19", "ORGANISM", 780, 788], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 441, 449], ["COVID-19", "SPECIES", 780, 788], ["mild and moderate patients", "PROBLEM", 4, 30], ["suspending targeted therapy", "TREATMENT", 46, 73], ["chemotherapy", "TREATMENT", 100, 112], ["immunotherapy", "TREATMENT", 117, 130], ["COVID-19 treatment", "TREATMENT", 180, 198], ["targeted therapy", "TREATMENT", 200, 216], ["pneumonia cure", "PROBLEM", 260, 274], ["chemotherapy", "TREATMENT", 276, 288], ["immunotherapy", "TREATMENT", 290, 303], ["intravenous anti-angiogenesis therapy", "TREATMENT", 308, 345], ["pneumonia cure", "PROBLEM", 400, 414], ["advanced NSCLC", "PROBLEM", 426, 440], ["COVID-19 infection", "PROBLEM", 458, 476], ["routine antitumor therapy", "TREATMENT", 478, 503], ["Non-small cell lung cancer", "PROBLEM", 538, 564], ["cancers", "PROBLEM", 598, 605], ["COVID", "TEST", 609, 614], ["the symptoms", "PROBLEM", 666, 678], ["interstitial pneumonia", "PROBLEM", 703, 725], ["immunotherapy", "TREATMENT", 736, 749], ["COVID-19 pneumonia", "PROBLEM", 780, 798], ["immunotherapy", "TREATMENT", 840, 853], ["interstitial pneumonia", "PROBLEM", 862, 884], ["COVID", "TEST", 890, 895], ["mild", "OBSERVATION_MODIFIER", 4, 8], ["moderate", "OBSERVATION_MODIFIER", 13, 21], ["pneumonia", "OBSERVATION", 400, 409], ["NSCLC", "OBSERVATION", 435, 440], ["infection", "OBSERVATION", 467, 476], ["cell", "OBSERVATION", 548, 552], ["lung", "ANATOMY", 553, 557], ["cancer", "OBSERVATION", 558, 564], ["cancers", "OBSERVATION", 598, 605], ["interstitial", "ANATOMY_MODIFIER", 703, 715], ["pneumonia", "OBSERVATION", 716, 725], ["pneumonia", "OBSERVATION", 789, 798], ["interstitial", "ANATOMY_MODIFIER", 862, 874], ["pneumonia", "OBSERVATION", 875, 884]]], ["As COVID-19 has been widespread in the world, it is difficult to distinguish them accurately just with the epidemiological history and etiology any longer.", [["COVID-19", "CHEMICAL", 3, 11], ["COVID-19", "GENE_OR_GENE_PRODUCT", 3, 11], ["COVID-19", "DNA", 3, 11], ["COVID", "TEST", 3, 8], ["widespread", "OBSERVATION_MODIFIER", 21, 31]]], ["Then, RT-PCR (real-time polymerase chain reaction) detection for SARS-COV-2 should be performed actively in these patients.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["RT-PCR", "TEST", 6, 12], ["SARS", "PROBLEM", 65, 69], ["COV", "TEST", 70, 73]]], ["Meanwhile, immunotherapy should be undertaken with caution in the special epidemic period to avoid this problem (20, 22).", [["immunotherapy", "TREATMENT", 11, 24]]], ["Instead, if the pneumonia is mild, simultaneously EGFR-TKI therapy and antiviral therapy may be safe for patients infected with COVID-19.", [["pneumonia", "DISEASE", 16, 25], ["EGFR", "GENE_OR_GENE_PRODUCT", 50, 54], ["patients", "ORGANISM", 105, 113], ["EGFR", "PROTEIN", 50, 54], ["patients", "SPECIES", 105, 113], ["the pneumonia", "PROBLEM", 12, 25], ["mild", "PROBLEM", 29, 33], ["simultaneously EGFR", "TREATMENT", 35, 54], ["TKI therapy", "TREATMENT", 55, 66], ["antiviral therapy", "TREATMENT", 71, 88], ["COVID", "TEST", 128, 133], ["pneumonia", "OBSERVATION", 16, 25], ["mild", "OBSERVATION_MODIFIER", 29, 33]]], ["It\u2019s reported that a patient with NSCLC was treated with Kaletra (lopinavir/ritonavir) and osimertinib at the same time after the diagnosis of mild COVID-19 infection; 2 weeks after Kaletra treatment, pneumonia was cured and the tumor remained stable (23).", [["NSCLC", "ANATOMY", 34, 39], ["tumor", "ANATOMY", 229, 234], ["NSCLC", "DISEASE", 34, 39], ["Kaletra", "CHEMICAL", 57, 64], ["lopinavir/ritonavir", "CHEMICAL", 66, 85], ["osimertinib", "CHEMICAL", 91, 102], ["COVID", "DISEASE", 148, 153], ["infection", "DISEASE", 157, 166], ["Kaletra", "CHEMICAL", 182, 189], ["pneumonia", "DISEASE", 201, 210], ["tumor", "DISEASE", 229, 234], ["Kaletra", "CHEMICAL", 57, 64], ["lopinavir", "CHEMICAL", 66, 75], ["ritonavir", "CHEMICAL", 76, 85], ["osimertinib", "CHEMICAL", 91, 102], ["patient", "ORGANISM", 21, 28], ["NSCLC", "CANCER", 34, 39], ["Kaletra", "SIMPLE_CHEMICAL", 57, 64], ["lopinavir", "SIMPLE_CHEMICAL", 66, 75], ["ritonavir", "SIMPLE_CHEMICAL", 76, 85], ["osimertinib", "SIMPLE_CHEMICAL", 91, 102], ["tumor", "CANCER", 229, 234], ["patient", "SPECIES", 21, 28], ["NSCLC", "PROBLEM", 34, 39], ["Kaletra", "TREATMENT", 57, 64], ["lopinavir", "TREATMENT", 66, 75], ["ritonavir", "TREATMENT", 76, 85], ["osimertinib", "TREATMENT", 91, 102], ["mild COVID-19 infection", "PROBLEM", 143, 166], ["Kaletra treatment", "TREATMENT", 182, 199], ["pneumonia", "PROBLEM", 201, 210], ["the tumor", "PROBLEM", 225, 234], ["NSCLC", "OBSERVATION", 34, 39], ["mild", "OBSERVATION_MODIFIER", 143, 147], ["infection", "OBSERVATION", 157, 166], ["pneumonia", "OBSERVATION", 201, 210], ["tumor", "OBSERVATION", 229, 234], ["stable", "OBSERVATION_MODIFIER", 244, 250]]], ["However, in the randomized, controlled, open-label trial evaluating the efficacy of lopinavir/ritonavir in patients with confirmed SARS-CoV-2 infection, there is no difference in the time to clinical improvement between lopinavir/ritonavir and standard treatment [hazard ratio for clinical improvement, 1.24; 95% confidence interval (CI), 0.90\u20131.72] (24).", [["lopinavir/ritonavir", "CHEMICAL", 84, 103], ["SARS-CoV-2 infection", "DISEASE", 131, 151], ["lopinavir/ritonavir", "CHEMICAL", 220, 239], ["lopinavir", "CHEMICAL", 84, 93], ["ritonavir", "CHEMICAL", 94, 103], ["lopinavir", "CHEMICAL", 220, 229], ["ritonavir", "CHEMICAL", 230, 239], ["lopinavir", "SIMPLE_CHEMICAL", 84, 93], ["ritonavir", "SIMPLE_CHEMICAL", 94, 103], ["patients", "ORGANISM", 107, 115], ["SARS-CoV-2", "ORGANISM", 131, 141], ["lopinavir", "SIMPLE_CHEMICAL", 220, 229], ["ritonavir", "SIMPLE_CHEMICAL", 230, 239], ["patients", "SPECIES", 107, 115], ["SARS-CoV-2", "SPECIES", 131, 141], ["lopinavir", "TREATMENT", 84, 93], ["ritonavir", "TREATMENT", 94, 103], ["SARS", "PROBLEM", 131, 135], ["CoV-2 infection", "PROBLEM", 136, 151], ["lopinavir", "TREATMENT", 220, 229], ["ritonavir", "TREATMENT", 230, 239], ["standard treatment", "TREATMENT", 244, 262], ["CI", "TEST", 334, 336], ["infection", "OBSERVATION", 142, 151], ["no", "UNCERTAINTY", 162, 164]]], ["The case report had suggested that the combination of lopinavir/ritonavir with osimertinib resulted in virologic clearance and stable tumor.", [["tumor", "ANATOMY", 134, 139], ["lopinavir/ritonavir", "CHEMICAL", 54, 73], ["osimertinib", "CHEMICAL", 79, 90], ["tumor", "DISEASE", 134, 139], ["lopinavir", "CHEMICAL", 54, 63], ["ritonavir", "CHEMICAL", 64, 73], ["osimertinib", "CHEMICAL", 79, 90], ["lopinavir", "SIMPLE_CHEMICAL", 54, 63], ["ritonavir", "SIMPLE_CHEMICAL", 64, 73], ["osimertinib", "SIMPLE_CHEMICAL", 79, 90], ["tumor", "CANCER", 134, 139], ["lopinavir", "TREATMENT", 54, 63], ["ritonavir", "TREATMENT", 64, 73], ["osimertinib", "TREATMENT", 79, 90], ["virologic clearance", "PROBLEM", 103, 122], ["stable tumor", "PROBLEM", 127, 139], ["stable", "OBSERVATION_MODIFIER", 127, 133], ["tumor", "OBSERVATION", 134, 139]]], ["However, because convincing data about the efficacy of this approach in patients with confirmed SARS-CoV-2 infection and NSCLC is lacking, future trials are needed to further identify the safety of targeted therapy combined with antiviral therapy.Small cell lung cancer ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)Small cell lung cancer (SCLC) progresses rapidly, and the median survival time of patients with extensive stage SCLC is only 9\u201311 months.", [["NSCLC", "ANATOMY", 121, 126], ["Small cell lung cancer", "ANATOMY", 247, 269], ["cancers", "ANATOMY", 303, 310], ["Small cell lung cancer", "ANATOMY", 347, 369], ["SCLC", "ANATOMY", 371, 375], ["SCLC", "ANATOMY", 459, 463], ["SARS-CoV-2 infection", "DISEASE", 96, 116], ["NSCLC", "DISEASE", 121, 126], ["Small cell lung cancer", "DISEASE", 247, 269], ["cancers", "DISEASE", 303, 310], ["Small cell lung cancer", "DISEASE", 347, 369], ["SCLC", "DISEASE", 371, 375], ["SCLC", "DISEASE", 459, 463], ["patients", "ORGANISM", 72, 80], ["SARS-CoV-2", "ORGANISM", 96, 106], ["NSCLC", "CANCER", 121, 126], ["Small cell lung cancer", "CANCER", 247, 269], ["cancers", "CANCER", 303, 310], ["Small cell lung cancer", "CANCER", 347, 369], ["SCLC", "CANCER", 371, 375], ["patients", "ORGANISM", 429, 437], ["SCLC", "CANCER", 459, 463], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 429, 437], ["this approach", "TREATMENT", 55, 68], ["SARS", "PROBLEM", 96, 100], ["CoV-2 infection", "PROBLEM", 101, 116], ["NSCLC", "PROBLEM", 121, 126], ["targeted therapy", "TREATMENT", 198, 214], ["antiviral therapy", "TREATMENT", 229, 246], ["Small cell lung cancer", "PROBLEM", 247, 269], ["cancers", "PROBLEM", 303, 310], ["COVID", "TEST", 314, 319], ["Small cell lung cancer", "PROBLEM", 347, 369], ["SCLC", "PROBLEM", 371, 375], ["extensive stage SCLC", "PROBLEM", 443, 463], ["infection", "OBSERVATION", 107, 116], ["NSCLC", "OBSERVATION", 121, 126], ["cell", "OBSERVATION", 253, 257], ["lung", "ANATOMY", 258, 262], ["cancer", "OBSERVATION", 263, 269], ["cancers", "OBSERVATION", 303, 310], ["cell", "OBSERVATION", 353, 357], ["lung", "ANATOMY", 358, 362], ["cancer", "OBSERVATION", 363, 369], ["SCLC", "OBSERVATION", 371, 375], ["extensive", "OBSERVATION_MODIFIER", 443, 452], ["stage", "OBSERVATION_MODIFIER", 453, 458], ["SCLC", "OBSERVATION", 459, 463]]], ["Delayed treatment will lead tumor progression and worse prognosis in patients with extensive stage SCLC.", [["tumor", "ANATOMY", 28, 33], ["SCLC", "ANATOMY", 99, 103], ["tumor", "DISEASE", 28, 33], ["SCLC", "DISEASE", 99, 103], ["tumor", "CANCER", 28, 33], ["patients", "ORGANISM", 69, 77], ["extensive stage SCLC", "CANCER", 83, 103], ["patients", "SPECIES", 69, 77], ["Delayed treatment", "TREATMENT", 0, 17], ["lead tumor progression", "PROBLEM", 23, 45], ["extensive stage SCLC", "PROBLEM", 83, 103], ["tumor", "OBSERVATION", 28, 33], ["extensive", "OBSERVATION_MODIFIER", 83, 92], ["stage", "OBSERVATION_MODIFIER", 93, 98], ["SCLC", "OBSERVATION", 99, 103]]], ["Therefore, for patients with extensive stage SCLC, regular chemotherapy should be carried out in local hospitals on the premise of excluding COVID-19.", [["SCLC", "ANATOMY", 45, 49], ["SCLC", "DISEASE", 45, 49], ["COVID-19", "CHEMICAL", 141, 149], ["patients", "ORGANISM", 15, 23], ["SCLC", "CANCER", 45, 49], ["patients", "SPECIES", 15, 23], ["extensive stage SCLC", "PROBLEM", 29, 49], ["regular chemotherapy", "TREATMENT", 51, 71], ["COVID", "TEST", 141, 146], ["SCLC", "OBSERVATION", 45, 49]]], ["If the disease progresses, chemotherapy regimens can be adjusted according to the condition, and oral anlotinib is also an option in China, which has been approved by the National Medical Products Administration only in China as a third-line or beyond therapy for SCLC based on the results of the phase II clinical trial (ALTER 1202) (20, 25).Endoscopy ::: Digestive tumors ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)During the outbreak of COVID-19, it should be careful to conduct endoscopy for medical institutions because there is a relatively high risk of cross-infection (26).", [["oral", "ANATOMY", 97, 101], ["SCLC", "ANATOMY", 264, 268], ["Digestive tumors", "ANATOMY", 357, 373], ["cancers", "ANATOMY", 407, 414], ["anlotinib", "CHEMICAL", 102, 111], ["SCLC", "DISEASE", 264, 268], ["Digestive tumors", "DISEASE", 357, 373], ["cancers", "DISEASE", 407, 414], ["anlotinib", "CHEMICAL", 102, 111], ["oral", "ORGANISM_SUBDIVISION", 97, 101], ["anlotinib", "SIMPLE_CHEMICAL", 102, 111], ["SCLC", "CANCER", 264, 268], ["Digestive tumors", "CANCER", 357, 373], ["cancers", "CANCER", 407, 414], ["the disease", "PROBLEM", 3, 14], ["chemotherapy regimens", "TREATMENT", 27, 48], ["oral anlotinib", "TREATMENT", 97, 111], ["a third-line", "TREATMENT", 229, 241], ["therapy", "TREATMENT", 252, 259], ["SCLC", "PROBLEM", 264, 268], ["Endoscopy", "TEST", 343, 352], ["cancers", "PROBLEM", 407, 414], ["COVID", "TEST", 418, 423], ["COVID", "TEST", 474, 479], ["endoscopy", "TEST", 516, 525], ["cross-infection", "PROBLEM", 594, 609], ["disease", "OBSERVATION", 7, 14], ["tumors", "OBSERVATION", 367, 373], ["cancers", "OBSERVATION", 407, 414], ["cross-infection", "OBSERVATION", 594, 609]]], ["This brings difficulties in the diagnosis and treatment of digestive tract tumors.", [["digestive tract tumors", "ANATOMY", 59, 81], ["digestive tract tumors", "DISEASE", 59, 81], ["digestive tract tumors", "CANCER", 59, 81], ["treatment", "TREATMENT", 46, 55], ["digestive tract tumors", "PROBLEM", 59, 81], ["digestive tract", "ANATOMY", 59, 74], ["tumors", "OBSERVATION", 75, 81]]], ["Yun Zhang (27) suggested that noninvasive inspections should be preferred in the diagnosis of digestisve system cancers during the outbreak, such as by MRI and PET-CT imaging examinations and tumor markers in the laboratory and needle biopsy of metastatic lesions when necessary.", [["digestisve system cancers", "ANATOMY", 94, 119], ["tumor", "ANATOMY", 192, 197], ["metastatic lesions", "ANATOMY", 245, 263], ["digestisve system cancers", "DISEASE", 94, 119], ["tumor", "DISEASE", 192, 197], ["digestisve system cancers", "CANCER", 94, 119], ["tumor", "CANCER", 192, 197], ["metastatic lesions", "CANCER", 245, 263], ["noninvasive inspections", "TEST", 30, 53], ["digestisve system cancers", "PROBLEM", 94, 119], ["MRI", "TEST", 152, 155], ["PET-CT imaging examinations", "TEST", 160, 187], ["tumor markers", "TEST", 192, 205], ["needle biopsy", "TEST", 228, 241], ["metastatic lesions", "PROBLEM", 245, 263], ["metastatic", "OBSERVATION", 245, 255]]], ["For patients who must undergo endoscopic examination, COVID-19 should be completely excluded first.Early and local advanced stages ::: Digestive tumors ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)For endoscopically resectable malignant tumors of the digestive system, due to the slow growth of early tumors, appropriate delayed resection during the epidemic period has no significant impact on the prognosis of tumors.", [["Digestive tumors", "ANATOMY", 135, 151], ["cancers", "ANATOMY", 185, 192], ["malignant tumors", "ANATOMY", 259, 275], ["digestive system", "ANATOMY", 283, 299], ["tumors", "ANATOMY", 333, 339], ["tumors", "ANATOMY", 444, 450], ["Digestive tumors", "DISEASE", 135, 151], ["cancers", "DISEASE", 185, 192], ["malignant tumors", "DISEASE", 259, 275], ["tumors", "DISEASE", 333, 339], ["tumors", "DISEASE", 444, 450], ["patients", "ORGANISM", 4, 12], ["Digestive tumors", "CANCER", 135, 151], ["cancers", "CANCER", 185, 192], ["malignant tumors", "CANCER", 259, 275], ["digestive", "ORGAN", 283, 292], ["system", "ANATOMICAL_SYSTEM", 293, 299], ["tumors", "CANCER", 333, 339], ["tumors", "CANCER", 444, 450], ["patients", "SPECIES", 4, 12], ["endoscopic examination", "TEST", 30, 52], ["COVID", "TEST", 54, 59], ["treatment", "TREATMENT", 172, 181], ["cancers", "PROBLEM", 185, 192], ["COVID", "TEST", 196, 201], ["endoscopically resectable malignant tumors of the digestive system", "PROBLEM", 233, 299], ["the slow growth of early tumors", "PROBLEM", 308, 339], ["appropriate delayed resection", "TREATMENT", 341, 370], ["tumors", "PROBLEM", 444, 450], ["tumors", "OBSERVATION", 145, 151], ["cancers", "OBSERVATION", 185, 192], ["digestive system", "ANATOMY", 283, 299], ["slow", "OBSERVATION_MODIFIER", 312, 316], ["growth", "OBSERVATION_MODIFIER", 317, 323], ["early", "OBSERVATION_MODIFIER", 327, 332], ["tumors", "OBSERVATION", 333, 339], ["delayed", "OBSERVATION_MODIFIER", 353, 360], ["resection", "OBSERVATION", 361, 370], ["no", "UNCERTAINTY", 402, 404], ["significant", "OBSERVATION_MODIFIER", 405, 416], ["tumors", "OBSERVATION", 444, 450]]], ["For operable esophageal, gastric and colorectal cancers, 2\u20134 cycles of neoadjuvant therapy could be selected, followed by surgery after the epidemic is over.", [["esophageal", "ANATOMY", 13, 23], ["gastric", "ANATOMY", 25, 32], ["colorectal cancers", "ANATOMY", 37, 55], ["esophageal, gastric and colorectal cancers", "DISEASE", 13, 55], ["esophageal", "CANCER", 13, 23], ["gastric", "CANCER", 25, 32], ["colorectal cancers", "CANCER", 37, 55], ["operable esophageal, gastric and colorectal cancers", "PROBLEM", 4, 55], ["neoadjuvant therapy", "TREATMENT", 71, 90], ["surgery", "TREATMENT", 122, 129], ["esophageal", "ANATOMY", 13, 23], ["gastric", "ANATOMY", 25, 32], ["colorectal", "ANATOMY", 37, 47], ["cancers", "OBSERVATION", 48, 55]]], ["However, surgery should be performed as early as possible after assessing the risk of COVID-19 in patients with bleeding, perforation, or obstruction.", [["bleeding", "DISEASE", 112, 120], ["perforation", "DISEASE", 122, 133], ["obstruction", "DISEASE", 138, 149], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["surgery", "TREATMENT", 9, 16], ["COVID", "TEST", 86, 91], ["bleeding", "PROBLEM", 112, 120], ["perforation", "PROBLEM", 122, 133], ["obstruction", "PROBLEM", 138, 149], ["bleeding", "OBSERVATION", 112, 120], ["perforation", "OBSERVATION", 122, 133], ["obstruction", "OBSERVATION", 138, 149]]], ["It is recommended to choose a long cycle chemotherapy regimen of 3\u20134 weeks in neoadjuvant therapy during the epidemic period to shorten hospital exposure time and reduce the risk of infection.", [["infection", "DISEASE", 182, 191], ["a long cycle chemotherapy regimen", "TREATMENT", 28, 61], ["neoadjuvant therapy", "TREATMENT", 78, 97], ["infection", "PROBLEM", 182, 191], ["infection", "OBSERVATION", 182, 191]]], ["In the period of neoadjuvant chemoradiotherapy for esophageal cancer and rectal cancer, it is recommended to choose long-term radiotherapy to reduce the waiting time for surgery after chemoradiotherapy.", [["esophageal cancer", "ANATOMY", 51, 68], ["rectal cancer", "ANATOMY", 73, 86], ["esophageal cancer", "DISEASE", 51, 68], ["rectal cancer", "DISEASE", 73, 86], ["esophageal cancer", "CANCER", 51, 68], ["rectal cancer", "CANCER", 73, 86], ["neoadjuvant chemoradiotherapy", "TREATMENT", 17, 46], ["esophageal cancer", "PROBLEM", 51, 68], ["rectal cancer", "PROBLEM", 73, 86], ["long-term radiotherapy", "TREATMENT", 116, 138], ["surgery", "TREATMENT", 170, 177], ["chemoradiotherapy", "TREATMENT", 184, 201], ["neoadjuvant chemoradiotherapy", "OBSERVATION", 17, 46], ["esophageal", "ANATOMY", 51, 61], ["cancer", "OBSERVATION", 62, 68], ["rectal", "ANATOMY", 73, 79], ["cancer", "OBSERVATION", 80, 86]]], ["For patients with early tumors of the hepatobiliary and pancreatic systems, surgery as early as possible is recommended on the premise of assessing the risk of COVID-19 due to their relatively rapid progression and poor outcome of chemotherapy (27).", [["tumors", "ANATOMY", 24, 30], ["hepatobiliary", "ANATOMY", 38, 51], ["pancreatic systems", "ANATOMY", 56, 74], ["tumors of the hepatobiliary and pancreatic systems", "DISEASE", 24, 74], ["patients", "ORGANISM", 4, 12], ["tumors", "CANCER", 24, 30], ["hepatobiliary", "ORGAN", 38, 51], ["pancreatic", "ORGAN", 56, 66], ["patients", "SPECIES", 4, 12], ["early tumors of the hepatobiliary and pancreatic systems", "PROBLEM", 18, 74], ["surgery", "TREATMENT", 76, 83], ["COVID", "TEST", 160, 165], ["chemotherapy", "TREATMENT", 231, 243], ["tumors", "OBSERVATION", 24, 30], ["hepatobiliary", "ANATOMY", 38, 51], ["pancreatic", "ANATOMY", 56, 66], ["rapid", "OBSERVATION_MODIFIER", 193, 198], ["progression", "OBSERVATION_MODIFIER", 199, 210]]], ["For colorectal cancer, laparoscopic surgery should be the first choice to reduce the risk of virus exposure.", [["colorectal cancer", "ANATOMY", 4, 21], ["colorectal cancer", "DISEASE", 4, 21], ["colorectal cancer", "CANCER", 4, 21], ["colorectal cancer", "PROBLEM", 4, 21], ["laparoscopic surgery", "TREATMENT", 23, 43], ["virus exposure", "PROBLEM", 93, 107], ["colorectal", "ANATOMY", 4, 14], ["cancer", "OBSERVATION", 15, 21], ["virus", "OBSERVATION", 93, 98]]], ["Meanwhile, in order to reduce the infection fever caused by anastomotic leakage after digestive tract reconstruction, it is recommended to perform preventive stoma for patients with risk factors of anastomotic leakage, but the risk of virus infection during the postoperative care of enterostomy should be considered during the epidemic (28).Advanced stage ::: Digestive tumors ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)Advanced tumors of the digestive system progress relatively quickly, and systemic treatment is the main option.", [["digestive tract", "ANATOMY", 86, 101], ["anastomotic", "ANATOMY", 198, 209], ["Digestive tumors", "ANATOMY", 361, 377], ["cancers", "ANATOMY", 411, 418], ["tumors", "ANATOMY", 464, 470], ["digestive system", "ANATOMY", 478, 494], ["infection", "DISEASE", 34, 43], ["fever", "DISEASE", 44, 49], ["anastomotic leakage", "DISEASE", 60, 79], ["anastomotic leakage", "DISEASE", 198, 217], ["infection", "DISEASE", 241, 250], ["Digestive tumors", "DISEASE", 361, 377], ["cancers", "DISEASE", 411, 418], ["tumors of the digestive system", "DISEASE", 464, 494], ["anastomotic leakage", "PATHOLOGICAL_FORMATION", 60, 79], ["digestive tract", "ORGANISM_SUBDIVISION", 86, 101], ["stoma", "PATHOLOGICAL_FORMATION", 158, 163], ["patients", "ORGANISM", 168, 176], ["anastomotic", "PATHOLOGICAL_FORMATION", 198, 209], ["Digestive tumors", "CANCER", 361, 377], ["cancers", "CANCER", 411, 418], ["tumors", "CANCER", 464, 470], ["digestive", "ORGAN", 478, 487], ["system", "ANATOMICAL_SYSTEM", 488, 494], ["patients", "SPECIES", 168, 176], ["the infection fever", "PROBLEM", 30, 49], ["anastomotic leakage", "PROBLEM", 60, 79], ["digestive tract reconstruction", "TREATMENT", 86, 116], ["preventive stoma", "TREATMENT", 147, 163], ["anastomotic leakage", "PROBLEM", 198, 217], ["virus infection", "PROBLEM", 235, 250], ["enterostomy", "TREATMENT", 284, 295], ["cancers", "PROBLEM", 411, 418], ["COVID", "TEST", 422, 427], ["Advanced tumors", "PROBLEM", 455, 470], ["systemic treatment", "TREATMENT", 528, 546], ["infection", "OBSERVATION", 34, 43], ["anastomotic leakage", "OBSERVATION", 60, 79], ["stoma", "OBSERVATION", 158, 163], ["anastomotic leakage", "OBSERVATION", 198, 217], ["virus", "OBSERVATION", 235, 240], ["enterostomy", "OBSERVATION", 284, 295], ["tumors", "OBSERVATION", 371, 377], ["cancers", "OBSERVATION", 411, 418], ["tumors", "OBSERVATION", 464, 470], ["digestive system", "ANATOMY", 478, 494]]], ["During the outbreak, it is recommended to choose the treatment with long interval and short stay in hospital; oral chemotherapy or targeted therapy should be preferred.", [["oral", "ANATOMY", 110, 114], ["oral", "ORGANISM_SUBDIVISION", 110, 114], ["the treatment", "TREATMENT", 49, 62], ["oral chemotherapy", "TREATMENT", 110, 127], ["targeted therapy", "TREATMENT", 131, 147]]], ["In the AXEPT research for metastatic colorectal cancer, the efficacy of irinotecan combined with capecitabine was not inferior to FOLFIRI.", [["metastatic colorectal cancer", "ANATOMY", 26, 54], ["colorectal cancer", "DISEASE", 37, 54], ["irinotecan", "CHEMICAL", 72, 82], ["capecitabine", "CHEMICAL", 97, 109], ["FOLFIRI", "CHEMICAL", 130, 137], ["irinotecan", "CHEMICAL", 72, 82], ["capecitabine", "CHEMICAL", 97, 109], ["FOLFIRI", "CHEMICAL", 130, 137], ["colorectal cancer", "CANCER", 37, 54], ["irinotecan", "SIMPLE_CHEMICAL", 72, 82], ["capecitabine", "SIMPLE_CHEMICAL", 97, 109], ["FOLFIRI", "SIMPLE_CHEMICAL", 130, 137], ["metastatic colorectal cancer", "PROBLEM", 26, 54], ["irinotecan", "TREATMENT", 72, 82], ["capecitabine", "TREATMENT", 97, 109], ["FOLFIRI", "TREATMENT", 130, 137], ["metastatic", "OBSERVATION_MODIFIER", 26, 36], ["colorectal cancer", "OBSERVATION", 37, 54]]], ["Therefore, CapeOX and XELIRI should be preferred for patients with metastatic colorectal cancer in the context of COVID-19 epidemic (27, 29).Breast cancer ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)As most breast cancer is a chronic disease, professor Xu suggested that appropriate countermeasures should be selected according to the regional epidemic severity and status of tumor disease.", [["metastatic colorectal cancer", "ANATOMY", 67, 95], ["Breast cancer", "ANATOMY", 141, 154], ["cancers", "ANATOMY", 188, 195], ["breast cancer", "ANATOMY", 240, 253], ["tumor", "ANATOMY", 409, 414], ["CapeOX", "CHEMICAL", 11, 17], ["XELIRI", "CHEMICAL", 22, 28], ["colorectal cancer", "DISEASE", 78, 95], ["Breast cancer", "DISEASE", 141, 154], ["cancers", "DISEASE", 188, 195], ["breast cancer", "DISEASE", 240, 253], ["tumor", "DISEASE", 409, 414], ["CapeOX", "CHEMICAL", 11, 17], ["CapeOX", "SIMPLE_CHEMICAL", 11, 17], ["XELIRI", "SIMPLE_CHEMICAL", 22, 28], ["patients", "ORGANISM", 53, 61], ["metastatic colorectal cancer", "CANCER", 67, 95], ["Breast cancer", "CANCER", 141, 154], ["cancers", "CANCER", 188, 195], ["breast cancer", "CANCER", 240, 253], ["tumor", "CANCER", 409, 414], ["patients", "SPECIES", 53, 61], ["CapeOX", "TREATMENT", 11, 17], ["XELIRI", "TREATMENT", 22, 28], ["metastatic colorectal cancer", "PROBLEM", 67, 95], ["COVID", "TEST", 114, 119], ["Breast cancer", "PROBLEM", 141, 154], ["cancers", "PROBLEM", 188, 195], ["COVID", "TEST", 199, 204], ["most breast cancer", "PROBLEM", 235, 253], ["a chronic disease", "PROBLEM", 257, 274], ["the regional epidemic severity", "PROBLEM", 364, 394], ["tumor disease", "PROBLEM", 409, 422], ["metastatic", "OBSERVATION_MODIFIER", 67, 77], ["colorectal cancer", "OBSERVATION", 78, 95], ["cancer", "OBSERVATION", 148, 154], ["cancers", "OBSERVATION", 188, 195], ["breast", "ANATOMY", 240, 246], ["cancer", "OBSERVATION", 247, 253], ["chronic", "OBSERVATION_MODIFIER", 259, 266], ["disease", "OBSERVATION", 267, 274], ["tumor", "OBSERVATION", 409, 414]]], ["In the severe epidemic areas of COVID-19, stable breast cancer patients may appropriately postpone the admission for review or treatment.", [["breast cancer", "ANATOMY", 49, 62], ["breast cancer", "DISEASE", 49, 62], ["breast cancer", "CANCER", 49, 62], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["COVID", "TEST", 32, 37], ["stable breast cancer", "PROBLEM", 42, 62], ["treatment", "TREATMENT", 127, 136], ["severe", "OBSERVATION_MODIFIER", 7, 13], ["epidemic", "OBSERVATION_MODIFIER", 14, 22], ["areas", "OBSERVATION_MODIFIER", 23, 28], ["stable", "OBSERVATION_MODIFIER", 42, 48], ["breast", "ANATOMY", 49, 55], ["cancer", "OBSERVATION", 56, 62]]], ["For breast cancer patients undergoing postoperative adjuvant chemotherapy, there was no difference between starting adjuvant chemotherapy 90 and 30 days after surgery in efficacy.", [["breast cancer", "ANATOMY", 4, 17], ["breast cancer", "DISEASE", 4, 17], ["breast cancer", "CANCER", 4, 17], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["breast cancer", "PROBLEM", 4, 17], ["postoperative adjuvant chemotherapy", "TREATMENT", 38, 73], ["adjuvant chemotherapy", "TREATMENT", 116, 137], ["surgery", "TREATMENT", 159, 166], ["breast", "ANATOMY", 4, 10], ["cancer", "OBSERVATION", 11, 17], ["no", "UNCERTAINTY", 85, 87]]], ["Deferment of medication for 4\u20136 weeks will not significantly affect the efficacy for patients receiving oral endocrine drugs or maintenance therapy with trastuzumab, while, for patients requiring pharmacologic ovarian function suppression, a long-acting preparation once every 3 months can be used to reduce the number of patients\u2019 visits.", [["oral", "ANATOMY", 104, 108], ["ovarian", "ANATOMY", 210, 217], ["trastuzumab", "CHEMICAL", 153, 164], ["patients", "ORGANISM", 85, 93], ["oral", "ORGANISM_SUBDIVISION", 104, 108], ["trastuzumab", "SIMPLE_CHEMICAL", 153, 164], ["patients", "ORGANISM", 177, 185], ["ovarian", "ORGAN", 210, 217], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 177, 185], ["patients", "SPECIES", 322, 330], ["medication", "TREATMENT", 13, 23], ["oral endocrine drugs", "TREATMENT", 104, 124], ["maintenance therapy", "TREATMENT", 128, 147], ["trastuzumab", "TREATMENT", 153, 164], ["pharmacologic ovarian function suppression", "TREATMENT", 196, 238], ["a long-acting preparation", "TREATMENT", 240, 265]]], ["For patients with advanced breast cancer, individual treatment plan should be performed according to the patient\u2019s situation.", [["breast cancer", "ANATOMY", 27, 40], ["breast cancer", "DISEASE", 27, 40], ["patients", "ORGANISM", 4, 12], ["breast cancer", "CANCER", 27, 40], ["patient", "ORGANISM", 105, 112], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 105, 112], ["advanced breast cancer", "PROBLEM", 18, 40], ["individual treatment plan", "TREATMENT", 42, 67], ["breast", "ANATOMY", 27, 33], ["cancer", "OBSERVATION", 34, 40]]], ["Endocrine therapy or oral chemotherapy drugs can be considered to replace the intravenous treatment, so as to ensure the continuity of treatment during the epidemic (30).Hematological malignancies ::: Suggestions for treatment of cancers in COVID-19 epidemic (what we learn)As COVID-19 spreads widely in the community, the unique impact on hematology patients and the practical measures should be urgently taken into consideration to reduce their risk during ongoing treatment.", [["Endocrine", "ANATOMY", 0, 9], ["oral", "ANATOMY", 21, 25], ["intravenous", "ANATOMY", 78, 89], ["Hematological malignancies", "ANATOMY", 170, 196], ["cancers", "ANATOMY", 230, 237], ["Hematological malignancies", "DISEASE", 170, 196], ["cancers", "DISEASE", 230, 237], ["oral", "ORGANISM_SUBDIVISION", 21, 25], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 89], ["Hematological malignancies", "CANCER", 170, 196], ["cancers", "CANCER", 230, 237], ["patients", "ORGANISM", 351, 359], ["COVID-19", "DNA", 277, 285], ["patients", "SPECIES", 351, 359], ["Endocrine therapy", "TREATMENT", 0, 17], ["oral chemotherapy drugs", "TREATMENT", 21, 44], ["the intravenous treatment", "TREATMENT", 74, 99], ["treatment", "TREATMENT", 135, 144], ["cancers", "PROBLEM", 230, 237], ["COVID", "TEST", 241, 246], ["COVID", "TEST", 277, 282], ["the practical measures", "TREATMENT", 364, 386], ["ongoing treatment", "TREATMENT", 459, 476], ["malignancies", "OBSERVATION", 184, 196], ["cancers", "OBSERVATION", 230, 237], ["19 spreads", "OBSERVATION_MODIFIER", 283, 293], ["widely", "OBSERVATION_MODIFIER", 294, 300]]], ["Patients who are conducted outpatient hematopoietic cell transplantations (HCTs) should remain near the transplant center.", [["hematopoietic cell", "ANATOMY", 38, 56], ["HCTs", "ANATOMY", 75, 79], ["Patients", "ORGANISM", 0, 8], ["hematopoietic cell", "CELL", 38, 56], ["Patients", "SPECIES", 0, 8], ["outpatient hematopoietic cell transplantations", "TREATMENT", 27, 73], ["HCTs", "TEST", 75, 79], ["hematopoietic cell transplantations", "OBSERVATION", 38, 73]]], ["While community transmission of COVID-19 has been confirmed, patients with HCT who are actively undergoing conditioning or treatment at the pre-implantation stage can be admitted early.", [["COVID-19", "CHEMICAL", 32, 40], ["HCT", "DISEASE", 75, 78], ["COVID-19", "CHEMICAL", 32, 40], ["COVID-19", "CELL", 32, 40], ["patients", "ORGANISM", 61, 69], ["HCT", "CANCER", 75, 78], ["COVID-19", "DNA", 32, 40], ["patients", "SPECIES", 61, 69], ["COVID", "TEST", 32, 37], ["HCT", "TEST", 75, 78], ["conditioning", "TREATMENT", 107, 119], ["treatment", "TREATMENT", 123, 132]]], ["The Worldwide Network for Blood and Marrow Transplantation (WBMT) recommends postponing non-emergency HCT in endemic or high-frequency COVID-19 infected areas (31).", [["Blood", "ANATOMY", 26, 31], ["Marrow", "ANATOMY", 36, 42], ["Blood", "ORGANISM_SUBSTANCE", 26, 31], ["Marrow", "TISSUE", 36, 42], ["Blood and Marrow Transplantation", "TREATMENT", 26, 58], ["non-emergency HCT", "TEST", 88, 105], ["endemic", "PROBLEM", 109, 116], ["high-frequency COVID", "TREATMENT", 120, 140], ["Marrow", "ANATOMY", 36, 42], ["infected", "OBSERVATION_MODIFIER", 144, 152]]], ["In the absence of vaccines or effective antiviral drugs at this stage, personal protection should be emphasized to the greatest extent, and good hygiene should be maintained for patients at home but still receiving immunosuppressive treatment.", [["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["vaccines", "TREATMENT", 18, 26], ["effective antiviral drugs", "TREATMENT", 30, 55], ["personal protection", "TREATMENT", 71, 90], ["immunosuppressive treatment", "TREATMENT", 215, 242], ["greatest extent", "OBSERVATION_MODIFIER", 119, 134]]], ["For patients who had a requirement for chemotherapy, regular chemotherapy should be carried out in local hospitals on the premise of excluding COVID-19.Recommendations for screening COVID-19 for cancer patients upon admissionIn the early stage of the epidemic, cross-infection in hospital is one of the most risk for patients and medical workers, so it is very important to screen COVID-19 patients as soon as admission of patients for cancer hospitals.", [["cancer", "ANATOMY", 195, 201], ["cancer", "ANATOMY", 436, 442], ["cancer", "DISEASE", 195, 201], ["cancer", "DISEASE", 436, 442], ["COVID-19", "CHEMICAL", 143, 151], ["patients", "ORGANISM", 4, 12], ["cancer", "CANCER", 195, 201], ["patients", "ORGANISM", 202, 210], ["patients", "ORGANISM", 317, 325], ["patients", "ORGANISM", 390, 398], ["patients", "ORGANISM", 423, 431], ["cancer", "CANCER", 436, 442], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 202, 210], ["patients", "SPECIES", 317, 325], ["patients", "SPECIES", 390, 398], ["patients", "SPECIES", 423, 431], ["chemotherapy", "TREATMENT", 39, 51], ["regular chemotherapy", "TREATMENT", 53, 73], ["COVID", "TEST", 143, 148], ["screening COVID", "TEST", 172, 187], ["cancer", "PROBLEM", 195, 201], ["cancer", "PROBLEM", 436, 442], ["early stage", "OBSERVATION_MODIFIER", 232, 243], ["epidemic", "OBSERVATION_MODIFIER", 251, 259]]], ["Because the most common symptom of COVID-19 infection is fever, a study with 1099 COVID-19 patients showed that 88.7% had fever (32).", [["COVID", "DISEASE", 35, 40], ["infection", "DISEASE", 44, 53], ["fever", "DISEASE", 57, 62], ["fever", "DISEASE", 122, 127], ["COVID-19", "ORGANISM", 35, 43], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["COVID-19 infection", "PROBLEM", 35, 53], ["fever", "PROBLEM", 57, 62], ["a study", "TEST", 64, 71], ["COVID", "TEST", 82, 87], ["fever", "PROBLEM", 122, 127], ["infection", "OBSERVATION", 44, 53]]], ["As a consequence, our hospital has developed an admission screening process according to this symptom (Fig. 1).", [["this symptom", "PROBLEM", 89, 101]]], ["First, temperature tests are performed at the entrances of the hospital, the outpatient clinic and the wards.", [["temperature tests", "TEST", 7, 24]]], ["Second, for patients preparing to be admitted, mandatory routine blood tests and high-resolution computed tomography scans of the lungs are performed.", [["blood", "ANATOMY", 65, 70], ["lungs", "ANATOMY", 130, 135], ["patients", "ORGANISM", 12, 20], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["lungs", "ORGAN", 130, 135], ["patients", "SPECIES", 12, 20], ["mandatory routine blood tests", "TEST", 47, 76], ["high-resolution computed tomography scans of the lungs", "TEST", 81, 135], ["lungs", "ANATOMY", 130, 135]]], ["COVID-19 virus nucleic acid tests and IgM/G ELISA will be carried out for patients with suspected pneumonia on computed tomography imaging.", [["COVID-19 virus nucleic acid", "CHEMICAL", 0, 27], ["pneumonia", "DISEASE", 98, 107], ["patients", "ORGANISM", 74, 82], ["IgM", "PROTEIN", 38, 41], ["patients", "SPECIES", 74, 82], ["COVID-19 virus", "SPECIES", 0, 14], ["COVID", "TEST", 0, 5], ["virus nucleic acid tests", "TEST", 9, 33], ["IgM/G ELISA", "TEST", 38, 49], ["pneumonia", "PROBLEM", 98, 107], ["computed tomography imaging", "TEST", 111, 138], ["pneumonia", "OBSERVATION", 98, 107]]], ["Patients excluded from COVID-19 will receive antitumor treatment.Recommendations for screening COVID-19 for cancer patients upon admissionThe patients that met screening criteria for COVID-19 include those with influenza-like symptoms (such as fever, sore throat or cough), significant respiratory symptoms (such as, shortness of breath) and/or exposure risk to COVID-19 (33).", [["antitumor", "ANATOMY", 45, 54], ["cancer", "ANATOMY", 108, 114], ["respiratory", "ANATOMY", 286, 297], ["cancer", "DISEASE", 108, 114], ["influenza-like symptoms", "DISEASE", 211, 234], ["fever", "DISEASE", 244, 249], ["sore throat", "DISEASE", 251, 262], ["cough", "DISEASE", 266, 271], ["respiratory symptoms", "DISEASE", 286, 306], ["shortness of breath", "DISEASE", 317, 336], ["COVID-19", "CHEMICAL", 362, 370], ["Patients", "ORGANISM", 0, 8], ["antitumor", "CANCER", 45, 54], ["cancer", "CANCER", 108, 114], ["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 142, 150], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 142, 150], ["COVID", "TEST", 23, 28], ["antitumor treatment", "TREATMENT", 45, 64], ["screening COVID", "TEST", 85, 100], ["cancer", "PROBLEM", 108, 114], ["screening criteria", "TEST", 160, 178], ["COVID", "TEST", 183, 188], ["influenza", "PROBLEM", 211, 220], ["like symptoms", "PROBLEM", 221, 234], ["fever", "PROBLEM", 244, 249], ["sore throat", "PROBLEM", 251, 262], ["cough", "PROBLEM", 266, 271], ["significant respiratory symptoms", "PROBLEM", 274, 306], ["shortness of breath", "PROBLEM", 317, 336], ["COVID", "TEST", 362, 367]]], ["As the asymptomatic COVID-19 infection had been widely documented in the literature (34, 35).", [["infection", "DISEASE", 29, 38], ["the asymptomatic COVID-19 infection", "PROBLEM", 3, 38], ["infection", "OBSERVATION", 29, 38]]], ["We suggested currently that the RT-PCR test should be carried out for all patients with potential exposure history even without any respiratory symptoms.Recommendations for screening COVID-19 for cancer patients upon admissionIn the screening of COVID-19 infections, it should be noticed that the detection sensitivity of SARS-COV-2 by RT-PCR was not high enough.", [["respiratory", "ANATOMY", 132, 143], ["cancer", "ANATOMY", 196, 202], ["cancer", "DISEASE", 196, 202], ["infections", "DISEASE", 255, 265], ["SARS", "DISEASE", 322, 326], ["patients", "ORGANISM", 74, 82], ["cancer", "CANCER", 196, 202], ["patients", "ORGANISM", 203, 211], ["COVID-19", "CELL", 246, 254], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 322, 332], ["SARS-COV-2", "DNA", 322, 332], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 203, 211], ["COVID-19", "SPECIES", 246, 254], ["the RT-PCR test", "TEST", 28, 43], ["any respiratory symptoms", "PROBLEM", 128, 152], ["screening COVID", "TEST", 173, 188], ["cancer", "PROBLEM", 196, 202], ["COVID-19 infections", "PROBLEM", 246, 265], ["the detection sensitivity", "TEST", 293, 318], ["SARS", "TEST", 322, 326], ["COV", "TEST", 327, 330], ["RT", "TEST", 336, 338], ["PCR", "TEST", 339, 342], ["infections", "OBSERVATION", 255, 265]]], ["The sensitivity for a single respiratory swab was 70% and can increase to 94% with a second test, and 98% with a third test (36).", [["respiratory swab", "ANATOMY", 29, 45], ["a single respiratory swab", "TEST", 20, 45], ["a second test", "TEST", 83, 96], ["a third test", "TEST", 111, 123]]], ["Thus, repeating testing may be important and necessary to make a diagnosis of COVID-19 (37).", [["COVID-19", "CHEMICAL", 78, 86], ["repeating testing", "TEST", 6, 23], ["COVID", "TEST", 78, 83]]], ["In the case of poor detection sensitivity of RT-PCR, the pulmonary CT findings are of great value for the early diagnosis of COVID-19.", [["pulmonary", "ANATOMY", 57, 66], ["pulmonary", "ORGAN", 57, 66], ["RT-PCR", "TEST", 45, 51], ["the pulmonary CT", "TEST", 53, 69], ["COVID", "TEST", 125, 130], ["pulmonary", "ANATOMY", 57, 66]]], ["Multiple reports have revealed the significance of CT chest with a higher sensitivity in early detection of COVID-19 cases.", [["chest", "ANATOMY", 54, 59], ["COVID", "DISEASE", 108, 113], ["chest", "ORGAN", 54, 59], ["CT chest", "TEST", 51, 59], ["COVID", "TEST", 108, 113], ["chest", "ANATOMY", 54, 59]]], ["In most cases, concordant CT scan and PCR test results were used to diagnose COVID-19 (38).", [["COVID-19", "CHEMICAL", 77, 85], ["concordant CT scan", "TEST", 15, 33], ["PCR test", "TEST", 38, 46], ["COVID", "TEST", 77, 82]]], ["In the study involved 1014 SARS-CoV-2 patients, 59% of which had positive RT-PCR, while 88% had positive CT scan.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 27, 35], ["the study", "TEST", 3, 12], ["CoV", "TEST", 32, 35], ["positive RT-PCR", "PROBLEM", 65, 80], ["positive CT scan", "TEST", 96, 112]]], ["The sensitivity of chest CT imaging was 97%, which is higher than that of RT-PCR (39).", [["chest", "ANATOMY", 19, 24], ["chest", "ORGAN", 19, 24], ["chest CT imaging", "TEST", 19, 35], ["RT-PCR", "TEST", 74, 80], ["chest", "ANATOMY", 19, 24], ["higher", "OBSERVATION_MODIFIER", 54, 60]]], ["Therefore, in the admission screening of COVID-19 for cancer patients, attention should be paid to the chest CT performance.", [["cancer", "ANATOMY", 54, 60], ["chest", "ANATOMY", 103, 108], ["cancer", "DISEASE", 54, 60], ["cancer", "CANCER", 54, 60], ["patients", "ORGANISM", 61, 69], ["chest", "ORGANISM_SUBDIVISION", 103, 108], ["patients", "SPECIES", 61, 69], ["COVID", "TEST", 41, 46], ["cancer", "PROBLEM", 54, 60], ["the chest CT performance", "TEST", 99, 123], ["chest", "ANATOMY", 103, 108]]], ["However, the dose delivered to patients through CT scans is much greater than that produced by modalities including plain radiograph, which may cause serious problems in the future, including carcinogenesis and heritable issues (40).Recommendations for screening COVID-19 for cancer patients upon admissionThe National Lung Screening Trial (NLST) from the USA showed low-dose computed tomography (LDCT) can reduce the mortality of lung cancer, which is a safe tool for screening (41).", [["cancer", "ANATOMY", 276, 282], ["Lung", "ANATOMY", 319, 323], ["lung cancer", "ANATOMY", 431, 442], ["carcinogenesis", "DISEASE", 192, 206], ["COVID-19", "CHEMICAL", 263, 271], ["cancer", "DISEASE", 276, 282], ["lung cancer", "DISEASE", 431, 442], ["patients", "ORGANISM", 31, 39], ["cancer", "CANCER", 276, 282], ["patients", "ORGANISM", 283, 291], ["Lung", "ORGAN", 319, 323], ["lung cancer", "CANCER", 431, 442], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 283, 291], ["CT scans", "TEST", 48, 56], ["plain radiograph", "TEST", 116, 132], ["serious problems", "PROBLEM", 150, 166], ["carcinogenesis and heritable issues", "PROBLEM", 192, 227], ["screening COVID", "TEST", 253, 268], ["cancer", "PROBLEM", 276, 282], ["the USA", "TEST", 352, 359], ["computed tomography", "TEST", 376, 395], ["LDCT", "TEST", 397, 401], ["lung cancer", "PROBLEM", 431, 442], ["screening", "TEST", 469, 478], ["Lung", "ANATOMY", 319, 323], ["lung", "ANATOMY", 431, 435], ["cancer", "OBSERVATION", 436, 442]]], ["And international academic organizations and many medical institutions have proposed low-dose spiral CT screening and developed corresponding screening guidelines (42).", [["spiral CT screening", "TEST", 94, 113]]], ["The median duration of IgM antibody produced against SARS-CoV-2 was 5 days.", [["SARS", "DISEASE", 53, 57], ["IgM antibody", "GENE_OR_GENE_PRODUCT", 23, 35], ["SARS-CoV-2", "ORGANISM", 53, 63], ["IgM antibody", "PROTEIN", 23, 35], ["SARS-CoV", "SPECIES", 53, 61], ["IgM antibody", "TEST", 23, 35], ["SARS", "PROBLEM", 53, 57], ["CoV", "TEST", 58, 61]]], ["IgM detection resulted in a higher efficiency compared with qPCR detection after 5.5 days of symptom set.", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgM", "PROTEIN", 0, 3], ["IgM detection", "TEST", 0, 13], ["a higher efficiency", "PROBLEM", 26, 45], ["qPCR detection", "TEST", 60, 74], ["symptom", "PROBLEM", 93, 100], ["higher efficiency", "OBSERVATION_MODIFIER", 28, 45]]], ["The positive rate of IgM ELISA assay accompanied with qPCR is significantly increased compared with a single qPCR test, including in subclinical cases (43).Recommendations for screening COVID-19 for cancer patients upon admissionFor those patients whose imaging cannot exclude COVID-19, further judgment should be made based on the patients\u2019 epidemiological history, clinical symptoms and complete blood count (CBC) results.", [["cancer", "ANATOMY", 199, 205], ["blood", "ANATOMY", 398, 403], ["cancer", "DISEASE", 199, 205], ["IgM", "GENE_OR_GENE_PRODUCT", 21, 24], ["cancer", "CANCER", 199, 205], ["patients", "ORGANISM", 206, 214], ["patients", "ORGANISM", 239, 247], ["patients", "ORGANISM", 332, 340], ["blood", "ORGANISM_SUBSTANCE", 398, 403], ["IgM", "PROTEIN", 21, 24], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 239, 247], ["patients", "SPECIES", 332, 340], ["IgM ELISA assay", "TEST", 21, 36], ["qPCR", "TEST", 54, 58], ["a single qPCR test", "TEST", 100, 118], ["screening COVID", "TEST", 176, 191], ["cancer", "PROBLEM", 199, 205], ["imaging", "TEST", 254, 261], ["COVID", "TEST", 277, 282], ["clinical symptoms", "PROBLEM", 367, 384], ["complete blood count", "TEST", 389, 409], ["CBC", "TEST", 411, 414], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["significantly", "OBSERVATION_MODIFIER", 62, 75], ["increased", "OBSERVATION_MODIFIER", 76, 85]]], ["Suspected cases should be isolated and treated as soon as possible.ConclusionCOVID-19 is a major global human threat that has turned into a pandemic and has specifically high morbidity in the elderly and in comorbid populations.", [["human", "ORGANISM", 104, 109], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["ConclusionCOVID", "TEST", 67, 82], ["high", "OBSERVATION_MODIFIER", 170, 174], ["morbidity", "OBSERVATION", 175, 184]]], ["Cancer patients may be more susceptible to infection, and tumor history is defined as an important factor of poor prognosis, which challenges both doctors and patients.", [["Cancer", "ANATOMY", 0, 6], ["tumor", "ANATOMY", 58, 63], ["Cancer", "DISEASE", 0, 6], ["infection", "DISEASE", 43, 52], ["tumor", "DISEASE", 58, 63], ["Cancer", "CANCER", 0, 6], ["patients", "ORGANISM", 7, 15], ["tumor", "CANCER", 58, 63], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 159, 167], ["Cancer", "PROBLEM", 0, 6], ["infection", "PROBLEM", 43, 52], ["infection", "OBSERVATION", 43, 52], ["tumor", "OBSERVATION", 58, 63]]], ["However, the countermeasures of integrative cancer therapy in the epidemic of COVID-19 are not fully understood and more clinical studies are needed.", [["cancer", "ANATOMY", 44, 50], ["cancer", "DISEASE", 44, 50], ["COVID-19", "CHEMICAL", 78, 86], ["cancer", "CANCER", 44, 50], ["integrative cancer therapy", "TREATMENT", 32, 58], ["COVID", "TEST", 78, 83], ["clinical studies", "TEST", 121, 137], ["integrative", "OBSERVATION_MODIFIER", 32, 43], ["cancer", "OBSERVATION", 44, 50]]], ["During the epidemic, in addition to assessing the stage of the tumor and the status of the patient, treatment of the tumor needs to make necessary adjustments according to the local epidemic status to reduce the risk of tumor progression and COVID 19 infection (44).ConclusionUnder the epidemic of COVID-19 worldwide, it is very important to balance the effective prevention of cross infection of COVID-19 and the rational arrangement of anticancer treatment.", [["tumor", "ANATOMY", 63, 68], ["tumor", "ANATOMY", 117, 122], ["tumor", "ANATOMY", 220, 225], ["anticancer", "ANATOMY", 438, 448], ["tumor", "DISEASE", 63, 68], ["tumor", "DISEASE", 117, 122], ["tumor", "DISEASE", 220, 225], ["infection", "DISEASE", 251, 260], ["COVID-19", "CHEMICAL", 298, 306], ["infection", "DISEASE", 384, 393], ["COVID-19", "CHEMICAL", 397, 405], ["tumor", "CANCER", 63, 68], ["patient", "ORGANISM", 91, 98], ["tumor", "CANCER", 117, 122], ["tumor", "CANCER", 220, 225], ["anticancer", "CANCER", 438, 448], ["patient", "SPECIES", 91, 98], ["the tumor", "PROBLEM", 59, 68], ["treatment", "TREATMENT", 100, 109], ["the tumor", "PROBLEM", 113, 122], ["tumor progression", "PROBLEM", 220, 237], ["COVID 19 infection", "PROBLEM", 242, 260], ["COVID", "TEST", 298, 303], ["cross infection of COVID", "PROBLEM", 378, 402], ["anticancer treatment", "TREATMENT", 438, 458], ["tumor", "OBSERVATION", 63, 68], ["tumor", "OBSERVATION", 117, 122], ["tumor", "OBSERVATION", 220, 225]]], ["As the spread of COVID-19 in China is effectively controlled after taking strict prevention and control measures, medical work gradually returned to normal, including anticancer treatment.", [["anticancer", "ANATOMY", 167, 177], ["COVID-19", "CHEMICAL", 17, 25], ["anticancer", "CANCER", 167, 177], ["COVID", "TEST", 17, 22], ["strict prevention", "TREATMENT", 74, 91], ["control measures", "TREATMENT", 96, 112], ["anticancer treatment", "TREATMENT", 167, 187], ["spread", "OBSERVATION_MODIFIER", 7, 13]]], ["However, because the cases imported from outside mainland China and asymptomatic infected persons may also be infectious, the contact and travel histories regarding the epidemic area of all individual record is always needed in controlled phase.", [["persons", "ORGANISM", 90, 97], ["persons", "SPECIES", 90, 97], ["infectious", "PROBLEM", 110, 120], ["asymptomatic", "OBSERVATION_MODIFIER", 68, 80], ["infected", "OBSERVATION", 81, 89], ["may also be", "UNCERTAINTY", 98, 109], ["infectious", "OBSERVATION", 110, 120]]], ["And COVID-19 virus nucleic acid tests should be carried out for patients preparing to be admitted if available.", [["COVID-19 virus nucleic acid", "CHEMICAL", 4, 31], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["COVID-19 virus", "SPECIES", 4, 18], ["COVID", "TEST", 4, 9], ["virus nucleic acid tests", "TEST", 13, 37]]], ["Overall, to ensure the normal treatment of patients with cancer and simultaneously avoid cross infection of COVID-19, more attention should be paid by clinicians to meet the challenges of different COVID-19 epidemic phases.FundingThis work was supported by a project cosponsored by the Henan Province and Ministry of Health Medical Science and Technology Program (No. 201601026) and in part by the National Natural Science Foundation of China (No. 81272600), Zhongyuan 1000 Talents Plan, Natural Science Foundation of Henan Province (No. 162300410300) and the 51282 project Leading Talent of Henan Provincial Health Science and Technology Innovation Talents (No.", [["cancer", "ANATOMY", 57, 63], ["cancer", "DISEASE", 57, 63], ["infection", "DISEASE", 95, 104], ["patients", "ORGANISM", 43, 51], ["cancer", "CANCER", 57, 63], ["patients", "SPECIES", 43, 51], ["cancer", "PROBLEM", 57, 63], ["cross infection", "PROBLEM", 89, 104], ["COVID", "TEST", 108, 113], ["different COVID", "TEST", 188, 203], ["cancer", "OBSERVATION", 57, 63]]], ["The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.Conflict of interest statementNone declared.", [["the study", "TEST", 27, 36], ["data collection", "TEST", 45, 60], ["analysis", "TEST", 65, 73], ["no", "UNCERTAINTY", 16, 18]]]], "2d4246494e250c90bb5721a35e2b0a8e20100f20": [["hepatitis B virus).", [["hepatitis B", "DISEASE", 0, 11], ["hepatitis B virus", "ORGANISM", 0, 17], ["hepatitis B virus", "SPECIES", 0, 17], ["hepatitis B virus", "SPECIES", 0, 17], ["hepatitis B virus", "PROBLEM", 0, 17]]], ["Despite their shared replication strategy, host specificity and tissue tropism, HAV, HCV, and HEV share very little sequence conservation, indicative of their independent evolutionary origins.", [["tissue", "ANATOMY", 64, 70], ["tissue", "TISSUE", 64, 70], ["HAV", "ORGANISM", 80, 83], ["HCV", "ORGANISM", 85, 88], ["HEV", "ORGANISM", 94, 97], ["HAV", "SPECIES", 80, 83], ["HCV", "SPECIES", 85, 88], ["HEV", "SPECIES", 94, 97], ["host specificity", "TEST", 43, 59], ["tissue tropism", "TEST", 64, 78], ["HAV", "PROBLEM", 80, 83], ["HCV", "PROBLEM", 85, 88], ["evolutionary origins", "OBSERVATION", 171, 191]]], ["We compared the genome sequences of a large number of these three viral species to evaluate commonalities and differences between and within the respective clades.", [["these three viral species", "PROBLEM", 54, 79], ["large", "OBSERVATION_MODIFIER", 38, 43], ["viral species", "OBSERVATION", 66, 79]]]], "41e1e70c113c6b367cf9b056b21c167af7555eb0": [["Six HCoVs have been identified to date: HCoV-229E, OC43, NL63, HKU1, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) and Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV).", [["acute respiratory syndrome (SARS) coronavirus (SARS-CoV)", "DISEASE", 76, 132], ["Middle East respiratory syndrome (MERS) coronavirus", "DISEASE", 137, 188], ["HCoVs", "GENE_OR_GENE_PRODUCT", 4, 9], ["HCoV-229E", "CELL", 40, 49], ["OC43", "GENE_OR_GENE_PRODUCT", 51, 55], ["severe acute respiratory", "ORGANISM", 69, 93], ["SARS-CoV", "ORGANISM", 123, 131], ["Middle East respiratory syndrome (MERS) coronavirus", "ORGANISM", 137, 188], ["MERS-CoV", "ORGANISM", 190, 198], ["HCoVs", "PROTEIN", 4, 9], ["HCoV-229E", "SPECIES", 40, 49], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 69, 121], ["SARS-CoV", "SPECIES", 123, 131], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 137, 188], ["MERS-CoV", "SPECIES", 190, 198], ["HCoV", "TEST", 40, 44], ["OC43", "TEST", 51, 55], ["NL63", "TEST", 57, 61], ["HKU1", "TEST", 63, 67], ["severe acute respiratory syndrome", "PROBLEM", 69, 102], ["SARS)", "PROBLEM", 104, 109], ["coronavirus (SARS-CoV)", "PROBLEM", 110, 132], ["Middle East respiratory syndrome", "PROBLEM", 137, 169], ["coronavirus", "PROBLEM", 177, 188], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["respiratory syndrome", "OBSERVATION", 82, 102], ["Middle", "ANATOMY_MODIFIER", 137, 143], ["respiratory syndrome", "OBSERVATION", 149, 169]]], ["HCoV-229E and NL63 belong to the genus Alphacoronavirus, while the other four HCoVs belong to the genus Betacoronavirus, with HCoV-OC43 and HKU1 in lineage A, SARS-CoV in lineage B and MERS-CoV in lineage C .", [["HCoV-229E", "GENE_OR_GENE_PRODUCT", 0, 9], ["NL63", "GENE_OR_GENE_PRODUCT", 14, 18], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 39, 55], ["HCoVs", "GENE_OR_GENE_PRODUCT", 78, 83], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 104, 119], ["HCoV-OC43", "CELL", 126, 135], ["HKU1", "GENE_OR_GENE_PRODUCT", 140, 144], ["lineage A", "CANCER", 148, 157], ["SARS-CoV", "ORGANISM", 159, 167], ["lineage B", "CELL", 171, 180], ["MERS-CoV", "ORGANISM", 185, 193], ["lineage C", "CELL", 197, 206], ["HCoV", "PROTEIN", 0, 4], ["229E", "DNA", 5, 9], ["NL63", "DNA", 14, 18], ["HCoVs", "DNA", 78, 83], ["HKU1", "DNA", 140, 144], ["HCoV-229E", "SPECIES", 0, 9], ["SARS-CoV", "SPECIES", 159, 167], ["MERS-CoV", "SPECIES", 185, 193], ["HCoV", "TEST", 0, 4], ["HCoV", "TEST", 126, 130], ["HKU1", "TEST", 140, 144], ["SARS", "PROBLEM", 159, 163], ["genus Alphacoronavirus", "ANATOMY", 33, 55]]], ["SARS-CoV is the causative agent of SARS, which emerged as a previously unknown severe human respiratory infection in the Guangdong Province of China in 2002 (Drosten et al., 2003; Ksiazek et al., 2003) .", [["respiratory", "ANATOMY", 92, 103], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 35, 39], ["respiratory infection", "DISEASE", 92, 113], ["SARS-CoV", "ORGANISM", 0, 8], ["human", "ORGANISM", 86, 91], ["human", "SPECIES", 86, 91], ["SARS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 86, 91], ["SARS", "PROBLEM", 0, 4], ["SARS", "PROBLEM", 35, 39], ["a previously unknown severe human respiratory infection", "PROBLEM", 58, 113], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["respiratory", "ANATOMY", 92, 103], ["infection", "OBSERVATION", 104, 113]]], ["SARS is highly contagious, and by the end of the 2003 epidemic a total of 8098 probable SARS cases had been reported to the World Health Organization (WHO) from 29 countries, with 774 SARSrelated deaths (case fatality rate: 9.6 %) (WHO, 2004) .", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 88, 92], ["deaths", "DISEASE", 196, 202], ["SARS", "PROBLEM", 0, 4], ["SARS cases", "PROBLEM", 88, 98], ["fatality rate", "TEST", 209, 222], ["highly", "OBSERVATION_MODIFIER", 8, 14], ["contagious", "OBSERVATION_MODIFIER", 15, 25]]], ["Before the discovery of SARS-CoV in 2003, only two HCoVs, namely HCoV-229E and OC43, were known (Lu et al., 2012) ; however, these did not attract much attention as they only caused mild upper respiratory tract infections in humans (Wevers & van der Hoek, 2009 ).", [["upper respiratory tract", "ANATOMY", 187, 210], ["SARS", "DISEASE", 24, 28], ["respiratory tract infections", "DISEASE", 193, 221], ["SARS-CoV", "ORGANISM", 24, 32], ["HCoVs", "GENE_OR_GENE_PRODUCT", 51, 56], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 65, 74], ["upper", "ORGANISM_SUBDIVISION", 187, 192], ["respiratory tract", "ORGANISM_SUBDIVISION", 193, 210], ["humans", "ORGANISM", 225, 231], ["humans", "SPECIES", 225, 231], ["SARS-CoV", "SPECIES", 24, 32], ["HCoV-229E", "SPECIES", 65, 74], ["humans", "SPECIES", 225, 231], ["SARS", "PROBLEM", 24, 28], ["CoV", "TEST", 29, 32], ["HCoV", "TEST", 65, 69], ["OC43", "PROBLEM", 79, 83], ["mild upper respiratory tract infections", "PROBLEM", 182, 221], ["mild", "OBSERVATION_MODIFIER", 182, 186], ["upper", "ANATOMY_MODIFIER", 187, 192], ["respiratory tract", "ANATOMY", 193, 210], ["infections", "OBSERVATION", 211, 221]]], ["With surging interest in CoVs after the emergence of SARS, two additional novel HCoVs, NL63 and HKU1, were identified in , respectively (van der Hoek et al., 2004 Woo et al., 2005) , which also caused only mild upper respiratory tract infections (Wevers and van der Hoek, 2009 ).", [["upper respiratory tract", "ANATOMY", 211, 234], ["SARS", "DISEASE", 53, 57], ["respiratory tract infections", "DISEASE", 217, 245], ["CoVs", "CANCER", 25, 29], ["HCoVs", "GENE_OR_GENE_PRODUCT", 80, 85], ["NL63", "GENE_OR_GENE_PRODUCT", 87, 91], ["HKU1", "GENE_OR_GENE_PRODUCT", 96, 100], ["upper", "ORGANISM_SUBDIVISION", 211, 216], ["respiratory tract", "ORGANISM_SUBDIVISION", 217, 234], ["HCoVs", "DNA", 80, 85], ["NL63", "DNA", 87, 91], ["HKU1", "DNA", 96, 100], ["CoVs", "PROBLEM", 25, 29], ["SARS", "PROBLEM", 53, 57], ["mild upper respiratory tract infections", "PROBLEM", 206, 245], ["mild", "OBSERVATION_MODIFIER", 206, 210], ["upper", "ANATOMY_MODIFIER", 211, 216], ["respiratory tract", "ANATOMY", 217, 234], ["infections", "OBSERVATION", 235, 245]]], ["However, in 2012, MERS attracted more attention as an emerging infectious disease because it caused severe lower respiratory infection and renal failure, similar to the clinical manifestation of SARS.", [["respiratory", "ANATOMY", 113, 124], ["renal", "ANATOMY", 139, 144], ["infectious disease", "DISEASE", 63, 81], ["lower respiratory infection", "DISEASE", 107, 134], ["renal failure", "DISEASE", 139, 152], ["SARS", "DISEASE", 195, 199], ["renal", "ORGAN", 139, 144], ["an emerging infectious disease", "PROBLEM", 51, 81], ["severe lower respiratory infection", "PROBLEM", 100, 134], ["renal failure", "PROBLEM", 139, 152], ["SARS", "PROBLEM", 195, 199], ["infectious", "OBSERVATION", 63, 73], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["lower", "ANATOMY_MODIFIER", 107, 112], ["respiratory", "ANATOMY", 113, 124], ["infection", "OBSERVATION", 125, 134], ["renal", "ANATOMY", 139, 144], ["failure", "OBSERVATION", 145, 152]]], ["The responsible agent was identified as a novel HCoV named MERS-CoV .", [["HCoV", "GENE_OR_GENE_PRODUCT", 48, 52], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["HCoV named MERS-CoV", "DNA", 48, 67], ["HCoV", "SPECIES", 48, 52], ["MERS-CoV", "SPECIES", 59, 67]]]], "e74b86cb94cb1ce52180587fd527858239d1b889": [["IntroductionOver the last decade, there has been a remarkable increase in epidemics around the world.", [["remarkable", "OBSERVATION_MODIFIER", 51, 61], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["epidemics", "OBSERVATION", 74, 83]]], ["As a large portion of healthcare personnel, nurses have proximity with infected individuals, and this puts them at higher risk of being exposed to contagious diseases (Bernard et al., 2009; Branch-Elliman et al., 2015; International Council of Nurses [ICN], 2016) .", [["infected individuals", "PROBLEM", 71, 91], ["contagious diseases", "PROBLEM", 147, 166], ["large", "OBSERVATION_MODIFIER", 5, 10]]], ["During the worldwide epidemic of early 2003, healthcare workers accounted for a large proportion of persons with severe acute respiratory syndrome (Park et al., 2004) .", [["acute respiratory syndrome", "DISEASE", 120, 146], ["persons", "ORGANISM", 100, 107], ["persons", "SPECIES", 100, 107], ["severe acute respiratory syndrome", "PROBLEM", 113, 146], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["respiratory syndrome", "OBSERVATION", 126, 146]]], ["In recent years, during the Ebola disease outbreak in West Africa, 815 of healthcare workers infected with Ebola and two thirds of them died, > 50% were nurses (ICN, 2016) .", [["Ebola disease", "DISEASE", 28, 41], ["Ebola", "DISEASE", 107, 112], ["Ebola", "ORGANISM", 107, 112], ["Ebola", "TREATMENT", 107, 112], ["Ebola disease", "OBSERVATION", 28, 41]]], ["Kuncio et al. stated that pediatric health workers were often exposed to pertussis due to inadequate infection control measures (Kuncio et al., 2014) .", [["pertussis", "DISEASE", 73, 82], ["infection", "DISEASE", 101, 110], ["pertussis", "PROBLEM", 73, 82], ["inadequate infection control measures", "PROBLEM", 90, 127], ["infection", "OBSERVATION", 101, 110]]], ["From the perspective of patients, infections stemming from healthcare not only increase their health expenses, but also constitute a significant risk factor for morbidity and mortality (Luangasanatip et al., 2015; World Health Organization [WHO] , 2016).", [["infections", "DISEASE", 34, 44], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["infections", "PROBLEM", 34, 44], ["morbidity", "PROBLEM", 161, 170], ["infections", "OBSERVATION", 34, 44]]], ["More than 2.5 million cases of healthcareassociated infections (HAIs) occur in the Europe, total burden of HAIs in the EU of 501 DALYs per 100,000 people (Cassini et al., 2016) , 4.0% of inpatients in U.S. acute care hospitals had at least one HAI (Ray et al., 2015) .IntroductionOn the other hand, it is for sure that hand hygiene (HH) is the most important of all control measures against all infections for both healthcare personnel and patient safety (WHO, 2009; Sax et al., 2007; Allegranzi and Pittet, 2009) .", [["hand", "ANATOMY", 319, 323], ["healthcareassociated infections", "DISEASE", 31, 62], ["HAIs", "DISEASE", 64, 68], ["HAIs", "DISEASE", 107, 111], ["infections", "DISEASE", 395, 405], ["hand", "ORGANISM_SUBDIVISION", 319, 323], ["patient", "ORGANISM", 440, 447], ["people", "SPECIES", 147, 153], ["patient", "SPECIES", 440, 447], ["healthcareassociated infections (HAIs)", "PROBLEM", 31, 69], ["all control measures", "TREATMENT", 362, 382], ["infections", "OBSERVATION", 52, 62]]], ["World Health Organization suggests that alcohol based handrub (AHR) should be used as the first choice for hand hygiene of nonsoiled hands to safer care.", [["hand", "ANATOMY", 107, 111], ["alcohol", "CHEMICAL", 40, 47], ["handrub", "CHEMICAL", 54, 61], ["alcohol", "CHEMICAL", 40, 47], ["alcohol", "SIMPLE_CHEMICAL", 40, 47], ["hand", "ORGANISM_SUBDIVISION", 107, 111], ["hands", "ORGANISM_SUBDIVISION", 133, 138]]], ["If hands are visibly dirty or when exposure to potential spore-forming organisms, they need to be washed with soap and water (Boyce and Pittet, 2002; WHO, 2009 ).", [["hands", "ORGANISM_SUBDIVISION", 3, 8], ["visibly dirty", "PROBLEM", 13, 26], ["potential spore-forming organisms", "PROBLEM", 47, 80]]], ["Despite its ease and extensive regulations on HH, studies show that compliance with HH is below the desired level among nurses (Allegranzi and Pittet, 2009; Ward et al., 2014; Azim et al., 2016) .", [["studies", "TEST", 50, 57]]], ["The reasons that prevent compliance with HH are: increased care-giving and limited time for hand-washing, hand irritation, allergy to chemicals, insufficient supplies and resources and lack of knowledge, experience and education (\u00c7elik and Ko\u00e7a\u015fli, 2008; Hynes, 2015) .", [["hand", "ANATOMY", 92, 96], ["hand", "ANATOMY", 106, 110], ["hand irritation", "DISEASE", 106, 121], ["allergy", "DISEASE", 123, 130], ["hand", "ORGANISM_SUBDIVISION", 106, 110], ["increased care", "TREATMENT", 49, 63], ["hand-washing", "TREATMENT", 92, 104], ["hand irritation", "PROBLEM", 106, 121], ["hand", "ANATOMY", 106, 110], ["irritation", "OBSERVATION", 111, 121]]], ["Compliance with HH practices among nursing students is at lower levels than expectations similar to nurses (Van De Mortel et al., 2012; Nair et al., 2014; Av\u015far et al., 2015) .", [["HH practices", "TREATMENT", 16, 28]]], ["During clinical applications, due to direct patient contact or contaminant surfaces and devices, both nursing students and their patients are facing increasing the risk of healthcare-associated infections because of lack of knowledge, skills and experience (\u00c7elik and Ko\u00e7a\u015fli, 2008; Av\u015far et al., 2015) .", [["infections", "DISEASE", 194, 204], ["patient", "ORGANISM", 44, 51], ["patients", "ORGANISM", 129, 137], ["patient", "SPECIES", 44, 51], ["patients", "SPECIES", 129, 137], ["devices", "TREATMENT", 88, 95], ["healthcare-associated infections", "PROBLEM", 172, 204]]], ["Improving the education of nursing students is an effective and sustainable strategy for increasing nurses' compliance with HH.", [["increasing nurses' compliance", "TREATMENT", 89, 118]]], ["Furthermore, it is important to prevent health care-associated infections.IntroductionWhile AHR are widely used in hospitals, studies that focus on the proper use of AHR are very limited.", [["infections", "DISEASE", 63, 73], ["associated infections", "PROBLEM", 52, 73], ["AHR", "TEST", 166, 169], ["infections", "OBSERVATION", 63, 73]]], ["The aim of this study is to evaluate the factors that influence nursing students' hand hygiene compliance, the use of effective hand-washing techniques, and proper hand-rub application in line with standards.SettingThis cross-sectional study was carried out from May 3 to June 3, 2016 with the voluntary participation of 257 first-year and fourth-year students in the department of nursing at Mersin University.", [["hand", "ANATOMY", 82, 86], ["hand", "ANATOMY", 128, 132], ["hand", "ANATOMY", 164, 168], ["hand", "ORGANISM_SUBDIVISION", 82, 86], ["this study", "TEST", 11, 21], ["effective hand-washing techniques", "TREATMENT", 118, 151], ["proper hand-rub application", "TREATMENT", 157, 184], ["This cross-sectional study", "TEST", 215, 241]]], ["The reason choosing this institution was that it was the only public university that provided nursing education in the city as well as it contains many students.", [["nursing education", "TREATMENT", 94, 111]]], ["The students are admitted to the faculty with the exam conducted by the Higher Education Institution.", [["the exam", "TEST", 46, 54]]], ["They work as intern nurses at the hospital for a final term.SettingOf a total of 305 first and fourth year students, 28 students did not want to participate to the study, 20 students were not taken to study because of some dermatologic problems on the hands, nail polish and using henna.Instrument and Data CollectionThe instrument of this study contained three sections.", [["sections", "ANATOMY", 362, 370], ["hands", "ORGANISM_SUBDIVISION", 252, 257], ["the study", "TEST", 160, 169], ["some dermatologic problems on the hands", "PROBLEM", 218, 257], ["Instrument and Data Collection", "TEST", 287, 317], ["this study", "TEST", 335, 345], ["hands", "ANATOMY", 252, 257], ["nail", "ANATOMY", 259, 263]]], ["At the first section, the research data were collected using a questionnaire form that included personal data such as age, gender and class, as well as questions about frequently used HH methods, favorite gels or soaps, frequency and duration of washing hands, frequency of contact with patients, frequency of hand-washing in the clinic, washing hands when using gloves and dermatological problems on the hands.", [["hand", "ANATOMY", 310, 314], ["patients", "ORGANISM", 287, 295], ["hand", "ORGANISM_SUBDIVISION", 310, 314], ["hands", "ORGANISM_SUBDIVISION", 405, 410], ["patients", "SPECIES", 287, 295], ["HH methods", "TREATMENT", 184, 194], ["gloves", "TREATMENT", 363, 369], ["dermatological problems on the hands", "PROBLEM", 374, 410], ["hands", "ANATOMY", 405, 410]]], ["This form was prepared by the researchers according to literature (Av\u015far et al., 2015; Cole, 2009; WHO, 2009; Barrett and Randle, 2008) and filled out by students in the classroom in 10 min.Instrument and Data CollectionThe second and third sections of this research were carried out in the skills laboratory of the university.", [["Instrument and Data Collection", "TEST", 190, 220]]], ["Soap and paper towels were provided in the laboratories prior to the experiment.", [["Soap and paper towels", "TREATMENT", 0, 21]]], ["One drop of phosphorus (disodium distyylbiphenyl disulfoned, anios) was added to 75 ml hydroalcoholic solution (HAS) (80% ethyl alcohol, 10% prppan-2 ol and gliserin, deiyonize water) to prepare the AHR solution.", [["phosphorus", "CHEMICAL", 12, 22], ["disodium distyylbiphenyl disulfoned", "CHEMICAL", 24, 59], ["anios", "CHEMICAL", 61, 66], ["ethyl alcohol", "CHEMICAL", 122, 135], ["prppan-2 ol", "CHEMICAL", 141, 152], ["gliserin", "CHEMICAL", 157, 165], ["phosphorus", "CHEMICAL", 12, 22], ["disodium distyylbiphenyl disulfoned", "CHEMICAL", 24, 59], ["anios", "CHEMICAL", 61, 66], ["ethyl alcohol", "CHEMICAL", 122, 135], ["prppan-2 ol", "CHEMICAL", 141, 152], ["gliserin", "CHEMICAL", 157, 165], ["deiyonize", "CHEMICAL", 167, 176], ["phosphorus", "SIMPLE_CHEMICAL", 12, 22], ["disodium distyylbiphenyl disulfoned", "SIMPLE_CHEMICAL", 24, 59], ["anios", "SIMPLE_CHEMICAL", 61, 66], ["ethyl alcohol", "SIMPLE_CHEMICAL", 122, 135], ["prppan-2 ol", "SIMPLE_CHEMICAL", 141, 152], ["gliserin", "SIMPLE_CHEMICAL", 157, 165], ["deiyonize water", "SIMPLE_CHEMICAL", 167, 182], ["phosphorus (disodium distyylbiphenyl disulfoned", "TREATMENT", 12, 59], ["gliserin, deiyonize water)", "TREATMENT", 157, 183], ["the AHR solution", "TREATMENT", 195, 211], ["drop", "OBSERVATION_MODIFIER", 4, 8]]], ["Each student was asked to cover her hand with HAS as done in clinics.", [["hand", "ANATOMY", 36, 40], ["hand", "ORGANISM_SUBDIVISION", 36, 40]]], ["The students were not informed about the amount of solution to be used or the duration of its application.", [["solution", "TREATMENT", 51, 59], ["its application", "TREATMENT", 90, 105]]], ["Using this code, dorsal and palmar images of their right and left hands were photographed twice with a digital camera.", [["dorsal", "ANATOMY", 17, 23], ["palmar", "ANATOMY", 28, 34], ["right", "ANATOMY", 51, 56], ["left hands", "ANATOMY", 61, 71], ["dorsal", "MULTI-TISSUE_STRUCTURE", 17, 23], ["dorsal and palmar images", "TEST", 17, 41], ["a digital camera", "TEST", 101, 117], ["dorsal", "ANATOMY_MODIFIER", 17, 23], ["palmar", "ANATOMY", 28, 34], ["right", "ANATOMY_MODIFIER", 51, 56], ["left hands", "ANATOMY", 61, 71]]], ["An 50 \u00d7 40 cm lightproof black box with room for hands and taking photographs was used to diminish exposure to UV and to ensure better imaging of the fluorescent material.", [["An 50 \u00d7 40 cm lightproof black box", "TREATMENT", 0, 34], ["UV", "TREATMENT", 111, 113], ["hands", "ANATOMY", 49, 54]]], ["In addition, the room was made dim with curtains.Instrument and Data CollectionAt the third section of the study, the students were asked to wash their hands according to the antiseptic technique used in the clinic.", [["Instrument and Data Collection", "TEST", 49, 79], ["the study", "TEST", 103, 112], ["the antiseptic technique", "TREATMENT", 171, 195]]], ["After the photo-shoot, the students were informed what should be careful about within the stages of the technique of hand-washing by showing them the fluorescent remains on their hands.", [["hand", "ANATOMY", 117, 121], ["hand", "ORGANISM_SUBDIVISION", 117, 121], ["hands", "ORGANISM_SUBDIVISION", 179, 184]]], ["The participants were asked not to talk to other students who had not yet participated in the research in order to avoid any effect on them.", [["participants", "SPECIES", 4, 16]]], ["All the stages of this study were carried out by the researchers.Instrument and Data CollectionAlcohol-based hand-rub use and the practice of hand-washing were evaluated with the surface area covered by fluorescent material.", [["hand", "ANATOMY", 142, 146], ["surface area", "ANATOMY", 179, 191], ["this study", "TEST", 18, 28], ["CollectionAlcohol", "TEST", 85, 102], ["hand-washing", "TREATMENT", 142, 154], ["the surface area", "TREATMENT", 175, 191], ["fluorescent material", "OBSERVATION", 203, 223]]], ["The UV photographs of students' hands were converted JPEG format for analysis.", [["hands", "ORGANISM_SUBDIVISION", 32, 37], ["The UV photographs", "TEST", 0, 18], ["JPEG format", "TEST", 53, 64], ["analysis", "TEST", 69, 77]]], ["Measurements taken for each image were made according to blue areas and densities.", [["Measurements", "TEST", 0, 12], ["each image", "TEST", 23, 33], ["densities", "OBSERVATION", 72, 81]]], ["The study followed these stages to calculate the entire hand surface: distal phalanges (1a, 2a, 3a, 4a, 5a), intermediate-proximal phalanges (1b, 2b, 3b, 4b, 5b) and the areas where the metacarpal (metacarpal I area-close to fingers)carpal bones, (metacarpal II area -far from the fingers) are located were measured by a tape measure to identify the palmar and dorsal surface of the right and left hands (Fig. 1 ).", [["hand surface", "ANATOMY", 56, 68], ["distal phalanges", "ANATOMY", 70, 86], ["metacarpal", "ANATOMY", 186, 196], ["fingers", "ANATOMY", 225, 232], ["carpal bones", "ANATOMY", 233, 245], ["metacarpal II area", "ANATOMY", 248, 266], ["fingers", "ANATOMY", 281, 288], ["palmar", "ANATOMY", 350, 356], ["dorsal surface", "ANATOMY", 361, 375], ["right", "ANATOMY", 383, 388], ["left hands", "ANATOMY", 393, 403], ["hand", "ORGANISM_SUBDIVISION", 56, 60], ["metacarpal", "MULTI-TISSUE_STRUCTURE", 186, 196], ["fingers", "ORGANISM_SUBDIVISION", 225, 232], ["carpal bones", "MULTI-TISSUE_STRUCTURE", 233, 245], ["fingers", "ORGANISM_SUBDIVISION", 281, 288], ["palmar", "TISSUE", 350, 356], ["dorsal surface", "MULTI-TISSUE_STRUCTURE", 361, 375], ["The study", "TEST", 0, 9], ["a tape", "TEST", 319, 325], ["distal", "ANATOMY_MODIFIER", 70, 76], ["phalanges", "ANATOMY", 77, 86], ["proximal", "ANATOMY_MODIFIER", 122, 130], ["phalanges", "ANATOMY", 131, 140], ["areas", "ANATOMY_MODIFIER", 170, 175], ["metacarpal", "ANATOMY", 186, 196], ["metacarpal", "ANATOMY", 198, 208], ["fingers", "ANATOMY", 225, 232], ["carpal bones", "ANATOMY", 233, 245], ["metacarpal", "ANATOMY", 248, 258], ["fingers", "ANATOMY", 281, 288], ["palmar", "ANATOMY", 350, 356], ["dorsal", "ANATOMY_MODIFIER", 361, 367], ["surface", "ANATOMY_MODIFIER", 368, 375], ["right", "ANATOMY_MODIFIER", 383, 388], ["left", "ANATOMY_MODIFIER", 393, 397], ["hands", "ANATOMY", 398, 403]]], ["The surface of each hand was calculated in terms of cm 2 , and these measurements were later turned into percentages.", [["surface", "ANATOMY", 4, 11], ["hand", "ANATOMY", 20, 24], ["surface", "CELLULAR_COMPONENT", 4, 11], ["these measurements", "TEST", 63, 81], ["surface", "ANATOMY_MODIFIER", 4, 11]]], ["The dorsal/palmar surface and their percentages were: thumb, 22 cm 2 14.5%; 2nd, 3rd, 4th fingers, 40.5 cm 2 , 27%; little finger, 11 cm 2 , 7.5%, metacarpal area near fingers, 36 cm 2 , 24%; metacarpal and carpal area away from the fingers, 40.5 cm 2 , 27%; and the total area, 150 cm 2 , 100%.", [["dorsal/palmar surface", "ANATOMY", 4, 25], ["thumb", "ANATOMY", 54, 59], ["finger", "ANATOMY", 123, 129], ["metacarpal area", "ANATOMY", 147, 162], ["fingers", "ANATOMY", 168, 175], ["metacarpal", "ANATOMY", 192, 202], ["carpal area", "ANATOMY", 207, 218], ["fingers", "ANATOMY", 233, 240], ["area", "ANATOMY", 273, 277], ["palmar surface", "MULTI-TISSUE_STRUCTURE", 11, 25], ["metacarpal", "MULTI-TISSUE_STRUCTURE", 192, 202], ["fingers", "ORGANISM_SUBDIVISION", 233, 240], ["The dorsal/palmar surface", "TEST", 0, 25], ["thumb", "TEST", 54, 59], ["little finger", "TEST", 116, 129], ["metacarpal area near fingers", "TEST", 147, 175], ["the total area", "TEST", 263, 277], ["dorsal", "ANATOMY_MODIFIER", 4, 10], ["palmar", "ANATOMY", 11, 17], ["surface", "ANATOMY_MODIFIER", 18, 25], ["thumb", "ANATOMY", 54, 59], ["22 cm", "OBSERVATION_MODIFIER", 61, 66], ["4th fingers", "ANATOMY", 86, 97], ["40.5 cm", "OBSERVATION_MODIFIER", 99, 106], ["finger", "ANATOMY", 123, 129], ["11 cm", "OBSERVATION_MODIFIER", 131, 136], ["metacarpal", "ANATOMY", 147, 157], ["fingers", "ANATOMY", 168, 175], ["36 cm", "OBSERVATION_MODIFIER", 177, 182], ["metacarpal", "ANATOMY", 192, 202], ["carpal", "ANATOMY", 207, 213], ["area", "ANATOMY_MODIFIER", 214, 218], ["fingers", "ANATOMY", 233, 240], ["40.5 cm", "OBSERVATION_MODIFIER", 242, 249], ["total", "OBSERVATION_MODIFIER", 267, 272], ["150 cm", "OBSERVATION_MODIFIER", 279, 285]]], ["The entire dorsal and palmar surfaces of right and left hands were evaluated out of 4.000 points (Fig. 1) .", [["dorsal", "ANATOMY", 11, 17], ["palmar surfaces", "ANATOMY", 22, 37], ["right", "ANATOMY", 41, 46], ["left hands", "ANATOMY", 51, 61], ["dorsal", "MULTI-TISSUE_STRUCTURE", 11, 17], ["palmar surfaces", "MULTI-TISSUE_STRUCTURE", 22, 37], ["entire", "ANATOMY_MODIFIER", 4, 10], ["dorsal", "ANATOMY_MODIFIER", 11, 17], ["palmar", "ANATOMY", 22, 28], ["surfaces", "ANATOMY_MODIFIER", 29, 37], ["right", "ANATOMY_MODIFIER", 41, 46], ["left hands", "ANATOMY", 51, 61]]], ["Considering that the percentage distribution of individuals with different hand sizes may vary, measurements were carried out for two men and two women with different hand sizes.", [["hand", "ANATOMY", 75, 79], ["hand", "ANATOMY", 167, 171], ["hand", "ORGANISM_SUBDIVISION", 75, 79], ["men", "ORGANISM", 134, 137], ["women", "ORGANISM", 146, 151], ["hand", "ORGANISM_SUBDIVISION", 167, 171], ["men", "SPECIES", 134, 137], ["women", "SPECIES", 146, 151], ["percentage", "OBSERVATION_MODIFIER", 21, 31], ["distribution", "OBSERVATION_MODIFIER", 32, 44], ["sizes", "OBSERVATION_MODIFIER", 80, 85], ["sizes", "OBSERVATION_MODIFIER", 172, 177]]], ["Since the difference was only 1%, the same percentage was used for all participants.", [["participants", "SPECIES", 71, 83]]], ["If the total percentage of all hand surfaces covered with fluorescence was below 75%, disinfectant use was deemed insufficient.", [["hand", "ANATOMY", 31, 35], ["fluorescence", "TEST", 58, 70], ["total", "OBSERVATION_MODIFIER", 7, 12], ["percentage", "OBSERVATION_MODIFIER", 13, 23]]], ["For this reason, hand-washing was not calculated for these individuals.Statistical AnalysisThe data were analyzed using SPSS statistical package program (version 21, New York, USA).", [["hand", "ANATOMY", 17, 21], ["hand-washing", "TREATMENT", 17, 29], ["Statistical Analysis", "TEST", 71, 91], ["The data", "TEST", 91, 99]]], ["Descriptive statistical analyzes (Mean standard deviation, frequency, percentage) were used in the evaluation of the data; Shapiro-Wilk test was used while evaluating normal distribution; independent-samples t-test, ANOVA, Mann-Whitney U and Kruskal Wallis H test were used for normally and non-normally distributed variables, respectively, p < 0.05 was accepted as statistically significant.Ethical ConsiderationsApproval was obtained from the Mersin University Clinical Research Ethical Committee (08.04.2016 and 2016/134) and the institution.", [["the evaluation", "TEST", 95, 109], ["the data", "TEST", 113, 121], ["Shapiro-Wilk test", "TEST", 123, 140], ["ANOVA", "TEST", 216, 221], ["Kruskal Wallis H test", "TEST", 242, 263]]], ["At the beginning of the study, intervention procedure and details were explained to the students and a written consent was obtained from all of them.ResultsThe average age of the 257 students participated in the research was 20.54 \u00b1 1.87 years, 44.7% of them were females and 77.1% of them were first-year students.", [["the study", "TEST", 20, 29], ["intervention procedure", "TREATMENT", 31, 53]]], ["Of the students, 23.3% said that they made direct contact with patients 1 to 5 times a day while this number was 6 to 10 times for 38.9%, 11 to 15 times for 14.8%, and > 15 times for 23%.ResultsAn analysis of the frequency of applying HH in the clinic indicated that 14.8% of the students applied it 1 to 5 times a day, and this number was 6 to 10 times for 32.3%, 11 to 15 times for 23.3%, and > 15 times for 29.6%.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71]]], ["The percentage of students who said that they washed their hands to maintain HH was 90.3%, while 8.2% of the students noted that they preferred using antiseptic solution, and 1.6% chose to use gloves.", [["HH", "TEST", 77, 79], ["antiseptic solution", "TREATMENT", 150, 169], ["gloves", "TREATMENT", 193, 199]]], ["This rate was 21 to 40 s for 52.9%, 40 to seconds for 19.5%, and longer than 60 s for 7.4%.", [["This rate", "TEST", 0, 9]]], ["Among all students, 3.5% noted that they had dermatological problems on their hands.ResultsConcerning the usage of gloves and hand-washing, 66.9% expressed that they washed their hands before and after wearing gloves; 28% said that they washed their hands only after taking off their gloves, 3.9% did not wash their hands at all; and 1.2% highlighted that they wash their hands before wearing gloves.", [["hand", "ANATOMY", 126, 130], ["hands", "ORGANISM_SUBDIVISION", 78, 83], ["dermatological problems on their hands", "PROBLEM", 45, 83], ["gloves and hand-washing", "TREATMENT", 115, 138], ["gloves", "TREATMENT", 210, 216], ["hand", "ANATOMY", 126, 130]]], ["The students who stated that they always applied hand-washing procedures constituted 85.6% of the participants, and the percentage of those who did not regularly comply with hand-washing procedures due to limited time was 10.9%.", [["hand", "ANATOMY", 49, 53], ["hand", "ANATOMY", 174, 178], ["participants", "SPECIES", 98, 110], ["hand-washing procedures", "TREATMENT", 49, 72], ["hand-washing procedures", "TREATMENT", 174, 197]]], ["Of the students, 76.8% thought that sufficient supplies and resources (e.g., washrooms) were provided for hand-washing.", [["hand", "ANATOMY", 106, 110], ["washrooms)", "TREATMENT", 77, 87], ["hand-washing", "TREATMENT", 106, 118]]], ["In addition, 24.9% of the students thought that their hands could dry and their skin could be irritated if they applied hand-washing procedures regularly and 20.6% claimed that washing hands after each patient contact was unpractical.ResultsThe analysis of hand antiseptic use found that the percentage of covering both hands with alcohol hand rubs was 82%.", [["skin", "ANATOMY", 80, 84], ["hand", "ANATOMY", 120, 124], ["hand", "ANATOMY", 257, 261], ["hand", "ANATOMY", 339, 343], ["alcohol", "CHEMICAL", 331, 338], ["alcohol", "CHEMICAL", 331, 338], ["hands", "ORGANISM_SUBDIVISION", 54, 59], ["skin", "ORGAN", 80, 84], ["patient", "ORGANISM", 202, 209], ["hand", "ORGANISM_SUBDIVISION", 257, 261], ["hands", "ORGANISM_SUBDIVISION", 320, 325], ["patient", "SPECIES", 202, 209], ["hand antiseptic", "TREATMENT", 257, 272], ["hands", "ANATOMY", 54, 59], ["skin", "ANATOMY", 80, 84]]], ["The lowest percentages were found on the metacarpal II areas, which are far from the fingers.", [["metacarpal II areas", "ANATOMY", 41, 60], ["fingers", "ORGANISM_SUBDIVISION", 85, 92], ["The lowest percentages", "TEST", 0, 22], ["lowest", "OBSERVATION_MODIFIER", 4, 10], ["percentages", "OBSERVATION_MODIFIER", 11, 22], ["metacarpal", "ANATOMY", 41, 51], ["fingers", "ANATOMY", 85, 92]]], ["The percentages of covering the dorsal and palmar surfaces of right and left hands with alcohol-based hand rubs were similar at 74% and 89%, respectively (Fig. 2) .", [["dorsal", "ANATOMY", 32, 38], ["palmar surfaces", "ANATOMY", 43, 58], ["right", "ANATOMY", 62, 67], ["left hands", "ANATOMY", 72, 82], ["hand", "ANATOMY", 102, 106], ["alcohol", "CHEMICAL", 88, 95], ["alcohol", "CHEMICAL", 88, 95], ["dorsal", "MULTI-TISSUE_STRUCTURE", 32, 38], ["palmar surfaces", "MULTI-TISSUE_STRUCTURE", 43, 58], ["alcohol", "SIMPLE_CHEMICAL", 88, 95], ["percentages", "OBSERVATION_MODIFIER", 4, 15], ["dorsal", "ANATOMY_MODIFIER", 32, 38], ["palmar", "ANATOMY_MODIFIER", 43, 49], ["surfaces", "ANATOMY_MODIFIER", 50, 58], ["right", "ANATOMY_MODIFIER", 62, 67], ["left", "ANATOMY_MODIFIER", 72, 76], ["hands", "ANATOMY", 77, 82], ["alcohol", "OBSERVATION", 88, 95], ["rubs", "OBSERVATION", 107, 111]]], ["The median of AHR use points for the two hands was 3.380 (2960-4000), while it was found 1.710 (1491-1849) for the right hand and 1.695 (1452-1865) for the left.", [["right hand", "ANATOMY", 115, 125], ["left", "ANATOMY", 156, 160], ["median", "OBSERVATION_MODIFIER", 4, 10], ["right", "ANATOMY_MODIFIER", 115, 120], ["left", "ANATOMY_MODIFIER", 156, 160]]], ["No difference was found between right and left hands in terms of their AHR points (p > 0.05).", [["right", "ANATOMY", 32, 37], ["left hands", "ANATOMY", 42, 52], ["right", "ORGANISM_SUBDIVISION", 32, 37], ["difference", "OBSERVATION", 3, 13], ["right", "ANATOMY_MODIFIER", 32, 37], ["left", "ANATOMY_MODIFIER", 42, 46], ["hands", "ANATOMY", 47, 52]]], ["The median of disinfectant use points for the dorsal surfaces of hands was 1.616 (1222-1805) and 1.830 (1688-1945) for palmar surfaces.", [["dorsal surfaces", "ANATOMY", 46, 61], ["palmar surfaces", "ANATOMY", 119, 134], ["dorsal surfaces", "MULTI-TISSUE_STRUCTURE", 46, 61], ["median", "OBSERVATION_MODIFIER", 4, 10], ["disinfectant", "OBSERVATION", 14, 26], ["dorsal", "ANATOMY_MODIFIER", 46, 52], ["surfaces", "ANATOMY_MODIFIER", 53, 61], ["hands", "ANATOMY", 65, 70], ["palmar", "ANATOMY", 119, 125]]], ["There was a significant difference between the dorsal and palmar surfaces in terms of their AHR use points (p < 0.01) ( Table 1 ).", [["dorsal", "ANATOMY", 47, 53], ["palmar surfaces", "ANATOMY", 58, 73], ["dorsal", "TISSUE", 47, 53], ["palmar surfaces", "TISSUE", 58, 73], ["a significant difference between the dorsal and palmar surfaces", "PROBLEM", 10, 73], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34], ["dorsal", "ANATOMY_MODIFIER", 47, 53], ["palmar", "ANATOMY", 58, 64], ["surfaces", "ANATOMY_MODIFIER", 65, 73]]], ["The practice of hand-washing was not analyzed for 70 people due to their insufficient AHR use (the surface covered with AHR was below 75%).ResultsThe analysis of effectiveness of hand-washing found that the percentage of fluorescent traces after hand washing was 55%.", [["hand", "ANATOMY", 16, 20], ["surface", "ANATOMY", 99, 106], ["hand", "ANATOMY", 179, 183], ["hand", "ANATOMY", 246, 250], ["hand", "ORGANISM_SUBDIVISION", 16, 20], ["people", "ORGANISM", 53, 59], ["surface", "CELLULAR_COMPONENT", 99, 106], ["hand", "ORGANISM_SUBDIVISION", 179, 183], ["people", "SPECIES", 53, 59], ["hand-washing", "TREATMENT", 16, 28], ["AHR", "TEST", 120, 123], ["The analysis", "TEST", 146, 158], ["hand-washing", "TREATMENT", 179, 191], ["hand washing", "TREATMENT", 246, 258]]], ["The highest percentages were found on the metacarpal I areas, which are close to the fingers.", [["metacarpal I areas", "ANATOMY", 42, 60], ["fingers", "ORGANISM_SUBDIVISION", 85, 92], ["The highest percentages", "TEST", 0, 23], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["percentages", "OBSERVATION_MODIFIER", 12, 23], ["metacarpal", "ANATOMY", 42, 52], ["fingers", "ANATOMY", 85, 92]]], ["Hand-washing effectiveness decreases as percentages increase.", [["Hand-washing effectiveness", "TREATMENT", 0, 26]]], ["The percentages of hand washing points the dorsal and palmar surfaces of right and left hands were different, right hand points were higher than the left hands' (Fig. 2) .", [["hand", "ANATOMY", 19, 23], ["dorsal", "ANATOMY", 43, 49], ["palmar surfaces", "ANATOMY", 54, 69], ["right", "ANATOMY", 73, 78], ["left hands", "ANATOMY", 83, 93], ["right hand", "ANATOMY", 110, 120], ["left hands", "ANATOMY", 149, 159], ["hand", "ORGANISM_SUBDIVISION", 19, 23], ["dorsal", "MULTI-TISSUE_STRUCTURE", 43, 49], ["palmar surfaces", "MULTI-TISSUE_STRUCTURE", 54, 69], ["hands", "ORGANISM_SUBDIVISION", 88, 93], ["percentages", "OBSERVATION_MODIFIER", 4, 15], ["hand", "ANATOMY", 19, 23], ["washing", "OBSERVATION", 24, 31], ["dorsal", "ANATOMY_MODIFIER", 43, 49], ["palmar", "ANATOMY", 54, 60], ["surfaces", "ANATOMY_MODIFIER", 61, 69], ["right", "ANATOMY_MODIFIER", 73, 78], ["left", "ANATOMY_MODIFIER", 83, 87], ["hands", "ANATOMY", 88, 93], ["right", "ANATOMY_MODIFIER", 110, 115], ["higher", "OBSERVATION_MODIFIER", 133, 139], ["left hands", "ANATOMY", 149, 159]]], ["Evaluating whether there is a difference between right and left hands in terms of hand washing effectiveness, the median of points for fluorescent remains on hands after washing both hands was found 2.205 (1780-2625), while it was 1181 (955-1384) for the right hand and 1050 (798-1328) for the left (p < 0.01).", [["right", "ANATOMY", 49, 54], ["left hands", "ANATOMY", 59, 69], ["hand", "ANATOMY", 82, 86], ["right hand", "ANATOMY", 255, 265], ["left", "ANATOMY", 294, 298], ["right", "ORGANISM_SUBDIVISION", 49, 54], ["hand", "ORGANISM_SUBDIVISION", 82, 86], ["hand", "ORGAN", 261, 265], ["a difference between right and left hands", "PROBLEM", 28, 69], ["hand washing effectiveness", "TREATMENT", 82, 108], ["washing both hands", "TEST", 170, 188], ["right", "ANATOMY_MODIFIER", 49, 54], ["left", "ANATOMY_MODIFIER", 59, 63], ["hands", "ANATOMY", 64, 69], ["right", "ANATOMY_MODIFIER", 255, 260], ["left", "ANATOMY_MODIFIER", 294, 298]]], ["There was a difference between the right and left hand hand-washing points ( Table 2 ).", [["right", "ANATOMY", 35, 40], ["left hand hand", "ANATOMY", 45, 59], ["right", "ANATOMY_MODIFIER", 35, 40], ["left", "ANATOMY_MODIFIER", 45, 49], ["hand hand", "ANATOMY", 50, 59]]], ["The median of points for washing the dorsal surfaces of the hands was 890 (550-1200) and 1.355 (1010-1595) for palmar surfaces.", [["dorsal surfaces", "ANATOMY", 37, 52], ["palmar surfaces", "ANATOMY", 111, 126], ["dorsal surfaces", "MULTI-TISSUE_STRUCTURE", 37, 52], ["dorsal", "ANATOMY_MODIFIER", 37, 43], ["surfaces", "ANATOMY_MODIFIER", 44, 52], ["hands", "ANATOMY", 60, 65], ["palmar", "ANATOMY", 111, 117]]], ["There was a difference between the dorsal and palmar surfaces hand-washing points (p < 0.01) ( Table 2) .ResultsIt was found that the fourth-year male students' AHR use was worse, while effectiveness of their hand-washing was better than the other groups (p < 0.05).", [["dorsal", "ANATOMY", 35, 41], ["palmar surfaces hand", "ANATOMY", 46, 66], ["hand", "ANATOMY", 209, 213], ["dorsal", "ORGANISM_SUBDIVISION", 35, 41], ["hand", "ORGANISM_SUBDIVISION", 209, 213], ["difference", "OBSERVATION_MODIFIER", 12, 22], ["dorsal", "ANATOMY_MODIFIER", 35, 41], ["palmar", "ANATOMY", 46, 52], ["surfaces", "ANATOMY_MODIFIER", 53, 61]]], ["There was no difference between the use of AHR and the practice of hand-washing by frequency of patient contact (p > 0.05) ( Table 3) .DiscussionAlthough observation is considered the golden standard in the evaluation of hand-washing, it is also a time-consuming and expensive method (Ward et al., 2014) .", [["hand", "ANATOMY", 67, 71], ["hand", "ANATOMY", 221, 225], ["hand", "ORGANISM_SUBDIVISION", 67, 71], ["patient", "ORGANISM", 96, 103], ["hand", "ORGANISM_SUBDIVISION", 221, 225], ["patient", "SPECIES", 96, 103], ["AHR", "TREATMENT", 43, 46], ["the evaluation", "TEST", 203, 217], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["The proper use of AHR can be analyzed by monitoring the micro-organismic colonization of hands (The Joint Commission, 2009).", [["AHR", "TREATMENT", 18, 21], ["the micro-organismic colonization of hands", "PROBLEM", 52, 94], ["hands", "ANATOMY", 89, 94], ["Joint", "ANATOMY", 100, 105]]], ["Unlike these methods, this study used fluorescent material to evaluate hand-washing (Haas and Larson, 2007) .", [["hand", "ANATOMY", 71, 75], ["this study", "TEST", 22, 32], ["fluorescent material", "TEST", 38, 58]]], ["This research is significant because it evaluates both the proper use of AHR and effective hand washing techniques.DiscussionWhile there is no observational research analyzing nursing students' compliance with hand-washing procedures, the scholarly literature claims that nursing students 'compliance with HH is high based on nursing students' statements (Snow et al., 2006; Cole, 2009) .", [["hand", "ANATOMY", 91, 95], ["hand", "ANATOMY", 210, 214], ["AHR", "TREATMENT", 73, 76], ["effective hand washing techniques", "TREATMENT", 81, 114], ["hand-washing procedures", "TREATMENT", 210, 233], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["no", "UNCERTAINTY", 140, 142]]], ["This research shows that despite such statements effective hand-washing actually remains at low levels.", [["hand", "ANATOMY", 59, 63], ["hand", "ORGANISM_SUBDIVISION", 59, 63]]], ["Like the scholarly literature, this research found that the duration of hand-washing is below the standards for a great majority of the students (Av\u015far et al., 2015) .", [["hand", "ANATOMY", 72, 76], ["hand", "ORGANISM_SUBDIVISION", 72, 76]]], ["Insufficient resources for handwashing and students' belief in the probable dermatological problems to result from frequent hand-washing may be seen as potential obstacles to the transformation of education into behavioral change.DiscussionThe findings of this research indicate that approximately only one out of ten students preferred using alcohol hand rubs to ensure HH and one out of every four students used AHR at a significantly insufficient level.", [["hand", "ANATOMY", 124, 128], ["hand", "ANATOMY", 351, 355], ["alcohol", "CHEMICAL", 343, 350], ["alcohol", "CHEMICAL", 343, 350], ["dermatological problems", "PROBLEM", 76, 99], ["frequent hand-washing", "TREATMENT", 115, 136], ["AHR", "TREATMENT", 414, 417]]], ["Like other studies, these findings are important because students can be a serious source of infections in hospitals (\u00c7elik and Ko\u00e7a\u015fli, 2008; Van De Mortel et al., 2012; Kingston et al., 2017) .", [["infections", "DISEASE", 93, 103], ["other studies", "TEST", 5, 18], ["infections", "PROBLEM", 93, 103], ["infections", "OBSERVATION", 93, 103]]], ["It has been reported that AHR use is more effective than washing hands with water and soap (Boyce and Pittet, 2002; Picheansathian, 2004) .", [["AHR", "CHEMICAL", 26, 29]]], ["Voss and Widmer's study demonstrates that standard practice of washing hands with water and soap in 100% compliance with HH takes 56 min (Vos and Widmer, 1997) .", [["hands", "ORGANISM_SUBDIVISION", 71, 76], ["Widmer's study", "TEST", 9, 23], ["washing hands", "TREATMENT", 63, 76], ["water", "TREATMENT", 82, 87], ["soap", "TREATMENT", 92, 96]]], ["If the same practice is carried out with hand-rub, the duration falls to 18 min.", [["hand", "ANATOMY", 41, 45], ["hand", "ORGANISM_SUBDIVISION", 41, 45]]], ["Disseminating alcohol hand rubs to nursing students who have high frequencies and durations of contact with patients in clinical practices is an appropriate approach to ensuring effective time management in health care.DiscussionAlthough using gloves reduces the possibility of carrying microorganisms on the hands, it cannot substitute for HH.", [["hand", "ANATOMY", 22, 26], ["alcohol", "CHEMICAL", 14, 21], ["alcohol", "CHEMICAL", 14, 21], ["patients", "ORGANISM", 108, 116], ["hands", "ORGANISM_SUBDIVISION", 309, 314], ["patients", "SPECIES", 108, 116], ["gloves", "TREATMENT", 244, 250], ["carrying microorganisms on the hands", "PROBLEM", 278, 314], ["HH", "PROBLEM", 341, 343]]], ["Fuller et al. conducted an observational study that claims using gloves significantly decreases HH practices (Fuller et al., 2011) .", [["an observational study", "TEST", 24, 46], ["gloves", "TREATMENT", 65, 71]]], ["Like previous studies, our research showed that one of every 20 students found washing hands unnecessary when using gloves (Amin et al., 2013; Ratcliffe and Smith, 2014) .", [["previous studies", "TEST", 5, 21], ["our research", "TEST", 23, 35]]], ["Any training for developing hand-washing behavior relies on the adoption of this behavior.", [["hand", "ANATOMY", 28, 32], ["hand", "ORGANISM_SUBDIVISION", 28, 32], ["Any training", "TREATMENT", 0, 12]]], ["Like the scholarly literature, this research found that one of the factors that hinder HH compliance is E. \u00d6nc\u00fc et al. Nurse Education Today 65 (2018) 218-224 the belief that washing hands regularly will dry and irritate hands (Boyce and Pittet, 2002; Van De Mortel et al., 2012) .", [["hands", "ORGANISM_SUBDIVISION", 183, 188], ["hands", "ORGANISM_SUBDIVISION", 221, 226], ["hands", "ANATOMY", 221, 226]]], ["One way to overcome this bias may be to explain students that HAS is less damaging when used by adding glycerol and similar emollients and should be preferred when there is no visible dirt on hands (Picheansathian, 2004) .", [["HAS", "DISEASE", 62, 65], ["glycerol", "CHEMICAL", 103, 111], ["glycerol", "CHEMICAL", 103, 111], ["glycerol", "SIMPLE_CHEMICAL", 103, 111], ["glycerol", "TREATMENT", 103, 111], ["hands", "ANATOMY", 192, 197]]], ["Showing the students' hand surfaces covered a* = distal phalanges; b** = Intermadiate-proxismal phalanges. with fluorescent traces and informing them about micro organismic colonization on surfaces that are not covered with fluorescent remains could be an effective education tool for overcoming the deficiencies in HAS and developing a positive attitude towards HH (Picheansathian, 2004; \u0160kodov\u00e1 et al., 2015) .", [["hand", "ANATOMY", 22, 26], ["hand", "ORGANISM_SUBDIVISION", 22, 26], ["b**", "TEST", 67, 70], ["fluorescent traces", "TEST", 112, 130], ["micro organismic colonization", "PROBLEM", 156, 185], ["the deficiencies", "PROBLEM", 296, 312], ["distal", "ANATOMY_MODIFIER", 49, 55], ["phalanges", "ANATOMY", 56, 65], ["proxismal phalanges", "ANATOMY", 86, 105]]], ["We think that insufficient use of AHR as well as low use effectiveness may be related to a problem with the amount of AHR used by students.", [["AHR", "TREATMENT", 34, 37]]], ["It has been reported that AHR use in HH is influenced by characteristics such as the type of solution, duration of contact and the amount used (Kampf et al., 2008; Zingg et al., 2016) .", [["HH", "DISEASE", 37, 39]]], ["In our research, the students used AHR-just like in the clinic-in the amounts they chose for themselves.", [["AHR", "TEST", 35, 38]]], ["The WHO (2009) describes standard hand-washing without identifying any particular amount.", [["hand", "ANATOMY", 34, 38], ["standard hand-washing", "TREATMENT", 25, 46]]], ["It suggests that alcohol-based hand scrub should be used to cover the entire hand surface, and that the hands should be scrubbed for 20-30 s.", [["hand", "ANATOMY", 31, 35], ["hand surface", "ANATOMY", 77, 89], ["alcohol", "CHEMICAL", 17, 24], ["alcohol", "CHEMICAL", 17, 24], ["alcohol", "SIMPLE_CHEMICAL", 17, 24], ["hand", "ORGANISM_SUBDIVISION", 77, 81], ["hands", "ORGANISM_SUBDIVISION", 104, 109], ["hand scrub", "TREATMENT", 31, 41], ["hands", "ANATOMY", 104, 109]]], ["The WHO recommends washing hands according to standard procedures with water and soap for 40-60 s when there is visible dirt on hands.", [["hands", "ORGANISM_SUBDIVISION", 128, 133], ["washing hands", "TREATMENT", 19, 32], ["standard procedures", "TREATMENT", 46, 65], ["water", "TREATMENT", 71, 76], ["soap", "TREATMENT", 81, 85], ["hands", "ANATOMY", 128, 133]]], ["Although the European Centre for Disease Prevention and Control suggests 30 s of hand-washing, there are studies showing the insufficiency of this duration for HH (Kampf et al., 2008; Zingg et al., 2016) .Discussion\u0160kodov\u00e1 et al. used a technique similar to ours to evaluate the effectiveness of the HH practices of medical school and nursing school students (\u0160kodov\u00e1 et al., 2015) .", [["hand", "ANATOMY", 81, 85], ["Disease Prevention", "TREATMENT", 33, 51], ["hand-washing", "TREATMENT", 81, 93], ["studies", "TEST", 105, 112], ["the insufficiency", "PROBLEM", 121, 138], ["a technique", "TREATMENT", 235, 246], ["insufficiency", "OBSERVATION", 125, 138]]], ["They analyzed HH practices in five areas (palm, dorsum of the hand, interdigital area, fingers and finger tips) using a five-point scaling system from very sufficient to insufficient.", [["dorsum", "ANATOMY", 48, 54], ["hand", "ANATOMY", 62, 66], ["interdigital area", "ANATOMY", 68, 85], ["fingers", "ANATOMY", 87, 94], ["finger", "ANATOMY", 99, 105], ["palm", "ORGANISM_SUBDIVISION", 42, 46], ["dorsum", "ORGANISM_SUBDIVISION", 48, 54], ["hand", "ORGANISM_SUBDIVISION", 62, 66], ["interdigital area", "MULTI-TISSUE_STRUCTURE", 68, 85], ["fingers", "ORGANISM_SUBDIVISION", 87, 94], ["HH practices", "TREATMENT", 14, 26], ["a five-point scaling system", "TREATMENT", 118, 145], ["palm", "ANATOMY_MODIFIER", 42, 46], ["dorsum", "ANATOMY_MODIFIER", 48, 54], ["hand", "ANATOMY", 62, 66], ["interdigital area", "ANATOMY", 68, 85], ["fingers", "ANATOMY", 87, 94], ["finger tips", "ANATOMY", 99, 110]]], ["If two of the five areas were not covered with AHR, it was deemed insufficient.", [["AHR", "TREATMENT", 47, 50]]], ["In our research, if the area covered with disinfectants was below 75%, it was deemed insufficient disinfectant use.", [["disinfectants", "TREATMENT", 42, 55]]], ["The rates of AHR use were higher in our study, notwithstanding the differences between the analyses.DiscussionThe scholarly literature stresses that hand scrub technique robustly influences the antimicrobial effect (Widmer and Dangel, 2004) .", [["hand", "ANATOMY", 149, 153], ["hand", "ORGANISM_SUBDIVISION", 149, 153], ["our study", "TEST", 36, 45], ["the analyses", "TEST", 87, 99], ["hand scrub technique", "TREATMENT", 149, 169]]], ["Hautemanie're et al. found a negative relationship between covering the hands with sufficient HAS and the number of bacteria on the hands (Hautemani\u00e8re et al., 2009) .", [["negative", "OBSERVATION", 29, 37], ["hands", "ANATOMY", 72, 77], ["bacteria", "OBSERVATION", 116, 124], ["hands", "ANATOMY", 132, 137]]], ["For this reason, it is important to cover the entire hand with AHR in the appropriate way.", [["hand", "ANATOMY", 53, 57], ["hand", "ORGANISM_SUBDIVISION", 53, 57]]], ["\u0160kodov\u00e1 et al. showed that the distribution of fluorescent traces was the highest on the right and left hand palms and lowest on the thumbs.", [["right", "ANATOMY", 89, 94], ["left hand palms", "ANATOMY", 99, 114], ["thumbs", "ANATOMY", 133, 139], ["hand", "ORGANISM_SUBDIVISION", 104, 108], ["palms", "ORGANISM_SUBDIVISION", 109, 114], ["thumbs", "ORGANISM_SUBDIVISION", 133, 139], ["fluorescent traces", "TEST", 47, 65], ["distribution", "OBSERVATION_MODIFIER", 31, 43], ["fluorescent traces", "OBSERVATION", 47, 65], ["highest", "OBSERVATION_MODIFIER", 74, 81], ["right", "ANATOMY_MODIFIER", 89, 94], ["left", "ANATOMY_MODIFIER", 99, 103], ["hand palms", "ANATOMY", 104, 114], ["lowest", "OBSERVATION_MODIFIER", 119, 125], ["thumbs", "ANATOMY", 133, 139]]], ["Our research findings do not indicate any difference between right and left hands in terms of disinfectant distribution.", [["right", "ANATOMY", 61, 66], ["left hands", "ANATOMY", 71, 81], ["right", "ORGANISM_SUBDIVISION", 61, 66], ["right", "ANATOMY_MODIFIER", 61, 66], ["left", "ANATOMY_MODIFIER", 71, 75], ["hands", "ANATOMY", 76, 81], ["disinfectant distribution", "OBSERVATION", 94, 119]]], ["Like \u0160kodov\u00e1 et al. and Hautemanie're et al., palmar surfaces were covered with HAS in a more appropriate way than dorsal surfaces (Hautemani\u00e8re et al., 2009; \u0160kodov\u00e1 et al., 2015) .", [["palmar surfaces", "ANATOMY", 46, 61], ["dorsal surfaces", "ANATOMY", 115, 130], ["palmar surfaces", "TISSUE", 46, 61], ["palmar", "ANATOMY", 46, 52]]], ["Zingg et al. noted that 2 ml of AHR may be sufficient for palmar surfaces of medium and large hands, but not enough for dorsal surfaces (Kampf et al., 2008) .", [["palmar surfaces", "ANATOMY", 58, 73], ["dorsal surfaces", "ANATOMY", 120, 135], ["AHR", "PROBLEM", 32, 35], ["palmar surfaces of medium and large hands", "PROBLEM", 58, 99], ["medium", "OBSERVATION", 77, 83], ["large", "OBSERVATION_MODIFIER", 88, 93], ["hands", "ANATOMY", 94, 99]]], ["As \u0160kodov\u00e1 et al. show, our finding that men's hands were covered with less HAS may be due to their hand sizes.", [["hand", "ANATOMY", 100, 104], ["men", "ORGANISM", 41, 44], ["hands", "ORGANISM_SUBDIVISION", 47, 52], ["hand", "ORGANISM_SUBDIVISION", 100, 104], ["men", "SPECIES", 41, 44], ["sizes", "OBSERVATION_MODIFIER", 105, 110]]], ["In this research, the lowest points for dorsal surfaces of both hands were identified on surfaces near the wrist and thumbs.", [["dorsal surfaces", "ANATOMY", 40, 55], ["wrist", "ANATOMY", 107, 112], ["thumbs", "ANATOMY", 117, 123], ["dorsal surfaces", "MULTI-TISSUE_STRUCTURE", 40, 55], ["hands", "ORGANISM_SUBDIVISION", 64, 69], ["wrist", "ORGANISM_SUBDIVISION", 107, 112], ["thumbs", "ORGANISM_SUBDIVISION", 117, 123], ["dorsal", "ANATOMY_MODIFIER", 40, 46], ["surfaces", "ANATOMY_MODIFIER", 47, 55], ["both hands", "ANATOMY", 59, 69], ["wrist", "ANATOMY", 107, 112], ["thumbs", "ANATOMY", 117, 123]]], ["In curricula, students should be informed about hand antiseptic use and the practice of hand-washing in line with the WHO's regulations.", [["hand", "ANATOMY", 48, 52], ["hand", "ANATOMY", 88, 92], ["hand", "ORGANISM_SUBDIVISION", 48, 52], ["hand", "ORGANISM_SUBDIVISION", 88, 92], ["hand antiseptic use", "TREATMENT", 48, 67]]], ["Although the WHO suggests an 8-stage regulation of hand disinfectant use, Kampf et al. have proposed a new and less detailed 5stage technique.", [["hand", "ANATOMY", 51, 55], ["hand", "ORGANISM_SUBDIVISION", 51, 55], ["hand", "ANATOMY", 51, 55], ["disinfectant", "OBSERVATION", 56, 68], ["new", "OBSERVATION_MODIFIER", 103, 106]]], ["This new rub-in technique, which aims to prevent the omission of frequently missed surfaces in HH, may be considered as an alternative technique to the WHO's regulations.", [["This new rub-in technique", "TREATMENT", 0, 25]]], ["Thumbs are cleaned in the later stages of the WHO's regulation, while Kampf et al. does so in the third stage.", [["cleaned", "OBSERVATION", 11, 18]]], ["The right palm is described in the third stage of the WHO's regulation.", [["right palm", "ANATOMY", 4, 14], ["palm", "ORGANISM_SUBDIVISION", 10, 14], ["right", "ANATOMY_MODIFIER", 4, 9], ["palm", "ANATOMY", 10, 14]]], ["Yet, here it is possible to omit the surface near the wrist.", [["surface", "ANATOMY", 37, 44], ["wrist", "ANATOMY", 54, 59], ["surface", "CELLULAR_COMPONENT", 37, 44], ["wrist", "ORGANISM_SUBDIVISION", 54, 59], ["surface", "ANATOMY_MODIFIER", 37, 44], ["wrist", "ANATOMY", 54, 59]]], ["In the fourth stage of the new technique, both the dorsum of the hand and wrists may be covered with disinfectant by positioning and scrubbing the palmar surface of one hand to cover the metacarpal surface on the wrist of the other hand (Kampf et al., 2008) .", [["dorsum", "ANATOMY", 51, 57], ["hand", "ANATOMY", 65, 69], ["wrists", "ANATOMY", 74, 80], ["palmar surface", "ANATOMY", 147, 161], ["hand", "ANATOMY", 169, 173], ["metacarpal surface", "ANATOMY", 187, 205], ["wrist", "ANATOMY", 213, 218], ["hand", "ANATOMY", 232, 236], ["dorsum", "ORGANISM_SUBDIVISION", 51, 57], ["hand", "ORGANISM_SUBDIVISION", 65, 69], ["wrists", "ORGANISM_SUBDIVISION", 74, 80], ["hand", "ORGANISM_SUBDIVISION", 169, 173], ["metacarpal surface", "MULTI-TISSUE_STRUCTURE", 187, 205], ["wrist", "ORGANISM_SUBDIVISION", 213, 218], ["fourth stage", "OBSERVATION_MODIFIER", 7, 19], ["new", "OBSERVATION_MODIFIER", 27, 30], ["technique", "OBSERVATION", 31, 40], ["dorsum", "ANATOMY_MODIFIER", 51, 57], ["hand", "ANATOMY", 65, 69], ["wrists", "ANATOMY", 74, 80], ["disinfectant", "OBSERVATION", 101, 113], ["palmar", "ANATOMY", 147, 153], ["metacarpal", "ANATOMY", 187, 197], ["surface", "ANATOMY_MODIFIER", 198, 205], ["wrist", "ANATOMY", 213, 218], ["hand", "ANATOMY", 232, 236]]], ["However, there is a need for comparison of both techniques' efficacy.DiscussionThe findings of this research indicate that first year students' hand disinfectant use was higher than that of fourth year students.", [["hand", "ANATOMY", 144, 148], ["hand", "ORGANISM_SUBDIVISION", 144, 148]]], ["Differing HH practices observed in clinics may be confusing for students (Barrett and Randle, 2008) .DiscussionWhen the findings about hand-washing were evaluated, a difference was identified between points for washing right and left hands.", [["hand", "ANATOMY", 135, 139], ["right", "ANATOMY", 219, 224], ["left hands", "ANATOMY", 229, 239], ["hand", "ORGANISM_SUBDIVISION", 135, 139], ["hand-washing", "TREATMENT", 135, 147], ["right", "ANATOMY_MODIFIER", 219, 224], ["left", "ANATOMY_MODIFIER", 229, 233], ["hands", "ANATOMY", 234, 239]]], ["Av\u015far et al., observed that students did not use the proper technique to wash their palms (Av\u015far et al., 2015) .", [["palms", "ANATOMY", 84, 89], ["palms", "ORGANISM_SUBDIVISION", 84, 89]]], ["Our observation that there were more fluorescent traces on palms and surfaces near the wrist leads to the idea that the new technique of Kampf et al. may be effective for the practice of hand-washing, too.DiscussionLike our research, the scholarly literature reports that using fluorescent material is generally effective and may be used as a training tool for HH compliance (Picheansathian, 2004; Hautemani\u00e8re et al., 2009 ).", [["palms", "ANATOMY", 59, 64], ["wrist", "ANATOMY", 87, 92], ["hand", "ANATOMY", 187, 191], ["palms", "ORGANISM_SUBDIVISION", 59, 64], ["wrist", "ORGANISM_SUBDIVISION", 87, 92], ["hand", "ORGANISM_SUBDIVISION", 187, 191], ["Our observation", "TEST", 0, 15], ["more fluorescent traces on palms", "PROBLEM", 32, 64], ["Kampf et al", "TREATMENT", 137, 148], ["hand-washing", "TREATMENT", 187, 199], ["fluorescent traces", "OBSERVATION", 37, 55], ["wrist", "ANATOMY", 87, 92]]], ["In contrast, Miller's research findings indicate that the use of Glo Germs (the fluorescent that was used in that study) may be inappropriate for determining the effectiveness of hand-washing.", [["hand", "ANATOMY", 179, 183], ["Glo", "GENE_OR_GENE_PRODUCT", 65, 68], ["hand", "ORGANISM_SUBDIVISION", 179, 183], ["Glo Germs", "PROBLEM", 65, 74], ["hand-washing", "TREATMENT", 179, 191]]], ["They also show that there is no significant relationship between bacterial colonization and the amount of Glo Germs that remain on the hands.", [["Glo", "GENE_OR_GENE_PRODUCT", 106, 109], ["hands", "ORGANISM_SUBDIVISION", 135, 140], ["bacterial colonization", "PROBLEM", 65, 87], ["Glo Germs", "PROBLEM", 106, 115], ["no", "UNCERTAINTY", 29, 31], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["bacterial", "OBSERVATION_MODIFIER", 65, 74], ["colonization", "OBSERVATION", 75, 87], ["amount", "OBSERVATION_MODIFIER", 96, 102], ["Glo Germs", "OBSERVATION", 106, 115], ["hands", "ANATOMY", 135, 140]]], ["This may be related to the fact that analysis took place in daylight.", [["may be related to", "UNCERTAINTY", 5, 22]]], ["It is not possible to identify the boundaries of fluorescent traces on the hands without dimming the environment.", [["not possible", "UNCERTAINTY", 6, 18], ["fluorescent traces", "OBSERVATION", 49, 67]]], ["Therefore, appropriate arrangement of the environment is significant for accurate analysis (Hautemani\u00e8re et al., 2009) .ConclusionThe study results show that, using fluorescence-marked AHR can be considered as a good choice in evaluating compliance with alcoholbased HH.", [["The study", "TEST", 130, 139], ["fluorescence", "TEST", 165, 177], ["alcoholbased HH", "PROBLEM", 254, 269]]], ["The type of AHR, duration of contact, the amount used and new techniques in AHR use can increase the efficacy of HH.", [["new techniques in AHR", "TREATMENT", 58, 79]]], ["Presenting a guide for AHR use near the sinks in clinics may reduce the knowledge gap in HH compliance.Limitations of the StudyFirst, although our study presents useful information about the problems on HH, it does not replace practices at hospitals or direct observation.", [["the StudyFirst", "TEST", 118, 132], ["our study", "TEST", 143, 152], ["direct observation", "TEST", 253, 271]]], ["Second, our research did not consider the ingredients, amount and drying duration of AHR.", [["AHR", "PROBLEM", 85, 88]]], ["While the inability to evaluate photographs in three dimensions and the need for experienced observers bring certain limitations to this study, HH training with fluorescence is a preferable and cheaper technique that is also easy to learn for students.", [["photographs", "TEST", 32, 43], ["this study", "TEST", 132, 142], ["HH training", "TREATMENT", 144, 155], ["a preferable and cheaper technique", "TREATMENT", 177, 211]]], ["This limit may be exceeded with evaluation being made by taking a video to make three-dimensional evaluation.", [["evaluation", "TEST", 32, 42], ["dimensional evaluation", "TEST", 86, 108]]]], "9c60c44eeef6901be2fb1312ee66670fc2eae826": [["INTRODUCTIONThe SARS-CoV-2 novel coronavirus (and associated disease, COVID-19) became a World Health Organization-declared global pandemic in March 2020, three months after its initial identification in December 2019.", [["coronavirus", "DISEASE", 33, 44], ["SARS-CoV-2", "ORGANISM", 16, 26], ["coronavirus", "ORGANISM", 33, 44], ["coronavirus", "SPECIES", 33, 44], ["SARS-CoV-2 novel coronavirus", "SPECIES", 16, 44], ["novel coronavirus", "PROBLEM", 27, 44], ["associated disease", "PROBLEM", 50, 68], ["COVID", "TEST", 70, 75]]], ["[1] [2] [3] [4] On March 13, the United States Federal Government declared a national emergency and authorized the Secretary of the Department of Health and Human Services (HHS) to temporarily modify or waive certain requirements of the Health Insurance Portability and Accountability Act's (HIPAA) Privacy Rule and of safety net insurance policies to prepare for surging care demand.", [["[1] [2] [3", "SIMPLE_CHEMICAL", 0, 10], ["Human", "ORGANISM", 157, 162], ["Human", "SPECIES", 157, 162]]], ["[5] In response, the Office for Civil Rights (OCR) at HHS announced it would exercise its enforcement discretion and \"not impose penalties for noncompliance with the regulatory requirements under the HIPAA Rules against covered health care providers in connection with the good faith provision of telehealth during the COVID-19 nationwide public health emergency.\" [6] Governmental and social guidelines encouraged \"social distancing\" to reduce viral spread.", [["viral spread", "PROBLEM", 445, 457], ["viral spread", "OBSERVATION", 445, 457]]], ["[7 8 ] Similar guidelines, including those outlined in Tennessee Executive Orders 18 and 25, pushed for health systems to reduce nonurgent, in-person healthcare visits and elective scheduled procedures.", [["elective scheduled procedures", "TREATMENT", 172, 201]]], ["[12] [13] [14] Virtual clinic visits can help manage routine clinical care and surging demand in the setting of outpatient clinic closures during medical disasters, as documented during the rapid medical response following Hurricane Maria (Puerto Rico, 2017).", [["routine clinical care", "TREATMENT", 53, 74], ["surging demand", "TREATMENT", 79, 93]]], ["[15] During the COVID-19 pandemic, virtual visits can also connect patients to testing resources while honoring selfquarantine requirements.", [["patients", "ORGANISM", 67, 75], ["selfquarantine", "SIMPLE_CHEMICAL", 112, 126], ["patients", "SPECIES", 67, 75]]], ["[12 15-17] While telehealth holds great promise, its rapid expansion has created new challenges that may overwhelm existing infrastructure.", [["its rapid expansion", "PROBLEM", 49, 68], ["rapid", "OBSERVATION_MODIFIER", 53, 58], ["expansion", "OBSERVATION_MODIFIER", 59, 68], ["new", "OBSERVATION_MODIFIER", 81, 84], ["infrastructure", "OBSERVATION", 124, 138]]], ["[12] Vanderbilt University Medical Center (VUMC) is a large, private, nonprofit, academic medical center with telehealth capabilities integrated into its patient portal, My Health at Vanderbilt (MHAV).", [["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["telehealth capabilities", "TREATMENT", 110, 133], ["large", "OBSERVATION_MODIFIER", 54, 59], ["portal", "ANATOMY", 162, 168]]], ["MHAV was first deployed in 2004 to support secure messaging between provider and patient, appointment scheduling, billing management, access to laboratory results, and access to other electronic health record (EHR) data.", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["MHAV", "SPECIES", 0, 4]]], ["[18 19 ] VUMC previously implemented direct-topatient telehealth through MHAV to streamline the patient and provider experience.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103]]], ["By integrating telehealth within MHAV, patients benefit from using a familiar applicationlowering the barrier for entry into telehealth.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["Patient portal-based telehealth builds on existing clinical relationships and guides their conversion to a telehealth relationship.", [["Patient", "SPECIES", 0, 7], ["portal", "ANATOMY", 8, 14]]], ["In addition, patient portal integration allows clinicians the additional benefit of harnessing existing workflows, which facilitates access to the complete medical record while documenting, scheduling, and communicating with patients.INTRODUCTIONLike other institutions, VUMC has experienced unprecedented need for telehealth visits during the pandemic.", [["VUMC", "CHEMICAL", 271, 275], ["patient", "ORGANISM", 13, 20], ["patients", "ORGANISM", 225, 233], ["patient", "SPECIES", 13, 20], ["patients", "SPECIES", 225, 233], ["harnessing existing workflows", "TREATMENT", 84, 113], ["telehealth visits", "TREATMENT", 315, 332], ["portal", "ANATOMY", 21, 27]]], ["This led to new enrollment and customer support challenges, especially since patient portal activation is required for telehealth participation.", [["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["customer support challenges", "TREATMENT", 31, 58], ["new", "OBSERVATION_MODIFIER", 12, 15], ["enrollment", "OBSERVATION_MODIFIER", 16, 26], ["portal", "ANATOMY", 85, 91]]], ["Virtual identity verification of new patients using telehealth tools scaled smoothly for adults, but was more complicated for pediatric and adolescent patients.", [["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 151, 159], ["new", "OBSERVATION_MODIFIER", 33, 36]]], ["MHAV serves patients of all ages and, prior to the pandemic, had robust policies and procedures in place to support in-person enrollment for children and adolescents.", [["patients", "ORGANISM", 12, 20], ["children", "ORGANISM", 141, 149], ["patients", "SPECIES", 12, 20], ["children", "SPECIES", 141, 149], ["adolescents", "SPECIES", 154, 165], ["MHAV", "SPECIES", 0, 4], ["procedures", "TREATMENT", 85, 95]]], ["[18] In the existing MHAV policy framework, families with children (0-12 years) and adolescents (13-17 years) had to enroll in-person to verify identity and, in the case of adolescent patients, to ensure patient consent has been given for parental access to the patient's medical record.", [["children", "ORGANISM", 58, 66], ["patients", "ORGANISM", 184, 192], ["patient", "ORGANISM", 204, 211], ["patient", "ORGANISM", 262, 269], ["children", "SPECIES", 58, 66], ["adolescents", "SPECIES", 84, 95], ["person", "SPECIES", 127, 133], ["patients", "SPECIES", 184, 192], ["patient", "SPECIES", 204, 211], ["patient", "SPECIES", 262, 269]]], ["However, social distancing measures make in-person MHAV enrollment infeasible, and created a need for remote enrollment for MHAV to enable telehealth visits.INTRODUCTIONTo facilitate urgent and high-volume remote MHAV enrollment for pediatric patients, we defined five process requirements:INTRODUCTION1.", [["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 243, 251], ["MHAV", "SPECIES", 124, 128], ["urgent and high-volume remote MHAV enrollment", "TREATMENT", 183, 228]]], ["Efficient patient portal enrollment for new or existing pediatric patients 2.", [["patient", "ORGANISM", 10, 17], ["patients", "ORGANISM", 66, 74], ["patient", "SPECIES", 10, 17], ["patients", "SPECIES", 66, 74], ["portal", "ANATOMY", 18, 24], ["enrollment", "OBSERVATION", 25, 35]]], ["Remote ability to establish patient parentage 3.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35]]], ["Compliance with institutional privacy and security policies surrounding protected information collection and patient/parent identity confirmation.", [["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["institutional privacy and security policies", "TREATMENT", 16, 59], ["patient/parent identity confirmation", "TEST", 109, 145]]], ["This report describes our experience incorporating these requirements into the design and implementation of a process for rapid expansion of child and adolescent patient enrollment for telehealth visits during the COVID-19 pandemic.", [["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 162, 169], ["the COVID", "TEST", 210, 219], ["pandemic", "PROBLEM", 223, 231]]], ["VUMC has policies governing patient portal enrollment for children aged 0-12 years and for adolescents aged 13-17 years.", [["VUMC", "CHEMICAL", 0, 4], ["patient", "ORGANISM", 28, 35], ["portal", "MULTI-TISSUE_STRUCTURE", 36, 42], ["children", "ORGANISM", 58, 66], ["patient", "SPECIES", 28, 35], ["children", "SPECIES", 58, 66], ["adolescents", "SPECIES", 91, 102], ["portal", "ANATOMY", 36, 42]]], ["For children, caregivers can create accounts for their child after verifying their identity as parents, guardians, or conservators.", [["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12]]], ["For adolescents, both the caregiver and adolescent must mutually agree to joint access to the portal with biological parent, guardian, or conservator (in addition to the identity verification step used for children under 13).", [["children", "ORGANISM", 206, 214], ["adolescents", "SPECIES", 4, 15], ["children", "SPECIES", 206, 214], ["portal", "ANATOMY", 94, 100]]], ["This separate process for adolescent patients was instituted at VUMC to safeguard adolescents' right to confidentiality.MyHIPAA does not allow parents the right to access a minor's medical record for care episodes where the minor can consent unilaterally according to state law.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["adolescents", "SPECIES", 82, 93]]], ["[20] In Tennessee specifically, minors aged 16-17 are legally allowed to consent to substance use and mental health treatment without parental consent.", [["mental health treatment", "TREATMENT", 102, 125]]], ["[21] In practice, this enrollment process was historically conducted during in-person clinic visits to confirm capacity and consent for personal health information (PHI) use within MHAV portal, as well as to confirm identity.MyWhile being mindful of HIPAA restrictions, [14] we developed and implemented a novel process to support remote enrollment.", [["MHAV portal", "MULTI-TISSUE_STRUCTURE", 181, 192], ["a novel process", "TREATMENT", 304, 319], ["portal", "ANATOMY", 186, 192]]], ["For return patients 0-12 years old who had biological parents, the updated policies allowed enrollment to be performed over the phone because the necessary supporting information was minimal and identification had been confirmed during prior standard clinical intake.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["For new patients, the lack of existing supporting information and identification confirmation required an alternative process.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["identification confirmation", "TEST", 66, 93]]], ["Further, for patients 13-17 years old, the additional step of confirming adolescent assent required an alternative process (Tables 1 and 2 ).", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["This process needed to be accessible for patients while respecting information security (e.g. email is not considered secure, and secure fax-based approaches are not accessible to most families).MyTo fill this need, we created two electronic forms using the secure REDCap platform (REDCap Consortium, Nashville, TN): one for new patients 0-12 years old and one for all patients 13-17 years old (see Supplementary Table 1 for form components).", [["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 329, 337], ["patients", "ORGANISM", 369, 377], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 329, 337], ["patients", "SPECIES", 369, 377]]], ["[22] Patients with non-biological parents, guardians, or conservators required an additional process for legal representatives to submit appropriate paperwork demonstrating guardianship.", [["Patients", "ORGANISM", 5, 13], ["Patients", "SPECIES", 5, 13]]], ["As such, non-biological parents, guardians, and conservators were required to use the electronic sign-up process ( With the surging demand of new telehealth visits and, by extension, new MHAV enrollments, the combined burden of application processing and video identity confirmation falling under a single HealthIT team proved to be a significant bottleneck.", [["new MHAV enrollments", "TREATMENT", 183, 203], ["application processing", "TREATMENT", 228, 250], ["video identity confirmation", "TEST", 255, 282]]], ["To alleviate this burden, the process was modified to allow clinic staff to verify identity via two-way video for patients 0-12 years when the parent is a biological parent and, therefore, does not require additional paperwork.MyThese new MHAV enrollment processes underwent an expedited, temporary approval by the Office of Legal Affairs and Privacy Office by citing emergent telehealth needs, and launched on March 16, 2020.MySummary statistics are presented for each age group (0-12 years and 13-17 years).", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["this burden", "PROBLEM", 13, 24], ["new", "OBSERVATION_MODIFIER", 235, 238]]], ["Reported statistics include the weekly rates of new pediatric enrollments and weekly number of telehealth visits before and after the March 16 th launch of remote telehealth enrollment.RESULTSIn response to social distancing guidelines and efforts to reduce in-person routine clinical visits, VUMC put in place novel methods to allow remote patient portal enrollment of pediatric patients through clinic-based phone calls and electronic REDCap forms.", [["patient", "ORGANISM", 341, 348], ["patients", "ORGANISM", 380, 388], ["patient", "SPECIES", 341, 348], ["patients", "SPECIES", 380, 388], ["new pediatric enrollments", "TREATMENT", 48, 73], ["social distancing guidelines", "TREATMENT", 207, 235], ["VUMC", "TREATMENT", 293, 297], ["portal", "ANATOMY", 349, 355]]], ["Developing the new methods consisted of developing consensus among key institutional stakeholders, building electronic applications, testing the applications, and creating documentation to train others on how to process applications.", [["new", "OBSERVATION_MODIFIER", 15, 18]]], ["We were able to make these changes quickly, and the entire process took two days.DISCUSSIONThe COVID-19 pandemic has generated unprecedented demand for telehealth-based clinical services, which creates new challenges related to patient portal enrollment.", [["patient", "ORGANISM", 228, 235], ["portal", "MULTI-TISSUE_STRUCTURE", 236, 242], ["patient", "SPECIES", 228, 235], ["patient portal enrollment", "PROBLEM", 228, 253], ["portal", "ANATOMY", 236, 242], ["enrollment", "OBSERVATION", 243, 253]]], ["These challenges can be especially complex for pediatric and adolescent patients, who require identify verification, parentage documentation, and adolescent assent for enrollment.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["parentage documentation", "TEST", 117, 140]]], ["We describe a pathway for rapidly increasing capacity of remote pediatric and adolescent patient portal enrollment that fulfills privacy, security, and convenience concerns.DISCUSSIONAfter launching our remote enrollment method, weekly pediatric patient portal enrollments experienced a roughly 10-fold increase for ages 0-12 years and 1.2-fold increase for ages [13] [14] [15] [16] [17] years.", [["patient", "ORGANISM", 89, 96], ["patient", "ORGANISM", 246, 253], ["patient", "SPECIES", 89, 96], ["patient", "SPECIES", 246, 253], ["portal", "ANATOMY", 97, 103], ["portal", "ANATOMY", 254, 260]]], ["Weekly telehealth visits increased by roughly 200-fold for ages 0-12 years and 90-fold for ages 13-17 years.DISCUSSIONAs the healthcare community prepares for future disasters, it will be critical to extract successful strategies from the COVID-19 response.", [["the COVID", "TEST", 235, 244]]], ["Our experience with the rapid conversion of a patient enrollment process can provide guidance for telehealth surge management in the future.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["a patient enrollment process", "TREATMENT", 44, 72], ["telehealth surge management", "TREATMENT", 98, 125]]], ["In addition to efficiently enrolling patients, other barriers to rapidly increasing telehealth volume may include reimbursement policies, socioeconomic disparities in patient technology access, staffing shortages, creation of telehealth-enabled clinical workflows, and broadband infrastructure.", [["patients", "ORGANISM", 37, 45], ["patient", "ORGANISM", 167, 174], ["patients", "SPECIES", 37, 45], ["patient", "SPECIES", 167, 174], ["rapidly increasing telehealth volume", "PROBLEM", 65, 101], ["reimbursement policies", "TREATMENT", 114, 136]]], ["[25] In addition to recent temporary measures by the Centers for Medicare and Medicaid Services that broaden telehealth reimbursements, [26] collaborative policies at the federal, state, and organizational level will be necessary to ensure continued funding and development of telehealth capacity.", [["recent temporary measures", "TREATMENT", 20, 45], ["telehealth capacity", "PROBLEM", 277, 296]]], ["Table 1 : My Health at Vanderbilt (MHAV) patient portal enrollment process, before versus after changes allowing remote enrollment in response to the COVID-19 pandemic.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["Vanderbilt (MHAV) patient portal enrollment process", "TREATMENT", 23, 74], ["the COVID", "TEST", 146, 155], ["pandemic", "PROBLEM", 159, 167], ["portal", "ANATOMY", 49, 55], ["enrollment", "OBSERVATION", 56, 66]]], ["If electronic REDCap application is received from this process, next steps include:TABLES\uf0b7 HealthIT team organizes video call to confirm identity of parent and of patient (if patient is 13-17 years of age).TABLES\uf0b7 After identity confirmation, electronic applications are indexed into the EHR and processed by HealthIT team to activate MHAV access.TABLES\uf0b7 After MHAV account is created, telehealth visits are able to be scheduled by clinics.Before COVID-19After COVID-19 \"Children\" were defined as age 0-12 years.", [["patient", "ORGANISM", 163, 170], ["patient", "ORGANISM", 175, 182], ["MHAV", "GENE_OR_GENE_PRODUCT", 335, 339], ["patient", "SPECIES", 163, 170], ["patient", "SPECIES", 175, 182], ["Children", "SPECIES", 471, 479], ["electronic REDCap application", "TREATMENT", 3, 32], ["electronic applications", "TREATMENT", 243, 266], ["MHAV access", "TREATMENT", 335, 346]]], ["\"Adolescents\" were defined as age 13-17 years.", [["Adolescents", "SPECIES", 1, 12]]], ["\"Adolescents\" were defined as age 13-17 years.", [["Adolescents", "SPECIES", 1, 12]]]], "PMC7185441": [["IntroductionNeonatal calf diarrhea is the most common cause of illness and mortality in calves and a major cause of economic loss to cattle herds (Barragry, 1997, De la Fuente et al., 1999).", [["calf diarrhea", "DISEASE", 21, 34], ["illness", "DISEASE", 63, 70], ["calf", "ORGANISM", 21, 25], ["calves", "ORGANISM", 88, 94], ["calf", "SPECIES", 21, 25], ["calves", "SPECIES", 88, 94], ["cattle", "SPECIES", 133, 139], ["cattle", "SPECIES", 133, 139], ["Neonatal calf diarrhea", "PROBLEM", 12, 34], ["illness", "PROBLEM", 63, 70], ["mortality in calves", "PROBLEM", 75, 94], ["economic loss", "PROBLEM", 116, 129], ["calf", "ANATOMY", 21, 25], ["diarrhea", "OBSERVATION", 26, 34], ["most common", "OBSERVATION_MODIFIER", 42, 53], ["illness", "OBSERVATION", 63, 70]]], ["Economic losses, on top to mortality, is associated with treatment, veterinary and labor costs as well as with reduced growth rates of the affected calves (Anderson et al., 2003, Ok et al., 2009).", [["calves", "ORGANISM", 148, 154], ["calves", "SPECIES", 148, 154], ["Economic losses", "PROBLEM", 0, 15], ["treatment", "TREATMENT", 57, 66], ["veterinary and labor costs", "TREATMENT", 68, 94], ["losses", "OBSERVATION", 9, 15]]], ["The most important infectious agents associated with the disease are enterotoxic Escherichia coli K99/F5 (ETEC), Rotavirus A (RVA), Bovine coronavirus (BCoV), and Cryptosporidium spp. with RVA and Cryptosporidium spp. being most frequently identified in fecal samples from young calves (Gulliksen et al., 2009, Bartels et al., 2010, Silverl\u00e5s et al., 2010).", [["fecal samples", "ANATOMY", 254, 267], ["Rotavirus A", "DISEASE", 113, 124], ["Bovine coronavirus (BCoV)", "DISEASE", 132, 157], ["Cryptosporidium spp", "DISEASE", 163, 182], ["Cryptosporidium spp", "DISEASE", 197, 216], ["Escherichia coli K99/F5 (ETEC", "ORGANISM", 81, 110], ["Rotavirus A", "ORGANISM", 113, 124], ["Bovine coronavirus", "ORGANISM", 132, 150], ["BCoV", "ORGANISM", 152, 156], ["Cryptosporidium spp", "ORGANISM", 163, 182], ["Cryptosporidium spp", "ORGANISM", 197, 216], ["fecal samples", "ORGANISM_SUBSTANCE", 254, 267], ["calves", "ORGANISM", 279, 285], ["Escherichia coli", "SPECIES", 81, 97], ["Bovine coronavirus", "SPECIES", 132, 150], ["calves", "SPECIES", 279, 285], ["Escherichia coli", "SPECIES", 81, 97], ["ETEC", "SPECIES", 106, 110], ["Rotavirus A", "SPECIES", 113, 124], ["RVA", "SPECIES", 126, 129], ["Bovine coronavirus", "SPECIES", 132, 150], ["BCoV", "SPECIES", 152, 156], ["the disease", "PROBLEM", 53, 64], ["enterotoxic Escherichia coli K99", "PROBLEM", 69, 101], ["Rotavirus A (RVA", "TREATMENT", 113, 129], ["Bovine coronavirus (BCoV", "TEST", 132, 156], ["Cryptosporidium spp", "PROBLEM", 163, 182], ["RVA", "PROBLEM", 189, 192], ["Cryptosporidium spp", "PROBLEM", 197, 216], ["most important", "OBSERVATION_MODIFIER", 4, 18], ["infectious", "OBSERVATION", 19, 29], ["enterotoxic", "OBSERVATION_MODIFIER", 69, 80], ["Escherichia coli", "OBSERVATION", 81, 97], ["Cryptosporidium spp", "OBSERVATION", 163, 182], ["RVA", "OBSERVATION", 189, 192], ["Cryptosporidium spp", "OBSERVATION", 197, 216], ["fecal", "ANATOMY", 254, 259]]], ["Co-infections with more than one of these pathogens are frequently detected in diarrheic calves in clinical practice and are associated with increased morbidity and mortality rates (Blanchard, 2012).IntroductionIt is well documented that diarrheic calves, regardless of the causative agent or agents of diarrhea, often have small intestinal overgrowth of E. coli bacteria.", [["intestinal", "ANATOMY", 330, 340], ["Co-infections", "DISEASE", 0, 13], ["diarrheic", "DISEASE", 238, 247], ["diarrhea", "DISEASE", 303, 311], ["calves", "ORGANISM", 89, 95], ["calves", "ORGANISM", 248, 254], ["intestinal", "ORGAN", 330, 340], ["E. coli", "ORGANISM", 355, 362], ["calves", "SPECIES", 89, 95], ["calves", "SPECIES", 248, 254], ["E. coli", "SPECIES", 355, 362], ["E. coli", "SPECIES", 355, 362], ["Co-infections", "PROBLEM", 0, 13], ["these pathogens", "PROBLEM", 36, 51], ["increased morbidity", "PROBLEM", 141, 160], ["mortality rates", "TEST", 165, 180], ["diarrheic calves", "PROBLEM", 238, 254], ["diarrhea", "PROBLEM", 303, 311], ["small intestinal overgrowth", "PROBLEM", 324, 351], ["E. coli bacteria", "PROBLEM", 355, 371], ["pathogens", "OBSERVATION", 42, 51], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["morbidity", "OBSERVATION", 151, 160], ["small", "OBSERVATION_MODIFIER", 324, 329], ["intestinal", "ANATOMY", 330, 340], ["overgrowth", "OBSERVATION", 341, 351], ["E. coli bacteria", "OBSERVATION", 355, 371]]], ["This overgrowth increases the severity of diarrhea, retards the recovery and increases the risk of bacteremia and death (Constable, 2004).", [["diarrhea", "DISEASE", 42, 50], ["bacteremia", "DISEASE", 99, 109], ["death", "DISEASE", 114, 119], ["This overgrowth", "PROBLEM", 0, 15], ["diarrhea", "PROBLEM", 42, 50], ["bacteremia", "PROBLEM", 99, 109], ["death", "PROBLEM", 114, 119], ["overgrowth", "OBSERVATION", 5, 15], ["severity", "OBSERVATION_MODIFIER", 30, 38], ["diarrhea", "OBSERVATION", 42, 50], ["bacteremia", "OBSERVATION", 99, 109]]], ["In respect to this, oral administration of antibacterial agents that inhibit coliform bacterial overgrowth in calves with diarrhea might have beneficial effects on the disease outcome by decreasing the duration and the severity of the disease and by preventing the development of bacteremia.IntroductionOregano essential oil could be used as such an antibacterial agent providing an antibiotic alternative for this purpose.", [["oral", "ANATOMY", 20, 24], ["oil", "ANATOMY", 321, 324], ["bacterial overgrowth", "DISEASE", 86, 106], ["diarrhea", "DISEASE", 122, 130], ["bacteremia", "DISEASE", 280, 290], ["oral", "ORGANISM_SUBDIVISION", 20, 24], ["calves", "ORGANISM", 110, 116], ["oil", "ORGANISM_SUBSTANCE", 321, 324], ["calves", "SPECIES", 110, 116], ["calves", "SPECIES", 110, 116], ["antibacterial agents", "TREATMENT", 43, 63], ["coliform bacterial overgrowth in calves", "PROBLEM", 77, 116], ["diarrhea", "PROBLEM", 122, 130], ["the disease outcome", "PROBLEM", 164, 183], ["the disease", "PROBLEM", 231, 242], ["bacteremia", "PROBLEM", 280, 290], ["IntroductionOregano essential oil", "TREATMENT", 291, 324], ["an antibacterial agent", "TREATMENT", 347, 369], ["an antibiotic alternative", "TREATMENT", 380, 405], ["overgrowth", "OBSERVATION", 96, 106], ["disease", "OBSERVATION", 235, 242], ["bacteremia", "OBSERVATION", 280, 290]]], ["It has been proven in many experiments in vitro that oregano essential oil and its main constituents, carvacrol and thymol, have strong antibacterial activity against gram negative bacteria and especially E. coli (Elgayyar et al., 2001, Si et al., 2008, Nazzaro et al., 2013).", [["carvacrol", "CHEMICAL", 102, 111], ["thymol", "CHEMICAL", 116, 122], ["carvacrol", "CHEMICAL", 102, 111], ["thymol", "CHEMICAL", 116, 122], ["oregano", "SIMPLE_CHEMICAL", 53, 60], ["oil", "ORGANISM_SUBSTANCE", 71, 74], ["carvacrol", "SIMPLE_CHEMICAL", 102, 111], ["thymol", "SIMPLE_CHEMICAL", 116, 122], ["E. coli", "ORGANISM", 205, 212], ["E. coli", "SPECIES", 205, 212], ["oregano", "SPECIES", 53, 60], ["E. coli", "SPECIES", 205, 212], ["carvacrol", "TREATMENT", 102, 111], ["thymol", "TREATMENT", 116, 122], ["gram negative bacteria", "PROBLEM", 167, 189], ["E. coli", "PROBLEM", 205, 212], ["E. coli", "OBSERVATION_MODIFIER", 205, 212]]], ["Apart from its antibacterial properties, oregano essential oil was also found to have antiviral (Pilau et al., 2011) and anticryptosporidial (Gaur et al., 2016) effects in vitro.", [["oregano", "SIMPLE_CHEMICAL", 41, 48], ["oil", "ORGANISM_SUBSTANCE", 59, 62], ["oregano", "SPECIES", 41, 48], ["its antibacterial properties", "TREATMENT", 11, 39], ["antibacterial properties", "OBSERVATION", 15, 39], ["oil", "OBSERVATION_MODIFIER", 59, 62]]], ["Based on these properties it could be hypothesized that the administration of oregano essential oil in newborn calves might have beneficial effects not only in treating but also in preventing diarrhea syndrome.", [["oil", "ANATOMY", 96, 99], ["oregano", "CHEMICAL", 78, 85], ["diarrhea", "DISEASE", 192, 200], ["oregano", "SIMPLE_CHEMICAL", 78, 85], ["oil", "ORGANISM_SUBSTANCE", 96, 99], ["calves", "ORGANISM", 111, 117], ["calves", "SPECIES", 111, 117], ["oregano", "SPECIES", 78, 85], ["oregano essential oil in newborn calves", "TREATMENT", 78, 117], ["diarrhea syndrome", "PROBLEM", 192, 209]]], ["In the available literature there is not any relevant controlled research evaluating potential prophylactic or treatment effects of oregano essential oil on diarrhea in calves aged < 15 days.", [["oil", "ANATOMY", 150, 153], ["diarrhea", "DISEASE", 157, 165], ["oregano", "SIMPLE_CHEMICAL", 132, 139], ["oil", "ORGANISM_SUBSTANCE", 150, 153], ["calves", "ORGANISM", 169, 175], ["calves", "SPECIES", 169, 175], ["oregano", "SPECIES", 132, 139], ["prophylactic or treatment effects", "TREATMENT", 95, 128], ["diarrhea", "PROBLEM", 157, 165], ["oil", "OBSERVATION_MODIFIER", 150, 153]]], ["In the only available study it was observed that the administration of oregano leaves had comparable effects with neomycin on the duration of diarrhea in diarrheic calves aged 7 to 20 days without however using control group (Bampidis et al., 2006).IntroductionThe objective of the present study was to evaluate under field conditions whether daily administration of oregano essential oil is effective in preventing and/or diminishing the severity of neonatal diarrhea syndrome in calves aged < 15 days.Animals and experimental design ::: Materials and methodsPrior to the onset of the experiment the minimum required total sample size was calculated using General Linear Multivariate Model with Wilks Likelihood Ratioprocedure at the GLIMMPSE software (http://glimmpse.samplesizeshop.org/).", [["oil", "ANATOMY", 385, 388], ["oregano leaves", "CHEMICAL", 71, 85], ["neomycin", "CHEMICAL", 114, 122], ["diarrhea", "DISEASE", 142, 150], ["diarrheic", "DISEASE", 154, 163], ["oregano", "CHEMICAL", 367, 374], ["neonatal diarrhea syndrome", "DISEASE", 451, 477], ["neomycin", "CHEMICAL", 114, 122], ["oregano", "ORGANISM", 71, 78], ["neomycin", "SIMPLE_CHEMICAL", 114, 122], ["calves", "ORGANISM", 164, 170], ["oregano", "SIMPLE_CHEMICAL", 367, 374], ["oil", "ORGANISM_SUBSTANCE", 385, 388], ["calves", "ORGANISM", 481, 487], ["calves", "SPECIES", 164, 170], ["calves", "SPECIES", 481, 487], ["oregano", "SPECIES", 71, 78], ["oregano", "SPECIES", 367, 374], ["oregano leaves", "TREATMENT", 71, 85], ["neomycin", "TREATMENT", 114, 122], ["diarrhea", "PROBLEM", 142, 150], ["the present study", "TEST", 278, 295], ["oregano essential oil", "TREATMENT", 367, 388], ["neonatal diarrhea syndrome", "PROBLEM", 451, 477], ["total sample size", "TREATMENT", 618, 635], ["size", "OBSERVATION_MODIFIER", 631, 635]]], ["The desired power was set at 0.8, the type I error rate at 0.05, the desired detectable difference of days with diarrhea at 2 days with standard deviation 1; the means scale factor was set at 0.5 and the variability scale factor at 2.", [["diarrhea", "DISEASE", 112, 120], ["diarrhea", "PROBLEM", 112, 120], ["the means scale factor", "TEST", 158, 180], ["the variability scale factor", "TEST", 200, 228]]], ["The results of the analysis revealed that a minimum sample size of 66 calves (33 per group) was required (Power = 0.808).Animals and experimental design ::: Materials and methodsNinety-one newborn Holstein calves (48 females and 43 males) from three dairy farms were finally used in the study.", [["calves", "ORGANISM", 70, 76], ["calves", "ORGANISM", 206, 212], ["calves", "SPECIES", 70, 76], ["calves", "SPECIES", 206, 212], ["Holstein", "SPECIES", 197, 205], ["the analysis", "TEST", 15, 27], ["a minimum sample size", "TEST", 42, 63], ["the study", "TEST", 283, 292], ["size", "OBSERVATION_MODIFIER", 59, 63]]], ["They were all born to dams that were vaccinated against Rotavirus, Coronavirus and E. coli F5 (K99)/F41 antigens (Lactovac C; Zoetis, Hellas) one month prior to the expected day of calving.", [["Rotavirus", "DISEASE", 56, 65], ["dams", "ORGANISM", 22, 26], ["Rotavirus", "ORGANISM", 56, 65], ["E. coli F5", "ORGANISM", 83, 93], ["K99", "ORGANISM", 95, 98], ["Lactovac C", "SIMPLE_CHEMICAL", 114, 124], ["E. coli", "SPECIES", 83, 90], ["E. coli", "SPECIES", 83, 90], ["Rotavirus", "PROBLEM", 56, 65], ["Coronavirus", "PROBLEM", 67, 78], ["E. coli F5", "TEST", 83, 93], ["K99", "TEST", 95, 98], ["Lactovac C", "TREATMENT", 114, 124]]], ["The calves were randomly alternately assigned into one of two groups according to their birth date in each farm until the total number of 30 calves per farm was reached.", [["calves", "ORGANISM", 4, 10], ["calves", "ORGANISM", 141, 147], ["calves", "SPECIES", 4, 10], ["calves", "SPECIES", 141, 147], ["calves", "ANATOMY", 4, 10]]], ["In Farm 1 however 31 calves were finally used due to a twin birth at the last calving.", [["calves", "ORGANISM", 21, 27], ["calves", "SPECIES", 21, 27], ["a twin birth", "PROBLEM", 53, 65]]], ["The animals of Eco group (n = 46) were orally drenched with Greek oregano (Origanum vulgare ssp. hirtum) essential oil (ECODIAR\u00ae liquid 5%; Ecopharm Hellas S.A., Kilkis, Greece) at the dose of 12.5 mg/kg body weight once per day for the first 10 days of their life whereas those of Conts group (n = 45) were left untreated and served as controls.Animals and experimental design ::: Materials and methodsThe experiment started at the day of calving (day 1) and lasted until day 15.", [["oil", "ANATOMY", 115, 118], ["body", "ANATOMY", 204, 208], ["Greek oregano", "CHEMICAL", 60, 73], ["Origanum vulgare", "ORGANISM", 75, 91], ["ssp", "ORGANISM", 92, 95], ["oil", "ORGANISM_SUBSTANCE", 115, 118], ["body", "ORGANISM_SUBDIVISION", 204, 208], ["oregano", "SPECIES", 66, 73], ["Origanum vulgare", "SPECIES", 75, 91], ["Greek oregano", "SPECIES", 60, 73], ["Origanum vulgare ssp", "SPECIES", 75, 95], ["essential oil (ECODIAR\u00ae liquid", "TREATMENT", 105, 135], ["left", "ANATOMY_MODIFIER", 308, 312]]], ["Each calf was separated from its dam after calving, weighed, its navel was disinfected using an antibiotic spray (TERRAMYCIN\u2122 AEROSOL SPRAY; Zoetis, Hellas) and was offered its first colostrum meal.", [["calf", "ANATOMY", 5, 9], ["navel", "ANATOMY", 65, 70], ["colostrum", "ANATOMY", 183, 192], ["calf", "ORGANISM", 5, 9], ["navel", "ORGANISM_SUBDIVISION", 65, 70], ["colostrum", "ORGANISM", 183, 192], ["calf", "SPECIES", 5, 9], ["an antibiotic spray (TERRAMYCIN\u2122 AEROSOL SPRAY", "TREATMENT", 93, 139], ["Zoetis, Hellas)", "TREATMENT", 141, 156], ["calf", "ANATOMY", 5, 9]]], ["The calves of Eco group were orally drenched immediately afterwards with the respective amount of oregano essential oil that was diluted with normal saline up to the volume of 60 ml with the aid of a feeding syringe of equal volume.", [["oil", "ANATOMY", 116, 119], ["calves", "ORGANISM", 4, 10], ["oregano", "SIMPLE_CHEMICAL", 98, 105], ["oil", "ORGANISM_SUBSTANCE", 116, 119], ["saline", "SIMPLE_CHEMICAL", 149, 155], ["calves", "SPECIES", 4, 10], ["oregano", "SPECIES", 98, 105], ["oregano essential oil", "TREATMENT", 98, 119], ["normal saline", "TREATMENT", 142, 155], ["a feeding syringe", "TREATMENT", 198, 215], ["calves", "ANATOMY", 4, 10], ["oil", "OBSERVATION_MODIFIER", 116, 119]]], ["The following days and until day 10, oregano essential oil was administered in the calves of this group at the same way after the morning feeding.", [["oil", "ANATOMY", 55, 58], ["oregano", "SIMPLE_CHEMICAL", 37, 44], ["oil", "ORGANISM_SUBSTANCE", 55, 58], ["calves", "ORGANISM", 83, 89], ["calves", "SPECIES", 83, 89], ["oregano", "SPECIES", 37, 44], ["oregano essential oil", "TREATMENT", 37, 58]]], ["The same procedures were followed in all farms.Animals and experimental design ::: Materials and methodsFeces were scored every day throughout the experiment after the morning feeding by the same person who was blinded to group allocation using a three point scale with 1 = normal, 2 = intermediate and 3 = watery and the score was recorded.", [["watery", "DISEASE", 307, 313], ["person", "SPECIES", 196, 202], ["The same procedures", "TREATMENT", 0, 19]]], ["Calves with fecal scores \u2265 2 were considered diarrheic.", [["fecal", "ANATOMY", 12, 17], ["diarrheic", "DISEASE", 45, 54], ["Calves", "ORGANISM", 0, 6], ["fecal", "ORGANISM_SUBSTANCE", 12, 17], ["Calves", "SPECIES", 0, 6], ["fecal scores", "TEST", 12, 24], ["diarrheic", "PROBLEM", 45, 54], ["fecal", "ANATOMY", 12, 17], ["diarrheic", "OBSERVATION", 45, 54]]], ["Based on these records, number of days with diarrhea (fecal score \u2265 2) was determined and diarrhea index (DI) was calculated: DI = number of days with diarrhea \u00d7 average fecal score on these days.Animals and experimental design ::: Materials and methodsFecal samples were collected on days 3, 6 and 10 of the experiment for microbiological and parasitological evaluation.", [["Fecal samples", "ANATOMY", 253, 266], ["diarrhea", "DISEASE", 44, 52], ["diarrhea", "DISEASE", 90, 98], ["diarrhea", "DISEASE", 151, 159], ["fecal", "ORGANISM_SUBDIVISION", 170, 175], ["Fecal samples", "CANCER", 253, 266], ["diarrhea", "PROBLEM", 44, 52], ["fecal score", "TEST", 54, 65], ["diarrhea index (DI)", "PROBLEM", 90, 109], ["diarrhea", "PROBLEM", 151, 159], ["methodsFecal samples", "TEST", 246, 266], ["microbiological and parasitological evaluation", "TEST", 324, 370]]], ["The samples were obtained directly from the rectum using sterile latex gloves, were separated into 3 aliquots in sterile containers and were transferred refrigerated to the laboratories for analysis.", [["samples", "ANATOMY", 4, 11], ["rectum", "ANATOMY", 44, 50], ["rectum", "ORGAN", 44, 50], ["The samples", "TEST", 0, 11], ["sterile latex gloves", "TREATMENT", 57, 77], ["sterile containers", "TREATMENT", 113, 131], ["analysis", "TEST", 190, 198], ["rectum", "ANATOMY", 44, 50], ["latex gloves", "OBSERVATION", 65, 77]]], ["On the same days, the calves of Eco group were weighed and the daily dosage of oregano essential oil was modified accordingly.", [["oil", "ANATOMY", 97, 100], ["calves", "ORGANISM", 22, 28], ["oregano", "SIMPLE_CHEMICAL", 79, 86], ["oil", "ORGANISM_SUBSTANCE", 97, 100], ["calves", "SPECIES", 22, 28], ["oregano", "SPECIES", 79, 86], ["Eco group", "TREATMENT", 32, 41], ["the daily dosage of oregano essential oil", "TREATMENT", 59, 100], ["calves", "ANATOMY", 22, 28]]], ["On day 3 a blood sample was also collected via jugular vein-puncture (21 G) into evacuated glass tubes from all calves and transferred refrigerated in the laboratory for the evaluation of passive immunity transfer.Animals and experimental design ::: Materials and methodsAll calves were routinely clinically examined by the same person who was blinded to group allocation at the fecal sampling days (days 3, 6 and 10) and at the end of the experiment (day 15).", [["blood sample", "ANATOMY", 11, 23], ["jugular vein-", "ANATOMY", 47, 60], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["jugular vein-", "MULTI-TISSUE_STRUCTURE", 47, 60], ["calves", "ORGANISM", 112, 118], ["calves", "ORGANISM", 275, 281], ["calves", "SPECIES", 112, 118], ["calves", "SPECIES", 275, 281], ["person", "SPECIES", 329, 335], ["a blood sample", "TEST", 9, 23], ["jugular vein-puncture", "TREATMENT", 47, 68], ["evacuated glass tubes", "TREATMENT", 81, 102], ["the evaluation", "TEST", 170, 184], ["passive immunity transfer", "TREATMENT", 188, 213], ["jugular", "ANATOMY", 47, 54], ["glass tubes", "OBSERVATION", 91, 102], ["all calves", "ANATOMY", 108, 118], ["calves", "OBSERVATION", 275, 281], ["fecal", "ANATOMY", 379, 384]]], ["In cases of diarrhea the animals were clinically evaluated daily until recovery.", [["diarrhea", "DISEASE", 12, 20], ["animals", "ORGANISM", 25, 32], ["diarrhea", "PROBLEM", 12, 20], ["diarrhea", "OBSERVATION", 12, 20]]], ["Diarrheic calves in all farms continued milk feeding and were receiving an extra meal per day with oral electrolytes (Diaproof K\u00ae; Virbac, Hellas).", [["milk", "ANATOMY", 40, 44], ["oral", "ANATOMY", 99, 103], ["calves", "ORGANISM", 10, 16], ["milk", "ORGANISM_SUBSTANCE", 40, 44], ["oral", "ORGANISM_SUBDIVISION", 99, 103], ["calves", "SPECIES", 10, 16], ["Diarrheic calves", "PROBLEM", 0, 16], ["milk feeding", "TREATMENT", 40, 52], ["an extra meal", "TREATMENT", 72, 85], ["oral electrolytes", "TEST", 99, 116]]], ["In cases of dehydration or inappetence the calves were receiving Lactated Ringers solution intravenously and, if blood serum glucose concentration was lower than 3 mmol/l (as determined on farm with a handheld glucose meter; FreeStyle Precision, Abbott, UK), a dextrose 10% solution was also administered intravenously.", [["blood", "ANATOMY", 113, 118], ["serum", "ANATOMY", 119, 124], ["intravenously", "ANATOMY", 305, 318], ["dehydration", "DISEASE", 12, 23], ["inappetence", "DISEASE", 27, 38], ["Lactated Ringers", "CHEMICAL", 65, 81], ["glucose", "CHEMICAL", 125, 132], ["dextrose", "CHEMICAL", 261, 269], ["glucose", "CHEMICAL", 125, 132], ["glucose", "CHEMICAL", 210, 217], ["dextrose", "CHEMICAL", 261, 269], ["calves", "ORGANISM", 43, 49], ["Ringers", "SIMPLE_CHEMICAL", 74, 81], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["glucose", "SIMPLE_CHEMICAL", 125, 132], ["glucose", "SIMPLE_CHEMICAL", 210, 217], ["dextrose", "SIMPLE_CHEMICAL", 261, 269], ["calves", "SPECIES", 43, 49], ["dehydration", "PROBLEM", 12, 23], ["inappetence the calves", "PROBLEM", 27, 49], ["Lactated Ringers solution intravenously", "TREATMENT", 65, 104], ["blood serum glucose concentration", "TEST", 113, 146], ["a handheld glucose meter", "TREATMENT", 199, 223], ["a dextrose", "TREATMENT", 259, 269], ["dehydration", "OBSERVATION", 12, 23], ["calves", "ANATOMY", 43, 49]]], ["Calves with inappetence, hypoglycemia, depression and fever or hypothermia were also treated with antibiotics, based on antimicrobial susceptibility tests the last six months (Farm 2: enrofloxacin 5 mg/kg SC, Baytril\u00ae, Bayer Animal Health GmbH, Germany; Farms 1 and 3: ceftiofour 2.2 mg/kg SC, Excenel\u00ae RTU, Zoetis, Hellas) and non-steroid anti-inflammatory drugs (carprofen 1.4 mg/kg SC, Rimadyl\u00ae Cattle, Zoetis, Hellas).", [["inappetence", "DISEASE", 12, 23], ["hypoglycemia", "DISEASE", 25, 37], ["depression", "DISEASE", 39, 49], ["fever", "DISEASE", 54, 59], ["hypothermia", "DISEASE", 63, 74], ["enrofloxacin", "CHEMICAL", 184, 196], ["carprofen", "CHEMICAL", 365, 374], ["enrofloxacin", "CHEMICAL", 184, 196], ["carprofen", "CHEMICAL", 365, 374], ["Calves", "ORGANISM", 0, 6], ["enrofloxacin", "SIMPLE_CHEMICAL", 184, 196], ["Zoetis", "SIMPLE_CHEMICAL", 308, 314], ["Hellas", "SIMPLE_CHEMICAL", 316, 322], ["non-steroid anti-inflammatory drugs", "SIMPLE_CHEMICAL", 328, 363], ["carprofen", "SIMPLE_CHEMICAL", 365, 374], ["Calves", "SPECIES", 0, 6], ["inappetence", "PROBLEM", 12, 23], ["hypoglycemia", "PROBLEM", 25, 37], ["depression", "PROBLEM", 39, 49], ["fever", "PROBLEM", 54, 59], ["hypothermia", "PROBLEM", 63, 74], ["antibiotics", "TREATMENT", 98, 109], ["antimicrobial susceptibility tests", "TEST", 120, 154], ["enrofloxacin", "TREATMENT", 184, 196], ["Baytril\u00ae", "TREATMENT", 209, 217], ["ceftiofour", "TREATMENT", 269, 279], ["Excenel\u00ae RTU", "TREATMENT", 294, 306], ["Zoetis", "TREATMENT", 308, 314], ["Hellas", "TREATMENT", 316, 322], ["non-steroid anti-inflammatory drugs", "TREATMENT", 328, 363], ["carprofen", "TREATMENT", 365, 374], ["Rimadyl\u00ae Cattle", "TREATMENT", 389, 404], ["inappetence", "OBSERVATION", 12, 23], ["hypoglycemia", "OBSERVATION", 25, 37]]], ["In calves of Eco group that were still diarrheic after day 10, administration of oregano essential oil continued until recovery.Calf housing and feeding management ::: Materials and methodsNewborn calves in Farm 1, were housed in individual pens in a separate building.", [["oil", "ANATOMY", 99, 102], ["diarrheic", "DISEASE", 39, 48], ["calves", "ORGANISM", 3, 9], ["oregano", "SIMPLE_CHEMICAL", 81, 88], ["oil", "ORGANISM_SUBSTANCE", 99, 102], ["Calf", "ORGANISM_SUBSTANCE", 128, 132], ["calves", "ORGANISM", 197, 203], ["calves", "SPECIES", 3, 9], ["calves", "SPECIES", 197, 203], ["oregano", "SPECIES", 81, 88], ["still diarrheic", "PROBLEM", 33, 48], ["oregano essential oil", "TREATMENT", 81, 102], ["Eco group", "OBSERVATION_MODIFIER", 13, 22]]], ["Windows (1 m by 0,5 m) served as ventilation inlets, situated 1 m above the pens and oil heaters were used for heat supplementation when ambient temperature was below 4 \u00b0C. Each individual pen had a concrete floor area of 2 m2, with visual access to neighboring pens.", [["oil", "ANATOMY", 85, 88], ["ventilation inlets", "TREATMENT", 33, 51], ["the pens", "TREATMENT", 72, 80], ["oil heaters", "TREATMENT", 85, 96], ["heat supplementation", "TREATMENT", 111, 131], ["ambient temperature", "TEST", 137, 156]]], ["Long stem wheat straw bedding was layed at a density of 70 kg/m3.", [["wheat", "SPECIES", 10, 15], ["wheat", "SPECIES", 10, 15], ["Long stem wheat straw bedding", "TREATMENT", 0, 29], ["straw bedding", "OBSERVATION", 16, 29]]], ["Wet bedding was removed and replaced twice a week.", [["Wet bedding", "TREATMENT", 0, 11], ["bedding", "OBSERVATION", 4, 11]]], ["All rails, gates, partitions, walls, feeders and floors were cleaned on a weekly basis and after each calf was removed from the building.", [["calf", "ORGANISM_SUBDIVISION", 102, 106], ["calf", "SPECIES", 102, 106], ["calf", "ANATOMY", 102, 106]]], ["A pressure water system and a broad spectrum disinfectant were used and adequate time for drying was provided.", [["A pressure water system", "TREATMENT", 0, 23], ["a broad spectrum disinfectant", "TREATMENT", 28, 57], ["drying", "TREATMENT", 90, 96], ["pressure", "OBSERVATION", 2, 10]]], ["Farm 2 housed newborn calves outdoors, in individual polyethylene hutches with an outside run for the calves to move around.", [["polyethylene", "CHEMICAL", 53, 65], ["calves", "ORGANISM", 22, 28], ["calves", "ORGANISM", 102, 108], ["calves", "SPECIES", 22, 28], ["calves", "SPECIES", 102, 108]]], ["Hutches were situated on free draining concrete and were placed 0,3 m apart, enabling visual contact between calves.", [["calves", "ORGANISM", 109, 115], ["calves", "SPECIES", 109, 115], ["calves", "ANATOMY", 109, 115]]], ["Each individual hatch had a concrete floor area of 2.4 m2.", [["2.4 m2", "OBSERVATION_MODIFIER", 51, 57]]], ["Newborn calves in Farm 3 were open housed in group pens partially enclosed under a metallic shed.", [["calves", "ORGANISM", 8, 14], ["calves", "SPECIES", 8, 14], ["calves", "OBSERVATION", 8, 14]]], ["Each group pen had a concrete floor area of 12 m2 for approximately 15 calves.Calf housing and feeding management ::: Materials and methodsClean, dry straw bedding which was disposed of after each batch of calves, was used in all Farms.", [["Calf", "ORGANISM_SUBSTANCE", 78, 82], ["calves", "ORGANISM", 206, 212], ["calves", "SPECIES", 71, 77], ["calves", "SPECIES", 206, 212], ["methods", "TREATMENT", 132, 139], ["dry straw bedding", "TREATMENT", 146, 163], ["each batch of calves", "TREATMENT", 192, 212], ["Clean", "OBSERVATION", 139, 144], ["dry", "OBSERVATION_MODIFIER", 146, 149], ["straw bedding", "OBSERVATION", 150, 163], ["calves", "ANATOMY", 206, 212]]], ["Concrete feed troughs on the external side of the pens and water bowls mounted inside the pens were used in Farm 1.", [["Concrete feed troughs", "TREATMENT", 0, 21], ["the pens and water bowls", "TREATMENT", 46, 70], ["the pens", "TREATMENT", 86, 94], ["troughs", "OBSERVATION_MODIFIER", 14, 21]]], ["Feed and water buckets were secured outside individual pens and hutches in Farms 2 and 3, respectively.Calf housing and feeding management ::: Materials and methodsNewborn calves were bottle-fed fresh colostrum from their respective mothers in all Farms.", [["colostrum", "ANATOMY", 201, 210], ["Calf", "ORGANISM_SUBSTANCE", 103, 107], ["calves", "ORGANISM", 172, 178], ["colostrum", "ORGANISM_SUBSTANCE", 201, 210], ["calves", "SPECIES", 172, 178], ["water buckets", "TREATMENT", 9, 22]]], ["Each calf was fed 2 l of colostrum within 2 h after birth and another 2 l after 6 h.", [["calf", "ANATOMY", 5, 9], ["colostrum", "ANATOMY", 25, 34], ["calf", "ORGANISM", 5, 9], ["colostrum", "ORGANISM_SUBSTANCE", 25, 34], ["calf", "SPECIES", 5, 9], ["calf", "ANATOMY", 5, 9]]], ["At days two and three of their lives, all calves were fed colostrum/milk from their respective dams, at 10% of their bodyweight.", [["milk", "ANATOMY", 68, 72], ["calves", "ORGANISM", 42, 48], ["colostrum", "ORGANISM", 58, 67], ["milk", "ORGANISM_SUBSTANCE", 68, 72], ["dams", "ORGANISM", 95, 99], ["calves", "SPECIES", 42, 48]]], ["At four days old and afterwards, calves in all Farms consumed milk replacer meal.", [["calves", "ORGANISM", 33, 39], ["milk", "ORGANISM_SUBSTANCE", 62, 66], ["calves", "SPECIES", 33, 39], ["milk", "SPECIES", 62, 66]]], ["The nutrient analysis of the milk replacer used is presented in Table 1.", [["milk replacer", "ANATOMY", 29, 42], ["milk", "ORGANISM_SUBSTANCE", 29, 33], ["the milk replacer", "TREATMENT", 25, 42]]], ["Milk replacer was offered at 39 \u00b0C, the optimal drinking temperature, twice a day.", [["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["Milk replacer", "TREATMENT", 0, 13]]], ["Calves were fed 10% of their bodyweight in milk replacer.", [["Calves", "ORGANISM", 0, 6], ["milk", "ORGANISM_SUBSTANCE", 43, 47], ["Calves", "SPECIES", 0, 6], ["milk replacer", "TREATMENT", 43, 56]]], ["The same calf starter (Table 2) was also offered starting at day five in all Farms.", [["calf", "ORGANISM", 9, 13], ["calf", "SPECIES", 9, 13], ["The same calf starter (Table 2)", "TREATMENT", 0, 31]]], ["Approximately 250 g of calf starter per day were offered in a shallow bucket.", [["calf", "ORGANISM", 23, 27], ["calf", "SPECIES", 23, 27]]], ["The amount increased gradually, as calves started consuming all of the feed.", [["calves", "ORGANISM", 35, 41], ["calves", "SPECIES", 35, 41], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["increased", "OBSERVATION_MODIFIER", 11, 20], ["gradually", "OBSERVATION_MODIFIER", 21, 30]]], ["All buckets were emptied and refreshed every 12 h with clean feed.Parasitological analysis ::: Materials and methodsThe fecal samples were diluted (1:1) with tap water and passed through a sieve (no. 150) in a centrifuge tube, centrifuged at 500g for 3 min and smears of 20 \u03bcl of the sediment were dried, stained using the acid-fast Ziehl-Neelsen technique (Henriksen and Pohlenz, 1981), and examined at 1000 \u00d7 magnification for Cryptosporidium spp. oocysts.", [["fecal samples", "ANATOMY", 120, 133], ["sediment", "ANATOMY", 284, 292], ["Cryptosporidium spp", "DISEASE", 429, 448], ["fecal samples", "ORGANISM_SUBSTANCE", 120, 133], ["tube", "TISSUE", 221, 225], ["oocysts", "ORGANISM_SUBSTANCE", 450, 457], ["Parasitological analysis", "TEST", 66, 90], ["The fecal samples", "TEST", 116, 133], ["tap water", "TREATMENT", 158, 167], ["a centrifuge tube", "TREATMENT", 208, 225], ["smears", "TEST", 261, 267], ["the acid", "TEST", 319, 327], ["Cryptosporidium spp", "PROBLEM", 429, 448], ["oocysts", "PROBLEM", 450, 457], ["fecal", "ANATOMY", 120, 125]]], ["Oocyst shedding was estimated semiquantitatively according to the average number of oocysts in 10 random fields.", [["Oocyst", "ANATOMY", 0, 6], ["Oocyst", "CELL", 0, 6], ["Oocyst shedding", "PROBLEM", 0, 15], ["oocysts", "OBSERVATION", 84, 91]]], ["Calves found positive at at least one sampling were considered as positive for Cryptosporidium spp.Virological analysis ::: Materials and methodsTen percent suspensions of each fecal sample were prepared in phosphate-buffered saline (PBS), and RNA was extracted according to RNA extraction method C described by Pappi et al. (2015).", [["fecal sample", "ANATOMY", 177, 189], ["Cryptosporidium spp", "DISEASE", 79, 98], ["phosphate", "CHEMICAL", 207, 216], ["phosphate", "CHEMICAL", 207, 216], ["Calves", "ORGANISM", 0, 6], ["Cryptosporidium spp", "ORGANISM", 79, 98], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 207, 232], ["Calves", "SPECIES", 0, 6], ["Calves", "PROBLEM", 0, 6], ["Cryptosporidium spp", "PROBLEM", 79, 98], ["Virological analysis", "TEST", 99, 119], ["Ten percent suspensions of each fecal sample", "TREATMENT", 145, 189], ["phosphate-buffered saline (PBS", "TREATMENT", 207, 237], ["RNA", "TREATMENT", 244, 247], ["positive", "OBSERVATION", 13, 21]]], ["RNA extracts were stored at \u2212 80 \u00b0C until testing.", [["extracts", "ANATOMY", 4, 12], ["extracts", "ORGANISM_SUBSTANCE", 4, 12], ["RNA extracts", "TEST", 0, 12], ["testing", "TEST", 42, 49]]], ["Two different real-time quantitative reverse transcription-PCR (qRT-PCR) assays were applied for the detection of RVA (Freeman et al., 2008) and BCoV (Decaro et al., 2008).", [["PCR", "TEST", 59, 62], ["qRT", "TEST", 64, 67], ["assays", "TEST", 73, 79], ["RVA", "PROBLEM", 114, 117]]], ["Calves found positive even at one sapling were considered as positive for the respective virus.Bacteriological analysis ::: Materials and methodsTo enumerate the population of E. coli in fecal samples viable plate count method was used.", [["fecal samples", "ANATOMY", 187, 200], ["Calves", "ORGANISM", 0, 6], ["E. coli", "ORGANISM", 176, 183], ["fecal samples", "ORGANISM_SUBSTANCE", 187, 200], ["Calves", "SPECIES", 0, 6], ["E. coli", "SPECIES", 176, 183], ["E. coli", "SPECIES", 176, 183], ["Calves", "PROBLEM", 0, 6], ["the respective virus", "PROBLEM", 74, 94], ["Bacteriological analysis", "TEST", 95, 119], ["E. coli", "PROBLEM", 176, 183], ["fecal samples", "TEST", 187, 200], ["plate count method", "TEST", 208, 226], ["positive", "OBSERVATION", 13, 21], ["respective virus", "OBSERVATION", 78, 94], ["E. coli", "OBSERVATION", 176, 183], ["fecal", "ANATOMY", 187, 192]]], ["Initially 1 g of the sample was diluted in 9 subsequent ten-fold dilutions in phosphate buffer saline.", [["sample", "ANATOMY", 21, 27], ["phosphate", "CHEMICAL", 78, 87], ["phosphate", "CHEMICAL", 78, 87], ["phosphate buffer saline", "SIMPLE_CHEMICAL", 78, 101], ["the sample", "TEST", 17, 27], ["9 subsequent ten-fold dilutions", "TREATMENT", 43, 74], ["phosphate buffer saline", "TREATMENT", 78, 101]]], ["One hundred microliters of each diluent was plated on TBX agar medium (Merck KGaA; Darmstadt, Germany) and incubated aerobically at 37 \u00b0C. Plates with 30 to 300 typical X-glucuronide positive colonies (blue in color) were calculated.", [["colonies", "ANATOMY", 192, 200], ["TBX agar", "CHEMICAL", 54, 62], ["X-glucuronide", "CHEMICAL", 169, 182], ["X-glucuronide", "CHEMICAL", 169, 182], ["X-glucuronide", "SIMPLE_CHEMICAL", 169, 182], ["X-glucuronide positive colonies", "CELL_LINE", 169, 200], ["Plates", "TEST", 139, 145], ["blue in color", "TEST", 202, 215], ["30 to", "OBSERVATION_MODIFIER", 151, 156]]], ["Each colony was represented as colony forming unit (CFU) and measured with the formula shown below in CFUs/ml:Cell density=number of colonies\u00d7Dilution factor of the plate counted", [["colony", "ANATOMY", 5, 11], ["colony", "ANATOMY", 31, 37], ["Cell", "ANATOMY", 110, 114], ["colonies", "ANATOMY", 133, 141], ["Cell", "CELL", 110, 114], ["the formula", "TEST", 75, 86], ["Cell density", "TEST", 110, 122], ["colony", "OBSERVATION", 5, 11], ["Cell density", "OBSERVATION", 110, 122], ["plate counted", "OBSERVATION_MODIFIER", 165, 178]]]], "PMC6531299": [["IntroductionFOXP3+ regulatory T cells (Tregs), a subset of CD4+ T cells, maintain immune homeostasis and prevent autoimmunity by suppressing auto-reactivity and regulating immune responses to foreign and self-antigens 1.", [["IntroductionFOXP3+ regulatory T cells", "ANATOMY", 0, 37], ["Tregs", "ANATOMY", 39, 44], ["CD4+ T cells", "ANATOMY", 59, 71], ["autoimmunity", "DISEASE", 113, 125], ["IntroductionFOXP3", "GENE_OR_GENE_PRODUCT", 0, 17], ["Tregs", "CELL", 39, 44], ["CD4", "GENE_OR_GENE_PRODUCT", 59, 62], ["IntroductionFOXP3", "PROTEIN", 0, 17], ["regulatory T cells", "CELL_TYPE", 19, 37], ["Tregs", "CELL_TYPE", 39, 44], ["CD4+ T cells", "CELL_TYPE", 59, 71], ["foreign and self-antigens 1", "PROTEIN", 192, 219], ["CD4+ T cells", "PROBLEM", 59, 71], ["immune homeostasis", "TREATMENT", 82, 100], ["autoimmunity", "PROBLEM", 113, 125], ["suppressing auto-reactivity", "PROBLEM", 129, 156], ["regulatory T cells", "OBSERVATION", 19, 37]]], ["A hallmark of Tregs is their expression of the transcription factor, FOXP3, and the high level of CD25, the IL2 receptor alpha chain 2.", [["Tregs", "ANATOMY", 14, 19], ["Tregs", "CELL", 14, 19], ["FOXP3", "GENE_OR_GENE_PRODUCT", 69, 74], ["CD25", "GENE_OR_GENE_PRODUCT", 98, 102], ["IL2 receptor alpha chain 2", "GENE_OR_GENE_PRODUCT", 108, 134], ["Tregs", "CELL_TYPE", 14, 19], ["transcription factor", "PROTEIN", 47, 67], ["FOXP3", "PROTEIN", 69, 74], ["CD25", "PROTEIN", 98, 102], ["IL2 receptor alpha chain 2", "PROTEIN", 108, 134], ["FOXP3", "TEST", 69, 74], ["the IL2 receptor alpha chain", "TREATMENT", 104, 132], ["hallmark", "OBSERVATION_MODIFIER", 2, 10], ["Tregs", "OBSERVATION", 14, 19]]], ["Due to their role in maintaining immune homeostasis and tolerance, Tregs have been considered as potentially immunotherapy to prevent a variety of immunological diseases in human.", [["Tregs", "ANATOMY", 67, 72], ["immunological diseases", "DISEASE", 147, 169], ["Tregs", "CELL", 67, 72], ["human", "ORGANISM", 173, 178], ["Tregs", "CELL_TYPE", 67, 72], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 173, 178], ["Tregs", "TREATMENT", 67, 72], ["immunotherapy", "TREATMENT", 109, 122], ["immunological diseases in human", "PROBLEM", 147, 178], ["immunological diseases", "OBSERVATION", 147, 169]]], ["Among potential diseases that may be tackled with such immune-modulators are most graft versus host disease (GVHD), a frequent and often severe complication following allogeneic hematopoietic cell transplantation 3.", [["graft", "ANATOMY", 82, 87], ["hematopoietic cell", "ANATOMY", 178, 196], ["graft versus host disease", "DISEASE", 82, 107], ["GVHD", "DISEASE", 109, 113], ["graft", "TISSUE", 82, 87], ["hematopoietic cell", "CELL", 178, 196], ["Among potential diseases", "PROBLEM", 0, 24], ["such immune-modulators", "TREATMENT", 50, 72], ["graft versus host disease", "PROBLEM", 82, 107], ["GVHD", "PROBLEM", 109, 113], ["a frequent and often severe complication", "PROBLEM", 116, 156], ["allogeneic hematopoietic cell transplantation", "TREATMENT", 167, 212], ["diseases", "OBSERVATION", 16, 24], ["host disease", "OBSERVATION", 95, 107], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["complication", "OBSERVATION", 144, 156], ["allogeneic hematopoietic cell transplantation", "OBSERVATION", 167, 212]]], ["Murine studies have demonstrated convincing evidence of the power of Tregs as a cell therapy to prevent and treat various immunological conditions, such as multiple sclerosis, GVHD, inflammatory bowel disease and lupus 4-10.", [["Tregs", "ANATOMY", 69, 74], ["cell", "ANATOMY", 80, 84], ["bowel", "ANATOMY", 195, 200], ["multiple sclerosis", "DISEASE", 156, 174], ["GVHD", "DISEASE", 176, 180], ["inflammatory bowel disease", "DISEASE", 182, 208], ["lupus", "DISEASE", 213, 218], ["Murine", "ORGANISM", 0, 6], ["Tregs", "CELL", 69, 74], ["cell", "CELL", 80, 84], ["bowel", "ORGAN", 195, 200], ["Tregs", "CELL_TYPE", 69, 74], ["Murine studies", "TEST", 0, 14], ["Tregs", "TREATMENT", 69, 74], ["a cell therapy", "TREATMENT", 78, 92], ["various immunological conditions", "PROBLEM", 114, 146], ["multiple sclerosis", "PROBLEM", 156, 174], ["GVHD", "PROBLEM", 176, 180], ["inflammatory bowel disease", "PROBLEM", 182, 208], ["lupus", "PROBLEM", 213, 218], ["cell therapy", "OBSERVATION", 80, 92], ["multiple", "OBSERVATION_MODIFIER", 156, 164], ["sclerosis", "OBSERVATION", 165, 174], ["GVHD", "OBSERVATION", 176, 180], ["inflammatory", "OBSERVATION_MODIFIER", 182, 194], ["bowel", "ANATOMY", 195, 200], ["disease", "OBSERVATION", 201, 208], ["lupus", "OBSERVATION", 213, 218]]], ["In translating these studies to human therapeutic applications, one major limitation is the expansion of Tregs ex vivo to achieve consistently sufficient number and purity of bona fide Tregs.", [["Tregs", "ANATOMY", 105, 110], ["Tregs", "ANATOMY", 185, 190], ["human", "ORGANISM", 32, 37], ["Tregs", "CELL", 105, 110], ["Tregs", "CELL", 185, 190], ["Tregs", "CELL_TYPE", 105, 110], ["bona fide Tregs", "CELL_TYPE", 175, 190], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["these studies", "TEST", 15, 28], ["human therapeutic applications", "TREATMENT", 32, 62], ["Tregs ex vivo", "TREATMENT", 105, 118], ["Tregs", "OBSERVATION", 105, 110], ["bona fide Tregs", "OBSERVATION", 175, 190]]], ["In the peripheral blood of healthy adults, there are ~5-10% FOXP3+ Tregs within total CD4+ T cells.", [["peripheral blood", "ANATOMY", 7, 23], ["Tregs", "ANATOMY", 67, 72], ["CD4+ T cells", "ANATOMY", 86, 98], ["peripheral blood", "ORGANISM_SUBSTANCE", 7, 23], ["FOXP3", "GENE_OR_GENE_PRODUCT", 60, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 86, 89], ["FOXP3", "PROTEIN", 60, 65], ["Tregs", "CELL_TYPE", 67, 72], ["CD4+ T cells", "CELL_TYPE", 86, 98], ["peripheral", "ANATOMY_MODIFIER", 7, 17], ["blood", "ANATOMY", 18, 23], ["T cells", "OBSERVATION", 91, 98]]], ["Since FOXP3 is an intracellular transcription factor, only the CD4+ T cells with low CD127 and high CD25 expression, i.e., no more than 2-4% can be sorted to functionally isolate >90% FOXP3 purity.", [["intracellular", "ANATOMY", 18, 31], ["CD4+ T cells", "ANATOMY", 63, 75], ["FOXP3", "GENE_OR_GENE_PRODUCT", 6, 11], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 31], ["CD4", "GENE_OR_GENE_PRODUCT", 63, 66], ["CD127", "GENE_OR_GENE_PRODUCT", 85, 90], ["CD25", "GENE_OR_GENE_PRODUCT", 100, 104], ["FOXP3", "GENE_OR_GENE_PRODUCT", 184, 189], ["FOXP3", "PROTEIN", 6, 11], ["intracellular transcription factor", "PROTEIN", 18, 52], ["CD4", "PROTEIN", 63, 66], ["T cells", "CELL_TYPE", 68, 75], ["CD127", "PROTEIN", 85, 90], ["CD25", "PROTEIN", 100, 104], ["FOXP3", "PROTEIN", 184, 189], ["an intracellular transcription factor", "PROBLEM", 15, 52], ["low CD127", "PROBLEM", 81, 90], ["intracellular transcription", "OBSERVATION", 18, 45], ["low CD127", "OBSERVATION", 81, 90], ["high CD25 expression", "OBSERVATION", 95, 115], ["FOXP3 purity", "OBSERVATION", 184, 196]]], ["However, this population is not homogeneously Tregs, particularly in diseases where these markers are less correlative due to activated T cells.", [["Tregs", "ANATOMY", 46, 51], ["T cells", "ANATOMY", 136, 143], ["Tregs", "CELL", 46, 51], ["T cells", "CELL", 136, 143], ["Tregs", "CELL_TYPE", 46, 51], ["activated T cells", "CELL_TYPE", 126, 143], ["homogeneously Tregs", "PROBLEM", 32, 51], ["diseases", "PROBLEM", 69, 77], ["these markers", "TEST", 84, 97], ["activated T cells", "PROBLEM", 126, 143], ["not", "UNCERTAINTY", 28, 31], ["homogeneously", "OBSERVATION_MODIFIER", 32, 45], ["Tregs", "OBSERVATION", 46, 51]]], ["It has been established that there are two subsets of Tregs: those developed in the thymus (tTregs) and those generated in the periphery (pTregs).", [["Tregs", "ANATOMY", 54, 59], ["thymus", "ANATOMY", 84, 90], ["Tregs", "ANATOMY", 93, 98], ["periphery", "ANATOMY", 127, 136], ["Tregs", "ANATOMY", 139, 144], ["Tregs", "CELL", 54, 59], ["thymus", "ORGAN", 84, 90], ["Tregs", "CELL", 93, 98], ["Tregs", "CELL", 139, 144], ["Tregs", "CELL_TYPE", 54, 59], ["tTregs", "CELL_TYPE", 92, 98], ["Tregs", "CELL_TYPE", 139, 144], ["two", "OBSERVATION_MODIFIER", 39, 42], ["subsets", "OBSERVATION_MODIFIER", 43, 50], ["Tregs", "OBSERVATION", 54, 59], ["thymus", "ANATOMY", 84, 90], ["periphery", "ANATOMY_MODIFIER", 127, 136]]], ["Moreover, na\u00efve CD4+ T cells can be induced in vitro with TCR stimulation in the presence of TGF\u03b21 and IL2 to express FOXP3 (iTregs) 11.", [["CD4+ T cells", "ANATOMY", 16, 28], ["TCR", "CHEMICAL", 58, 61], ["CD4", "GENE_OR_GENE_PRODUCT", 16, 19], ["TCR", "GENE_OR_GENE_PRODUCT", 58, 61], ["TGF\u03b21", "GENE_OR_GENE_PRODUCT", 93, 98], ["IL2", "GENE_OR_GENE_PRODUCT", 103, 106], ["FOXP3", "GENE_OR_GENE_PRODUCT", 118, 123], ["na\u00efve CD4+ T cells", "CELL_TYPE", 10, 28], ["TCR", "PROTEIN", 58, 61], ["TGF\u03b21", "PROTEIN", 93, 98], ["IL2", "PROTEIN", 103, 106], ["FOXP3 (iTregs) 11", "PROTEIN", 118, 135], ["T cells", "PROBLEM", 21, 28], ["TCR stimulation", "TREATMENT", 58, 73], ["TGF", "TEST", 93, 96], ["FOXP3 (iTregs)", "TREATMENT", 118, 132]]], ["The functional patterns for these different subgroups of Tregs are widely varying during the expansion of Tregs over a 3-4 week period.", [["Tregs", "ANATOMY", 57, 62], ["Tregs", "ANATOMY", 106, 111], ["Tregs", "CELL", 57, 62], ["Tregs", "CELL", 106, 111], ["Tregs", "CELL_TYPE", 57, 62], ["Tregs", "CELL_TYPE", 106, 111], ["Tregs", "OBSERVATION", 57, 62], ["widely", "OBSERVATION_MODIFIER", 67, 73], ["varying", "OBSERVATION_MODIFIER", 74, 81], ["expansion", "OBSERVATION_MODIFIER", 93, 102]]], ["In addition, the purity and composition of Tregs frequencies with respect to tTregs, iTregs, pTregs and CD4+FOXP3- nonTregs are also varying, resulting in an impure Treg product.IntroductionWe have demonstrated previously that iTregs lack the cardinal features of tTregs based on anergy and suppressive function 11.", [["Tregs", "ANATOMY", 43, 48], ["iTregs", "ANATOMY", 85, 91], ["pTregs", "ANATOMY", 93, 99], ["CD4+FOXP3- nonTregs", "ANATOMY", 104, 123], ["Treg", "ANATOMY", 165, 169], ["Tregs", "CELL", 43, 48], ["tTregs", "GENE_OR_GENE_PRODUCT", 77, 83], ["iTregs", "GENE_OR_GENE_PRODUCT", 85, 91], ["pTregs", "GENE_OR_GENE_PRODUCT", 93, 99], ["CD4", "GENE_OR_GENE_PRODUCT", 104, 107], ["FOXP3", "GENE_OR_GENE_PRODUCT", 108, 113], ["Treg", "CELL", 165, 169], ["iTregs", "CELL", 227, 233], ["tTregs", "GENE_OR_GENE_PRODUCT", 264, 270], ["Tregs", "CELL_TYPE", 43, 48], ["tTregs", "CELL_TYPE", 77, 83], ["iTregs", "CELL_TYPE", 85, 91], ["pTregs", "CELL_TYPE", 93, 99], ["CD4", "PROTEIN", 104, 107], ["FOXP3", "PROTEIN", 108, 113], ["Tregs", "CELL_TYPE", 118, 123], ["Treg product", "PROTEIN", 165, 177], ["the purity", "TREATMENT", 13, 23], ["Tregs frequencies", "TREATMENT", 43, 60], ["tTregs", "TEST", 77, 83], ["iTregs", "TREATMENT", 85, 91], ["pTregs", "TEST", 93, 99], ["CD4", "TEST", 104, 107], ["Treg product", "TREATMENT", 165, 177]]], ["While >90% FOXP3+ cells can be isolated by FACS-sorting, frequently the percentage of FOXP3+ T cells decreases to 75% after two weeks and 50% after three weeks of expansion 12-14.", [["FOXP3+ cells", "ANATOMY", 11, 23], ["FOXP3+ T cells", "ANATOMY", 86, 100], ["FOXP3", "GENE_OR_GENE_PRODUCT", 11, 16], ["FOXP3", "GENE_OR_GENE_PRODUCT", 86, 91], ["FOXP3", "PROTEIN", 11, 16], ["FOXP3", "PROTEIN", 86, 91], ["T cells", "CELL_TYPE", 93, 100], ["FACS", "TEST", 43, 47], ["FOXP3", "TEST", 86, 91], ["T cells", "PROBLEM", 93, 100], ["expansion", "TEST", 163, 172]]], ["Due to these limitations that have hindered the advancement of Treg analysis and therapy, we have developed an innovative technique to repurify Tregs from expanded cultures contaminated with activated nonTregs.", [["Treg", "ANATOMY", 63, 67], ["Tregs", "ANATOMY", 144, 149], ["cultures", "ANATOMY", 164, 172], ["nonTregs", "ANATOMY", 201, 209], ["Treg", "CELL", 63, 67], ["Tregs", "CELL", 144, 149], ["nonTregs", "CELL", 201, 209], ["Tregs", "CELL_TYPE", 144, 149], ["expanded cultures", "CELL_LINE", 155, 172], ["activated nonTregs", "CELL_TYPE", 191, 209], ["Treg analysis", "TEST", 63, 76], ["therapy", "TREATMENT", 81, 88], ["an innovative technique", "TREATMENT", 108, 131], ["Tregs", "PROBLEM", 144, 149], ["expanded cultures", "TEST", 155, 172], ["activated nonTregs", "TREATMENT", 191, 209]]], ["By targeting the selective expression of latency-associated peptide (LAP), this novel method allows for expansion and consistent re-purification of sufficient quantity of highly purified, bona fide Tregs (>90% FOXP3), even from an initial limited blood volume of 5-10 ml 15.", [["Tregs", "ANATOMY", 198, 203], ["blood", "ANATOMY", 247, 252], ["LAP", "GENE_OR_GENE_PRODUCT", 69, 72], ["Tregs", "CELL", 198, 203], ["FOXP3", "GENE_OR_GENE_PRODUCT", 210, 215], ["blood", "ORGANISM_SUBSTANCE", 247, 252], ["LAP", "PROTEIN", 69, 72], ["bona fide Tregs", "CELL_TYPE", 188, 203], ["FOXP3", "PROTEIN", 210, 215], ["expansion", "PROBLEM", 104, 113], ["an initial limited blood volume", "TEST", 228, 259], ["fide Tregs", "OBSERVATION", 193, 203]]], ["Without this technique, it has been difficult to analyze and assess definitively the function of Tregs due to variable contaminants of nonTregs.", [["Tregs", "ANATOMY", 97, 102], ["Tregs", "CELL", 97, 102], ["nonTregs", "CELL", 135, 143], ["Tregs", "CELL_TYPE", 97, 102], ["this technique", "TREATMENT", 8, 22], ["Tregs", "PROBLEM", 97, 102], ["variable contaminants of nonTregs", "PROBLEM", 110, 143]]], ["Moreover, this method has the potential to optimize Treg therapy by permitting the manufacturing of a Treg product that is consistently >90% bona fide Tregs regardless of methods of expansion or donor's variability.", [["Treg", "ANATOMY", 52, 56], ["Treg", "ANATOMY", 102, 106], ["Tregs", "ANATOMY", 151, 156], ["Treg", "CELL", 52, 56], ["Treg", "CELL", 102, 106], ["Tregs", "CELL", 151, 156], ["Treg product", "PROTEIN", 102, 114], ["Tregs", "CELL_TYPE", 151, 156], ["Treg therapy", "TREATMENT", 52, 64], ["a Treg product", "TREATMENT", 100, 114], ["expansion", "PROBLEM", 182, 191], ["donor's variability", "TEST", 195, 214], ["fide Tregs", "OBSERVATION", 146, 156]]], ["Using the LAP marker, we can selectively isolate LAP+ Tregs from any time point during expansion that are typically contaminated by >25% FOXP3+ and FOXP3- nonTregs.", [["Tregs", "ANATOMY", 54, 59], ["LAP", "GENE_OR_GENE_PRODUCT", 10, 13], ["LAP", "GENE_OR_GENE_PRODUCT", 49, 52], ["Tregs", "CELL", 54, 59], ["FOXP3", "GENE_OR_GENE_PRODUCT", 137, 142], ["FOXP3", "GENE_OR_GENE_PRODUCT", 148, 153], ["LAP", "PROTEIN", 10, 13], ["LAP", "PROTEIN", 49, 52], ["Tregs", "CELL_TYPE", 54, 59], ["FOXP3", "PROTEIN", 137, 142], ["FOXP3", "PROTEIN", 148, 153], ["the LAP marker", "TREATMENT", 6, 20], ["Tregs", "PROBLEM", 54, 59], ["FOXP3", "TEST", 148, 153]]], ["This purity and selectivity will allow for separation of different subsets and definitive determination of Tregs function in GVHD.", [["Tregs", "ANATOMY", 107, 112], ["GVHD", "DISEASE", 125, 129], ["Tregs", "CELL", 107, 112], ["Tregs", "CELL_TYPE", 107, 112], ["different subsets", "TREATMENT", 57, 74], ["Tregs function", "PROBLEM", 107, 121], ["GVHD", "PROBLEM", 125, 129]]], ["Another important factor is the cost effectiveness for production of a Treg product.", [["Treg", "ANATOMY", 71, 75], ["Treg", "CELL", 71, 75], ["Treg product", "PROTEIN", 71, 83], ["a Treg product", "TREATMENT", 69, 83]]], ["In this study, we use CD25+ cells isolated from buffy coats with anti-CD25 microbeads.", [["CD25+ cells", "ANATOMY", 22, 33], ["buffy coats", "ANATOMY", 48, 59], ["CD25", "GENE_OR_GENE_PRODUCT", 22, 26], ["buffy coats", "ORGANISM_SUBSTANCE", 48, 59], ["anti-CD25", "GENE_OR_GENE_PRODUCT", 65, 74], ["CD25", "PROTEIN", 22, 26], ["anti-CD25 microbeads", "PROTEIN", 65, 85], ["this study", "TEST", 3, 13], ["CD25+ cells", "TREATMENT", 22, 33], ["buffy coats", "TREATMENT", 48, 59], ["anti-CD25 microbeads", "TREATMENT", 65, 85], ["buffy coats", "OBSERVATION", 48, 59]]], ["These CD25+ cells are expanded with OKT3-loaded KT64/86 artificial APC (aAPC) expressing CD86 and CD64 and re-purified based on LAP expression.", [["CD25+ cells", "ANATOMY", 6, 17], ["aAPC", "ANATOMY", 72, 76], ["CD25", "GENE_OR_GENE_PRODUCT", 6, 10], ["OKT3", "GENE_OR_GENE_PRODUCT", 36, 40], ["APC", "GENE_OR_GENE_PRODUCT", 67, 70], ["aAPC", "CANCER", 72, 76], ["CD86", "GENE_OR_GENE_PRODUCT", 89, 93], ["CD64", "GENE_OR_GENE_PRODUCT", 98, 102], ["LAP", "GENE_OR_GENE_PRODUCT", 128, 131], ["CD25", "PROTEIN", 6, 10], ["OKT3", "PROTEIN", 36, 40], ["KT64", "PROTEIN", 48, 52], ["APC", "CELL_TYPE", 67, 70], ["aAPC", "PROTEIN", 72, 76], ["CD86", "PROTEIN", 89, 93], ["CD64", "PROTEIN", 98, 102], ["LAP", "PROTEIN", 128, 131], ["OKT3", "TEST", 36, 40], ["KT64", "TEST", 48, 52], ["artificial APC (aAPC", "TREATMENT", 56, 76], ["CD86", "TEST", 89, 93], ["CD64", "TEST", 98, 102], ["LAP expression", "TEST", 128, 142], ["LAP expression", "OBSERVATION", 128, 142]]], ["We perform an analysis of the TCR repertoire, function, and phenotype within CD25+ cells and the subsets of LAP+ Tregs and LAP- nonTregs isolated from expansion cultures.", [["CD25+ cells", "ANATOMY", 77, 88], ["Tregs", "ANATOMY", 113, 118], ["Tregs", "ANATOMY", 131, 136], ["cultures", "ANATOMY", 161, 169], ["TCR", "GENE_OR_GENE_PRODUCT", 30, 33], ["CD25", "GENE_OR_GENE_PRODUCT", 77, 81], ["LAP", "GENE_OR_GENE_PRODUCT", 108, 111], ["Tregs", "CELL", 113, 118], ["LAP", "GENE_OR_GENE_PRODUCT", 123, 126], ["Tregs", "CELL", 131, 136], ["TCR", "PROTEIN", 30, 33], ["CD25", "PROTEIN", 77, 81], ["LAP", "PROTEIN", 108, 111], ["Tregs", "CELL_TYPE", 113, 118], ["LAP", "PROTEIN", 123, 126], ["Tregs", "CELL_TYPE", 131, 136], ["expansion cultures", "CELL_LINE", 151, 169], ["an analysis", "TEST", 11, 22], ["the TCR repertoire", "TEST", 26, 44], ["LAP", "TEST", 108, 111], ["Tregs", "TEST", 113, 118], ["LAP", "TEST", 123, 126], ["expansion cultures", "TEST", 151, 169], ["LAP", "OBSERVATION", 108, 111], ["LAP", "OBSERVATION", 123, 126], ["nonTregs", "OBSERVATION_MODIFIER", 128, 136], ["expansion", "OBSERVATION_MODIFIER", 151, 160]]], ["We demonstrate that LAP+ Tregs after 4-week ex vivo expansion still maintain diverse TCR V\u03b2 repertoire, are highly demethylated in the TSDR region, and possess suppressive function.", [["Tregs", "ANATOMY", 25, 30], ["TSDR region", "ANATOMY", 135, 146], ["TCR", "CHEMICAL", 85, 88], ["LAP", "GENE_OR_GENE_PRODUCT", 20, 23], ["Tregs", "CELL", 25, 30], ["V\u03b2", "GENE_OR_GENE_PRODUCT", 89, 91], ["LAP", "PROTEIN", 20, 23], ["Tregs", "CELL_TYPE", 25, 30], ["TCR", "PROTEIN", 85, 88], ["V\u03b2 repertoire", "PROTEIN", 89, 102], ["TSDR region", "DNA", 135, 146], ["LAP", "TEST", 20, 23], ["4-week ex vivo expansion", "TREATMENT", 37, 61], ["LAP", "OBSERVATION", 20, 23], ["diverse TCR", "OBSERVATION", 77, 88], ["highly", "OBSERVATION_MODIFIER", 108, 114], ["demethylated", "OBSERVATION", 115, 127], ["suppressive function", "OBSERVATION", 160, 180]]], ["In contrast, the LAP- nonTregs possess no suppressive function, while the CD25+ parent population had variable functionality depending on the level of expanded, contaminated nonTregs.IntroductionOur study demonstrates a simple single-step CD25+ isolation, robust expansion on aAPCs, and LAP+ repurification to obtain highly purified, bona fide FOXP3+ Tregs.", [["Tregs", "ANATOMY", 25, 30], ["nonTregs", "ANATOMY", 174, 182], ["Tregs", "ANATOMY", 351, 356], ["LAP", "GENE_OR_GENE_PRODUCT", 17, 20], ["CD25", "GENE_OR_GENE_PRODUCT", 74, 78], ["nonTregs", "CELL", 174, 182], ["CD25", "GENE_OR_GENE_PRODUCT", 239, 243], ["aAPCs", "SIMPLE_CHEMICAL", 276, 281], ["LAP", "GENE_OR_GENE_PRODUCT", 287, 290], ["FOXP3", "GENE_OR_GENE_PRODUCT", 344, 349], ["Tregs", "CELL", 351, 356], ["LAP", "PROTEIN", 17, 20], ["Tregs", "CELL_TYPE", 25, 30], ["CD25", "PROTEIN", 74, 78], ["CD25", "PROTEIN", 239, 243], ["LAP", "PROTEIN", 287, 290], ["FOXP3", "PROTEIN", 344, 349], ["Tregs", "CELL_TYPE", 351, 356], ["the LAP", "TEST", 13, 20], ["suppressive function", "PROBLEM", 42, 62], ["variable functionality", "PROBLEM", 102, 124], ["IntroductionOur study", "TEST", 183, 204], ["aAPCs", "TEST", 276, 281], ["LAP", "TEST", 287, 290], ["LAP", "OBSERVATION", 17, 20], ["no", "UNCERTAINTY", 39, 41], ["suppressive function", "OBSERVATION", 42, 62], ["robust", "OBSERVATION_MODIFIER", 256, 262], ["expansion", "OBSERVATION_MODIFIER", 263, 272], ["FOXP3", "OBSERVATION", 344, 349]]], ["Ultimately, clinical investigators can apply our techniques to further define Tregs in patients with other immunologic conditions and generate highly purified Treg products for therapeutic use.", [["Tregs", "ANATOMY", 78, 83], ["Treg", "ANATOMY", 159, 163], ["Tregs", "CELL", 78, 83], ["patients", "ORGANISM", 87, 95], ["Treg", "CELL", 159, 163], ["Tregs", "CELL_TYPE", 78, 83], ["Treg products", "PROTEIN", 159, 172], ["patients", "SPECIES", 87, 95], ["other immunologic conditions", "PROBLEM", 101, 129], ["highly purified Treg products", "TREATMENT", 143, 172]]], ["A highly purified Treg product after ex vivo expansion would not only reduce any potential adverse reactions but would also enhance the efficacy and interpretability of multi-center clinical trials on Treg immunotherapy.Flow cytometry and Antibodies ::: Materials and MethodsVarious fluorescent conjugated antibodies to human CD4 (RPA-T4), CD8 (RPA-T8), CD16 (3G8), CD19 (HIB19), CD25 (BC96), LAP (TW4-2F8) and GARP (7B11) were from BioLegend.", [["Treg", "ANATOMY", 18, 22], ["Treg", "ANATOMY", 201, 205], ["Treg", "CELL", 18, 22], ["Treg", "CELL", 201, 205], ["human", "ORGANISM", 320, 325], ["CD4", "GENE_OR_GENE_PRODUCT", 326, 329], ["RPA-T4", "GENE_OR_GENE_PRODUCT", 331, 337], ["CD8", "GENE_OR_GENE_PRODUCT", 340, 343], ["RPA-T8", "GENE_OR_GENE_PRODUCT", 345, 351], ["CD16", "GENE_OR_GENE_PRODUCT", 354, 358], ["3G8", "GENE_OR_GENE_PRODUCT", 360, 363], ["CD19", "GENE_OR_GENE_PRODUCT", 366, 370], ["HIB19", "GENE_OR_GENE_PRODUCT", 372, 377], ["CD25", "GENE_OR_GENE_PRODUCT", 380, 384], ["BC96", "GENE_OR_GENE_PRODUCT", 386, 390], ["LAP", "GENE_OR_GENE_PRODUCT", 393, 396], ["TW4-2F8", "GENE_OR_GENE_PRODUCT", 398, 405], ["GARP", "GENE_OR_GENE_PRODUCT", 411, 415], ["BioLegend", "GENE_OR_GENE_PRODUCT", 433, 442], ["Treg product", "PROTEIN", 18, 30], ["Antibodies", "PROTEIN", 239, 249], ["MethodsVarious fluorescent conjugated antibodies", "PROTEIN", 268, 316], ["human CD4", "PROTEIN", 320, 329], ["RPA", "PROTEIN", 331, 334], ["T4", "PROTEIN", 335, 337], ["CD8", "PROTEIN", 340, 343], ["RPA", "PROTEIN", 345, 348], ["T8", "PROTEIN", 349, 351], ["CD16", "PROTEIN", 354, 358], ["3G8", "PROTEIN", 360, 363], ["CD19", "PROTEIN", 366, 370], ["HIB19", "PROTEIN", 372, 377], ["CD25", "PROTEIN", 380, 384], ["BC96", "PROTEIN", 386, 390], ["LAP", "PROTEIN", 393, 396], ["TW4", "PROTEIN", 398, 401], ["2F8", "PROTEIN", 402, 405], ["GARP", "PROTEIN", 411, 415], ["7B11", "PROTEIN", 417, 421], ["BioLegend", "PROTEIN", 433, 442], ["human", "SPECIES", 320, 325], ["human", "SPECIES", 320, 325], ["A highly purified Treg product", "TREATMENT", 0, 30], ["ex vivo expansion", "TREATMENT", 37, 54], ["any potential adverse reactions", "PROBLEM", 77, 108], ["multi-center clinical trials", "TREATMENT", 169, 197], ["Treg immunotherapy", "TREATMENT", 201, 219], ["Flow cytometry", "TEST", 220, 234], ["Materials", "TEST", 254, 263], ["MethodsVarious fluorescent conjugated antibodies", "TEST", 268, 316], ["human CD4", "TEST", 320, 329], ["RPA", "TEST", 331, 334], ["CD8", "TEST", 340, 343], ["RPA", "TEST", 345, 348], ["CD16", "TEST", 354, 358], ["CD19", "TEST", 366, 370], ["HIB19", "TEST", 372, 377], ["CD25", "TEST", 380, 384], ["BC96", "TEST", 386, 390], ["LAP", "TEST", 393, 396], ["TW4", "TEST", 398, 401], ["GARP", "TEST", 411, 415], ["Treg", "OBSERVATION", 18, 22], ["T4", "ANATOMY", 335, 337], ["T8", "ANATOMY", 349, 351], ["LAP", "ANATOMY", 393, 396]]], ["Cells were surface stained first using appropriate combinations of mAbs, and either used directly for flow cytometric analyses or further processed for intracellular staining of cytokines, FOXP3 and HELIOS.", [["Cells", "ANATOMY", 0, 5], ["surface", "ANATOMY", 11, 18], ["intracellular", "ANATOMY", 152, 165], ["Cells", "CELL", 0, 5], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 152, 165], ["FOXP3", "GENE_OR_GENE_PRODUCT", 189, 194], ["HELIOS", "GENE_OR_GENE_PRODUCT", 199, 205], ["mAbs", "PROTEIN", 67, 71], ["cytokines", "PROTEIN", 178, 187], ["FOXP3", "PROTEIN", 189, 194], ["HELIOS", "PROTEIN", 199, 205], ["mAbs", "TREATMENT", 67, 71], ["flow cytometric analyses", "TEST", 102, 126], ["intracellular staining of cytokines", "PROBLEM", 152, 187]]], ["The cells were fixed and permeabilized with a Fixation/Permeabilization kit (eBioscience) and stained with anti-FOXP3 (259D) and/or anti-HELIOS (22F6) mAbs (BioLegend).", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["anti-FOXP3", "GENE_OR_GENE_PRODUCT", 107, 117], ["anti-HELIOS", "GENE_OR_GENE_PRODUCT", 132, 143], ["BioLegend", "GENE_OR_GENE_PRODUCT", 157, 166], ["eBioscience", "PROTEIN", 77, 88], ["anti-FOXP3", "PROTEIN", 107, 117], ["259D", "PROTEIN", 119, 123], ["anti-HELIOS", "PROTEIN", 132, 143], ["22F6", "PROTEIN", 145, 149], ["mAbs", "PROTEIN", 151, 155], ["BioLegend", "PROTEIN", 157, 166], ["a Fixation/Permeabilization kit", "TREATMENT", 44, 75], ["anti-FOXP3", "TREATMENT", 107, 117], ["anti-HELIOS", "TREATMENT", 132, 143]]], ["FACSCalibur and Attune flow cytometers were used for data acquisition, and the data were analyzed with FlowJo software (TreeStar).Reagents ::: Materials and MethodsAnti-CD4, anti-biotin, anti-CD25 and anti-CD14 magnetic microbeads were from Miltenyi Biotec.", [["CD4", "GENE_OR_GENE_PRODUCT", 169, 172], ["anti-biotin", "SIMPLE_CHEMICAL", 174, 185], ["anti-CD25", "SIMPLE_CHEMICAL", 187, 196], ["anti-CD14", "SIMPLE_CHEMICAL", 201, 210], ["CD4", "PROTEIN", 169, 172], ["anti-biotin", "PROTEIN", 174, 185], ["anti-CD25", "PROTEIN", 187, 196], ["anti-CD14", "PROTEIN", 201, 210], ["Miltenyi Biotec", "PROTEIN", 241, 256], ["FACSCalibur", "TEST", 0, 11], ["Attune flow cytometers", "TEST", 16, 38], ["data acquisition", "TEST", 53, 69], ["the data", "TEST", 75, 83], ["MethodsAnti-CD4", "TREATMENT", 157, 172], ["anti-biotin", "TREATMENT", 174, 185], ["anti-CD25", "TREATMENT", 187, 196], ["anti-CD14 magnetic microbeads", "TREATMENT", 201, 230], ["Miltenyi Biotec", "TREATMENT", 241, 256]]], ["All cells were cultured in complete media consisting of RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 \u03bcg/mL), 1\u00d7GlutaMAX (Gibco) and 1% MEM non-essential amino acids, 1% sodium pyruvate (Hyclone).Treg isolation and expansion ::: Materials and MethodsPeripheral blood mononuclear cells (PBMC) were isolated from adult peripheral buffy coats (Gulf Coast Regional Blood Center) by Ficoll gradient centrifugation.", [["cells", "ANATOMY", 4, 9], ["fetal bovine serum", "ANATOMY", 105, 123], ["FBS", "ANATOMY", 125, 128], ["Treg", "ANATOMY", 266, 270], ["MethodsPeripheral blood mononuclear cells", "ANATOMY", 313, 354], ["PBMC", "ANATOMY", 356, 360], ["peripheral buffy coats", "ANATOMY", 387, 409], ["Blood", "ANATOMY", 431, 436], ["RPMI 1640", "CHEMICAL", 56, 65], ["penicillin", "CHEMICAL", 131, 141], ["streptomycin", "CHEMICAL", 154, 166], ["GlutaMAX", "CHEMICAL", 182, 190], ["amino acids", "CHEMICAL", 224, 235], ["sodium pyruvate", "CHEMICAL", 240, 255], ["penicillin", "CHEMICAL", 131, 141], ["streptomycin", "CHEMICAL", 154, 166], ["amino acids", "CHEMICAL", 224, 235], ["sodium pyruvate", "CHEMICAL", 240, 255], ["cells", "CELL", 4, 9], ["bovine", "ORGANISM", 111, 117], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["FBS", "ORGANISM_SUBSTANCE", 125, 128], ["penicillin", "SIMPLE_CHEMICAL", 131, 141], ["streptomycin", "SIMPLE_CHEMICAL", 154, 166], ["GlutaMAX", "SIMPLE_CHEMICAL", 182, 190], ["amino acids", "AMINO_ACID", 224, 235], ["sodium pyruvate", "SIMPLE_CHEMICAL", 240, 255], ["Hyclone", "ORGANISM_SUBSTANCE", 257, 264], ["Treg", "CELL", 266, 270], ["MethodsPeripheral blood mononuclear cells", "CELL", 313, 354], ["PBMC", "CELL", 356, 360], ["peripheral buffy coats", "ORGANISM_SUBSTANCE", 387, 409], ["Blood", "ORGANISM_SUBSTANCE", 431, 436], ["MethodsPeripheral blood mononuclear cells", "CELL_TYPE", 313, 354], ["PBMC", "CELL_TYPE", 356, 360], ["bovine", "SPECIES", 111, 117], ["bovine", "SPECIES", 111, 117], ["All cells", "TREATMENT", 0, 9], ["inactivated fetal bovine serum (FBS", "TREATMENT", 93, 128], ["penicillin", "TREATMENT", 131, 141], ["streptomycin", "TREATMENT", 154, 166], ["GlutaMAX (Gibco)", "TREATMENT", 182, 198], ["1% MEM non-essential amino acids", "TREATMENT", 203, 235], ["1% sodium pyruvate", "TREATMENT", 237, 255], ["Treg isolation", "TREATMENT", 266, 280], ["Materials", "TEST", 299, 308], ["MethodsPeripheral blood mononuclear cells", "TEST", 313, 354], ["PBMC", "TEST", 356, 360], ["Ficoll gradient centrifugation", "TREATMENT", 448, 478], ["expansion", "OBSERVATION_MODIFIER", 285, 294], ["mononuclear cells", "OBSERVATION", 337, 354], ["peripheral", "ANATOMY_MODIFIER", 387, 397], ["buffy coats", "OBSERVATION", 398, 409], ["Ficoll", "OBSERVATION", 448, 454], ["gradient centrifugation", "OBSERVATION", 455, 478]]], ["Tregs were purified from PBMC by positive selection using directly conjugated anti-CD25 magnetic microbeads with AutoMACS (Posseld2 program).", [["Tregs", "ANATOMY", 0, 5], ["PBMC", "ANATOMY", 25, 29], ["Tregs", "CELL", 0, 5], ["PBMC", "CELL", 25, 29], ["anti-CD25", "SIMPLE_CHEMICAL", 78, 87], ["Tregs", "CELL_TYPE", 0, 5], ["PBMC", "CELL_TYPE", 25, 29], ["anti-CD25 magnetic microbeads", "PROTEIN", 78, 107], ["directly conjugated anti-CD25 magnetic microbeads", "TREATMENT", 58, 107], ["AutoMACS (Posseld2 program", "TREATMENT", 113, 139]]], ["Bead-purified CD4+CD25high cells (~5-10\u00d7106) were stimulated with OKT3-loaded KT64/86 artificial APC (aAPC) expressing CD86 and CD64 at 1:1 ratio (kindly provided by Dr. Carl H. June and Dr. James L. Riley).", [["CD4+CD25high cells", "ANATOMY", 14, 32], ["aAPC", "ANATOMY", 102, 106], ["OKT3", "CHEMICAL", 66, 70], ["CD4", "GENE_OR_GENE_PRODUCT", 14, 17], ["OKT3", "GENE_OR_GENE_PRODUCT", 66, 70], ["APC", "GENE_OR_GENE_PRODUCT", 97, 100], ["aAPC", "CELL", 102, 106], ["CD86", "GENE_OR_GENE_PRODUCT", 119, 123], ["CD64", "GENE_OR_GENE_PRODUCT", 128, 132], ["Bead-purified CD4+CD25high cells", "CELL_LINE", 0, 32], ["OKT3", "PROTEIN", 66, 70], ["KT64", "PROTEIN", 78, 82], ["APC", "CELL_TYPE", 97, 100], ["aAPC", "CELL_TYPE", 102, 106], ["CD86", "PROTEIN", 119, 123], ["CD64", "PROTEIN", 128, 132], ["Dr. James L. Riley", "SPECIES", 187, 205], ["Bead", "TEST", 0, 4], ["CD25high cells", "PROBLEM", 18, 32], ["OKT3", "TEST", 66, 70], ["KT64", "TEST", 78, 82], ["artificial APC", "TREATMENT", 86, 100], ["aAPC", "TEST", 102, 106], ["CD86", "TEST", 119, 123], ["CD64", "TEST", 128, 132], ["CD25high cells", "OBSERVATION", 18, 32]]], ["KT64/86 cells were loaded with anti-CD3 mAb (OKT3, BioLegend).", [["KT64/86 cells", "ANATOMY", 0, 13], ["KT64/86 cells", "CELL", 0, 13], ["CD3", "GENE_OR_GENE_PRODUCT", 36, 39], ["OKT3", "GENE_OR_GENE_PRODUCT", 45, 49], ["BioLegend", "GENE_OR_GENE_PRODUCT", 51, 60], ["KT64/86 cells", "CELL_LINE", 0, 13], ["anti", "PROTEIN", 31, 35], ["CD3 mAb", "PROTEIN", 36, 43], ["OKT3", "PROTEIN", 45, 49], ["BioLegend", "PROTEIN", 51, 60], ["cells", "TEST", 8, 13], ["anti-CD3 mAb", "TREATMENT", 31, 43], ["OKT3", "TREATMENT", 45, 49]]], ["CD4+CD25high cells were cultured in complete media supplemented with 100 U/mL IL2 (PeproTech) in the presence of 25 nM rapamycin (Sigma-Aldrich).", [["CD4+CD25high cells", "ANATOMY", 0, 18], ["rapamycin", "CHEMICAL", 119, 128], ["rapamycin", "CHEMICAL", 119, 128], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL2", "GENE_OR_GENE_PRODUCT", 78, 81], ["PeproTech", "GENE_OR_GENE_PRODUCT", 83, 92], ["rapamycin", "SIMPLE_CHEMICAL", 119, 128], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 130, 143], ["CD4", "PROTEIN", 0, 3], ["CD25high cells", "CELL_TYPE", 4, 18], ["IL2", "PROTEIN", 78, 81], ["PeproTech", "PROTEIN", 83, 92], ["CD4", "TEST", 0, 3], ["CD25high cells", "PROBLEM", 4, 18], ["25 nM rapamycin", "TREATMENT", 113, 128], ["CD25high cells", "OBSERVATION", 4, 18]]], ["The cells were cultured in 25-cm2 culture flasks (ThermoFisher Scientific).", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["The cells", "TEST", 0, 9]]], ["On day 5, the cells were transferred to 75-cm2 culture flasks with additional fresh complete media containing 100 U/mL IL2.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["IL2", "GENE_OR_GENE_PRODUCT", 119, 122], ["IL2", "PROTEIN", 119, 122], ["culture flasks", "TEST", 47, 61], ["additional fresh complete media", "TREATMENT", 67, 98]]], ["No additional rapamycin was added to the cultures except for the first day.", [["rapamycin", "CHEMICAL", 14, 23], ["rapamycin", "CHEMICAL", 14, 23], ["rapamycin", "SIMPLE_CHEMICAL", 14, 23], ["additional rapamycin", "TREATMENT", 3, 23], ["the cultures", "TEST", 37, 49], ["rapamycin", "OBSERVATION", 14, 23]]], ["On day 8, the cells were transferred to 175-cm2 culture flasks with fresh IL2 media.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["IL2", "GENE_OR_GENE_PRODUCT", 74, 77], ["IL2", "PROTEIN", 74, 77], ["culture flasks", "TEST", 48, 62], ["fresh IL2 media", "TREATMENT", 68, 83]]], ["The cultures were maintained at cell concentration of 106/mL and split every 3 days with additional fresh IL2 media.", [["cultures", "ANATOMY", 4, 12], ["cell", "ANATOMY", 32, 36], ["cell", "CELL", 32, 36], ["IL2", "GENE_OR_GENE_PRODUCT", 106, 109], ["IL2", "PROTEIN", 106, 109], ["The cultures", "TEST", 0, 12], ["additional fresh IL2 media", "TREATMENT", 89, 115], ["IL2 media", "OBSERVATION", 106, 115]]], ["On day 10, the cells were spun down and given fresh IL2 media before re-stimulation with additional OKT3 loaded KT64/86 at 6:1 of cell: aAPC.", [["cells", "ANATOMY", 15, 20], ["cell", "ANATOMY", 130, 134], ["aAPC", "ANATOMY", 136, 140], ["OKT3", "CHEMICAL", 100, 104], ["cells", "CELL", 15, 20], ["IL2", "GENE_OR_GENE_PRODUCT", 52, 55], ["OKT3", "SIMPLE_CHEMICAL", 100, 104], ["cell", "CELL", 130, 134], ["aAPC", "CELL", 136, 140], ["IL2", "PROTEIN", 52, 55], ["OKT3", "PROTEIN", 100, 104], ["KT64", "PROTEIN", 112, 116], ["the cells", "TEST", 11, 20], ["fresh IL2 media", "TREATMENT", 46, 61], ["additional OKT3", "TREATMENT", 89, 104]]], ["After 48-hour stimulation, the cells were analyzed and purified based on the expression of LAP.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["LAP", "GENE_OR_GENE_PRODUCT", 91, 94], ["LAP", "PROTEIN", 91, 94], ["the cells", "TREATMENT", 27, 36], ["LAP", "TREATMENT", 91, 94], ["LAP", "OBSERVATION", 91, 94]]], ["For LAP+ cells isolation, biotinylated anti-hLAP mAbs (TW4-2F8, BioLegend) followed by secondary incubation with anti-biotin magnetic microbeads (Miltenyi Biotecs) were used.", [["LAP+ cells", "ANATOMY", 4, 14], ["TW4-2F8", "CHEMICAL", 55, 62], ["LAP", "GENE_OR_GENE_PRODUCT", 4, 7], ["anti-hLAP mAbs", "SIMPLE_CHEMICAL", 39, 53], ["TW4-2F8", "SIMPLE_CHEMICAL", 55, 62], ["BioLegend", "GENE_OR_GENE_PRODUCT", 64, 73], ["anti-biotin magnetic microbeads", "SIMPLE_CHEMICAL", 113, 144], ["LAP", "PROTEIN", 4, 7], ["biotinylated anti-hLAP mAbs", "PROTEIN", 26, 53], ["TW4", "PROTEIN", 55, 58], ["2F8", "PROTEIN", 59, 62], ["BioLegend", "PROTEIN", 64, 73], ["anti-biotin magnetic microbeads", "PROTEIN", 113, 144], ["Miltenyi Biotecs", "PROTEIN", 146, 162], ["LAP+ cells isolation", "TREATMENT", 4, 24], ["biotinylated anti-hLAP mAbs", "TREATMENT", 26, 53], ["TW4", "TEST", 55, 58], ["anti-biotin magnetic microbeads", "TREATMENT", 113, 144], ["Miltenyi Biotecs)", "TREATMENT", 146, 163], ["LAP+ cells isolation", "OBSERVATION", 4, 24]]], ["LAP+ Tregs were purified from expanded CD25+ cells by positive selection with AutoMACS (Posseld2 program).", [["Tregs", "ANATOMY", 5, 10], ["CD25+ cells", "ANATOMY", 39, 50], ["LAP", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD25", "GENE_OR_GENE_PRODUCT", 39, 43], ["LAP", "PROTEIN", 0, 3], ["Tregs", "CELL_TYPE", 5, 10], ["CD25", "PROTEIN", 39, 43], ["LAP+ Tregs", "TREATMENT", 0, 10], ["AutoMACS (Posseld2 program", "TREATMENT", 78, 104], ["+ Tregs", "OBSERVATION", 3, 10], ["CD25+ cells", "OBSERVATION", 39, 50]]], ["The CD25+, LAP+ and LAP- populations were cultured in fresh IL2 media and maintained at cell concentration of 106/mL, splitting every 3 days with additional fresh IL2 media.", [["cell", "ANATOMY", 88, 92], ["CD25", "GENE_OR_GENE_PRODUCT", 4, 8], ["LAP", "GENE_OR_GENE_PRODUCT", 11, 14], ["LAP", "GENE_OR_GENE_PRODUCT", 20, 23], ["IL2", "GENE_OR_GENE_PRODUCT", 60, 63], ["cell", "CELL", 88, 92], ["IL2", "GENE_OR_GENE_PRODUCT", 163, 166], ["CD25", "PROTEIN", 4, 8], ["LAP", "PROTEIN", 11, 14], ["LAP", "PROTEIN", 20, 23], ["IL2", "PROTEIN", 60, 63], ["IL2", "PROTEIN", 163, 166], ["The CD25", "TEST", 0, 8], ["LAP", "TEST", 11, 14], ["LAP- populations", "TREATMENT", 20, 36], ["fresh IL2 media", "TREATMENT", 54, 69], ["additional fresh IL2 media", "TREATMENT", 146, 172], ["CD25", "ANATOMY", 4, 8], ["LAP", "ANATOMY", 11, 14], ["LAP", "ANATOMY", 20, 23], ["IL2 media", "OBSERVATION", 163, 172]]], ["On day 20, these populations got the 3rd stimulation with OKT3-loaded KT64/86 cells at 6:1 ratio.In vitro suppression assay ::: Materials and MethodsCD4+CD25-and CD14+ cells were isolated from PBMC of healthy donor buffy coats using the AutoMACS and related Miltenyi Biotecs kits.", [["KT64/86 cells", "ANATOMY", 70, 83], ["MethodsCD4+CD25-and CD14+ cells", "ANATOMY", 142, 173], ["PBMC", "ANATOMY", 193, 197], ["buffy coats", "ANATOMY", 215, 226], ["OKT3", "CHEMICAL", 58, 62], ["OKT3", "SIMPLE_CHEMICAL", 58, 62], ["KT64/86 cells", "CELL", 70, 83], ["MethodsCD4", "GENE_OR_GENE_PRODUCT", 142, 152], ["CD25", "GENE_OR_GENE_PRODUCT", 153, 157], ["CD14", "GENE_OR_GENE_PRODUCT", 162, 166], ["PBMC", "CELL", 193, 197], ["OKT3", "PROTEIN", 58, 62], ["KT64/86 cells", "CELL_LINE", 70, 83], ["MethodsCD4", "PROTEIN", 142, 152], ["CD25", "PROTEIN", 153, 157], ["CD14", "PROTEIN", 162, 166], ["PBMC", "CELL_TYPE", 193, 197], ["OKT3", "TREATMENT", 58, 62], ["Materials", "TEST", 128, 137], ["MethodsCD4", "TEST", 142, 152], ["CD25", "TEST", 153, 157], ["CD14+ cells", "PROBLEM", 162, 173], ["healthy donor buffy coats", "TREATMENT", 201, 226], ["the AutoMACS", "TREATMENT", 233, 245], ["Miltenyi Biotecs kits", "TREATMENT", 258, 279], ["buffy coats", "OBSERVATION", 215, 226]]], ["Fresh CD4+CD25- T cells (50,000) were labeled with 2 \u03bcM CFSE (Invitrogen) and stimulated with non-irradiated CD14+ APC (12,500) loaded with 0.25 \u03bcg/mL OKT3 alone or with 2:1, 4:1, 8:1 and 16:1 responder to suppressor cells (CD25+, LAP+ Tregs or LAP- cells).", [["Fresh CD4+CD25- T cells", "ANATOMY", 0, 23], ["suppressor cells", "ANATOMY", 206, 222], ["CD25+, LAP+ Tregs", "ANATOMY", 224, 241], ["LAP- cells", "ANATOMY", 245, 255], ["CFSE", "CHEMICAL", 56, 60], ["OKT3", "CHEMICAL", 151, 155], ["CFSE", "CHEMICAL", 56, 60], ["CD4", "GENE_OR_GENE_PRODUCT", 6, 9], ["CD25", "GENE_OR_GENE_PRODUCT", 10, 14], ["CFSE", "SIMPLE_CHEMICAL", 56, 60], ["Invitrogen", "SIMPLE_CHEMICAL", 62, 72], ["CD14", "GENE_OR_GENE_PRODUCT", 109, 113], ["APC", "GENE_OR_GENE_PRODUCT", 115, 118], ["OKT3", "SIMPLE_CHEMICAL", 151, 155], ["cells", "CELL", 217, 222], ["CD25", "GENE_OR_GENE_PRODUCT", 224, 228], ["LAP", "GENE_OR_GENE_PRODUCT", 231, 234], ["CD4", "PROTEIN", 6, 9], ["CD25", "PROTEIN", 10, 14], ["T cells", "CELL_TYPE", 16, 23], ["CD14", "PROTEIN", 109, 113], ["APC", "CELL_TYPE", 115, 118], ["OKT3", "PROTEIN", 151, 155], ["suppressor cells", "CELL_TYPE", 206, 222], ["CD25", "PROTEIN", 224, 228], ["LAP", "PROTEIN", 231, 234], ["Tregs", "CELL_TYPE", 236, 241], ["LAP", "PROTEIN", 245, 248], ["Fresh CD4", "TEST", 0, 9], ["CD25- T cells", "TEST", 10, 23], ["Invitrogen", "TEST", 62, 72], ["non-irradiated CD14+ APC", "TREATMENT", 94, 118], ["OKT3", "TREATMENT", 151, 155], ["suppressor cells", "TEST", 206, 222], ["CD25", "TEST", 224, 228], ["LAP", "TEST", 231, 234], ["CD25", "ANATOMY", 10, 14], ["suppressor cells", "OBSERVATION", 206, 222], ["LAP", "ANATOMY", 231, 234], ["Tregs", "ANATOMY", 236, 241], ["LAP", "ANATOMY", 245, 248]]], ["The cells were cultured for 4 days in 96-well flat-bottom plates (Corning), and CFSE dilution was analyzed by FACS.Intracellular cytokine staining ::: Materials and MethodsFor analysis of intracellular cytokine production, the cells were stimulated for 5 hours with 50 ng/mL PMA, 1 \u03bcg/mL ionomycin and 3 \u03bcg/mL brefeldin A (Sigma-Aldrich).", [["cells", "ANATOMY", 4, 9], ["Intracellular", "ANATOMY", 115, 128], ["intracellular", "ANATOMY", 188, 201], ["cells", "ANATOMY", 227, 232], ["PMA", "CHEMICAL", 275, 278], ["ionomycin", "CHEMICAL", 288, 297], ["brefeldin A", "CHEMICAL", 310, 321], ["CFSE", "CHEMICAL", 80, 84], ["PMA", "CHEMICAL", 275, 278], ["ionomycin", "CHEMICAL", 288, 297], ["brefeldin A", "CHEMICAL", 310, 321], ["cells", "CELL", 4, 9], ["CFSE", "SIMPLE_CHEMICAL", 80, 84], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 115, 128], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 188, 201], ["cells", "CELL", 227, 232], ["PMA", "SIMPLE_CHEMICAL", 275, 278], ["ionomycin", "SIMPLE_CHEMICAL", 288, 297], ["brefeldin A", "SIMPLE_CHEMICAL", 310, 321], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 323, 336], ["cytokine", "PROTEIN", 129, 137], ["cytokine", "PROTEIN", 202, 210], ["CFSE dilution", "TEST", 80, 93], ["Intracellular cytokine staining", "TEST", 115, 146], ["intracellular cytokine production", "PROBLEM", 188, 221], ["the cells", "TREATMENT", 223, 232], ["ionomycin", "TREATMENT", 288, 297], ["cytokine staining", "OBSERVATION", 129, 146]]], ["Afterward, the cells were fixed and permeabilized with eBioscience FOXP3 kit and stained with mAbs against FOXP3 (259D), IL2 (MQ1-17H12), IL4 (8D4-8), IL10 (JES3-9D7), IL13 (JES10-5A2), IL17A (BL168) and IFN\u03b3 (4S.B3) (BioLegend) for FACS analysis.Xenogeneic GVHD model ::: Materials and MethodsNOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were obtained from Jackson Laboratory and maintained in specific pathogen free conditions at the CLAMC (University of Texas Health Science Center at Houston).", [["cells", "ANATOMY", 15, 20], ["GVHD", "DISEASE", 258, 262], ["cells", "CELL", 15, 20], ["FOXP3", "GENE_OR_GENE_PRODUCT", 67, 72], ["FOXP3", "GENE_OR_GENE_PRODUCT", 107, 112], ["IL2", "GENE_OR_GENE_PRODUCT", 121, 124], ["MQ1-17H12", "GENE_OR_GENE_PRODUCT", 126, 135], ["IL4", "GENE_OR_GENE_PRODUCT", 138, 141], ["8D4-8", "GENE_OR_GENE_PRODUCT", 143, 148], ["IL10", "GENE_OR_GENE_PRODUCT", 151, 155], ["JES3-9D7", "GENE_OR_GENE_PRODUCT", 157, 165], ["IL13", "GENE_OR_GENE_PRODUCT", 168, 172], ["JES10-5A2", "GENE_OR_GENE_PRODUCT", 174, 183], ["IL17A", "GENE_OR_GENE_PRODUCT", 186, 191], ["BL168", "GENE_OR_GENE_PRODUCT", 193, 198], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 204, 208], ["mice", "ORGANISM", 332, 336], ["FOXP3", "PROTEIN", 67, 72], ["mAbs", "PROTEIN", 94, 98], ["FOXP3", "PROTEIN", 107, 112], ["259D", "PROTEIN", 114, 118], ["IL2", "PROTEIN", 121, 124], ["MQ1", "PROTEIN", 126, 129], ["17H12", "PROTEIN", 130, 135], ["IL4", "PROTEIN", 138, 141], ["8D4", "PROTEIN", 143, 146], ["IL10", "PROTEIN", 151, 155], ["JES3", "PROTEIN", 157, 161], ["9D7", "PROTEIN", 162, 165], ["IL13", "PROTEIN", 168, 172], ["JES10", "PROTEIN", 174, 179], ["5A2", "PROTEIN", 180, 183], ["IL17A", "DNA", 186, 191], ["BL168", "DNA", 193, 198], ["IFN\u03b3", "DNA", 204, 208], ["4S.B3", "DNA", 210, 215], ["BioLegend", "DNA", 218, 227], ["mice", "SPECIES", 332, 336], ["mice", "SPECIES", 332, 336], ["FOXP3 kit", "TEST", 67, 76], ["mAbs", "TEST", 94, 98], ["FOXP3", "TEST", 107, 112], ["IL2", "TEST", 121, 124], ["MQ1", "TEST", 126, 129], ["IL4", "TEST", 138, 141], ["IL10", "TEST", 151, 155], ["JES3", "TEST", 157, 161], ["IL13", "TEST", 168, 172], ["JES10", "TEST", 174, 179], ["IL17A", "TEST", 186, 191], ["IFN", "TEST", 204, 207], ["FACS analysis", "TEST", 233, 246], ["MethodsNOD.Cg", "TEST", 287, 300]]], ["In this protocol, the mice were not irradiated.", [["mice", "ORGANISM", 22, 26], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["this protocol", "TREATMENT", 3, 16]]], ["On day 0, mice were injected with human CD25-PBMC (30\u00d7106) with or without expanded CD25+, LAP+ Tregs and LAP\u203e nonTregs (30\u00d7106).", [["CD25-PBMC", "ANATOMY", 40, 49], ["LAP+ Tregs", "ANATOMY", 91, 101], ["mice", "ORGANISM", 10, 14], ["human", "ORGANISM", 34, 39], ["CD25", "GENE_OR_GENE_PRODUCT", 40, 44], ["PBMC", "CELL", 45, 49], ["CD25", "GENE_OR_GENE_PRODUCT", 84, 88], ["LAP", "GENE_OR_GENE_PRODUCT", 91, 94], ["LAP", "GENE_OR_GENE_PRODUCT", 106, 109], ["CD25", "PROTEIN", 40, 44], ["PBMC", "CELL_TYPE", 45, 49], ["CD25", "PROTEIN", 84, 88], ["LAP", "PROTEIN", 91, 94], ["Tregs", "CELL_TYPE", 96, 101], ["LAP", "PROTEIN", 106, 109], ["mice", "SPECIES", 10, 14], ["human", "SPECIES", 34, 39], ["mice", "SPECIES", 10, 14], ["human", "SPECIES", 34, 39], ["human CD25-PBMC", "TREATMENT", 34, 49], ["expanded CD25", "TEST", 75, 88], ["LAP", "TEST", 91, 94], ["LAP\u203e nonTregs", "TEST", 106, 119], ["LAP", "ANATOMY", 91, 94], ["+ Tregs", "OBSERVATION", 94, 101], ["LAP", "ANATOMY", 106, 109]]], ["Following injection of cells, animals were monitored twice a week for weight loss and other signs of xGVHD, e.g. hunched back, ruffled fur and reduced mobility 16, 17.", [["cells", "ANATOMY", 23, 28], ["back", "ANATOMY", 121, 125], ["weight loss", "DISEASE", 70, 81], ["xGVHD", "DISEASE", 101, 106], ["cells", "CELL", 23, 28], ["injection of cells", "TREATMENT", 10, 28], ["weight loss", "PROBLEM", 70, 81], ["other signs of xGVHD", "PROBLEM", 86, 106], ["ruffled fur", "PROBLEM", 127, 138], ["ruffled fur", "OBSERVATION", 127, 138], ["reduced", "OBSERVATION_MODIFIER", 143, 150], ["mobility", "OBSERVATION_MODIFIER", 151, 159]]], ["Mice were euthanized if they experienced >15% weight loss or showed signs of compromised health and were considered to have human graft-related disease if an expanded population of human cells was detected simultaneously in blood.", [["graft", "ANATOMY", 130, 135], ["cells", "ANATOMY", 187, 192], ["blood", "ANATOMY", 224, 229], ["weight loss", "DISEASE", 46, 57], ["Mice", "ORGANISM", 0, 4], ["human", "ORGANISM", 124, 129], ["graft", "TISSUE", 130, 135], ["human", "ORGANISM", 181, 186], ["cells", "CELL", 187, 192], ["blood", "ORGANISM_SUBSTANCE", 224, 229], ["human cells", "CELL_TYPE", 181, 192], ["Mice", "SPECIES", 0, 4], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 181, 186], ["15% weight loss", "PROBLEM", 42, 57], ["signs of compromised health", "PROBLEM", 68, 95], ["human graft-related disease", "PROBLEM", 124, 151], ["human cells", "PROBLEM", 181, 192], ["graft", "OBSERVATION", 130, 135], ["expanded", "OBSERVATION_MODIFIER", 158, 166], ["population", "OBSERVATION_MODIFIER", 167, 177], ["human cells", "OBSERVATION", 181, 192]]], ["Mice were evaluated for human cells in blood by flow cytometer weekly until day 70 or until they were euthanized.", [["cells", "ANATOMY", 30, 35], ["blood", "ANATOMY", 39, 44], ["Mice", "ORGANISM", 0, 4], ["human", "ORGANISM", 24, 29], ["cells", "CELL", 30, 35], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["human cells", "CELL_TYPE", 24, 35], ["Mice", "SPECIES", 0, 4], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["human cells", "PROBLEM", 24, 35]]], ["To document CD25-PBMC-associated cell expansion, the animals were bled (10-40 \u03bcl) and red blood cells were lysed with ACK Lysing Buffer (Quality Biological, Inc.).", [["PBMC", "ANATOMY", 17, 21], ["cell", "ANATOMY", 33, 37], ["red blood cells", "ANATOMY", 86, 101], ["CD25", "GENE_OR_GENE_PRODUCT", 12, 16], ["PBMC", "CELL", 17, 21], ["cell", "CELL", 33, 37], ["animals", "ORGANISM", 53, 60], ["red blood cells", "CELL", 86, 101], ["CD25", "PROTEIN", 12, 16], ["PBMC", "CELL_TYPE", 17, 21], ["red blood cells", "CELL_TYPE", 86, 101], ["CD25", "TEST", 12, 16], ["PBMC", "TEST", 17, 21], ["associated cell expansion", "PROBLEM", 22, 47], ["red blood cells", "TEST", 86, 101], ["ACK Lysing Buffer", "TREATMENT", 118, 135], ["cell expansion", "OBSERVATION", 33, 47]]], ["All animal protocols were approved by CLAMC at the University of Texas Health Science Center at Houston.TSDR Methylation status ::: Materials and MethodsTo determine the methylation status of the Foxp3 gene, DNA was purified from frozen aliquots of expanded CD25+, LAP+ Tregs and LAP\u2012 nonTregs.", [["CD25+, LAP+ Tregs", "ANATOMY", 258, 275], ["Foxp3", "GENE_OR_GENE_PRODUCT", 196, 201], ["DNA", "CELLULAR_COMPONENT", 208, 211], ["CD25", "GENE_OR_GENE_PRODUCT", 258, 262], ["LAP", "GENE_OR_GENE_PRODUCT", 265, 268], ["LAP", "GENE_OR_GENE_PRODUCT", 280, 283], ["Foxp3 gene", "DNA", 196, 206], ["CD25", "PROTEIN", 258, 262], ["LAP", "PROTEIN", 265, 268], ["Tregs", "CELL_TYPE", 270, 275], ["LAP", "PROTEIN", 280, 283], ["nonTregs", "CELL_TYPE", 285, 293], ["All animal protocols", "TREATMENT", 0, 20], ["Methods", "TREATMENT", 146, 153], ["expanded CD25", "TEST", 249, 262], ["LAP+ Tregs", "TREATMENT", 265, 275], ["LAP\u2012 nonTregs", "TREATMENT", 280, 293], ["CD25", "ANATOMY", 258, 262], ["LAP", "ANATOMY", 265, 268], ["+ Tregs", "OBSERVATION", 268, 275], ["LAP", "ANATOMY", 280, 283]]], ["Coded samples were sent to Epiontis (Berlin, Germany) for bisulfite modification and quantification of TSDR methylation by epigenetic human FOXP3 qPCR Assay.TCR repertoire status ::: Materials and MethodsT cell receptor (TCR) V\u03b2 repertoire was analyzed using flow cytometry with the IOTest Beta Mark TCR Repertoire Kit (Beckman Coulter), which consists of fluorochrome conjugated monoclonal antibodies that identify 24 TCR V\u03b2 subfamilies, covering about 70% of the normal human V\u03b2 T cell repertoire.Statistical analysis ::: Materials and MethodsStatistical analyses were performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA).", [["samples", "ANATOMY", 6, 13], ["V\u03b2 T cell", "ANATOMY", 478, 487], ["bisulfite", "CHEMICAL", 58, 67], ["TCR", "CHEMICAL", 157, 160], ["bisulfite", "CHEMICAL", 58, 67], ["bisulfite", "SIMPLE_CHEMICAL", 58, 67], ["TSDR", "GENE_OR_GENE_PRODUCT", 103, 107], ["human", "ORGANISM", 134, 139], ["FOXP3", "GENE_OR_GENE_PRODUCT", 140, 145], ["TCR", "GENE_OR_GENE_PRODUCT", 157, 160], ["MethodsT cell receptor", "GENE_OR_GENE_PRODUCT", 197, 219], ["TCR", "GENE_OR_GENE_PRODUCT", 221, 224], ["V\u03b2", "GENE_OR_GENE_PRODUCT", 226, 228], ["V\u03b2", "GENE_OR_GENE_PRODUCT", 423, 425], ["human", "ORGANISM", 472, 477], ["V\u03b2 T cell", "CELL", 478, 487], ["TSDR", "DNA", 103, 107], ["FOXP3", "PROTEIN", 140, 145], ["TCR", "PROTEIN", 157, 160], ["MethodsT cell receptor (TCR) V\u03b2 repertoire", "PROTEIN", 197, 239], ["TCR", "PROTEIN", 300, 303], ["fluorochrome conjugated monoclonal antibodies", "PROTEIN", 356, 401], ["TCR V\u03b2 subfamilies", "PROTEIN", 419, 437], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 472, 477], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 472, 477], ["Coded samples", "TEST", 0, 13], ["bisulfite modification", "TREATMENT", 58, 80], ["TSDR methylation", "TREATMENT", 103, 119], ["MethodsT cell receptor", "TREATMENT", 197, 219], ["flow cytometry", "TEST", 259, 273], ["fluorochrome conjugated monoclonal antibodies", "TEST", 356, 401], ["MethodsStatistical analyses", "TEST", 538, 565]]], ["Data were analyzed by analysis of variance (ANOVA) or Student's t test.", [["Student's t test", "TEST", 54, 70]]], ["The paired Student's t test was used for the comparison of group values and discriminatory parameters, where appropriate.", [["The paired Student's t test", "TEST", 0, 27], ["group values", "TEST", 59, 71], ["discriminatory parameters", "TEST", 76, 101]]], ["Survival data was analyzed with SPSS software (version 16.0; SPSS Inc., Chicago, IL, USA) by using the Kaplan-Meier method and compared using a Log-rank Test. p values less than 0.05 were considered significant.Expansion and purification of LAP+ Tregs ::: ResultsPreviously, we have demonstrated that it is feasible and economical to use an initial one-step method with anti-CD25 bead to purify and expand Tregs with anti-CD3/CD28 beads 15.", [["Tregs", "ANATOMY", 246, 251], ["Tregs", "ANATOMY", 406, 411], ["LAP", "GENE_OR_GENE_PRODUCT", 241, 244], ["Tregs", "CELL", 246, 251], ["anti-CD25", "SIMPLE_CHEMICAL", 370, 379], ["Tregs", "CELL", 406, 411], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 417, 425], ["CD28", "GENE_OR_GENE_PRODUCT", 426, 430], ["LAP", "PROTEIN", 241, 244], ["Tregs", "CELL_TYPE", 246, 251], ["anti-CD25 bead", "PROTEIN", 370, 384], ["Tregs", "CELL_TYPE", 406, 411], ["anti-CD3", "PROTEIN", 417, 425], ["CD28", "PROTEIN", 426, 430], ["Survival data", "TEST", 0, 13], ["SPSS software", "TEST", 32, 45], ["version", "TEST", 47, 54], ["a Log-rank Test", "TEST", 142, 157], ["p values", "TEST", 159, 167], ["Expansion", "PROBLEM", 211, 220], ["LAP", "TEST", 241, 244], ["an initial one-step method", "TREATMENT", 338, 364], ["anti-CD25 bead", "TREATMENT", 370, 384], ["anti-CD3/CD28 beads", "TREATMENT", 417, 436], ["LAP", "OBSERVATION", 241, 244]]], ["This time we use aAPCs, because they are more cost-effective at large scale production and do not require a removal process.", [["aAPCs", "TREATMENT", 17, 22], ["a removal process", "TREATMENT", 106, 123]]], ["Figure 1A shows the expansion and re-isolation protocol.", [["re-isolation protocol", "TREATMENT", 34, 55], ["expansion", "OBSERVATION_MODIFIER", 20, 29]]], ["Instead of previously isolating for LAP+ Tregs at day 21 (3rd round of stimulation), this time we isolate LAP+ Tregs on the 2nd round of stimulation at day 12.", [["Tregs", "ANATOMY", 41, 46], ["Tregs", "ANATOMY", 111, 116], ["LAP", "GENE_OR_GENE_PRODUCT", 36, 39], ["Tregs", "CELL", 41, 46], ["LAP", "GENE_OR_GENE_PRODUCT", 106, 109], ["Tregs", "CELL", 111, 116], ["LAP", "PROTEIN", 36, 39], ["Tregs", "CELL_TYPE", 41, 46], ["LAP", "PROTEIN", 106, 109], ["Tregs", "CELL_TYPE", 111, 116], ["LAP", "TEST", 36, 39], ["LAP", "OBSERVATION", 106, 109]]], ["We choose this approach to reduce the amount of anti-LAP mAbs, since the cell numbers in the cultures are less.", [["cell", "ANATOMY", 73, 77], ["anti-LAP mAbs", "GENE_OR_GENE_PRODUCT", 48, 61], ["cell", "CELL", 73, 77], ["anti-LAP mAbs", "PROTEIN", 48, 61], ["this approach", "TREATMENT", 10, 23], ["anti-LAP mAbs", "TREATMENT", 48, 61], ["the cell numbers", "TEST", 69, 85], ["the cultures", "TEST", 89, 101]]], ["With this method, the CD25+ population contains an average of 72% FOXP3+ cells within CD4+ cells (range, 60%-84%), while the percentages of FOXP3 purity post LAP purification (LAP+) are typically \u226590%.", [["FOXP3+ cells", "ANATOMY", 66, 78], ["CD4+ cells", "ANATOMY", 86, 96], ["CD25", "GENE_OR_GENE_PRODUCT", 22, 26], ["FOXP3", "GENE_OR_GENE_PRODUCT", 66, 71], ["CD4", "GENE_OR_GENE_PRODUCT", 86, 89], ["FOXP3", "GENE_OR_GENE_PRODUCT", 140, 145], ["LAP", "GENE_OR_GENE_PRODUCT", 158, 161], ["CD25", "PROTEIN", 22, 26], ["FOXP3", "PROTEIN", 66, 71], ["CD4", "PROTEIN", 86, 89], ["FOXP3", "PROTEIN", 140, 145], ["LAP", "PROTEIN", 158, 161], ["LAP", "PROTEIN", 176, 179], ["this method", "TEST", 5, 16], ["the CD25", "TEST", 18, 26], ["CD4", "TEST", 86, 89], ["cells", "TEST", 91, 96], ["FOXP3 purity", "TREATMENT", 140, 152], ["LAP purification", "TREATMENT", 158, 174], ["LAP", "TEST", 176, 179], ["average", "OBSERVATION_MODIFIER", 51, 58], ["FOXP3 purity", "OBSERVATION", 140, 152]]], ["The LAP\u2012 population still has some FOXP3+ Tregs left.", [["Tregs", "ANATOMY", 42, 47], ["LAP", "GENE_OR_GENE_PRODUCT", 4, 7], ["FOXP3", "GENE_OR_GENE_PRODUCT", 35, 40], ["Tregs", "CELL", 42, 47], ["LAP", "PROTEIN", 4, 7], ["FOXP3", "PROTEIN", 35, 40], ["Tregs", "CELL_TYPE", 42, 47], ["The LAP\u2012 population", "TEST", 0, 19], ["LAP", "OBSERVATION", 4, 7], ["FOXP3+", "OBSERVATION", 35, 41], ["left", "ANATOMY_MODIFIER", 48, 52]]], ["Furthermore, the LAP+ cells are mainly GARP+ cells (Figure 1B).", [["LAP+ cells", "ANATOMY", 17, 27], ["GARP+ cells", "ANATOMY", 39, 50], ["LAP", "GENE_OR_GENE_PRODUCT", 17, 20], ["GARP", "GENE_OR_GENE_PRODUCT", 39, 43], ["LAP", "PROTEIN", 17, 20], ["GARP", "PROTEIN", 39, 43], ["the LAP+ cells", "TEST", 13, 27], ["LAP", "ANATOMY", 17, 20], ["GARP+ cells", "OBSERVATION", 39, 50]]], ["Starting with 4-25\u00d7106 LAP+ Tregs at day 12, we are able to achieve >1 billion LAP+ Tregs by day 30 of expansion (Figure 2A).", [["Tregs", "ANATOMY", 28, 33], ["Tregs", "ANATOMY", 84, 89], ["Tregs", "CELL", 28, 33], ["LAP", "GENE_OR_GENE_PRODUCT", 79, 82], ["Tregs", "CELL", 84, 89], ["LAP", "PROTEIN", 23, 26], ["Tregs", "CELL_TYPE", 28, 33], ["LAP", "PROTEIN", 79, 82], ["Tregs", "CELL_TYPE", 84, 89]]], ["The starting CD25+ population at day 0 contains mainly CD4+FOXP3+ Tregs with the remainder being CD8+ T, CD19+ B and CD16+ NK cells (Figure 2B and S1).", [["CD4+FOXP3+ Tregs", "ANATOMY", 55, 71], ["CD8+ T, CD19+ B", "ANATOMY", 97, 112], ["CD16+ NK cells", "ANATOMY", 117, 131], ["CD25", "GENE_OR_GENE_PRODUCT", 13, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 55, 58], ["FOXP3", "GENE_OR_GENE_PRODUCT", 59, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD19", "GENE_OR_GENE_PRODUCT", 105, 109], ["CD16", "GENE_OR_GENE_PRODUCT", 117, 121], ["CD25", "PROTEIN", 13, 17], ["CD4", "PROTEIN", 55, 58], ["FOXP3", "PROTEIN", 59, 64], ["Tregs", "CELL_TYPE", 66, 71], ["CD8", "PROTEIN", 97, 100], ["CD19", "PROTEIN", 105, 109], ["CD16", "PROTEIN", 117, 121], ["NK cells", "CELL_TYPE", 123, 131], ["S1", "PROTEIN", 147, 149], ["The starting CD25", "TEST", 0, 17], ["CD8", "TEST", 97, 100], ["T", "TEST", 102, 103], ["CD19", "TEST", 105, 109], ["CD16", "TEST", 117, 121], ["NK cells", "TEST", 123, 131], ["Figure", "TEST", 133, 139], ["NK cells", "OBSERVATION", 123, 131], ["S1", "ANATOMY", 147, 149]]], ["During the expansion, these contaminating non-T cells disappeared by day 10.", [["T cells", "ANATOMY", 46, 53], ["non-T cells", "CELL", 42, 53], ["T cells", "CELL_TYPE", 46, 53], ["the expansion", "TEST", 7, 20], ["these contaminating non-T cells", "PROBLEM", 22, 53], ["expansion", "OBSERVATION_MODIFIER", 11, 20]]], ["Furthermore, the CD8+ T cell population is mainly found in the LAP\u2012 population after repurification (Figure 2B).", [["CD8+ T cell", "ANATOMY", 17, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 17, 20], ["CD8", "PROTEIN", 17, 20], ["LAP", "PROTEIN", 63, 66], ["the CD8", "TEST", 13, 20], ["T cell population", "PROBLEM", 22, 39], ["repurification", "TEST", 85, 99], ["cell population", "OBSERVATION", 24, 39], ["LAP", "ANATOMY", 63, 66]]], ["There is a progressive reduction of FOXP3 purity in CD25+ population during the expansion from an average of 60% (range, 36%-74%) at the starting point to a mean of 73% (range, 46%-88%) on day 10 and 52% (range, 21%-87%) on day 30.", [["FOXP3", "GENE_OR_GENE_PRODUCT", 36, 41], ["CD25", "GENE_OR_GENE_PRODUCT", 52, 56], ["FOXP3", "PROTEIN", 36, 41], ["CD25", "PROTEIN", 52, 56], ["a progressive reduction of FOXP3 purity", "PROBLEM", 9, 48], ["the expansion", "TEST", 76, 89], ["progressive", "OBSERVATION_MODIFIER", 11, 22], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["FOXP3 purity", "OBSERVATION", 36, 48], ["population", "OBSERVATION_MODIFIER", 58, 68], ["expansion", "OBSERVATION_MODIFIER", 80, 89], ["average", "OBSERVATION_MODIFIER", 98, 105]]], ["After LAP repurification, the means of CD4+FOXP3+ T cells maintain higher than 90% in LAP+ Tregs and lower than 40% in LAP\u2012 population during expansion (Figure 2C and D).", [["CD4+FOXP3+ T cells", "ANATOMY", 39, 57], ["Tregs", "ANATOMY", 91, 96], ["LAP", "GENE_OR_GENE_PRODUCT", 6, 9], ["CD4", "GENE_OR_GENE_PRODUCT", 39, 42], ["FOXP3", "GENE_OR_GENE_PRODUCT", 43, 48], ["LAP", "GENE_OR_GENE_PRODUCT", 86, 89], ["Tregs", "CELL", 91, 96], ["LAP", "PROTEIN", 6, 9], ["CD4", "PROTEIN", 39, 42], ["FOXP3", "PROTEIN", 43, 48], ["T cells", "CELL_TYPE", 50, 57], ["LAP", "PROTEIN", 86, 89], ["Tregs", "CELL_TYPE", 91, 96], ["LAP", "PROTEIN", 119, 122], ["LAP repurification", "TEST", 6, 24], ["CD4", "TEST", 39, 42], ["FOXP3", "TEST", 43, 48], ["T cells", "PROBLEM", 50, 57], ["LAP", "TEST", 86, 89], ["Tregs", "TEST", 91, 96], ["LAP", "TREATMENT", 119, 122], ["LAP", "ANATOMY", 86, 89], ["lower", "OBSERVATION_MODIFIER", 101, 106]]], ["The mean percentages of FOXP3+HELIOS+ T cells maintain higher than 80% in LAP+ Tregs and lower than 40% in LAP\u2012 population during expansion (Figure 2C and E).TCR V\u03b2 diversity in expanded LAP+ Tregs ::: ResultsIn order to investigate the changes in TCR V\u03b2 repertoire during expansion, we next examine TCR repertoire usage of the Tregs (CD4+FOXP3+) before (day 0) and after (day 30) expansion.", [["FOXP3+HELIOS+ T cells", "ANATOMY", 24, 45], ["Tregs", "ANATOMY", 79, 84], ["Tregs", "ANATOMY", 192, 197], ["Tregs", "ANATOMY", 328, 333], ["TCR", "CHEMICAL", 158, 161], ["FOXP3", "GENE_OR_GENE_PRODUCT", 24, 29], ["LAP", "GENE_OR_GENE_PRODUCT", 74, 77], ["Tregs", "CELL", 79, 84], ["TCR", "GENE_OR_GENE_PRODUCT", 158, 161], ["LAP", "GENE_OR_GENE_PRODUCT", 187, 190], ["Tregs", "CELL", 192, 197], ["TCR V\u03b2", "GENE_OR_GENE_PRODUCT", 248, 254], ["TCR", "GENE_OR_GENE_PRODUCT", 300, 303], ["Tregs", "CELL", 328, 333], ["CD4", "GENE_OR_GENE_PRODUCT", 335, 338], ["FOXP3", "GENE_OR_GENE_PRODUCT", 339, 344], ["FOXP3", "PROTEIN", 24, 29], ["HELIOS", "PROTEIN", 30, 36], ["T cells", "CELL_TYPE", 38, 45], ["LAP", "PROTEIN", 74, 77], ["Tregs", "CELL_TYPE", 79, 84], ["LAP", "PROTEIN", 107, 110], ["TCR", "PROTEIN", 158, 161], ["LAP", "PROTEIN", 187, 190], ["Tregs", "CELL_TYPE", 192, 197], ["TCR V\u03b2 repertoire", "PROTEIN", 248, 265], ["TCR", "PROTEIN", 300, 303], ["Tregs", "CELL_TYPE", 328, 333], ["CD4", "PROTEIN", 335, 338], ["FOXP3", "PROTEIN", 339, 344], ["The mean percentages", "TEST", 0, 20], ["FOXP3", "TEST", 24, 29], ["T cells", "TEST", 38, 45], ["LAP", "TEST", 74, 77], ["Tregs", "TEST", 79, 84], ["LAP", "TREATMENT", 107, 110], ["expanded LAP", "TEST", 178, 190], ["the Tregs", "TEST", 324, 333], ["CD4", "TEST", 335, 338], ["LAP", "ANATOMY", 74, 77], ["lower", "OBSERVATION_MODIFIER", 89, 94], ["diversity", "OBSERVATION_MODIFIER", 165, 174], ["expanded", "OBSERVATION_MODIFIER", 178, 186], ["LAP", "OBSERVATION", 187, 190]]], ["After three rounds of stimulation and LAP purification, the total Treg TCR V\u03b2 usages are essentially unchanged between Day 0 and Day 30 (Figure 3A and B).", [["Treg", "ANATOMY", 66, 70], ["LAP", "GENE_OR_GENE_PRODUCT", 38, 41], ["Treg", "CELL", 66, 70], ["V\u03b2", "GENE_OR_GENE_PRODUCT", 75, 77], ["LAP", "PROTEIN", 38, 41], ["Treg TCR V\u03b2", "PROTEIN", 66, 77], ["stimulation", "TREATMENT", 22, 33], ["LAP purification", "TREATMENT", 38, 54], ["the total Treg TCR V\u03b2 usages", "TREATMENT", 56, 84], ["essentially", "OBSERVATION_MODIFIER", 89, 100], ["unchanged", "OBSERVATION_MODIFIER", 101, 110]]], ["Figure 3C shows data from three representative donors for TCR V\u03b2 distribution before and after expansion.Cytokine profile in LAP+ Tregs ::: ResultsEffector cells that secrete cytokines can exacerbate GVHD 18.", [["Tregs", "ANATOMY", 130, 135], ["ResultsEffector cells", "ANATOMY", 140, 161], ["TCR", "CHEMICAL", 58, 61], ["GVHD", "DISEASE", 200, 204], ["donors", "ORGANISM", 47, 53], ["TCR V\u03b2", "GENE_OR_GENE_PRODUCT", 58, 64], ["LAP", "GENE_OR_GENE_PRODUCT", 125, 128], ["Tregs", "CELL", 130, 135], ["ResultsEffector cells", "CELL", 140, 161], ["TCR", "PROTEIN", 58, 61], ["V\u03b2", "PROTEIN", 62, 64], ["Cytokine", "PROTEIN", 105, 113], ["LAP", "PROTEIN", 125, 128], ["Tregs", "CELL_TYPE", 130, 135], ["ResultsEffector cells", "CELL_TYPE", 140, 161], ["cytokines", "PROTEIN", 175, 184], ["Figure 3C", "TEST", 0, 9], ["Cytokine profile", "TEST", 105, 121], ["LAP", "TEST", 125, 128], ["GVHD", "PROBLEM", 200, 204], ["LAP", "OBSERVATION", 125, 128]]], ["A cardinal feature of Tregs is their anergic state.", [["Tregs", "ANATOMY", 22, 27], ["Tregs", "CELL", 22, 27], ["Tregs", "CELL_TYPE", 22, 27], ["their anergic state", "PROBLEM", 31, 50], ["Tregs", "OBSERVATION", 22, 27], ["anergic state", "OBSERVATION", 37, 50]]], ["The CD25+, LAP+ Tregs and LAP\u2012 nonTregs are stimulated to measure the levels of cytokine production at day 30 end of culture.", [["Tregs", "ANATOMY", 16, 21], ["Tregs", "ANATOMY", 34, 39], ["CD25", "GENE_OR_GENE_PRODUCT", 4, 8], ["LAP", "GENE_OR_GENE_PRODUCT", 11, 14], ["Tregs", "CELL", 16, 21], ["LAP", "GENE_OR_GENE_PRODUCT", 26, 29], ["Tregs", "CELL", 34, 39], ["CD25", "PROTEIN", 4, 8], ["LAP", "PROTEIN", 11, 14], ["Tregs", "CELL_TYPE", 16, 21], ["LAP", "PROTEIN", 26, 29], ["Tregs", "CELL_TYPE", 34, 39], ["cytokine", "PROTEIN", 80, 88], ["The CD25", "TEST", 0, 8], ["LAP", "TEST", 11, 14], ["LAP\u2012 nonTregs", "TREATMENT", 26, 39], ["cytokine production", "PROBLEM", 80, 99], ["culture", "TEST", 117, 124], ["CD25", "ANATOMY", 4, 8], ["LAP", "ANATOMY", 11, 14], ["LAP", "OBSERVATION_MODIFIER", 26, 29]]], ["There are substantially lower percentages of IL2+, IFN\u03b3+, IL17A+, IL4+, IL13+ and IL10+ producing cells out of CD4+ cells detected in the LAP+ Tregs as compared to the other two populations (Figure 4 and S2).LAP+ Tregs are highly demethylated in TSDR ::: ResultsThe level of methylation at the promoter region upstream of FOXP3 termed Treg-specific demethylated region (TSDR) has provided specific differentiation between activated T effector cells and bona fide Tregs 19, 20.", [["cells", "ANATOMY", 98, 103], ["CD4+ cells", "ANATOMY", 111, 121], ["Tregs", "ANATOMY", 143, 148], ["Tregs", "ANATOMY", 213, 218], ["Treg", "ANATOMY", 335, 339], ["T effector cells", "ANATOMY", 432, 448], ["IL2", "GENE_OR_GENE_PRODUCT", 45, 48], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL17A", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL4", "GENE_OR_GENE_PRODUCT", 66, 69], ["IL13", "GENE_OR_GENE_PRODUCT", 72, 76], ["IL10", "GENE_OR_GENE_PRODUCT", 82, 86], ["cells", "CELL", 98, 103], ["CD4", "GENE_OR_GENE_PRODUCT", 111, 114], ["LAP", "GENE_OR_GENE_PRODUCT", 138, 141], ["Tregs", "CELL", 143, 148], ["LAP", "GENE_OR_GENE_PRODUCT", 208, 211], ["FOXP3", "GENE_OR_GENE_PRODUCT", 322, 327], ["Treg-specific demethylated region", "GENE_OR_GENE_PRODUCT", 335, 368], ["T effector cells", "CELL", 432, 448], ["IL2", "PROTEIN", 45, 48], ["IFN\u03b3", "PROTEIN", 51, 55], ["IL17A", "PROTEIN", 58, 63], ["IL4", "PROTEIN", 66, 69], ["IL13", "PROTEIN", 72, 76], ["IL10", "PROTEIN", 82, 86], ["CD4", "PROTEIN", 111, 114], ["LAP", "PROTEIN", 138, 141], ["Tregs", "CELL_TYPE", 143, 148], ["LAP", "PROTEIN", 208, 211], ["Tregs", "CELL_TYPE", 213, 218], ["promoter region", "DNA", 294, 309], ["FOXP3", "PROTEIN", 322, 327], ["Treg", "PROTEIN", 335, 339], ["demethylated region", "DNA", 349, 368], ["TSDR", "DNA", 370, 374], ["activated T effector cells", "CELL_TYPE", 422, 448], ["IL2", "TEST", 45, 48], ["IFN", "TEST", 51, 54], ["IL17A", "TEST", 58, 63], ["IL4", "TEST", 66, 69], ["IL13", "TEST", 72, 76], ["IL10", "TEST", 82, 86], ["CD4+ cells", "PROBLEM", 111, 121], ["the LAP", "TEST", 134, 141], ["Tregs", "PROBLEM", 143, 148], ["LAP", "TEST", 208, 211], ["Tregs", "PROBLEM", 213, 218], ["bona fide Tregs", "TEST", 453, 468], ["substantially", "OBSERVATION_MODIFIER", 10, 23], ["lower", "OBSERVATION_MODIFIER", 24, 29], ["percentages", "OBSERVATION_MODIFIER", 30, 41], ["IL2", "ANATOMY", 45, 48], ["CD4+ cells", "OBSERVATION", 111, 121], ["LAP", "ANATOMY", 138, 141], ["+ Tregs", "OBSERVATION", 211, 218], ["demethylated", "OBSERVATION_MODIFIER", 230, 242], ["FOXP3 termed Treg", "OBSERVATION", 322, 339], ["fide Tregs", "OBSERVATION", 458, 468]]], ["Several studies have demonstrated that FOXP3- cells are fully methylated at this site, while iTregs are intermediate and tTregs are fully demethylated 21, 22.", [["FOXP3- cells", "ANATOMY", 39, 51], ["site", "ANATOMY", 81, 85], ["iTregs", "ANATOMY", 93, 99], ["FOXP3", "GENE_OR_GENE_PRODUCT", 39, 44], ["iTregs", "GENE_OR_GENE_PRODUCT", 93, 99], ["tTregs", "GENE_OR_GENE_PRODUCT", 121, 127], ["FOXP3", "PROTEIN", 39, 44], ["iTregs", "CELL_TYPE", 93, 99], ["Several studies", "TEST", 0, 15], ["FOXP3- cells", "PROBLEM", 39, 51], ["FOXP3", "OBSERVATION", 39, 44]]], ["The level of demethylation at the TSDR region is critical for establishment of a stable Treg lineage and correlation with suppressive function.", [["Treg lineage", "ANATOMY", 88, 100], ["Treg lineage", "CELL", 88, 100], ["TSDR region", "DNA", 34, 45], ["Treg lineage", "CELL_TYPE", 88, 100], ["demethylation at the TSDR region", "PROBLEM", 13, 45], ["Treg lineage", "TREATMENT", 88, 100], ["stable", "OBSERVATION_MODIFIER", 81, 87]]], ["In this study, we demonstrate that after 30 days expansion the purified LAP+ Tregs are highly demethylated with an average of 95% demethylation in the TSDR region, while the CD25+ cells with mean of 45% demethylation (Figure 5A).", [["Tregs", "ANATOMY", 77, 82], ["TSDR region", "ANATOMY", 151, 162], ["CD25+ cells", "ANATOMY", 174, 185], ["LAP", "GENE_OR_GENE_PRODUCT", 72, 75], ["Tregs", "CELL", 77, 82], ["CD25", "GENE_OR_GENE_PRODUCT", 174, 178], ["LAP", "PROTEIN", 72, 75], ["Tregs", "CELL_TYPE", 77, 82], ["TSDR region", "DNA", 151, 162], ["CD25", "PROTEIN", 174, 178], ["this study", "TEST", 3, 13], ["the purified LAP", "TEST", 59, 75], ["the CD25+ cells", "TEST", 170, 185], ["mean", "TEST", 191, 195], ["LAP", "OBSERVATION", 72, 75], ["highly", "OBSERVATION_MODIFIER", 87, 93], ["demethylated", "OBSERVATION_MODIFIER", 94, 106], ["average", "OBSERVATION_MODIFIER", 115, 122]]], ["The LAP\u2012 nonTregs are highly methylated, with less than 20% demethylation even when the population contains close to 60% FOXP3+ and HELIOS+ cells (Figure 5B and C).", [["Tregs", "ANATOMY", 12, 17], ["HELIOS+ cells", "ANATOMY", 132, 145], ["LAP", "GENE_OR_GENE_PRODUCT", 4, 7], ["FOXP3", "GENE_OR_GENE_PRODUCT", 121, 126], ["LAP", "PROTEIN", 4, 7], ["Tregs", "CELL_TYPE", 12, 17], ["FOXP3", "PROTEIN", 121, 126], ["HELIOS", "PROTEIN", 132, 138], ["The LAP", "TEST", 0, 7], ["FOXP3", "TEST", 121, 126], ["HELIOS+ cells", "TEST", 132, 145], ["Figure 5B", "TEST", 147, 156], ["LAP", "OBSERVATION", 4, 7], ["nonTregs", "OBSERVATION_MODIFIER", 9, 17], ["methylated", "OBSERVATION_MODIFIER", 29, 39]]], ["It should be noted that the LAP\u2012 populations still contain LAP+ cells ranging from 10-50% which represent most of the demethylated TSDR and HELIOS signals (Figure 1 and 2).LAP+ Tregs are anergic and suppressive in vitro ::: ResultsPreviously we have demonstrated that LAP+ Tregs isolated from CD3/CD28 Dynabead stimulated expansion cultures maintained suppressive function.", [["LAP+ cells", "ANATOMY", 59, 69], ["Tregs", "ANATOMY", 177, 182], ["Tregs", "ANATOMY", 273, 278], ["cultures", "ANATOMY", 332, 340], ["LAP", "GENE_OR_GENE_PRODUCT", 28, 31], ["LAP", "GENE_OR_GENE_PRODUCT", 59, 62], ["TSDR", "CANCER", 131, 135], ["LAP", "GENE_OR_GENE_PRODUCT", 172, 175], ["LAP", "GENE_OR_GENE_PRODUCT", 268, 271], ["Tregs", "CELL", 273, 278], ["CD3", "GENE_OR_GENE_PRODUCT", 293, 296], ["CD28", "GENE_OR_GENE_PRODUCT", 297, 301], ["LAP", "PROTEIN", 28, 31], ["LAP", "PROTEIN", 59, 62], ["TSDR", "PROTEIN", 131, 135], ["HELIOS", "PROTEIN", 140, 146], ["LAP", "PROTEIN", 172, 175], ["Tregs", "CELL_TYPE", 177, 182], ["LAP", "PROTEIN", 268, 271], ["Tregs", "CELL_TYPE", 273, 278], ["CD3", "PROTEIN", 293, 296], ["CD28", "PROTEIN", 297, 301], ["the LAP\u2012 populations", "TEST", 24, 44], ["LAP+ cells", "PROBLEM", 59, 69], ["HELIOS signals", "TEST", 140, 154], ["LAP", "TEST", 172, 175], ["Tregs", "PROBLEM", 177, 182], ["anergic", "PROBLEM", 187, 194], ["LAP", "TEST", 268, 271], ["Tregs", "TEST", 273, 278], ["CD3/CD28", "TREATMENT", 293, 301], ["stimulated expansion cultures", "TEST", 311, 340], ["LAP", "OBSERVATION", 28, 31], ["LAP+ cells", "OBSERVATION", 59, 69], ["+ Tregs", "OBSERVATION", 175, 182], ["anergic", "OBSERVATION", 187, 194], ["LAP", "OBSERVATION", 268, 271]]], ["Since these LAP+ Tregs are obtained from aAPC stimulated expansion cultures, it is important to confirm their suppressive function.", [["Tregs", "ANATOMY", 17, 22], ["aAPC", "ANATOMY", 41, 45], ["cultures", "ANATOMY", 67, 75], ["LAP", "GENE_OR_GENE_PRODUCT", 12, 15], ["Tregs", "CELL", 17, 22], ["aAPC", "CELL", 41, 45], ["cultures", "CELL", 67, 75], ["LAP", "PROTEIN", 12, 15], ["Tregs", "CELL_TYPE", 17, 22], ["aAPC stimulated expansion cultures", "CELL_LINE", 41, 75], ["these LAP", "TEST", 6, 15], ["Tregs", "PROBLEM", 17, 22], ["aAPC stimulated expansion cultures", "TEST", 41, 75], ["LAP", "OBSERVATION", 12, 15]]], ["We evaluate the capacity of purified LAP+ Tregs to suppress the proliferative responses of CD4+25- T cells in CFSE dilution assays.", [["Tregs", "ANATOMY", 42, 47], ["CD4+25- T cells", "ANATOMY", 91, 106], ["CFSE", "CHEMICAL", 110, 114], ["LAP", "GENE_OR_GENE_PRODUCT", 37, 40], ["Tregs", "CELL", 42, 47], ["CD4", "GENE_OR_GENE_PRODUCT", 91, 94], ["CFSE", "SIMPLE_CHEMICAL", 110, 114], ["LAP", "PROTEIN", 37, 40], ["Tregs", "CELL_TYPE", 42, 47], ["CD4", "PROTEIN", 91, 94], ["T cells", "CELL_TYPE", 99, 106], ["purified LAP", "TEST", 28, 40], ["Tregs", "TREATMENT", 42, 47], ["the proliferative responses", "TEST", 60, 87], ["CD4", "TEST", 91, 94], ["CFSE dilution assays", "TEST", 110, 130], ["LAP", "OBSERVATION", 37, 40], ["proliferative", "OBSERVATION_MODIFIER", 64, 77]]], ["As expected, LAP+ Tregs are the most potent suppressors among these three populations (Figure 6A and B).LAP+ Tregs ameliorate disease in a xenogeneic murine model of GVHD ::: ResultsTo determine whether expanded LAP+ Tregs are effective in suppressing human CD25-depleted PBMC-induced xenogeneic GVHD, we used a xenogeneic model of GVHD in which Tregs are co-transferred at a 1:1 ratio with allogeneic CD25-depleted PBMC (30 \u00d7 106 each) into NSG recipients to compare the potency and safety of in vitro-expanded LAP+ Tregs and LAP- cells (Figure 6C).", [["Tregs", "ANATOMY", 18, 23], ["Tregs", "ANATOMY", 109, 114], ["Tregs", "ANATOMY", 217, 222], ["PBMC", "ANATOMY", 272, 276], ["Tregs", "ANATOMY", 346, 351], ["PBMC", "ANATOMY", 416, 420], ["Tregs", "ANATOMY", 517, 522], ["LAP- cells", "ANATOMY", 527, 537], ["GVHD", "DISEASE", 166, 170], ["GVHD", "DISEASE", 296, 300], ["GVHD", "DISEASE", 332, 336], ["LAP", "GENE_OR_GENE_PRODUCT", 13, 16], ["Tregs", "CELL", 18, 23], ["B", "CELL", 101, 102], ["LAP", "GENE_OR_GENE_PRODUCT", 104, 107], ["murine", "ORGANISM", 150, 156], ["LAP", "GENE_OR_GENE_PRODUCT", 212, 215], ["Tregs", "CELL", 217, 222], ["human", "ORGANISM", 252, 257], ["CD25", "GENE_OR_GENE_PRODUCT", 258, 262], ["PBMC", "CELL", 272, 276], ["GVHD", "CANCER", 332, 336], ["Tregs", "CELL", 346, 351], ["CD25", "GENE_OR_GENE_PRODUCT", 402, 406], ["PBMC", "CELL", 416, 420], ["recipients", "ORGANISM", 446, 456], ["LAP", "GENE_OR_GENE_PRODUCT", 512, 515], ["Tregs", "CELL", 517, 522], ["LAP- cells", "CELL", 527, 537], ["LAP", "PROTEIN", 13, 16], ["Tregs", "CELL_TYPE", 18, 23], ["LAP", "PROTEIN", 104, 107], ["Tregs", "CELL_TYPE", 109, 114], ["LAP", "PROTEIN", 212, 215], ["Tregs", "CELL_TYPE", 217, 222], ["CD25", "PROTEIN", 258, 262], ["PBMC", "CELL_TYPE", 272, 276], ["Tregs", "CELL_TYPE", 346, 351], ["CD25", "PROTEIN", 402, 406], ["PBMC", "CELL_TYPE", 416, 420], ["LAP", "PROTEIN", 512, 515], ["Tregs", "CELL_TYPE", 517, 522], ["LAP- cells", "CELL_TYPE", 527, 537], ["murine", "SPECIES", 150, 156], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 252, 257], ["LAP", "TEST", 13, 16], ["Tregs", "TREATMENT", 18, 23], ["the most potent suppressors", "TREATMENT", 28, 55], ["LAP", "TEST", 104, 107], ["Tregs ameliorate disease", "PROBLEM", 109, 133], ["expanded LAP", "TEST", 203, 215], ["Tregs", "TREATMENT", 217, 222], ["PBMC", "TREATMENT", 272, 276], ["xenogeneic GVHD", "PROBLEM", 285, 300], ["a xenogeneic model of GVHD", "TREATMENT", 310, 336], ["allogeneic CD25", "TREATMENT", 391, 406], ["vitro-expanded LAP", "TREATMENT", 497, 515], ["Tregs", "TEST", 517, 522], ["LAP- cells", "TEST", 527, 537], ["LAP", "OBSERVATION", 13, 16], ["most potent", "OBSERVATION_MODIFIER", 32, 43], ["+ Tregs", "OBSERVATION", 107, 114], ["xenogeneic murine", "OBSERVATION", 139, 156], ["GVHD", "OBSERVATION", 166, 170], ["LAP", "OBSERVATION", 212, 215], ["xenogeneic GVHD", "OBSERVATION", 285, 300], ["LAP", "OBSERVATION", 512, 515], ["LAP", "ANATOMY", 527, 530]]], ["CD25-PBMC administered alone results in a median survival of 32 days.", [["PBMC", "ANATOMY", 5, 9], ["CD25", "GENE_OR_GENE_PRODUCT", 0, 4], ["PBMC", "CELL", 5, 9], ["CD25", "PROTEIN", 0, 4], ["PBMC", "CELL_TYPE", 5, 9]]], ["The co-transfer of LAP parent (CD25+) or LAP+ Tregs increased median survival to 39 (p < 0.05) and 47 days (p < 0.001), respectively.", [["Tregs", "ANATOMY", 46, 51], ["LAP", "GENE_OR_GENE_PRODUCT", 19, 22], ["CD25", "GENE_OR_GENE_PRODUCT", 31, 35], ["LAP", "GENE_OR_GENE_PRODUCT", 41, 44], ["Tregs", "CELL", 46, 51], ["LAP parent", "PROTEIN", 19, 29], ["CD25", "PROTEIN", 31, 35], ["LAP", "PROTEIN", 41, 44], ["Tregs", "CELL_TYPE", 46, 51], ["LAP", "TEST", 41, 44], ["LAP", "OBSERVATION", 19, 22], ["LAP", "ANATOMY", 41, 44]]], ["The LAP- nonTregs showed similar median survival (31 days) with PBMC group.", [["Tregs", "ANATOMY", 12, 17], ["PBMC", "ANATOMY", 64, 68], ["LAP", "GENE_OR_GENE_PRODUCT", 4, 7], ["PBMC", "CELL", 64, 68], ["LAP", "PROTEIN", 4, 7], ["Tregs", "CELL_TYPE", 12, 17], ["PBMC", "CELL_TYPE", 64, 68], ["The LAP", "TEST", 0, 7], ["PBMC group", "TREATMENT", 64, 74], ["LAP", "OBSERVATION", 4, 7]]], ["The survival of LAP+ group was significantly higher than LAP- group (p < 0.001).", [["LAP", "GENE_OR_GENE_PRODUCT", 16, 19], ["LAP", "PROTEIN", 16, 19], ["LAP", "PROTEIN", 57, 60], ["LAP+ group", "TEST", 16, 26], ["LAP", "TEST", 57, 60], ["LAP", "OBSERVATION", 16, 19]]], ["Compared with CD25+ group, LAP+ Tregs increased median survival from 39 to 47 days.", [["Tregs", "ANATOMY", 32, 37], ["CD25", "GENE_OR_GENE_PRODUCT", 14, 18], ["LAP", "GENE_OR_GENE_PRODUCT", 27, 30], ["Tregs", "CELL", 32, 37], ["CD25", "PROTEIN", 14, 18], ["LAP", "PROTEIN", 27, 30], ["Tregs", "CELL_TYPE", 32, 37], ["LAP", "TEST", 27, 30], ["Tregs increased median survival", "TREATMENT", 32, 63], ["LAP", "ANATOMY", 27, 30]]], ["However, no statistic different was found, since some of the CD25+ parent populations have less contaminating nonTregs and therefore higher level of FOXP3+ Tregs (Figure 2D, 5B).", [["Tregs", "ANATOMY", 113, 118], ["Tregs", "ANATOMY", 156, 161], ["CD25", "GENE_OR_GENE_PRODUCT", 61, 65], ["nonTregs", "CELL", 110, 118], ["FOXP3", "GENE_OR_GENE_PRODUCT", 149, 154], ["Tregs", "CELL", 156, 161], ["CD25", "PROTEIN", 61, 65], ["Tregs", "CELL_TYPE", 113, 118], ["FOXP3", "PROTEIN", 149, 154], ["Tregs", "CELL_TYPE", 156, 161], ["the CD25", "TEST", 57, 65], ["parent populations", "PROBLEM", 67, 85], ["no", "UNCERTAINTY", 9, 11], ["FOXP3", "OBSERVATION", 149, 154]]], ["Average body weight (% of initial weight) for mice surviving on given day for different groups was shown in Figure S3.DiscussionAdoptive transfer of FOXP3+ Tregs to prevent or cure multiple autoimmune diseases or GVHD has proven to be highly efficacious in animal models and human 23-25.", [["body", "ANATOMY", 8, 12], ["Tregs", "ANATOMY", 156, 161], ["autoimmune diseases", "DISEASE", 190, 209], ["GVHD", "DISEASE", 213, 217], ["body", "ORGANISM_SUBDIVISION", 8, 12], ["mice", "ORGANISM", 46, 50], ["FOXP3", "GENE_OR_GENE_PRODUCT", 149, 154], ["Tregs", "CELL", 156, 161], ["human", "ORGANISM", 275, 280], ["FOXP3", "PROTEIN", 149, 154], ["Tregs", "CELL_TYPE", 156, 161], ["mice", "SPECIES", 46, 50], ["human", "SPECIES", 275, 280], ["mice", "SPECIES", 46, 50], ["human", "SPECIES", 275, 280], ["Average body weight", "TEST", 0, 19], ["Tregs", "TREATMENT", 156, 161], ["cure multiple autoimmune diseases", "PROBLEM", 176, 209], ["GVHD", "PROBLEM", 213, 217], ["multiple", "OBSERVATION_MODIFIER", 181, 189], ["autoimmune", "OBSERVATION", 190, 200], ["GVHD", "OBSERVATION", 213, 217], ["highly", "OBSERVATION_MODIFIER", 235, 241], ["efficacious", "OBSERVATION_MODIFIER", 242, 253]]], ["But a major obstacle to overcome is to achieve a consistent and highly purified FOXP3+ Treg product after ex vivo expansion in a cost-effective manner.", [["Treg", "ANATOMY", 87, 91], ["FOXP3", "GENE_OR_GENE_PRODUCT", 80, 85], ["Treg", "CELL", 87, 91], ["FOXP3", "PROTEIN", 80, 85], ["Treg product", "PROTEIN", 87, 99], ["Treg product", "TREATMENT", 87, 99], ["ex vivo expansion", "TREATMENT", 106, 123], ["FOXP3", "OBSERVATION", 80, 85], ["ex vivo", "OBSERVATION_MODIFIER", 106, 113], ["expansion", "OBSERVATION_MODIFIER", 114, 123]]], ["In this study, we use LAP as a unique cell surface marker that distinguishes bona fide Tregs from activated FOXP3+ and FOXP3- nonTregs and show that it is feasible to sort expanded FOXP3+ Tregs from nonTregs based on expression of LAP.", [["cell surface", "ANATOMY", 38, 50], ["Tregs", "ANATOMY", 87, 92], ["FOXP3- nonTregs", "ANATOMY", 119, 134], ["Tregs", "ANATOMY", 188, 193], ["nonTregs", "ANATOMY", 199, 207], ["LAP", "GENE_OR_GENE_PRODUCT", 22, 25], ["cell", "CELL", 38, 42], ["Tregs", "CELL", 87, 92], ["FOXP3", "GENE_OR_GENE_PRODUCT", 108, 113], ["FOXP3", "GENE_OR_GENE_PRODUCT", 119, 124], ["FOXP3", "GENE_OR_GENE_PRODUCT", 181, 186], ["Tregs", "CELL", 188, 193], ["nonTregs", "CANCER", 199, 207], ["LAP", "GENE_OR_GENE_PRODUCT", 231, 234], ["LAP", "PROTEIN", 22, 25], ["Tregs", "CELL_TYPE", 87, 92], ["FOXP3", "PROTEIN", 108, 113], ["FOXP3", "PROTEIN", 119, 124], ["Tregs", "CELL_TYPE", 129, 134], ["FOXP3", "PROTEIN", 181, 186], ["Tregs", "CELL_TYPE", 188, 193], ["nonTregs", "CELL_TYPE", 199, 207], ["LAP", "PROTEIN", 231, 234], ["this study", "TEST", 3, 13], ["LAP", "TREATMENT", 22, 25], ["a unique cell surface marker", "TREATMENT", 29, 57], ["activated FOXP3", "TEST", 98, 113], ["FOXP3", "TEST", 119, 124], ["LAP", "TREATMENT", 231, 234], ["fide Tregs", "OBSERVATION", 82, 92], ["FOXP3", "OBSERVATION", 181, 186], ["LAP", "OBSERVATION", 231, 234]]], ["We obtain a post-sort FOXP3 purity of greater than 90% which would be ideal for cellular immunotherapy.", [["cellular", "ANATOMY", 80, 88], ["FOXP3", "GENE_OR_GENE_PRODUCT", 22, 27], ["cellular", "CELL", 80, 88], ["FOXP3", "PROTEIN", 22, 27], ["cellular immunotherapy", "TREATMENT", 80, 102]]], ["Furthermore, we find that ex vivo expanded LAP+ Tregs with aAPCs maintain TCR V\u03b2 repertoire diversity, instead of clonal expansion due to selective cell death.", [["Tregs", "ANATOMY", 48, 53], ["aAPCs", "ANATOMY", 59, 64], ["cell", "ANATOMY", 148, 152], ["death", "DISEASE", 153, 158], ["LAP", "GENE_OR_GENE_PRODUCT", 43, 46], ["Tregs", "CELL", 48, 53], ["aAPCs", "GENE_OR_GENE_PRODUCT", 59, 64], ["TCR", "GENE_OR_GENE_PRODUCT", 74, 77], ["cell", "CELL", 148, 152], ["LAP", "PROTEIN", 43, 46], ["Tregs", "CELL_TYPE", 48, 53], ["aAPCs", "CELL_TYPE", 59, 64], ["TCR", "PROTEIN", 74, 77], ["aAPCs", "TREATMENT", 59, 64], ["clonal expansion", "TREATMENT", 114, 130], ["selective cell death", "PROBLEM", 138, 158], ["LAP", "OBSERVATION", 43, 46], ["selective cell death", "OBSERVATION", 138, 158]]], ["Similar data has been detected in expanded cord blood (CB) Tregs: the process of ex vivo expansion did not skew the CB Tregs TCR V\u03b2 repertoire 26.DiscussionAlthough it is possible to obtain a highly purified FOXP3+ population after re-stimulation of the expanded CD25hi cells, it has also been shown that the effector T cells can transiently possess this feature, particularly after repeated in vitro stimulation 27.", [["cord blood (CB) Tregs", "ANATOMY", 43, 64], ["CB Tregs", "ANATOMY", 116, 124], ["CD25hi cells", "ANATOMY", 263, 275], ["T cells", "ANATOMY", 318, 325], ["TCR", "CHEMICAL", 125, 128], ["cord blood (CB) Tregs", "CELL", 43, 64], ["FOXP3", "GENE_OR_GENE_PRODUCT", 208, 213], ["CD25hi cells", "CELL", 263, 275], ["T cells", "CELL", 318, 325], ["expanded cord blood (CB) Tregs", "CELL_TYPE", 34, 64], ["TCR", "PROTEIN", 125, 128], ["V\u03b2 repertoire 26", "PROTEIN", 129, 145], ["FOXP3", "PROTEIN", 208, 213], ["CD25hi cells", "CELL_LINE", 263, 275], ["effector T cells", "CELL_TYPE", 309, 325], ["ex vivo expansion", "PROBLEM", 81, 98], ["V\u03b2 repertoire", "TEST", 129, 142], ["re-stimulation", "TREATMENT", 232, 246], ["the expanded CD25hi cells", "PROBLEM", 250, 275], ["the effector T cells", "PROBLEM", 305, 325], ["cord", "ANATOMY", 43, 47]]], ["Moreover, several studies have pointed out the potential plasticity of Tregs and caution that this instability could result in the generation of pathogenic memory T cells in vivo28.", [["Tregs", "ANATOMY", 71, 76], ["memory T cells", "ANATOMY", 156, 170], ["Tregs", "CELL", 71, 76], ["memory T cells", "CELL", 156, 170], ["vivo28", "CELL", 174, 180], ["Tregs", "CELL_TYPE", 71, 76], ["pathogenic memory T cells", "CELL_TYPE", 145, 170], ["several studies", "TEST", 10, 25], ["Tregs", "TREATMENT", 71, 76], ["this instability", "PROBLEM", 94, 110], ["Tregs", "OBSERVATION", 71, 76]]], ["In our study, a quantitative assay to assess the anergic state of Tregs is used to detect the cytokine secretion.", [["Tregs", "ANATOMY", 66, 71], ["Tregs", "CELL", 66, 71], ["Tregs", "CELL_TYPE", 66, 71], ["cytokine", "PROTEIN", 94, 102], ["our study", "TEST", 3, 12], ["a quantitative assay", "TEST", 14, 34], ["the cytokine secretion", "PROBLEM", 90, 112]]], ["Only minimal percentages of IL2, IFN\u03b3, IL17, IL4, IL13 and IL10 are detected in the purified LAP+ Tregs as compared to CD25+ and LAP\u203e population.", [["Tregs", "ANATOMY", 98, 103], ["IL2", "GENE_OR_GENE_PRODUCT", 28, 31], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 33, 37], ["IL17", "GENE_OR_GENE_PRODUCT", 39, 43], ["IL4", "GENE_OR_GENE_PRODUCT", 45, 48], ["IL13", "GENE_OR_GENE_PRODUCT", 50, 54], ["IL10", "GENE_OR_GENE_PRODUCT", 59, 63], ["LAP", "GENE_OR_GENE_PRODUCT", 93, 96], ["Tregs", "CELL", 98, 103], ["CD25", "GENE_OR_GENE_PRODUCT", 119, 123], ["LAP", "GENE_OR_GENE_PRODUCT", 129, 132], ["IL2", "PROTEIN", 28, 31], ["IFN\u03b3", "PROTEIN", 33, 37], ["IL17", "PROTEIN", 39, 43], ["IL4", "PROTEIN", 45, 48], ["IL13", "PROTEIN", 50, 54], ["IL10", "PROTEIN", 59, 63], ["LAP", "PROTEIN", 93, 96], ["Tregs", "CELL_TYPE", 98, 103], ["CD25", "PROTEIN", 119, 123], ["LAP", "PROTEIN", 129, 132], ["IL2", "TEST", 28, 31], ["IFN\u03b3", "TEST", 33, 37], ["IL17", "TEST", 39, 43], ["IL4", "TEST", 45, 48], ["IL13", "TEST", 50, 54], ["IL10", "PROBLEM", 59, 63], ["the purified LAP", "TEST", 80, 96], ["Tregs", "PROBLEM", 98, 103], ["CD25", "TEST", 119, 123], ["LAP\u203e population", "TREATMENT", 129, 144], ["minimal", "OBSERVATION_MODIFIER", 5, 12], ["percentages", "OBSERVATION_MODIFIER", 13, 24], ["IL2", "ANATOMY", 28, 31], ["LAP", "OBSERVATION", 93, 96], ["LAP", "ANATOMY", 129, 132]]], ["This method offers the opportunity to reduce most of the cytokine secreting cells in our culture compared with rapamycin culture system, which still has >50% of cells secreting IL4 (both FOXP3+ and FOXP3- cells) after the fourth re-stimulation 4.", [["cells", "ANATOMY", 76, 81], ["cells", "ANATOMY", 161, 166], ["FOXP3- cells", "ANATOMY", 198, 210], ["rapamycin", "CHEMICAL", 111, 120], ["rapamycin", "CHEMICAL", 111, 120], ["cells", "CELL", 76, 81], ["rapamycin", "SIMPLE_CHEMICAL", 111, 120], ["cells", "CELL", 161, 166], ["IL4", "GENE_OR_GENE_PRODUCT", 177, 180], ["FOXP3", "GENE_OR_GENE_PRODUCT", 187, 192], ["FOXP3", "GENE_OR_GENE_PRODUCT", 198, 203], ["cytokine secreting cells", "CELL_TYPE", 57, 81], ["IL4", "PROTEIN", 177, 180], ["FOXP3", "PROTEIN", 187, 192], ["FOXP3", "PROTEIN", 198, 203], ["the cytokine secreting cells", "PROBLEM", 53, 81], ["our culture", "TEST", 85, 96], ["rapamycin culture system", "TEST", 111, 135], ["cells secreting IL4", "TEST", 161, 180], ["FOXP3", "TEST", 187, 192], ["the fourth re-stimulation", "TREATMENT", 218, 243]]], ["In this study, only minimal percentages of LAP+ Treg cells secrete IL-10.", [["Treg cells", "ANATOMY", 48, 58], ["LAP", "GENE_OR_GENE_PRODUCT", 43, 46], ["Treg cells", "CELL", 48, 58], ["IL-10", "GENE_OR_GENE_PRODUCT", 67, 72], ["LAP", "PROTEIN", 43, 46], ["Treg cells", "CELL_TYPE", 48, 58], ["IL", "PROTEIN", 67, 69], ["this study", "TEST", 3, 13], ["LAP", "TEST", 43, 46], ["minimal", "OBSERVATION_MODIFIER", 20, 27], ["percentages", "OBSERVATION_MODIFIER", 28, 39], ["LAP", "OBSERVATION", 43, 46]]], ["While the LAP+ cells are mainly GARP+ cells, the immunosuppressive role of LAP+ might be through GARP/LAP complexes.", [["LAP+ cells", "ANATOMY", 10, 20], ["GARP+ cells", "ANATOMY", 32, 43], ["LAP", "GENE_OR_GENE_PRODUCT", 10, 13], ["GARP", "GENE_OR_GENE_PRODUCT", 32, 36], ["LAP", "GENE_OR_GENE_PRODUCT", 75, 78], ["GARP", "GENE_OR_GENE_PRODUCT", 97, 101], ["LAP", "GENE_OR_GENE_PRODUCT", 102, 105], ["LAP", "PROTEIN", 10, 13], ["GARP", "PROTEIN", 32, 36], ["LAP", "PROTEIN", 75, 78], ["GARP", "PROTEIN", 97, 101], ["LAP complexes", "PROTEIN", 102, 115], ["the LAP+ cells", "TEST", 6, 20], ["GARP+ cells", "PROBLEM", 32, 43], ["LAP", "TEST", 75, 78], ["GARP/LAP complexes", "PROBLEM", 97, 115], ["LAP", "ANATOMY", 10, 13], ["GARP+ cells", "OBSERVATION", 32, 43], ["LAP", "OBSERVATION", 75, 78], ["LAP complexes", "OBSERVATION", 102, 115]]], ["Glycoprotein A repetitions predominant (GARP), also known as leucine rich repeat containing 32 (LRRC32), plays important role in immunosuppressive function of Tregs by inhibiting T effector cell activity 29.", [["Tregs", "ANATOMY", 159, 164], ["T effector cell", "ANATOMY", 179, 194], ["leucine", "CHEMICAL", 61, 68], ["Glycoprotein A", "GENE_OR_GENE_PRODUCT", 0, 14], ["GARP", "GENE_OR_GENE_PRODUCT", 40, 44], ["leucine rich repeat containing 32", "GENE_OR_GENE_PRODUCT", 61, 94], ["LRRC32", "GENE_OR_GENE_PRODUCT", 96, 102], ["Tregs", "CELL", 159, 164], ["T effector cell", "CELL", 179, 194], ["Glycoprotein A", "PROTEIN", 0, 14], ["GARP", "PROTEIN", 40, 44], ["leucine rich repeat containing 32", "PROTEIN", 61, 94], ["LRRC32", "PROTEIN", 96, 102], ["Tregs", "CELL_TYPE", 159, 164], ["Glycoprotein A repetitions", "TEST", 0, 26]]], ["Targeting GARP by siRNA or monoclonal antibodies specific for GARP inhibit immunosuppressive activity of Treg in vitro and in vivo30, 31.", [["Treg", "ANATOMY", 105, 109], ["GARP", "GENE_OR_GENE_PRODUCT", 10, 14], ["GARP", "GENE_OR_GENE_PRODUCT", 62, 66], ["Treg", "CELL", 105, 109], ["GARP", "PROTEIN", 10, 14], ["monoclonal antibodies", "PROTEIN", 27, 48], ["GARP", "PROTEIN", 62, 66], ["Treg", "CELL_TYPE", 105, 109], ["siRNA", "TEST", 18, 23], ["monoclonal antibodies", "TEST", 27, 48], ["GARP", "PROBLEM", 62, 66], ["Treg in vitro", "TREATMENT", 105, 118]]], ["However, the role of LAP/GARP on Tregs remains unclear and controversial.", [["Tregs", "ANATOMY", 33, 38], ["LAP", "GENE_OR_GENE_PRODUCT", 21, 24], ["GARP", "GENE_OR_GENE_PRODUCT", 25, 29], ["Tregs", "CELL", 33, 38], ["LAP", "PROTEIN", 21, 24], ["GARP", "PROTEIN", 25, 29], ["Tregs", "CELL_TYPE", 33, 38], ["LAP/GARP on Tregs", "TEST", 21, 38], ["LAP", "OBSERVATION", 21, 24], ["GARP", "OBSERVATION", 25, 29]]], ["Deletion of GARP on mouse Tregs is not sufficient to inhibit the growth of transplanted tumors.", [["Tregs", "ANATOMY", 26, 31], ["tumors", "ANATOMY", 88, 94], ["tumors", "DISEASE", 88, 94], ["GARP", "GENE_OR_GENE_PRODUCT", 12, 16], ["mouse", "ORGANISM", 20, 25], ["Tregs", "CELL", 26, 31], ["tumors", "CANCER", 88, 94], ["GARP", "PROTEIN", 12, 16], ["mouse Tregs", "CELL_TYPE", 20, 31], ["mouse", "SPECIES", 20, 25], ["mouse", "SPECIES", 20, 25], ["Deletion of GARP on mouse Tregs", "PROBLEM", 0, 31], ["transplanted tumors", "PROBLEM", 75, 94], ["GARP", "OBSERVATION", 12, 16], ["growth", "OBSERVATION_MODIFIER", 65, 71], ["transplanted", "OBSERVATION_MODIFIER", 75, 87], ["tumors", "OBSERVATION", 88, 94]]], ["They found the suppressive function of Tregs was not affected by knockout of garp in Tregs 32.", [["Tregs", "ANATOMY", 39, 44], ["Tregs", "CELL", 39, 44], ["Tregs", "CELL_TYPE", 39, 44], ["Tregs 32", "CELL_LINE", 85, 93], ["suppressive", "OBSERVATION_MODIFIER", 15, 26]]], ["Further studies are needed to reveal the mechanisms responsible for suppressive function of LAP+ Tregs.DiscussionTregs represent a heterogeneous population comprised of a committed lineage and an uncommitted subpopulation with developmental plasticity 33.", [["Tregs", "ANATOMY", 97, 102], ["LAP", "GENE_OR_GENE_PRODUCT", 92, 95], ["Tregs", "CELL", 97, 102], ["lineage", "CELL", 181, 188], ["LAP", "PROTEIN", 92, 95], ["Tregs", "CELL_TYPE", 97, 102], ["committed lineage", "CELL_TYPE", 171, 188], ["Further studies", "TEST", 0, 15], ["LAP", "TEST", 92, 95], ["a heterogeneous population", "PROBLEM", 129, 155], ["LAP", "OBSERVATION", 92, 95], ["heterogeneous", "OBSERVATION_MODIFIER", 131, 144], ["population", "OBSERVATION", 145, 155], ["committed lineage", "OBSERVATION", 171, 188], ["uncommitted", "OBSERVATION_MODIFIER", 196, 207], ["subpopulation", "OBSERVATION_MODIFIER", 208, 221], ["developmental plasticity", "OBSERVATION", 227, 251]]], ["Therefore, it is crucial to certify that the final Treg products consist of a committed Treg lineage and possess a stable phenotype with the highest purity as possible.", [["Treg", "ANATOMY", 51, 55], ["Treg lineage", "ANATOMY", 88, 100], ["Treg", "CELL", 51, 55], ["Treg lineage", "CELL", 88, 100], ["Treg products", "PROTEIN", 51, 64], ["Treg lineage", "CELL_TYPE", 88, 100], ["the final Treg products", "TREATMENT", 41, 64], ["Treg lineage", "TREATMENT", 88, 100], ["stable", "OBSERVATION_MODIFIER", 115, 121]]], ["A reliable method is the quantification of demethylation in the TSDR, which correlates positively with Treg phenotype and function.", [["Treg", "ANATOMY", 103, 107], ["TSDR", "CANCER", 64, 68], ["Treg", "CELL", 103, 107], ["TSDR", "PROTEIN", 64, 68], ["demethylation in the TSDR", "PROBLEM", 43, 68], ["demethylation", "OBSERVATION", 43, 56]]], ["This epigenetic marker is highly specific for Tregs and can discriminate them from activated FOXP3+ conventional T cells 34, 35.", [["Tregs", "ANATOMY", 46, 51], ["T cells", "ANATOMY", 113, 120], ["Tregs", "CELL", 46, 51], ["FOXP3", "GENE_OR_GENE_PRODUCT", 93, 98], ["Tregs", "CELL_TYPE", 46, 51], ["FOXP3", "PROTEIN", 93, 98], ["T cells", "CELL_TYPE", 113, 120], ["Tregs", "PROBLEM", 46, 51], ["conventional T cells", "TEST", 100, 120]]], ["When compared with LAP+ Tregs, significant levels of FOXP3 TSDR methylation are demonstrated in the LAP- nonTregs.", [["Tregs", "ANATOMY", 24, 29], ["LAP- nonTregs", "ANATOMY", 100, 113], ["LAP", "GENE_OR_GENE_PRODUCT", 19, 22], ["Tregs", "CELL", 24, 29], ["FOXP3", "GENE_OR_GENE_PRODUCT", 53, 58], ["TSDR", "GENE_OR_GENE_PRODUCT", 59, 63], ["LAP", "GENE_OR_GENE_PRODUCT", 100, 103], ["LAP", "PROTEIN", 19, 22], ["Tregs", "CELL_TYPE", 24, 29], ["FOXP3", "PROTEIN", 53, 58], ["TSDR", "PROTEIN", 59, 63], ["LAP", "PROTEIN", 100, 103], ["LAP", "TEST", 19, 22], ["Tregs", "PROBLEM", 24, 29], ["FOXP3 TSDR methylation", "TREATMENT", 53, 75], ["the LAP", "TEST", 96, 103], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["levels", "OBSERVATION_MODIFIER", 43, 49], ["FOXP3 TSDR", "OBSERVATION", 53, 63], ["LAP", "ANATOMY", 100, 103]]], ["Even after 30 days expansion, the purified LAP+ Tregs are highly demethylated in the TSDR region.", [["Tregs", "ANATOMY", 48, 53], ["TSDR region", "ANATOMY", 85, 96], ["LAP", "GENE_OR_GENE_PRODUCT", 43, 46], ["Tregs", "CELL", 48, 53], ["LAP", "PROTEIN", 43, 46], ["Tregs", "CELL_TYPE", 48, 53], ["TSDR region", "DNA", 85, 96], ["the purified LAP", "TEST", 30, 46], ["LAP", "OBSERVATION", 43, 46], ["highly", "OBSERVATION_MODIFIER", 58, 64], ["demethylated", "OBSERVATION_MODIFIER", 65, 77], ["TSDR", "ANATOMY", 85, 89], ["region", "ANATOMY_MODIFIER", 90, 96]]], ["Some of the LAP- populations contain over 40% FOXP3+ cells, yet they have <20% TSDR demethylation, supporting that these FOXP3+ cells are not bona fide Tregs.DiscussionAdoptive transfer of LAP+ Tregs delayed the development of xenogeneic GVHD.", [["FOXP3+ cells", "ANATOMY", 46, 58], ["FOXP3+ cells", "ANATOMY", 121, 133], ["Tregs", "ANATOMY", 152, 157], ["Tregs", "ANATOMY", 194, 199], ["GVHD", "DISEASE", 238, 242], ["LAP", "GENE_OR_GENE_PRODUCT", 12, 15], ["FOXP3", "GENE_OR_GENE_PRODUCT", 46, 51], ["TSDR", "GENE_OR_GENE_PRODUCT", 79, 83], ["FOXP3", "GENE_OR_GENE_PRODUCT", 121, 126], ["Tregs", "CELL", 152, 157], ["LAP", "GENE_OR_GENE_PRODUCT", 189, 192], ["Tregs", "CELL", 194, 199], ["LAP", "PROTEIN", 12, 15], ["FOXP3", "PROTEIN", 46, 51], ["FOXP3", "PROTEIN", 121, 126], ["bona fide Tregs", "CELL_TYPE", 142, 157], ["LAP", "PROTEIN", 189, 192], ["Tregs", "CELL_TYPE", 194, 199], ["the LAP", "TEST", 8, 15], ["LAP", "TEST", 189, 192], ["xenogeneic GVHD", "PROBLEM", 227, 242], ["LAP", "OBSERVATION", 12, 15], ["fide Tregs", "OBSERVATION", 147, 157], ["LAP", "OBSERVATION", 189, 192], ["xenogeneic GVHD", "OBSERVATION", 227, 242]]], ["Our finding supports a prior observation showing that GARP+ Treg protect from xGVHD.", [["Treg", "ANATOMY", 60, 64], ["xGVHD", "DISEASE", 78, 83], ["GARP", "GENE_OR_GENE_PRODUCT", 54, 58], ["Treg", "CELL", 60, 64], ["xGVHD", "CANCER", 78, 83], ["GARP", "PROTEIN", 54, 58], ["Treg", "CELL_TYPE", 60, 64], ["a prior observation", "TEST", 21, 40]]], ["Dr. Lucas group found that the administration of antibody blocking GARP or GARP/TGF-\u03b21 abrogate the protection of Tregs in xGVHD 31.", [["Tregs", "ANATOMY", 114, 119], ["Dr. Lucas", "ORGANISM", 0, 9], ["GARP", "GENE_OR_GENE_PRODUCT", 67, 71], ["GARP", "GENE_OR_GENE_PRODUCT", 75, 79], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 80, 86], ["Tregs", "CELL", 114, 119], ["xGVHD 31", "CELL", 123, 131], ["GARP", "PROTEIN", 67, 71], ["GARP", "PROTEIN", 75, 79], ["TGF-\u03b21", "PROTEIN", 80, 86], ["Tregs", "CELL_TYPE", 114, 119], ["xGVHD 31", "CELL_LINE", 123, 131], ["antibody blocking GARP", "TEST", 49, 71], ["GARP/TGF", "TEST", 75, 83]]], ["While we are able to demonstrate the suppressive function of LAP+ Tregs, these assays have limitations.", [["Tregs", "ANATOMY", 66, 71], ["LAP", "GENE_OR_GENE_PRODUCT", 61, 64], ["Tregs", "CELL", 66, 71], ["LAP", "PROTEIN", 61, 64], ["Tregs", "CELL_TYPE", 66, 71], ["LAP", "TEST", 61, 64], ["these assays", "TEST", 73, 85], ["LAP", "OBSERVATION", 61, 64]]], ["Although the LAP+ Tregs demonstrate suppressive function by delaying the development of xenogeneic GVHD, we are unable to detect their existence in peripheral blood and spleens of the NSG mice by day 14 post adoptive transfer.", [["Tregs", "ANATOMY", 18, 23], ["peripheral blood", "ANATOMY", 148, 164], ["spleens", "ANATOMY", 169, 176], ["GVHD", "DISEASE", 99, 103], ["LAP", "GENE_OR_GENE_PRODUCT", 13, 16], ["Tregs", "CELL", 18, 23], ["peripheral blood", "ORGANISM_SUBSTANCE", 148, 164], ["spleens", "ORGAN", 169, 176], ["NSG mice", "ORGANISM", 184, 192], ["LAP", "PROTEIN", 13, 16], ["Tregs", "CELL_TYPE", 18, 23], ["mice", "SPECIES", 188, 192], ["mice", "SPECIES", 188, 192], ["the LAP", "TEST", 9, 16], ["suppressive function", "PROBLEM", 36, 56], ["xenogeneic GVHD", "PROBLEM", 88, 103], ["peripheral blood", "TEST", 148, 164], ["LAP", "OBSERVATION", 13, 16], ["suppressive function", "OBSERVATION", 36, 56], ["xenogeneic GVHD", "OBSERVATION", 88, 103], ["peripheral", "ANATOMY_MODIFIER", 148, 158], ["blood", "ANATOMY", 159, 164], ["spleens", "ANATOMY", 169, 176]]], ["Similar to our finding, Parmar et al. have previously shown that ex vivo-expanded cord blood Tregs in NSG xenogeneic model did not persist beyond day 3 26.", [["cord blood Tregs", "ANATOMY", 82, 98], ["cord blood Tregs", "CELL", 82, 98], ["cord blood Tregs", "CELL_TYPE", 82, 98], ["ex vivo-expanded cord blood Tregs", "TREATMENT", 65, 98], ["NSG xenogeneic model", "TREATMENT", 102, 122], ["cord", "ANATOMY", 82, 86]]], ["One possible explanation might be due to cytokine deprivation, particularly IL2.", [["IL2", "GENE_OR_GENE_PRODUCT", 76, 79], ["cytokine", "PROTEIN", 41, 49], ["IL2", "PROTEIN", 76, 79], ["cytokine deprivation", "PROBLEM", 41, 61], ["IL2", "PROBLEM", 76, 79], ["possible explanation might be due to", "UNCERTAINTY", 4, 40], ["cytokine deprivation", "OBSERVATION", 41, 61]]], ["Enhancing the stability of LAP+ Tregs is critical for the development of an efficacious cell therapy.", [["Tregs", "ANATOMY", 32, 37], ["cell", "ANATOMY", 88, 92], ["LAP", "GENE_OR_GENE_PRODUCT", 27, 30], ["Tregs", "CELL", 32, 37], ["cell", "CELL", 88, 92], ["LAP", "PROTEIN", 27, 30], ["Tregs", "CELL_TYPE", 32, 37], ["an efficacious cell therapy", "TREATMENT", 73, 100], ["stability", "OBSERVATION_MODIFIER", 14, 23], ["LAP", "OBSERVATION", 27, 30], ["efficacious cell therapy", "OBSERVATION", 76, 100]]], ["At this point, we are unclear whether their lack of persistence is intrinsic to the human Tregs or extrinsic due to the absence of critical growth factors compatible with human Tregs in the NSG mice.", [["Tregs", "ANATOMY", 90, 95], ["Tregs", "ANATOMY", 177, 182], ["human", "ORGANISM", 84, 89], ["Tregs", "CELL", 90, 95], ["human", "ORGANISM", 171, 176], ["Tregs", "CELL", 177, 182], ["NSG mice", "ORGANISM", 190, 198], ["Tregs", "CELL_TYPE", 90, 95], ["growth factors", "PROTEIN", 140, 154], ["human Tregs", "CELL_TYPE", 171, 182], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 171, 176], ["mice", "SPECIES", 194, 198], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 171, 176], ["Tregs", "PROBLEM", 90, 95], ["critical growth factors", "PROBLEM", 131, 154], ["human Tregs", "TREATMENT", 171, 182]]], ["Further studies are needed to answer these two issues.DiscussionIn the absence of a repurification process, the final expanded Treg product would have highly variable content of bona fide Tregs and contaminated, expanded nonTregs (Figure 2D).", [["Treg", "ANATOMY", 127, 131], ["Tregs", "ANATOMY", 188, 193], ["Treg", "CELL", 127, 131], ["Tregs", "CELL", 188, 193], ["Treg product", "PROTEIN", 127, 139], ["bona fide Tregs", "CELL_TYPE", 178, 193], ["Further studies", "TEST", 0, 15], ["a repurification process", "PROBLEM", 82, 106], ["bona fide Tregs", "OBSERVATION", 178, 193]]], ["To address this issue, other protocols have implemented rapamycin which has improved the percentage of Tregs, but variability still exists 15, 36.", [["Tregs", "ANATOMY", 103, 108], ["rapamycin", "CHEMICAL", 56, 65], ["rapamycin", "CHEMICAL", 56, 65], ["rapamycin", "SIMPLE_CHEMICAL", 56, 65], ["Tregs", "CELL", 103, 108], ["Tregs", "CELL_TYPE", 103, 108], ["other protocols", "TREATMENT", 23, 38], ["rapamycin", "TREATMENT", 56, 65]]], ["Consistent with other studies, some of our expanded CD25+ populations maintained >75% FOXP3+ and >60% TSDR demethylation (Figure 5B).", [["CD25", "GENE_OR_GENE_PRODUCT", 52, 56], ["FOXP3", "GENE_OR_GENE_PRODUCT", 86, 91], ["CD25", "PROTEIN", 52, 56], ["FOXP3", "PROTEIN", 86, 91], ["TSDR", "PROTEIN", 102, 106], ["other studies", "TEST", 16, 29], ["our expanded CD25", "TEST", 39, 56], ["populations", "TEST", 58, 69], ["FOXP3", "TEST", 86, 91]]], ["These CD25+ populations did possess sufficient suppressive function similar to the repurified LAP+ Tregs (Figure 6A, C).", [["Tregs", "ANATOMY", 99, 104], ["CD25", "GENE_OR_GENE_PRODUCT", 6, 10], ["LAP", "GENE_OR_GENE_PRODUCT", 94, 97], ["Tregs", "CELL", 99, 104], ["CD25", "PROTEIN", 6, 10], ["LAP", "PROTEIN", 94, 97], ["Tregs", "CELL_TYPE", 99, 104], ["the repurified LAP", "TEST", 79, 97]]], ["We were unable to demonstrate a statistical difference between CD25+ populations and LAP+ Tregs due to the high variability in Treg percentage within some of the CD25+ populations.", [["Tregs", "ANATOMY", 90, 95], ["Treg", "ANATOMY", 127, 131], ["CD25", "GENE_OR_GENE_PRODUCT", 63, 67], ["LAP", "GENE_OR_GENE_PRODUCT", 85, 88], ["Tregs", "CELL", 90, 95], ["Treg", "CELL", 127, 131], ["CD25", "GENE_OR_GENE_PRODUCT", 162, 166], ["CD25", "PROTEIN", 63, 67], ["LAP", "PROTEIN", 85, 88], ["Tregs", "CELL_TYPE", 90, 95], ["Treg", "CELL_TYPE", 127, 131], ["CD25", "PROTEIN", 162, 166], ["LAP", "TEST", 85, 88], ["Tregs", "PROBLEM", 90, 95], ["the high variability in Treg percentage", "PROBLEM", 103, 142], ["LAP", "OBSERVATION", 85, 88], ["high", "OBSERVATION_MODIFIER", 107, 111], ["variability", "OBSERVATION_MODIFIER", 112, 123], ["Treg percentage", "OBSERVATION", 127, 142]]], ["Therefore, it would be prudent to manufacture highly purified Treg immunotherapy, similar to the standard required for conventional drug manufacturing.", [["Treg", "ANATOMY", 62, 66], ["Treg", "CELL", 62, 66], ["highly purified Treg immunotherapy", "TREATMENT", 46, 80], ["conventional drug manufacturing", "TREATMENT", 119, 150]]], ["Regardless of the variability in bona fide Tregs within the final product, implementing LAP repurification would normalize and produce a highly purified and more homogenous Treg product.DiscussionOverall, our study provides greater characterizations of LAP+ Tregs to support their therapeutic application for GVHD and other autoimmune conditions.", [["Tregs", "ANATOMY", 43, 48], ["Treg", "ANATOMY", 173, 177], ["Tregs", "ANATOMY", 258, 263], ["GVHD", "DISEASE", 309, 313], ["Tregs", "CELL", 43, 48], ["LAP", "GENE_OR_GENE_PRODUCT", 88, 91], ["Treg", "CELL", 173, 177], ["LAP", "GENE_OR_GENE_PRODUCT", 253, 256], ["Tregs", "CELL", 258, 263], ["Tregs", "CELL_TYPE", 43, 48], ["LAP", "PROTEIN", 88, 91], ["Treg product", "PROTEIN", 173, 185], ["LAP", "PROTEIN", 253, 256], ["Tregs", "CELL_TYPE", 258, 263], ["implementing LAP repurification", "TEST", 75, 106], ["Treg product", "TREATMENT", 173, 185], ["our study", "TEST", 205, 214], ["LAP", "TEST", 253, 256], ["Tregs", "TREATMENT", 258, 263], ["their therapeutic application", "TREATMENT", 275, 304], ["GVHD", "PROBLEM", 309, 313], ["other autoimmune conditions", "PROBLEM", 318, 345], ["bona fide Tregs", "OBSERVATION", 33, 48], ["homogenous", "OBSERVATION_MODIFIER", 162, 172], ["LAP", "OBSERVATION", 253, 256]]], ["Regardless of the methods and strategies used to expand Tregs, co-expansion of other cells, particularly FOXP3+ nonTregs, is almost inevitable.", [["Tregs", "ANATOMY", 56, 61], ["cells", "ANATOMY", 85, 90], ["Tregs", "CELL", 56, 61], ["cells", "CELL", 85, 90], ["FOXP3", "GENE_OR_GENE_PRODUCT", 105, 110], ["Tregs", "CELL_TYPE", 56, 61], ["FOXP3", "PROTEIN", 105, 110], ["the methods", "TREATMENT", 14, 25], ["Tregs", "TEST", 56, 61], ["co-expansion of other cells", "PROBLEM", 63, 90], ["FOXP3", "TEST", 105, 110]]], ["With the application of LAP or GARP repurification, a highly purified, TSDR demethylated Treg population can be achieved which maintains diversity and functionality.", [["Treg", "ANATOMY", 89, 93], ["LAP", "GENE_OR_GENE_PRODUCT", 24, 27], ["GARP", "GENE_OR_GENE_PRODUCT", 31, 35], ["TSDR", "CELL", 71, 75], ["Treg", "CELL", 89, 93], ["LAP", "PROTEIN", 24, 27], ["GARP", "PROTEIN", 31, 35], ["TSDR demethylated Treg population", "CELL_LINE", 71, 104], ["LAP", "TREATMENT", 24, 27], ["GARP repurification", "TREATMENT", 31, 50], ["TSDR demethylated Treg population", "TREATMENT", 71, 104], ["LAP", "OBSERVATION", 24, 27], ["diversity", "OBSERVATION_MODIFIER", 137, 146]]], ["The next step is to demonstrate their safety, stability and functionality in a human clinical trial.", [["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["a human clinical trial", "TREATMENT", 77, 99]]]], "PMC7256401": [["IntroductionIn the era of IoT, edge computing with energy-efficient machine learning models keeps data processing close to end-users.", [["IoT", "DNA", 26, 29]]], ["Meanwhile, multi-task learning (MTL) is grabbing attention recently since a single model can accommodate multiple cognitive tasks is more desirable for the future of IoT [2].IntroductionBrain-inspired Hyperdimensional (HD) computing emulates the operations of brains and handles cognitive tasks in a hyperdimensional space with well-defined vector space operations [3].", [["Brain", "ANATOMY", 186, 191], ["brains", "ANATOMY", 260, 266], ["brains", "ORGAN", 260, 266], ["multiple cognitive tasks", "TREATMENT", 105, 129], ["inspired Hyperdimensional (HD)", "TREATMENT", 192, 222], ["the operations of brains", "TREATMENT", 242, 266], ["a hyperdimensional space", "PROBLEM", 298, 322], ["well-defined vector space operations", "TREATMENT", 328, 364], ["Brain", "ANATOMY", 186, 191], ["brains", "ANATOMY", 260, 266]]], ["As an energy-efficient and fast-learning computational paradigm, HD computing has shown successful progress in many real-world applications such as gesture recognition [4], language recognition [5], and general bio-signal processing [6, 7].", [["HD computing", "TREATMENT", 65, 77]]], ["Moreover, HD computing can operate at an ultra low-power condition with lower latency through massively parallel bitwise operation [8].", [["HD", "TREATMENT", 10, 12], ["lower latency", "PROBLEM", 72, 85], ["massively parallel bitwise operation", "TREATMENT", 94, 130], ["lower latency", "OBSERVATION_MODIFIER", 72, 85]]], ["These advantages make HD computing suitable for efficient signal processing, e.g., 2\u00d7 lower energy at iso-accuracy when compared to a highly-optimized SVM on an ARM Cortex M4 [9].", [["HD", "TREATMENT", 22, 24], ["ARM Cortex", "ANATOMY", 161, 171]]], ["The phenomenon is called catastrophic forgetting [10].", [["catastrophic forgetting", "PROBLEM", 25, 48], ["catastrophic", "OBSERVATION_MODIFIER", 25, 37]]], ["To the best of our knowledge, no study has been conducted to overcome this problem and investigate the feasibility of applying MTL to HD computing.IntroductionThis paper aims to establish a reliable MTL framework based on HD computing to minimize the negative impact of catastrophic forgetting.", [["study", "TEST", 33, 38], ["HD computing", "TREATMENT", 134, 146], ["HD", "TREATMENT", 222, 224], ["catastrophic forgetting", "PROBLEM", 270, 293], ["catastrophic forgetting", "OBSERVATION", 270, 293]]], ["Over-parameterization in DNN implies that only a small subspace spanned by the optimal parameters is occupied by a given task [11].", [["DNN", "DNA", 25, 28], ["a small subspace", "PROBLEM", 47, 63], ["small", "OBSERVATION_MODIFIER", 49, 54]]], ["Based on this phenomenon, [12] exploits the redundant subspace in DNN to superimpose multiple models into one.", [["DNN", "SIMPLE_CHEMICAL", 66, 69], ["DNN", "DNA", 66, 69], ["the redundant subspace", "PROBLEM", 40, 62], ["multiple", "OBSERVATION_MODIFIER", 85, 93]]], ["We are inspired by this concept and propose to exploit the unused capacity in the hyperspace to project each task into a separate subspace for learning.", [["the unused capacity", "PROBLEM", 55, 74]]], ["Our approach efficiently mitigates the interferences between different tasks and keeps the knowledge learned from numerous tasks stored in one HD model with minimal accuracy degradation.IntroductionThe rest of the paper is organized as follows.", [["the interferences between different tasks", "PROBLEM", 35, 76], ["minimal accuracy degradation", "PROBLEM", 157, 185]]], ["Section 2 provides a review of HD computing.", [["HD computing", "TREATMENT", 31, 43]]], ["Section 3 describes the proposed Task-projected Hyperdimensional Computing (TP-HDC) for multi-task learning.", [["TP-HDC", "TREATMENT", 76, 82]]]], "dbdd3f14a564b6545cf95d025cbe36af1ca4fea3": [["Aging is associated with increased frailty of the body functions, particularly of the cardiovascular system [3, 4] , increased oxidative stress [5] , and decreased endogenous protective mechanisms [6] [7] [8] .", [["body", "ANATOMY", 50, 54], ["cardiovascular system", "ANATOMY", 86, 107], ["Aging", "DISEASE", 0, 5], ["body", "ORGANISM_SUBDIVISION", 50, 54], ["cardiovascular", "ANATOMICAL_SYSTEM", 86, 100], ["increased frailty of the body functions", "PROBLEM", 25, 64], ["increased oxidative stress", "PROBLEM", 117, 143], ["decreased endogenous protective mechanisms", "PROBLEM", 154, 196], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["frailty", "OBSERVATION", 35, 42], ["cardiovascular system", "ANATOMY", 86, 107]]], ["Moreover, increasing age is associated with reduced efficiency of thrombolysis [9] , lower protection afforded by physical exercise against myocardial ischemia [7, 10] , as well as increased incidence of heart failure [11] .IntroductionMany pathogens are more aggressive and prevalent in the elderly population [12] .", [["myocardial", "ANATOMY", 140, 150], ["heart", "ANATOMY", 204, 209], ["myocardial ischemia", "DISEASE", 140, 159], ["heart failure", "DISEASE", 204, 217], ["myocardial", "MULTI-TISSUE_STRUCTURE", 140, 150], ["heart", "ORGAN", 204, 209], ["reduced efficiency of thrombolysis", "PROBLEM", 44, 78], ["lower protection afforded", "TREATMENT", 85, 110], ["myocardial ischemia", "PROBLEM", 140, 159], ["heart failure", "PROBLEM", 204, 217], ["thrombolysis", "OBSERVATION", 66, 78], ["ischemia", "OBSERVATION", 151, 159], ["increased", "OBSERVATION_MODIFIER", 181, 190], ["heart", "ANATOMY", 204, 209], ["failure", "OBSERVATION", 210, 217]]], ["SARS-CoV-2 betacoronavirus (large RNA virus) is the virus responsible for Corona Virus Disease 2019 , a respiratory infection, with relevant effects on the cardiovascular system [13, 14] .IntroductionFurthermore, patients with pre-existing cardiovascular conditions represent a relevant subset of elderly patients with symptomatic form of the disease and consequent worse outcomes [13, 15] .", [["respiratory", "ANATOMY", 104, 115], ["cardiovascular", "ANATOMY", 156, 170], ["cardiovascular", "ANATOMY", 240, 254], ["SARS-CoV-2 betacoronavirus", "CHEMICAL", 0, 26], ["Corona Virus Disease", "DISEASE", 74, 94], ["respiratory infection", "DISEASE", 104, 125], ["SARS-CoV-2 betacoronavirus", "ORGANISM", 0, 26], ["large RNA virus", "ORGANISM", 28, 43], ["Corona Virus", "ORGANISM", 74, 86], ["cardiovascular", "ANATOMICAL_SYSTEM", 156, 170], ["system", "ANATOMICAL_SYSTEM", 171, 177], ["patients", "ORGANISM", 213, 221], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 213, 221], ["patients", "SPECIES", 305, 313], ["SARS-CoV-2 betacoronavirus", "SPECIES", 0, 26], ["Corona Virus Disease 2019", "SPECIES", 74, 99], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["betacoronavirus", "PROBLEM", 11, 26], ["large RNA virus", "PROBLEM", 28, 43], ["the virus", "PROBLEM", 48, 57], ["Corona Virus Disease", "PROBLEM", 74, 94], ["a respiratory infection", "PROBLEM", 102, 125], ["pre-existing cardiovascular conditions", "PROBLEM", 227, 265], ["the disease", "PROBLEM", 339, 350], ["consequent worse outcomes", "PROBLEM", 355, 380], ["respiratory", "ANATOMY", 104, 115], ["infection", "OBSERVATION", 116, 125], ["disease", "OBSERVATION", 343, 350]]], ["Table 1 shows clinical studies regarding COVID-19 that have stratified cardiac vs non-cardiac patients according to increasing age and gender [16] [17] [18] [19] [20] .IntroductionHere, we describe the pathogenic events occurring in the cardiovascular system of elderly patients affected by COVID-19 and their possible clinical management.IntroductionJ o u r n a l P r e -p r o o f Older age, D-dimer levels greater than 1 \u03bcg/mL, and higher SOFA score on admission were associated with higher in-hospital death [20] Abbreviations: CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease; HF: Heart Failure; SOFA: Sequential Organ Failure Assessment.Heart involvementPatients suffering of COVID-19 infection can present cardiac arrhythmias, heart failure, myocarditis, pericarditis, and vasculitis [21, 22] with increased troponin release [13, 23, 24] .", [["cardiac", "ANATOMY", 71, 78], ["cardiovascular system", "ANATOMY", 237, 258], ["Coronary", "ANATOMY", 536, 544], ["Pulmonary", "ANATOMY", 586, 595], ["Heart", "ANATOMY", 609, 614], ["Organ", "ANATOMY", 641, 646], ["Heart", "ANATOMY", 666, 671], ["cardiac", "ANATOMY", 736, 743], ["heart", "ANATOMY", 757, 762], ["COVID-19", "CHEMICAL", 291, 299], ["death", "DISEASE", 505, 510], ["CHD", "DISEASE", 531, 534], ["Coronary Heart Disease", "DISEASE", 536, 558], ["COPD", "DISEASE", 560, 564], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 566, 603], ["HF", "DISEASE", 605, 607], ["Heart Failure", "DISEASE", 609, 622], ["COVID-19", "CHEMICAL", 705, 713], ["infection", "DISEASE", 714, 723], ["cardiac arrhythmias", "DISEASE", 736, 755], ["heart failure", "DISEASE", 757, 770], ["myocarditis", "DISEASE", 772, 783], ["pericarditis", "DISEASE", 785, 797], ["vasculitis", "DISEASE", 803, 813], ["cardiac", "ORGAN", 71, 78], ["patients", "ORGANISM", 94, 102], ["[16] [17] [18] [19] [20]", "SIMPLE_CHEMICAL", 142, 166], ["cardiovascular", "ANATOMICAL_SYSTEM", 237, 251], ["system", "ANATOMICAL_SYSTEM", 252, 258], ["patients", "ORGANISM", 270, 278], ["D-dimer", "SIMPLE_CHEMICAL", 393, 400], ["Heart", "ORGAN", 666, 671], ["Patients", "ORGANISM", 683, 691], ["cardiac", "ORGAN", 736, 743], ["heart", "ORGAN", 757, 762], ["troponin", "GENE_OR_GENE_PRODUCT", 838, 846], ["troponin", "PROTEIN", 838, 846], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 270, 278], ["Patients", "SPECIES", 683, 691], ["clinical studies", "TEST", 14, 30], ["COVID", "TEST", 41, 46], ["the pathogenic events", "PROBLEM", 198, 219], ["COVID", "TEST", 291, 296], ["clinical management", "TREATMENT", 319, 338], ["IntroductionJ", "TEST", 339, 352], ["Older age", "TEST", 382, 391], ["D-dimer levels", "TEST", 393, 407], ["SOFA score", "TEST", 441, 451], ["Coronary Heart Disease", "PROBLEM", 536, 558], ["COPD", "PROBLEM", 560, 564], ["Chronic Obstructive Pulmonary Disease", "PROBLEM", 566, 603], ["HF", "PROBLEM", 605, 607], ["Heart Failure", "PROBLEM", 609, 622], ["Sequential Organ Failure Assessment", "TEST", 630, 665], ["Heart involvement", "PROBLEM", 666, 683], ["COVID-19 infection", "PROBLEM", 705, 723], ["cardiac arrhythmias", "PROBLEM", 736, 755], ["heart failure", "PROBLEM", 757, 770], ["myocarditis", "PROBLEM", 772, 783], ["pericarditis", "PROBLEM", 785, 797], ["vasculitis", "PROBLEM", 803, 813], ["increased troponin release", "PROBLEM", 828, 854], ["cardiac", "ANATOMY", 71, 78], ["Coronary Heart", "ANATOMY", 536, 550], ["Disease", "OBSERVATION", 551, 558], ["COPD", "OBSERVATION", 560, 564], ["Chronic", "OBSERVATION_MODIFIER", 566, 573], ["Obstructive", "OBSERVATION", 574, 585], ["Pulmonary", "ANATOMY", 586, 595], ["Disease", "OBSERVATION", 596, 603], ["Heart", "ANATOMY", 609, 614], ["Failure", "OBSERVATION", 615, 622], ["Organ", "ANATOMY", 641, 646], ["Failure", "OBSERVATION", 647, 654], ["involvement", "OBSERVATION", 672, 683], ["infection", "OBSERVATION", 714, 723], ["cardiac", "ANATOMY", 736, 743], ["arrhythmias", "OBSERVATION", 744, 755], ["heart", "ANATOMY", 757, 762], ["failure", "OBSERVATION", 763, 770], ["myocarditis", "OBSERVATION", 772, 783], ["pericarditis", "OBSERVATION", 785, 797], ["vasculitis", "OBSERVATION", 803, 813]]], ["The structure of the SARS-CoV-2 binding site shows enhanced affinity for the angiotensin I converting enzyme 2 (ACE2) receptor which is expressed mainly in the lung and other tissues including vascular endothelial cells [25, 26] .", [["lung", "ANATOMY", 160, 164], ["tissues", "ANATOMY", 175, 182], ["vascular endothelial cells", "ANATOMY", 193, 219], ["angiotensin", "CHEMICAL", 77, 88], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["angiotensin I converting enzyme 2", "GENE_OR_GENE_PRODUCT", 77, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["lung", "ORGAN", 160, 164], ["tissues", "TISSUE", 175, 182], ["vascular endothelial cells", "CELL", 193, 219], ["SARS-CoV-2 binding site", "DNA", 21, 44], ["angiotensin I converting enzyme 2 (ACE2) receptor", "PROTEIN", 77, 126], ["vascular endothelial cells", "CELL_TYPE", 193, 219], ["the SARS", "TEST", 17, 25], ["enhanced affinity", "PROBLEM", 51, 68], ["the angiotensin I converting enzyme 2 (ACE2) receptor", "TREATMENT", 73, 126], ["vascular endothelial cells", "TEST", 193, 219], ["SARS", "OBSERVATION", 21, 25], ["enhanced affinity", "OBSERVATION", 51, 68], ["lung", "ANATOMY", 160, 164], ["vascular endothelial", "ANATOMY", 193, 213]]], ["Patients with cardiovascular diseases are more prone to respiratory virus illness, thus constituting a high-risk group [27] [28] [29] .", [["cardiovascular", "ANATOMY", 14, 28], ["cardiovascular diseases", "DISEASE", 14, 37], ["respiratory virus illness", "DISEASE", 56, 81], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["cardiovascular diseases", "PROBLEM", 14, 37], ["respiratory virus illness", "PROBLEM", 56, 81], ["cardiovascular", "ANATOMY", 14, 28], ["diseases", "OBSERVATION", 29, 37]]], ["Viral entry into the myocardium and artery vessels through ACE2 receptor can enhance the risk for myocardial injury and inflammatory response (Figure 1 ) [30] .", [["myocardium", "ANATOMY", 21, 31], ["artery vessels", "ANATOMY", 36, 50], ["myocardial", "ANATOMY", 98, 108], ["myocardial injury", "DISEASE", 98, 115], ["myocardium", "MULTI-TISSUE_STRUCTURE", 21, 31], ["artery vessels", "MULTI-TISSUE_STRUCTURE", 36, 50], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 59, 72], ["myocardial", "MULTI-TISSUE_STRUCTURE", 98, 108], ["ACE2 receptor", "PROTEIN", 59, 72], ["ACE2 receptor", "TREATMENT", 59, 72], ["myocardial injury", "PROBLEM", 98, 115], ["inflammatory response", "PROBLEM", 120, 141], ["myocardium", "ANATOMY", 21, 31], ["artery vessels", "ANATOMY", 36, 50], ["myocardial", "ANATOMY", 98, 108], ["injury", "OBSERVATION", 109, 115], ["inflammatory", "OBSERVATION_MODIFIER", 120, 132]]], ["However, it remains to be established whether a higher rate of cardiac injury with increasing age is due to a direct viral injury or an overwhelming immunological response within myocardium and microvasculature, or both [31] [32] [33] [34] .Heart involvementACE2 has been confirmed as the SARS-CoV-2 internalization receptor [26, 35, 36] together with the TMPRSS2 membrane protease that primes the spike S protein of the virus [37] and significantly enhances viral shedding [38] .", [["cardiac", "ANATOMY", 63, 70], ["myocardium", "ANATOMY", 179, 189], ["microvasculature", "ANATOMY", 194, 210], ["Heart", "ANATOMY", 241, 246], ["cardiac injury", "DISEASE", 63, 77], ["cardiac", "ORGAN", 63, 70], ["myocardium", "MULTI-TISSUE_STRUCTURE", 179, 189], ["microvasculature", "TISSUE", 194, 210], ["[31] [32] [33", "SIMPLE_CHEMICAL", 220, 233], ["Heart", "ORGAN", 241, 246], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 289, 299], ["TMPRSS2 membrane protease", "GENE_OR_GENE_PRODUCT", 356, 381], ["involvementACE2", "PROTEIN", 247, 262], ["SARS-CoV-2 internalization receptor", "PROTEIN", 289, 324], ["TMPRSS2 membrane protease", "PROTEIN", 356, 381], ["spike S protein", "PROTEIN", 398, 413], ["cardiac injury", "PROBLEM", 63, 77], ["a direct viral injury", "PROBLEM", 108, 129], ["Heart involvementACE2", "PROBLEM", 241, 262], ["the SARS", "TEST", 285, 293], ["CoV", "TEST", 294, 297], ["the TMPRSS2 membrane protease", "TREATMENT", 352, 381], ["the spike S protein", "TEST", 394, 413], ["the virus", "PROBLEM", 417, 426], ["viral shedding", "PROBLEM", 459, 473], ["cardiac", "ANATOMY", 63, 70], ["injury", "OBSERVATION", 71, 77]]], ["In heart failure, expression of ACE2 is downregulated, though its function may be upregulated [39] , reflecting increased ACE2 activity.", [["heart", "ANATOMY", 3, 8], ["heart failure", "DISEASE", 3, 16], ["heart", "ORGAN", 3, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 122, 126], ["ACE2", "PROTEIN", 32, 36], ["ACE2", "PROTEIN", 122, 126], ["heart failure", "PROBLEM", 3, 16], ["ACE2", "PROBLEM", 32, 36], ["increased ACE2 activity", "PROBLEM", 112, 135], ["heart", "ANATOMY", 3, 8], ["failure", "OBSERVATION", 9, 16], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["ACE2 activity", "OBSERVATION", 122, 135]]], ["Relevantly, ACE2Heart involvementis an immune modulator interacting with macrophages in the setting of inflammation [40] , and it also reduces the levels of angiotensin II which is pro-inflammatory and pro-oxidant, while increasing angiotensin 1-7 concentrations that exert opposite effects [41] .", [["macrophages", "ANATOMY", 73, 84], ["inflammation", "DISEASE", 103, 115], ["angiotensin II", "CHEMICAL", 157, 171], ["angiotensin 1-7", "CHEMICAL", 232, 247], ["ACE2Heart", "SIMPLE_CHEMICAL", 12, 21], ["macrophages", "CELL", 73, 84], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 157, 171], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 232, 247], ["macrophages", "CELL_TYPE", 73, 84], ["angiotensin II", "PROTEIN", 157, 171], ["ACE2Heart involvementis", "TREATMENT", 12, 35], ["inflammation", "PROBLEM", 103, 115], ["angiotensin II", "PROBLEM", 157, 171], ["increasing angiotensin", "TREATMENT", 221, 243], ["inflammation", "OBSERVATION", 103, 115], ["pro-inflammatory", "OBSERVATION_MODIFIER", 181, 197]]], ["In terms of cardiac manifestations of COVID-19, the spectrum is similar to a general viral myocarditis [42] .Inflammatory eventsInfected subjects with robust immune response can manifest acute myocarditis with heart failure, accompanied by elevations of cytokines and inflammatory cell infiltration of the heart [43] .Inflammatory eventsLymphopenia occurs in over 80% of patients with marked reductions in circulating levels of CD4 + and CD8 + T lymphocytes, and relative prevalence of mononuclear cells (monocytes and macrophages) in target injury tissues [43] (Figure 1) .", [["cardiac", "ANATOMY", 12, 19], ["heart", "ANATOMY", 210, 215], ["inflammatory cell", "ANATOMY", 268, 285], ["heart", "ANATOMY", 306, 311], ["CD4 + and CD8 + T lymphocytes", "ANATOMY", 428, 457], ["mononuclear cells", "ANATOMY", 486, 503], ["monocytes", "ANATOMY", 505, 514], ["macrophages", "ANATOMY", 519, 530], ["tissues", "ANATOMY", 549, 556], ["viral myocarditis", "DISEASE", 85, 102], ["myocarditis", "DISEASE", 193, 204], ["heart failure", "DISEASE", 210, 223], ["eventsLymphopenia", "DISEASE", 331, 348], ["COVID-19", "CHEMICAL", 38, 46], ["cardiac", "ORGAN", 12, 19], ["heart", "ORGAN", 210, 215], ["inflammatory cell", "CELL", 268, 285], ["heart", "ORGAN", 306, 311], ["patients", "ORGANISM", 371, 379], ["CD4", "GENE_OR_GENE_PRODUCT", 428, 431], ["CD8", "GENE_OR_GENE_PRODUCT", 438, 441], ["mononuclear cells", "CELL", 486, 503], ["monocytes", "CELL", 505, 514], ["macrophages", "CELL", 519, 530], ["tissues", "TISSUE", 549, 556], ["cytokines", "PROTEIN", 254, 263], ["CD4", "PROTEIN", 428, 431], ["CD8", "PROTEIN", 438, 441], ["T lymphocytes", "CELL_TYPE", 444, 457], ["mononuclear cells", "CELL_TYPE", 486, 503], ["monocytes", "CELL_TYPE", 505, 514], ["macrophages", "CELL_TYPE", 519, 530], ["patients", "SPECIES", 371, 379], ["COVID", "TEST", 38, 43], ["a general viral myocarditis", "PROBLEM", 75, 102], ["Inflammatory events", "PROBLEM", 109, 128], ["Infected subjects", "PROBLEM", 128, 145], ["robust immune response", "PROBLEM", 151, 173], ["acute myocarditis", "PROBLEM", 187, 204], ["heart failure", "PROBLEM", 210, 223], ["elevations of cytokines", "PROBLEM", 240, 263], ["inflammatory cell infiltration of the heart", "PROBLEM", 268, 311], ["Inflammatory eventsLymphopenia", "PROBLEM", 318, 348], ["marked reductions", "PROBLEM", 385, 402], ["circulating levels", "TEST", 406, 424], ["CD4", "TEST", 428, 431], ["CD8", "TEST", 438, 441], ["lymphocytes", "TEST", 446, 457], ["mononuclear cells", "PROBLEM", 486, 503], ["monocytes", "TEST", 505, 514], ["macrophages", "TEST", 519, 530], ["target injury tissues", "PROBLEM", 535, 556], ["cardiac", "ANATOMY", 12, 19], ["manifestations", "OBSERVATION", 20, 34], ["myocarditis", "OBSERVATION", 91, 102], ["Infected", "OBSERVATION", 128, 136], ["acute", "OBSERVATION_MODIFIER", 187, 192], ["myocarditis", "OBSERVATION", 193, 204], ["heart", "ANATOMY", 210, 215], ["failure", "OBSERVATION", 216, 223], ["elevations", "OBSERVATION_MODIFIER", 240, 250], ["cytokines", "OBSERVATION_MODIFIER", 254, 263], ["inflammatory cell infiltration", "OBSERVATION", 268, 298], ["heart", "ANATOMY", 306, 311], ["marked", "OBSERVATION_MODIFIER", 385, 391], ["reductions", "OBSERVATION_MODIFIER", 392, 402], ["T lymphocytes", "ANATOMY", 444, 457], ["mononuclear cells", "OBSERVATION", 486, 503]]], ["Thus, decreased capacity to phagocytose J o u r n a l P r e -p r o o f apoptotic cells by senescent macrophages may induce a vascular pro-inflammatory state.", [["cells", "ANATOMY", 81, 86], ["macrophages", "ANATOMY", 100, 111], ["vascular", "ANATOMY", 125, 133], ["cells", "CELL", 81, 86], ["macrophages", "CELL", 100, 111], ["vascular", "MULTI-TISSUE_STRUCTURE", 125, 133], ["apoptotic cells", "CELL_TYPE", 71, 86], ["senescent macrophages", "CELL_TYPE", 90, 111], ["decreased capacity", "PROBLEM", 6, 24], ["phagocytose", "TEST", 28, 39], ["a l P r e -p r o o f", "TEST", 50, 70], ["apoptotic cells", "PROBLEM", 71, 86], ["senescent macrophages", "PROBLEM", 90, 111], ["a vascular pro-inflammatory state", "PROBLEM", 123, 156], ["apoptotic cells", "OBSERVATION", 71, 86], ["senescent macrophages", "OBSERVATION", 90, 111], ["vascular", "ANATOMY", 125, 133], ["pro-inflammatory state", "OBSERVATION", 134, 156]]], ["The immune system imbalance is typical of aging and is exacerbated upon SARS-CoV-2 infection leading to further depletion of CD4 + T cells and macrophage response [34] .", [["immune system", "ANATOMY", 4, 17], ["CD4 + T cells", "ANATOMY", 125, 138], ["macrophage", "ANATOMY", 143, 153], ["infection", "DISEASE", 83, 92], ["SARS-CoV-2", "ORGANISM", 72, 82], ["CD4", "GENE_OR_GENE_PRODUCT", 125, 128], ["macrophage", "CELL", 143, 153], ["CD4", "PROTEIN", 125, 128], ["T cells", "CELL_TYPE", 131, 138], ["The immune system imbalance", "PROBLEM", 0, 27], ["SARS", "PROBLEM", 72, 76], ["CoV-2 infection", "PROBLEM", 77, 92], ["CD4 + T cells", "PROBLEM", 125, 138], ["macrophage response", "TEST", 143, 162]]], ["Thus, elderly subjects may have a natural tendency to have reduced virus clearance, which in turn generates an inappropriate cytokine storm, with inadequate immune response and immunologic memory.EndothelialitisAnother pathogenetic hallmark of COVID-19, which distinguishes it from most infectious diseases, is the ability of the virus to directly infect endothelial cells and cause their perturbation and injury, leading to a pro-inflammatory status as well as plasminogen activator release (responsible for very high levels of D-dimers) and high molecular size multimeric von Willebrand factor levels which cause thrombotic microangiopathy [30, 43] .", [["endothelial cells", "ANATOMY", 355, 372], ["Endothelialitis", "DISEASE", 196, 211], ["COVID-19", "CHEMICAL", 244, 252], ["infectious diseases", "DISEASE", 287, 306], ["thrombotic microangiopathy", "DISEASE", 615, 641], ["subjects", "ORGANISM", 14, 22], ["COVID-19", "CELL", 244, 252], ["endothelial cells", "CELL", 355, 372], ["plasminogen activator", "GENE_OR_GENE_PRODUCT", 462, 483], ["D-dimers", "GENE_OR_GENE_PRODUCT", 529, 537], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 574, 595], ["cytokine", "PROTEIN", 125, 133], ["endothelial cells", "CELL_TYPE", 355, 372], ["plasminogen", "PROTEIN", 462, 473], ["D-dimers", "PROTEIN", 529, 537], ["von Willebrand factor", "PROTEIN", 574, 595], ["a natural tendency", "PROBLEM", 32, 50], ["reduced virus clearance", "PROBLEM", 59, 82], ["an inappropriate cytokine storm", "PROBLEM", 108, 139], ["inadequate immune response", "PROBLEM", 146, 172], ["COVID", "TEST", 244, 249], ["most infectious diseases", "PROBLEM", 282, 306], ["the virus", "PROBLEM", 326, 335], ["their perturbation", "PROBLEM", 383, 401], ["injury", "PROBLEM", 406, 412], ["a pro-inflammatory status", "PROBLEM", 425, 450], ["plasminogen activator release", "TEST", 462, 491], ["very high levels of D-dimers", "PROBLEM", 509, 537], ["high molecular size multimeric von Willebrand factor levels", "PROBLEM", 543, 602], ["thrombotic microangiopathy", "PROBLEM", 615, 641], ["cytokine storm", "OBSERVATION", 125, 139], ["most", "OBSERVATION_MODIFIER", 282, 286], ["infectious", "OBSERVATION", 287, 297], ["size", "OBSERVATION_MODIFIER", 558, 562], ["von Willebrand", "OBSERVATION", 574, 588], ["thrombotic", "OBSERVATION_MODIFIER", 615, 625], ["microangiopathy", "OBSERVATION", 626, 641]]], ["In a very recent study, Ackermann et al. [44] have analyzed the up-regulation of genes regulating the \"intussusceptive angiogenesis\" process by using direct multiplexed measurements in the autopsy of COVID-19 patients compared to H1N1 and healthy lungs.", [["intussusceptive", "ANATOMY", 103, 118], ["lungs", "ANATOMY", 247, 252], ["patients", "ORGANISM", 209, 217], ["lungs", "ORGAN", 247, 252], ["patients", "SPECIES", 209, 217], ["COVID", "TEST", 200, 205], ["H1N1", "PROBLEM", 230, 234], ["lungs", "ANATOMY", 247, 252]]], ["An \"attachment of lymphocytes to the vascular wall\", a feature called \"endothelialitis\" or \"endothelitis\", has been initially documented in liver biopsies [45] and arteriosclerosis in heart transplant recipients [46] .", [["lymphocytes", "ANATOMY", 18, 29], ["vascular wall", "ANATOMY", 37, 50], ["liver biopsies", "ANATOMY", 140, 154], ["heart", "ANATOMY", 184, 189], ["endothelialitis", "DISEASE", 71, 86], ["endothelitis", "DISEASE", 92, 104], ["arteriosclerosis", "DISEASE", 164, 180], ["lymphocytes", "CELL", 18, 29], ["vascular wall", "TISSUE", 37, 50], ["liver biopsies", "MULTI-TISSUE_STRUCTURE", 140, 154], ["heart", "ORGAN", 184, 189], ["lymphocytes", "CELL_TYPE", 18, 29], ["endothelialitis", "PROBLEM", 71, 86], ["\"endothelitis\"", "PROBLEM", 91, 105], ["liver biopsies", "TEST", 140, 154], ["arteriosclerosis", "PROBLEM", 164, 180], ["heart transplant recipients", "TREATMENT", 184, 211], ["lymphocytes", "OBSERVATION", 18, 29], ["vascular wall", "ANATOMY", 37, 50], ["liver", "ANATOMY", 140, 145], ["arteriosclerosis", "OBSERVATION", 164, 180], ["heart", "ANATOMY", 184, 189], ["transplant", "OBSERVATION", 190, 200]]], ["COVID-19 induces reduction of lymphocytes, mainly CD4 + and CD8 + T cells, and secondary viral sepsis [47] .", [["lymphocytes", "ANATOMY", 30, 41], ["CD4 + and CD8 + T cells", "ANATOMY", 50, 73], ["COVID-19", "CHEMICAL", 0, 8], ["sepsis", "DISEASE", 95, 101], ["COVID-19", "CHEMICAL", 0, 8], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["lymphocytes", "CELL", 30, 41], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD8", "GENE_OR_GENE_PRODUCT", 60, 63], ["COVID-19", "PROTEIN", 0, 8], ["lymphocytes", "CELL_TYPE", 30, 41], ["CD4", "PROTEIN", 50, 53], ["CD8", "PROTEIN", 60, 63], ["T cells", "CELL_TYPE", 66, 73], ["COVID", "TEST", 0, 5], ["lymphocytes", "PROBLEM", 30, 41], ["CD4", "TEST", 50, 53], ["CD8 + T cells", "PROBLEM", 60, 73], ["secondary viral sepsis", "PROBLEM", 79, 101], ["lymphocytes", "ANATOMY", 30, 41], ["viral sepsis", "OBSERVATION", 89, 101]]], ["Viral particles and SARS-CoV2EndothelialitisRNA have been detected in T lymphocytes from peripheral blood, spleen, and lymph nodes, suggesting that SARS-CoV2 infects T cells directly [47] .", [["T lymphocytes", "ANATOMY", 70, 83], ["peripheral blood", "ANATOMY", 89, 105], ["spleen", "ANATOMY", 107, 113], ["lymph nodes", "ANATOMY", 119, 130], ["T cells", "ANATOMY", 166, 173], ["SARS", "DISEASE", 148, 152], ["Viral", "ORGANISM", 0, 5], ["SARS-CoV2EndothelialitisRNA", "GENE_OR_GENE_PRODUCT", 20, 47], ["T lymphocytes", "CELL", 70, 83], ["peripheral blood", "ORGANISM_SUBSTANCE", 89, 105], ["spleen", "ORGAN", 107, 113], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 119, 130], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 148, 157], ["T cells", "CELL", 166, 173], ["SARS-CoV2EndothelialitisRNA", "PROTEIN", 20, 47], ["T lymphocytes", "CELL_TYPE", 70, 83], ["T cells", "CELL_TYPE", 166, 173], ["Viral particles", "TEST", 0, 15], ["SARS-CoV2EndothelialitisRNA", "PROBLEM", 20, 47], ["peripheral blood, spleen, and lymph nodes", "PROBLEM", 89, 130], ["SARS", "PROBLEM", 148, 152], ["particles", "OBSERVATION", 6, 15], ["peripheral", "ANATOMY_MODIFIER", 89, 99], ["blood", "ANATOMY", 100, 105], ["spleen", "ANATOMY", 107, 113], ["lymph nodes", "OBSERVATION", 119, 130]]], ["The master gene hypoxia-inducible factor (HIF) regulates genes of adaptive response including modulators of inflammation but also of angiogenesis suggesting novel potential therapeutic strategies [48] .", [["inflammation", "DISEASE", 108, 120], ["hypoxia-inducible factor", "GENE_OR_GENE_PRODUCT", 16, 40], ["HIF", "GENE_OR_GENE_PRODUCT", 42, 45], ["master gene hypoxia-inducible factor", "PROTEIN", 4, 40], ["HIF", "PROTEIN", 42, 45], ["The master gene hypoxia-inducible factor", "PROBLEM", 0, 40], ["adaptive response", "PROBLEM", 66, 83], ["inflammation", "PROBLEM", 108, 120], ["angiogenesis", "PROBLEM", 133, 145], ["inflammation", "OBSERVATION", 108, 120]]], ["Further studies will determine whether differences in angiogenesis and endothelialitis represent distinct points in a similar process of pneumonia or a true endotype occurring selectively during the cytokine storm seen in COVID-19Endothelialitispatients (Figure 1) .EndothelialitisPatients with clinical evidence of vasculitis, or laboratory indicators of thrombotic risk, such as higher D-dimer levels, should be considered with no doubt for early treatment with J o u r n a l P r e -p r o o f antithrombotic drugs.", [["endothelialitis", "DISEASE", 71, 86], ["pneumonia", "DISEASE", 137, 146], ["vasculitis", "DISEASE", 316, 326], ["thrombotic", "DISEASE", 356, 366], ["D-dimer", "GENE_OR_GENE_PRODUCT", 388, 395], ["f antithrombotic drugs", "SIMPLE_CHEMICAL", 493, 515], ["cytokine", "PROTEIN", 199, 207], ["COVID-19Endothelialitispatients", "SPECIES", 222, 253], ["Further studies", "TEST", 0, 15], ["angiogenesis", "PROBLEM", 54, 66], ["endothelialitis", "PROBLEM", 71, 86], ["distinct points", "PROBLEM", 97, 112], ["pneumonia", "PROBLEM", 137, 146], ["a true endotype", "PROBLEM", 150, 165], ["the cytokine storm", "TREATMENT", 195, 213], ["vasculitis", "PROBLEM", 316, 326], ["thrombotic risk", "PROBLEM", 356, 371], ["higher D-dimer levels", "PROBLEM", 381, 402], ["antithrombotic drugs", "TREATMENT", 495, 515], ["pneumonia", "OBSERVATION", 137, 146], ["evidence of", "UNCERTAINTY", 304, 315], ["vasculitis", "OBSERVATION", 316, 326], ["thrombotic", "OBSERVATION", 356, 366]]], ["Moreover, many of these patients should be considered also for full anticoagulation, such as heparin, depending on individual risk versus benefit, especially in elderly individuals [49] .", [["heparin", "CHEMICAL", 93, 100], ["patients", "ORGANISM", 24, 32], ["heparin", "SIMPLE_CHEMICAL", 93, 100], ["patients", "SPECIES", 24, 32], ["full anticoagulation", "TREATMENT", 63, 83], ["heparin", "TREATMENT", 93, 100]]], ["In elderly patients with potential dysfunctional immune responses there are early warning signals, such as lymphopenia, troponin release, elevated BNP, rising inflammatory markers such as cRP, IL-1\u03b2 and IL-6 [56] .", [["lymphopenia", "DISEASE", 107, 118], ["patients", "ORGANISM", 11, 19], ["troponin", "GENE_OR_GENE_PRODUCT", 120, 128], ["BNP", "GENE_OR_GENE_PRODUCT", 147, 150], ["cRP", "GENE_OR_GENE_PRODUCT", 188, 191], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 193, 198], ["IL-6", "GENE_OR_GENE_PRODUCT", 203, 207], ["troponin", "PROTEIN", 120, 128], ["BNP", "PROTEIN", 147, 150], ["inflammatory markers", "PROTEIN", 159, 179], ["cRP", "PROTEIN", 188, 191], ["IL-1\u03b2", "PROTEIN", 193, 198], ["IL", "PROTEIN", 203, 205], ["patients", "SPECIES", 11, 19], ["potential dysfunctional immune responses", "PROBLEM", 25, 65], ["early warning signals", "PROBLEM", 76, 97], ["lymphopenia", "PROBLEM", 107, 118], ["troponin release", "PROBLEM", 120, 136], ["elevated BNP", "PROBLEM", 138, 150], ["rising inflammatory markers", "PROBLEM", 152, 179], ["cRP", "TEST", 188, 191], ["IL", "TEST", 193, 195], ["IL", "TEST", 203, 205], ["rising", "OBSERVATION_MODIFIER", 152, 158], ["inflammatory", "OBSERVATION_MODIFIER", 159, 171]]], ["These aging patients should be followed closely and monitored for early evidence of organ failure, with efforts made to restore immunosenescence and cellular-mediated response [34] .EndothelialitisIf viral proliferation is still continuing, strategies to attenuate the virus may be critical.", [["organ", "ANATOMY", 84, 89], ["cellular", "ANATOMY", 149, 157], ["organ failure", "DISEASE", 84, 97], ["Endothelialitis", "DISEASE", 182, 197], ["patients", "ORGANISM", 12, 20], ["organ", "ORGAN", 84, 89], ["cellular", "CELL", 149, 157], ["patients", "SPECIES", 12, 20], ["organ failure", "PROBLEM", 84, 97], ["Endothelialitis", "PROBLEM", 182, 197], ["viral proliferation", "PROBLEM", 200, 219], ["the virus", "PROBLEM", 265, 274], ["organ", "ANATOMY", 84, 89], ["failure", "OBSERVATION", 90, 97], ["viral proliferation", "OBSERVATION", 200, 219]]], ["However, the intervention will need to be instituted early, before the immune amplification process is fully underway.EndothelialitisFurthermore, obesity which is common among elderly subjects represents another independent risk factor linked to severe COVID-19 illness and its complications [57] .", [["obesity", "DISEASE", 146, 153], ["COVID", "DISEASE", 253, 258], ["illness", "DISEASE", 262, 269], ["the intervention", "TREATMENT", 9, 25], ["the immune amplification process", "PROBLEM", 67, 99], ["obesity", "PROBLEM", 146, 153], ["severe COVID-19 illness", "PROBLEM", 246, 269], ["its complications", "PROBLEM", 274, 291], ["obesity", "OBSERVATION", 146, 153]]], ["Indeed, obesity triggers a chronic pro-inflammatory state characterized by elevated levels of IL-6, CRP, and adipokine which are further increased upon viral infection leading to the dangerous cytokine storm J o u r n a l P r e -p r o o f [57] .", [["obesity", "DISEASE", 8, 15], ["infection", "DISEASE", 158, 167], ["IL-6", "GENE_OR_GENE_PRODUCT", 94, 98], ["CRP", "GENE_OR_GENE_PRODUCT", 100, 103], ["adipokine", "GENE_OR_GENE_PRODUCT", 109, 118], ["IL-6", "PROTEIN", 94, 98], ["CRP", "PROTEIN", 100, 103], ["adipokine", "PROTEIN", 109, 118], ["cytokine", "PROTEIN", 193, 201], ["obesity", "PROBLEM", 8, 15], ["a chronic pro-inflammatory state", "PROBLEM", 25, 57], ["elevated levels of IL", "PROBLEM", 75, 96], ["CRP", "TEST", 100, 103], ["adipokine", "PROBLEM", 109, 118], ["viral infection", "PROBLEM", 152, 167], ["obesity", "OBSERVATION", 8, 15], ["chronic", "OBSERVATION_MODIFIER", 27, 34], ["pro-inflammatory", "OBSERVATION", 35, 51], ["adipokine", "ANATOMY", 109, 118], ["increased", "OBSERVATION_MODIFIER", 137, 146], ["viral infection", "OBSERVATION", 152, 167]]], ["Besides, elderly patients with chronic obstructive pulmonary disease (COPD) were at high risk of the involvement of the severe and critical clinical forms of COVID-19 resulting in high mortality rate [58] .EndothelialitisWhereas the release of troponin is relatively modest during COVID-19, this may be an indication of either viral or immune-mediated cardiac injury.", [["pulmonary", "ANATOMY", 51, 60], ["cardiac", "ANATOMY", 352, 359], ["chronic obstructive pulmonary disease", "DISEASE", 31, 68], ["COPD", "DISEASE", 70, 74], ["COVID", "DISEASE", 158, 163], ["Endothelialitis", "DISEASE", 206, 221], ["cardiac injury", "DISEASE", 352, 366], ["COVID-19", "CHEMICAL", 158, 166], ["COVID-19", "CHEMICAL", 281, 289], ["patients", "ORGANISM", 17, 25], ["pulmonary", "ORGAN", 51, 60], ["troponin", "GENE_OR_GENE_PRODUCT", 244, 252], ["cardiac", "ORGAN", 352, 359], ["troponin", "PROTEIN", 244, 252], ["patients", "SPECIES", 17, 25], ["chronic obstructive pulmonary disease", "PROBLEM", 31, 68], ["COPD", "PROBLEM", 70, 74], ["the severe", "PROBLEM", 116, 126], ["COVID", "TEST", 158, 163], ["high mortality rate", "PROBLEM", 180, 199], ["Endothelialitis", "PROBLEM", 206, 221], ["troponin", "TEST", 244, 252], ["COVID", "TEST", 281, 286], ["viral or immune-mediated cardiac injury", "PROBLEM", 327, 366], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["obstructive", "OBSERVATION_MODIFIER", 39, 50], ["pulmonary", "ANATOMY", 51, 60], ["disease", "OBSERVATION", 61, 68], ["COPD", "OBSERVATION", 70, 74], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["viral", "OBSERVATION", 327, 332], ["cardiac", "ANATOMY", 352, 359], ["injury", "OBSERVATION", 360, 366]]], ["The release of \"danger signals\" from myocytes in patients with heightened immune response can further amplify myocardial injury [16] [17] [18] 23, 59] .", [["myocytes", "ANATOMY", 37, 45], ["myocardial", "ANATOMY", 110, 120], ["myocardial injury", "DISEASE", 110, 127], ["myocytes", "CELL", 37, 45], ["patients", "ORGANISM", 49, 57], ["myocardial", "MULTI-TISSUE_STRUCTURE", 110, 120], ["patients", "SPECIES", 49, 57], ["myocytes", "PROBLEM", 37, 45], ["heightened immune response", "PROBLEM", 63, 89], ["myocardial injury", "PROBLEM", 110, 127]]], ["Thus, patients with cardiac injury and/or stress marker release warrant more careful monitoring and institution of cardioprotective agents to minimize ongoing damage [16] [17] [18] 23, 59] .", [["cardiac", "ANATOMY", 20, 27], ["cardiac injury", "DISEASE", 20, 34], ["patients", "ORGANISM", 6, 14], ["cardiac", "ORGAN", 20, 27], ["patients", "SPECIES", 6, 14], ["cardiac injury", "PROBLEM", 20, 34], ["stress marker release", "PROBLEM", 42, 63], ["careful monitoring", "TEST", 77, 95], ["cardioprotective agents", "TREATMENT", 115, 138], ["ongoing damage", "PROBLEM", 151, 165], ["cardiac", "ANATOMY", 20, 27], ["injury", "OBSERVATION", 28, 34]]], ["In patients with suspected acute myocarditis, inflammatory cardiomyopathy, and pericarditis, appropriate investigations, such as magnetic resonance imaging where feasible and safe to perform, can be helpful [60, 61] .", [["myocarditis", "DISEASE", 33, 44], ["inflammatory cardiomyopathy", "DISEASE", 46, 73], ["pericarditis", "DISEASE", 79, 91], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["acute myocarditis", "PROBLEM", 27, 44], ["inflammatory cardiomyopathy", "PROBLEM", 46, 73], ["pericarditis", "PROBLEM", 79, 91], ["appropriate investigations", "TEST", 93, 119], ["magnetic resonance imaging", "TEST", 129, 155], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["myocarditis", "OBSERVATION", 33, 44], ["inflammatory", "OBSERVATION_MODIFIER", 46, 58], ["pericarditis", "OBSERVATION", 79, 91]]], ["Moreover, electrocardiographic abnormalities reflecting cardiovascular dysfunction have been reported in elderly patients affected by severe COVID-19 [62] .", [["cardiovascular", "ANATOMY", 56, 70], ["electrocardiographic abnormalities", "DISEASE", 10, 44], ["cardiovascular dysfunction", "DISEASE", 56, 82], ["COVID-19", "CHEMICAL", 141, 149], ["cardiovascular", "ANATOMICAL_SYSTEM", 56, 70], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["electrocardiographic abnormalities", "PROBLEM", 10, 44], ["cardiovascular dysfunction", "PROBLEM", 56, 82], ["severe COVID", "PROBLEM", 134, 146], ["cardiovascular dysfunction", "OBSERVATION", 56, 82]]], ["Furthermore, chest X-ray plays a relevant role in the early diagnosis and treatment for patients with suspected or confirmed COVID-19 [63] as well as lung computed tomography is recommended during hospitalization to monitor COVID-19 and heart failure [64] .", [["lung", "ANATOMY", 150, 154], ["heart", "ANATOMY", 237, 242], ["heart failure", "DISEASE", 237, 250], ["patients", "ORGANISM", 88, 96], ["lung", "ORGAN", 150, 154], ["heart", "ORGAN", 237, 242], ["patients", "SPECIES", 88, 96], ["chest X-ray", "TEST", 13, 24], ["treatment", "TREATMENT", 74, 83], ["COVID", "TEST", 125, 130], ["lung computed tomography", "TEST", 150, 174], ["COVID", "TEST", 224, 229], ["heart failure", "PROBLEM", 237, 250], ["chest", "ANATOMY", 13, 18], ["lung", "ANATOMY", 150, 154], ["heart", "ANATOMY", 237, 242], ["failure", "OBSERVATION", 243, 250]]], ["A great attention should also be devoted to pulmonary and cardiac rehabilitation of COVID-19 survivors [65] .Cardiovascular drugs during COVID-19Multiple clinical trials are currently in progress using drug interventions to treat COVID-19 [66] and many others are under development.", [["pulmonary", "ANATOMY", 44, 53], ["cardiac", "ANATOMY", 58, 65], ["Cardiovascular", "ANATOMY", 109, 123], ["COVID", "DISEASE", 230, 235], ["pulmonary", "ORGAN", 44, 53], ["cardiac", "ORGAN", 58, 65], ["COVID", "TEST", 84, 89], ["Cardiovascular drugs", "TREATMENT", 109, 129], ["COVID", "TREATMENT", 137, 142], ["clinical trials", "TREATMENT", 154, 169], ["drug interventions", "TREATMENT", 202, 220], ["COVID", "TEST", 230, 235], ["pulmonary", "ANATOMY", 44, 53], ["cardiac", "ANATOMY", 58, 65]]], ["Down-regulation of ACE2 with viral infection may predispose to relatively unopposed angiotensin II effects, such as hypertension, enhanced inflammation, and thrombosis [41] .", [["viral infection", "DISEASE", 29, 44], ["angiotensin II", "CHEMICAL", 84, 98], ["hypertension", "DISEASE", 116, 128], ["inflammation", "DISEASE", 139, 151], ["thrombosis", "DISEASE", 157, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 84, 98], ["ACE2", "PROTEIN", 19, 23], ["angiotensin II", "PROTEIN", 84, 98], ["ACE2", "PROBLEM", 19, 23], ["viral infection", "PROBLEM", 29, 44], ["unopposed angiotensin II effects", "PROBLEM", 74, 106], ["hypertension", "PROBLEM", 116, 128], ["enhanced inflammation", "PROBLEM", 130, 151], ["thrombosis", "PROBLEM", 157, 167], ["viral infection", "OBSERVATION", 29, 44], ["hypertension", "OBSERVATION", 116, 128], ["enhanced", "OBSERVATION_MODIFIER", 130, 138], ["inflammation", "OBSERVATION", 139, 151], ["thrombosis", "OBSERVATION", 157, 167]]], ["Most patients with cardiovascular diseases are treated withCardiovascular drugs during COVID-19ACEi or ARB therapy [67] .", [["cardiovascular", "ANATOMY", 19, 33], ["withCardiovascular", "ANATOMY", 55, 73], ["cardiovascular diseases", "DISEASE", 19, 42], ["COVID-19ACEi", "CHEMICAL", 87, 99], ["ARB", "CHEMICAL", 103, 106], ["COVID-19ACEi", "CHEMICAL", 87, 99], ["patients", "ORGANISM", 5, 13], ["COVID-19ACEi", "SIMPLE_CHEMICAL", 87, 99], ["ARB", "SIMPLE_CHEMICAL", 103, 106], ["patients", "SPECIES", 5, 13], ["cardiovascular diseases", "PROBLEM", 19, 42], ["withCardiovascular drugs", "TREATMENT", 55, 79], ["COVID", "TREATMENT", 87, 92], ["ARB therapy", "TREATMENT", 103, 114]]], ["Since both ACEI and ARB could significantly increase the amount of cardiac ACE2 mRNA, it has been hypothesized that these drugs might impact the cardiac transcriptome, contributing to the aggressive course of COVID-19 [68] .", [["cardiac", "ANATOMY", 67, 74], ["cardiac", "ANATOMY", 145, 152], ["ACEI", "CHEMICAL", 11, 15], ["ARB", "CHEMICAL", 20, 23], ["COVID", "DISEASE", 209, 214], ["COVID-19", "CHEMICAL", 209, 217], ["ACEI", "SIMPLE_CHEMICAL", 11, 15], ["ARB", "SIMPLE_CHEMICAL", 20, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["cardiac", "ORGAN", 145, 152], ["cardiac ACE2 mRNA", "RNA", 67, 84], ["ACEI", "TREATMENT", 11, 15], ["ARB", "TREATMENT", 20, 23], ["cardiac ACE2 mRNA", "TREATMENT", 67, 84], ["these drugs", "TREATMENT", 116, 127], ["COVID", "TEST", 209, 214], ["amount", "OBSERVATION_MODIFIER", 57, 63], ["cardiac", "ANATOMY", 67, 74], ["ACE2 mRNA", "OBSERVATION", 75, 84], ["cardiac", "ANATOMY", 145, 152]]], ["However, major J o u r n a l P r e -p r o o f cardiology scientific associations, such as ESC Hypertension Council, HFSA, ACC, and AHA have rejected this correlation hypothesis concluding that there is no significant evidence to stop therapeutic treatment with these drugs [61, 69] .", [["Hypertension", "DISEASE", 94, 106], ["ACC", "PROBLEM", 122, 125], ["therapeutic treatment", "TREATMENT", 234, 255], ["these drugs", "TREATMENT", 261, 272]]], ["Indeed, as there are no definitive data on the risk versus benefit of ACE inhibitors or ARBs in COVID-19, most professional organizations have recommended continuation of RAS inhibitors in patients who have been prescribed them [61, 69] .Cardiovascular drugs during COVID-19Actually, emerging data suggests that benefits may outweigh risks in patients with COVID-19 and hypertension when prescribed ACE inhibitors or ARBs [67] [68] [69] [70] .", [["Cardiovascular", "ANATOMY", 238, 252], ["ARBs", "CHEMICAL", 88, 92], ["hypertension", "DISEASE", 370, 382], ["ACE inhibitors", "CHEMICAL", 399, 413], ["ARBs", "CHEMICAL", 417, 421], ["COVID-19", "CHEMICAL", 357, 365], ["ACE", "GENE_OR_GENE_PRODUCT", 70, 73], ["ARBs", "SIMPLE_CHEMICAL", 88, 92], ["RAS", "GENE_OR_GENE_PRODUCT", 171, 174], ["patients", "ORGANISM", 189, 197], ["patients", "ORGANISM", 343, 351], ["ACE", "GENE_OR_GENE_PRODUCT", 399, 402], ["ARBs [67] [68] [69] [70]", "SIMPLE_CHEMICAL", 417, 441], ["patients", "SPECIES", 189, 197], ["patients", "SPECIES", 343, 351], ["ACE inhibitors", "TREATMENT", 70, 84], ["ARBs", "TREATMENT", 88, 92], ["COVID", "TEST", 96, 101], ["RAS inhibitors", "TREATMENT", 171, 185], ["Cardiovascular drugs", "TREATMENT", 238, 258], ["COVID", "TEST", 266, 271], ["COVID", "TEST", 357, 362], ["hypertension", "PROBLEM", 370, 382], ["ACE inhibitors", "TREATMENT", 399, 413], ["ARBs", "TEST", 417, 421], ["no", "UNCERTAINTY", 21, 23]]], ["Ongoing randomized trials will help providing definitive answers.", [["Ongoing randomized trials", "TREATMENT", 0, 25]]], ["In patients with heart failure, appropriate medications, including RAS inhibitors, should be considered [61] .", [["heart", "ANATOMY", 17, 22], ["heart failure", "DISEASE", 17, 30], ["patients", "ORGANISM", 3, 11], ["heart", "ORGAN", 17, 22], ["RAS", "GENE_OR_GENE_PRODUCT", 67, 70], ["patients", "SPECIES", 3, 11], ["heart failure", "PROBLEM", 17, 30], ["appropriate medications", "TREATMENT", 32, 55], ["RAS inhibitors", "TREATMENT", 67, 81], ["heart", "ANATOMY", 17, 22], ["failure", "OBSERVATION", 23, 30]]], ["The risk/benefit of statin use is still controversial in patients affected by COVID-19, except for patients with diabetes, history of stroke or acute coronary syndrome, and familial hypercholesterolemia [71, 72] .", [["coronary", "ANATOMY", 150, 158], ["statin", "CHEMICAL", 20, 26], ["diabetes", "DISEASE", 113, 121], ["stroke", "DISEASE", 134, 140], ["acute coronary syndrome", "DISEASE", 144, 167], ["hypercholesterolemia", "DISEASE", 182, 202], ["statin", "CHEMICAL", 20, 26], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 99, 107], ["statin", "TREATMENT", 20, 26], ["COVID", "TEST", 78, 83], ["diabetes", "PROBLEM", 113, 121], ["stroke", "PROBLEM", 134, 140], ["acute coronary syndrome", "PROBLEM", 144, 167], ["familial hypercholesterolemia", "PROBLEM", 173, 202], ["stroke", "OBSERVATION", 134, 140], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["coronary", "ANATOMY", 150, 158], ["syndrome", "OBSERVATION", 159, 167]]], ["However, a molecular docking study has suggested that statins may act as SARS-CoV-2 Mpro inhibitors (a protein of the viral envelope); clinical investigations are needed to clarify whether statins could exert beneficial effects in the treatment of COVID-19 disease [73] .Repurposed drugsLow resting heart rate (RHR) is associated with health and longevity, and conversely, high RHR associated with disease and adverse events [74] [75] [76] [77] [78] .", [["heart", "ANATOMY", 299, 304], ["statins", "CHEMICAL", 54, 61], ["statins", "CHEMICAL", 189, 196], ["COVID-19 disease", "DISEASE", 248, 264], ["statins", "CHEMICAL", 54, 61], ["statins", "CHEMICAL", 189, 196], ["statins", "SIMPLE_CHEMICAL", 54, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 73, 83], ["Mpro", "GENE_OR_GENE_PRODUCT", 84, 88], ["statins", "SIMPLE_CHEMICAL", 189, 196], ["heart", "ORGAN", 299, 304], ["RHR", "PROTEIN", 378, 381], ["a molecular docking study", "TEST", 9, 34], ["statins", "TREATMENT", 54, 61], ["SARS", "TEST", 73, 77], ["CoV", "TEST", 78, 81], ["2 Mpro inhibitors", "TREATMENT", 82, 99], ["the viral envelope", "PROBLEM", 114, 132], ["clinical investigations", "TEST", 135, 158], ["statins", "TREATMENT", 189, 196], ["COVID-19 disease", "PROBLEM", 248, 264], ["Repurposed drugs", "TREATMENT", 271, 287], ["disease and adverse events", "PROBLEM", 398, 424]]], ["Advances in technology have provided new insights into genetic factors related to RHR as well as insights into whether elevated RHR is a risk factor or risk marker [79] .", [["RHR", "GENE_OR_GENE_PRODUCT", 128, 131], ["RHR", "PROTEIN", 82, 85], ["RHR", "PROTEIN", 128, 131], ["RHR", "PROBLEM", 82, 85], ["elevated RHR", "PROBLEM", 119, 131]]], ["Besides, genome-wide association studies in the general population usingRepurposed drugsMendelian randomization have demonstrated a causal link between RHR and longevity [74] .", [["RHR", "PROTEIN", 152, 155], ["Mendelian randomization", "TREATMENT", 88, 111]]], ["Since the COVID-19 pandemic was a global disaster, many repurposed drugs are being tested.Repurposed drugsChloroquine or hydroxychloroquine may interfere with cellular endocytosis of the virus [80] ;Repurposed drugshowever, these drugs may prolong QT and, thus, ECG monitoring needs to be performed [81] .", [["cellular", "ANATOMY", 159, 167], ["Chloroquine", "CHEMICAL", 106, 117], ["hydroxychloroquine", "CHEMICAL", 121, 139], ["Chloroquine", "CHEMICAL", 106, 117], ["hydroxychloroquine", "CHEMICAL", 121, 139], ["Chloroquine", "SIMPLE_CHEMICAL", 106, 117], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 121, 139], ["cellular", "CELL", 159, 167], ["many repurposed drugs", "TREATMENT", 51, 72], ["Repurposed drugs", "TREATMENT", 90, 106], ["Chloroquine", "TREATMENT", 106, 117], ["hydroxychloroquine", "TREATMENT", 121, 139], ["cellular endocytosis", "PROBLEM", 159, 179], ["the virus", "PROBLEM", 183, 192], ["these drugs", "TREATMENT", 224, 235], ["ECG monitoring", "TEST", 262, 276]]], ["In this regard, data from Wuhan, China, has indicated that arrhythmias and acute cardiac injury are among the most prevalent heart complications in hospitalized patients (16.7% and 7.2%, respectively) [50] .", [["cardiac", "ANATOMY", 81, 88], ["heart", "ANATOMY", 125, 130], ["arrhythmias", "DISEASE", 59, 70], ["cardiac injury", "DISEASE", 81, 95], ["heart complications", "DISEASE", 125, 144], ["cardiac", "ORGAN", 81, 88], ["heart", "ORGAN", 125, 130], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["arrhythmias", "PROBLEM", 59, 70], ["acute cardiac injury", "PROBLEM", 75, 95], ["arrhythmias", "OBSERVATION", 59, 70], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["cardiac", "ANATOMY", 81, 88], ["injury", "OBSERVATION", 89, 95], ["heart", "ANATOMY", 125, 130], ["complications", "OBSERVATION", 131, 144]]], ["Recent studies have questioned the benefit of hydroxychloroquine or chloroquine J o u r n a l P r e -p r o o f in the treatment of patients affected by COVID-19 owing to serious side effects disturbing the heart rhythm when prescribed at high doses or combined with azithromycin [82, 83] .", [["heart", "ANATOMY", 206, 211], ["hydroxychloroquine", "CHEMICAL", 46, 64], ["chloroquine", "CHEMICAL", 68, 79], ["COVID-19", "CHEMICAL", 152, 160], ["azithromycin", "CHEMICAL", 266, 278], ["hydroxychloroquine", "CHEMICAL", 46, 64], ["chloroquine", "CHEMICAL", 68, 79], ["COVID-19", "CHEMICAL", 152, 160], ["azithromycin", "CHEMICAL", 266, 278], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 46, 64], ["chloroquine", "SIMPLE_CHEMICAL", 68, 79], ["patients", "ORGANISM", 131, 139], ["heart", "ORGAN", 206, 211], ["azithromycin", "SIMPLE_CHEMICAL", 266, 278], ["patients", "SPECIES", 131, 139], ["Recent studies", "TEST", 0, 14], ["hydroxychloroquine", "TREATMENT", 46, 64], ["chloroquine J", "TREATMENT", 68, 81], ["the treatment", "TREATMENT", 114, 127], ["COVID", "TEST", 152, 157], ["serious side effects", "PROBLEM", 170, 190], ["azithromycin", "TREATMENT", 266, 278], ["heart", "ANATOMY", 206, 211]]], ["Abnormal QT prolongation, defined as a prolongation to a QTc >500 msec, has been documented for 10%-25% of COVID-19 patients treated with hydroxychloroquine/azithromycin.", [["Abnormal QT prolongation", "DISEASE", 0, 24], ["hydroxychloroquine", "CHEMICAL", 138, 156], ["azithromycin", "CHEMICAL", 157, 169], ["hydroxychloroquine", "CHEMICAL", 138, 156], ["azithromycin", "CHEMICAL", 157, 169], ["patients", "ORGANISM", 116, 124], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 138, 156], ["azithromycin", "SIMPLE_CHEMICAL", 157, 169], ["patients", "SPECIES", 116, 124], ["Abnormal QT prolongation", "PROBLEM", 0, 24], ["a QTc", "TEST", 55, 60], ["COVID", "TEST", 107, 112], ["hydroxychloroquine", "TREATMENT", 138, 156], ["azithromycin", "TREATMENT", 157, 169], ["QT prolongation", "OBSERVATION", 9, 24]]], ["Many of these patients were elderly and had comorbidities increasing the risk of drug-induced long QTS.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["comorbidities", "PROBLEM", 44, 57], ["drug-induced long QTS", "PROBLEM", 81, 102]]], ["Physicians should pay particular attention to elderly females, patients with structural heart disease, baseline QT interval on ECG, concomitant use of other QT-prolonging drugs, potassium or magnesium abnormalities, and recorded episodes of bradycardia [84] .", [["heart", "ANATOMY", 88, 93], ["heart disease", "DISEASE", 88, 101], ["potassium", "CHEMICAL", 178, 187], ["magnesium", "CHEMICAL", 191, 200], ["bradycardia", "DISEASE", 241, 252], ["potassium", "CHEMICAL", 178, 187], ["magnesium", "CHEMICAL", 191, 200], ["patients", "ORGANISM", 63, 71], ["heart", "ORGAN", 88, 93], ["potassium", "SIMPLE_CHEMICAL", 178, 187], ["magnesium", "SIMPLE_CHEMICAL", 191, 200], ["patients", "SPECIES", 63, 71], ["structural heart disease", "PROBLEM", 77, 101], ["baseline QT interval", "PROBLEM", 103, 123], ["ECG", "TEST", 127, 130], ["other QT-prolonging drugs", "TREATMENT", 151, 176], ["potassium", "TREATMENT", 178, 187], ["magnesium abnormalities", "PROBLEM", 191, 214], ["bradycardia", "PROBLEM", 241, 252], ["heart", "ANATOMY", 88, 93], ["disease", "OBSERVATION", 94, 101]]], ["However, only results from ongoing randomized trials will provide definitive answers raising the issue of needing more rigorous data during COVID-19Repurposed drugspandemic [85] .Repurposed drugsThe ability to restore immune balance, with approaches such as type I interferon,Repurposed drugsimmunoglobulin, and recovered serum, may be considered.", [["serum", "ANATOMY", 322, 327], ["type I interferon", "GENE_OR_GENE_PRODUCT", 258, 275], ["drugsimmunoglobulin", "SIMPLE_CHEMICAL", 287, 306], ["serum", "ORGANISM_SUBSTANCE", 322, 327], ["type I interferon", "PROTEIN", 258, 275], ["ongoing randomized trials", "TREATMENT", 27, 52], ["Repurposed drugs", "TREATMENT", 179, 195], ["approaches", "TREATMENT", 239, 249], ["type I interferon", "TREATMENT", 258, 275], ["Repurposed drugsimmunoglobulin", "TREATMENT", 276, 306]]], ["Among the most important cells of primary immunity that causes cytokine storm there are mast cells that reside in all vascularized tissues generating pro-inflammatory cytokines such as IL-1 and IL-6 [86] [87] [88] [89] .", [["cells", "ANATOMY", 25, 30], ["mast cells", "ANATOMY", 88, 98], ["tissues", "ANATOMY", 131, 138], ["cells", "CELL", 25, 30], ["mast cells", "CELL", 88, 98], ["tissues", "TISSUE", 131, 138], ["IL-1", "GENE_OR_GENE_PRODUCT", 185, 189], ["IL-6 [86] [87] [88", "SIMPLE_CHEMICAL", 194, 212], ["cytokine", "PROTEIN", 63, 71], ["mast cells", "CELL_TYPE", 88, 98], ["pro-inflammatory cytokines", "PROTEIN", 150, 176], ["IL", "PROTEIN", 185, 187], ["cytokine storm", "PROBLEM", 63, 77], ["mast cells", "PROBLEM", 88, 98], ["pro-inflammatory cytokines", "TEST", 150, 176], ["IL", "TEST", 185, 187], ["cytokine storm", "OBSERVATION", 63, 77], ["mast cells", "OBSERVATION", 88, 98], ["vascularized tissues", "ANATOMY", 118, 138]]], ["Remarkably, suppression both of IL-1 and IL-6 have been shown to have a therapeutic effect in patients with immune system suppression and advanced form of COVID-19 [86] [87] [88] [89] .", [["immune system", "ANATOMY", 108, 121], ["COVID-19", "CHEMICAL", 155, 163], ["IL-1", "GENE_OR_GENE_PRODUCT", 32, 36], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["patients", "ORGANISM", 94, 102], ["COVID-19 [86] [87] [88", "SIMPLE_CHEMICAL", 155, 177], ["IL-1 and IL-6", "PROTEIN", 32, 45], ["patients", "SPECIES", 94, 102], ["IL", "TEST", 32, 34], ["immune system suppression", "TREATMENT", 108, 133], ["COVID", "TEST", 155, 160]]], ["Anti-inflammatory strategies, whether anti-IL-1 or anti-IL-6 approaches (such as tocilizumab), will be determined in randomized trials.", [["anti-IL-1", "GENE_OR_GENE_PRODUCT", 38, 47], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 51, 60], ["tocilizumab", "SIMPLE_CHEMICAL", 81, 92], ["Anti-inflammatory strategies", "TREATMENT", 0, 28], ["anti-IL", "TREATMENT", 38, 45], ["anti-IL-6 approaches", "TREATMENT", 51, 71], ["tocilizumab", "TREATMENT", 81, 92]]], ["Preliminary studies indicated some beneficial effects of tocilizumab, a IL-6 receptor antagonist, in the clinical management of COVID-19 [90] [91] [92] .Antivirals and vaccine developmentMany antivirals have been administered to COVID-19 patients.", [["tocilizumab", "CHEMICAL", 57, 68], ["COVID-19 [90]", "CHEMICAL", 128, 141], ["COVID-19", "CHEMICAL", 128, 136], ["tocilizumab", "SIMPLE_CHEMICAL", 57, 68], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 72, 85], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["Preliminary studies", "TEST", 0, 19], ["tocilizumab", "TREATMENT", 57, 68], ["a IL-6 receptor antagonist", "TREATMENT", 70, 96], ["COVID", "TEST", 128, 133], ["Antivirals", "TREATMENT", 153, 163], ["vaccine development", "TREATMENT", 168, 187], ["Many antivirals", "TREATMENT", 187, 202]]], ["A recent trial with Lopinavir-Ritonavir gave disappointing results [93] .", [["Lopinavir-Ritonavir", "CHEMICAL", 20, 39], ["Lopinavir", "CHEMICAL", 20, 29], ["Ritonavir", "CHEMICAL", 30, 39], ["Lopinavir-Ritonavir", "SIMPLE_CHEMICAL", 20, 39], ["Lopinavir", "TREATMENT", 20, 29], ["Ritonavir", "TREATMENT", 30, 39]]], ["Viral proliferation can be blocked at multiple stages, including inhibition of RNA polymerase with remdesivir.", [["Viral", "ANATOMY", 0, 5], ["remdesivir", "CHEMICAL", 99, 109], ["remdesivir", "CHEMICAL", 99, 109], ["Viral", "ORGANISM", 0, 5], ["remdesivir", "SIMPLE_CHEMICAL", 99, 109], ["RNA polymerase", "PROTEIN", 79, 93], ["Viral proliferation", "PROBLEM", 0, 19], ["inhibition of RNA polymerase", "TREATMENT", 65, 93], ["remdesivir", "TREATMENT", 99, 109], ["proliferation", "OBSERVATION", 6, 19]]], ["Preliminary data seems to indicate that remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with COVID-19 [94, 95] .", [["remdesivir", "CHEMICAL", 40, 50], ["remdesivir", "CHEMICAL", 40, 50], ["COVID-19", "CHEMICAL", 138, 146], ["remdesivir", "SIMPLE_CHEMICAL", 40, 50], ["Preliminary data", "TEST", 0, 16], ["COVID", "TEST", 138, 143]]], ["Among the regions of the S protein (S1, S2, RBD), RBD is one accessible target for vaccine.", [["S1", "GENE_OR_GENE_PRODUCT", 36, 38], ["S2", "GENE_OR_GENE_PRODUCT", 40, 42], ["RBD", "GENE_OR_GENE_PRODUCT", 44, 47], ["RBD", "GENE_OR_GENE_PRODUCT", 50, 53], ["S protein", "PROTEIN", 25, 34], ["S1", "PROTEIN", 36, 38], ["S2", "PROTEIN", 40, 42], ["RBD", "PROTEIN", 44, 47], ["RBD", "PROTEIN", 50, 53], ["the S protein", "TEST", 21, 34], ["vaccine", "TREATMENT", 83, 90]]], ["Nevertheless, RBD is a genomic variable region [96] with a risk for J o u r n a l P r e -p r o o f immunologic \"escape\" [97] .", [["RBD", "DISEASE", 14, 17], ["RBD", "PROTEIN", 14, 17], ["a genomic variable region", "PROBLEM", 21, 46]]], ["The immunogenic role of the N protein, a more conserved region of the genome, is still poorly understood in immune response to SARS-CoV-2 both in adult and elderly patients [96, 97] .", [["genome", "CELLULAR_COMPONENT", 70, 76], ["SARS-CoV-2", "ORGANISM", 127, 137], ["patients", "ORGANISM", 164, 172], ["N protein", "PROTEIN", 28, 37], ["patients", "SPECIES", 164, 172], ["SARS-CoV", "SPECIES", 127, 135], ["SARS", "TEST", 127, 131], ["CoV", "TEST", 132, 135]]], ["Vaccine development is the best successful approach for reducing viral diseases, including COVID-19.", [["viral diseases", "DISEASE", 65, 79], ["Vaccine", "TREATMENT", 0, 7], ["reducing viral diseases", "PROBLEM", 56, 79], ["COVID", "TEST", 91, 96]]], ["Until now, there are 70 active clinical trials related to a SARS-CoV2 vaccine (see ClinicalTrials.gov).", [["SARS", "DISEASE", 60, 64], ["a SARS-CoV2 vaccine", "TREATMENT", 58, 77]]], ["Overall, people who have more than 60 years are believed to have lesser protective effects by vaccines due to age-related declines in immune function [98] .Antivirals and vaccine developmentThus, even when a vaccine for SARS-CoV2 will become available, particular attention will be due to elderly subjects.Concluding remarksElderly patients, particularly those with underlying structural heart disease, are among the highest risk group for severe COVID-19 illness and its complications.", [["heart", "ANATOMY", 388, 393], ["SARS", "DISEASE", 220, 224], ["structural heart disease", "DISEASE", 377, 401], ["COVID", "DISEASE", 447, 452], ["illness", "DISEASE", 456, 463], ["people", "ORGANISM", 9, 15], ["SARS-CoV2", "ORGANISM", 220, 229], ["patients", "ORGANISM", 332, 340], ["heart", "ORGAN", 388, 393], ["people", "SPECIES", 9, 15], ["patients", "SPECIES", 332, 340], ["Antivirals", "TREATMENT", 156, 166], ["vaccine development", "TREATMENT", 171, 190], ["a vaccine", "TREATMENT", 206, 215], ["SARS", "PROBLEM", 220, 224], ["underlying structural heart disease", "PROBLEM", 366, 401], ["severe COVID-19 illness", "PROBLEM", 440, 463], ["its complications", "PROBLEM", 468, 485], ["heart", "ANATOMY", 388, 393], ["disease", "OBSERVATION", 394, 401]]], ["Currently, diagnostics and personalized therapy of severe and critically ill patients remain the major challenges.", [["critically ill", "DISEASE", 62, 76], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["diagnostics", "TEST", 11, 22], ["personalized therapy", "TREATMENT", 27, 47], ["severe and critically ill", "PROBLEM", 51, 76], ["severe", "OBSERVATION_MODIFIER", 51, 57]]], ["In the early stage of the disease, we need to avoid \"fever phobia\" [99] .", [["fever", "DISEASE", 53, 58], ["phobia", "DISEASE", 59, 65], ["the disease", "PROBLEM", 22, 33], ["fever phobia", "PROBLEM", 53, 65], ["early stage", "OBSERVATION_MODIFIER", 7, 18], ["disease", "OBSERVATION", 26, 33]]], ["The greatest benefit would be seen when drugs are administered 30 hours before severe symptom onset, especially in elderly subjects [100] .Concluding remarksIn this regard, network medicine [101, 102] and precision medicine [103] would be helpful in the clinical evaluation of these patients.", [["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291], ["drugs", "TREATMENT", 40, 45], ["severe symptom onset", "PROBLEM", 79, 99], ["the clinical evaluation", "TEST", 250, 273], ["greatest", "OBSERVATION_MODIFIER", 4, 12]]], ["Cardiovascular dysfunction, cytokine storm, and lymphocytopenia are hallmarks of COVID-19 disease associated with a poor clinical outcome;Concluding remarkshowever, the precise mechanistic basis is unknown.", [["Cardiovascular", "ANATOMY", 0, 14], ["Cardiovascular dysfunction", "DISEASE", 0, 26], ["lymphocytopenia", "DISEASE", 48, 63], ["Cardiovascular", "MULTI-TISSUE_STRUCTURE", 0, 14], ["cytokine", "PROTEIN", 28, 36], ["Cardiovascular dysfunction", "PROBLEM", 0, 26], ["cytokine storm", "PROBLEM", 28, 42], ["lymphocytopenia", "PROBLEM", 48, 63], ["COVID-19 disease", "PROBLEM", 81, 97], ["a poor clinical outcome", "PROBLEM", 114, 137], ["dysfunction", "OBSERVATION", 15, 26], ["cytokine storm", "OBSERVATION", 28, 42], ["lymphocytopenia", "OBSERVATION", 48, 63]]], ["Despite several clinical trials are ongoing to assess the effectiveness of repurposed drugs, no definitive therapies are currently available.", [["repurposed drugs", "TREATMENT", 75, 91], ["definitive therapies", "TREATMENT", 96, 116]]], ["Only dedicated prospective trials in patients of different ages will provide definitive answers to the precise role of aging in COVID-19 therapy.", [["COVID-19", "CHEMICAL", 128, 136], ["COVID-19", "CHEMICAL", 128, 136], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["COVID-19 therapy", "TREATMENT", 128, 144]]], ["Among gender-related differences, females seem to have a higher susceptibility to Sars-CoV-2 but lower severity and mortality [104, 105] .", [["Sars-CoV", "SPECIES", 82, 90], ["CoV", "TEST", 87, 90], ["lower severity", "PROBLEM", 97, 111]]], ["However, further investigations are required to better understand the gender-specific difference in the development of COVID-19.", [["COVID-19", "CHEMICAL", 119, 127], ["further investigations", "TEST", 9, 31], ["COVID", "TEST", 119, 124]]], ["Much advance in the knowledge of SARS-CoV-2 pathogenic mechanisms is coming from network-oriented analysis which provides maps of human proteins J o u r n a l P r e -p r o o f interacting with SARS-CoV-2 proteins suggesting putative candidate repurposed drugs and potential combination therapies [106] .", [["SARS", "DISEASE", 33, 37], ["SARS-CoV-2", "ORGANISM", 33, 43], ["human", "ORGANISM", 130, 135], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 193, 203], ["human proteins", "PROTEIN", 130, 144], ["SARS-CoV-2 proteins", "PROTEIN", 193, 212], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 130, 135], ["SARS", "PROBLEM", 33, 37], ["CoV", "TEST", 38, 41], ["pathogenic mechanisms", "PROBLEM", 44, 65], ["interacting", "PROBLEM", 176, 187], ["SARS", "PROBLEM", 193, 197], ["CoV", "TEST", 198, 201], ["repurposed drugs", "TREATMENT", 243, 259], ["potential combination therapies", "TREATMENT", 264, 295]]], ["The elderly population residing in long-term care facilities suffering from multiple comorbidities [107] and thus more prone to COVID-19 related sequelae.Concluding remarksThe Italian National Institute of Health COVID-19 mortality group showed that elderly adults (\u2265 65 years) had a higher number of comorbidities compared to those aged <65 years [108] .", [["multiple comorbidities", "PROBLEM", 76, 98]]], ["Interestingly, the prevalence of CHD, atrial fibrillation, heart failure, hypertension, COPD, was higher in older patients (\u2265 65 years).", [["atrial", "ANATOMY", 38, 44], ["heart", "ANATOMY", 59, 64], ["CHD", "DISEASE", 33, 36], ["atrial fibrillation", "DISEASE", 38, 57], ["heart failure", "DISEASE", 59, 72], ["hypertension", "DISEASE", 74, 86], ["COPD", "DISEASE", 88, 92], ["atrial", "MULTI-TISSUE_STRUCTURE", 38, 44], ["heart", "ORGAN", 59, 64], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["CHD", "PROBLEM", 33, 36], ["atrial fibrillation", "PROBLEM", 38, 57], ["heart failure", "PROBLEM", 59, 72], ["hypertension", "PROBLEM", 74, 86], ["COPD", "PROBLEM", 88, 92], ["atrial", "ANATOMY", 38, 44], ["fibrillation", "OBSERVATION", 45, 57], ["heart", "ANATOMY", 59, 64], ["failure", "OBSERVATION", 65, 72], ["hypertension", "OBSERVATION", 74, 86], ["COPD", "OBSERVATION", 88, 92], ["higher", "OBSERVATION_MODIFIER", 98, 104]]], ["Thus, cardiovascular aging needs to be evaluated carefully in the context of COVID-19.Conflict of interestThe authors declare they have no conflict of interest.FundingThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Provenance and peer reviewNot commissioned, externally peer reviewed.", [["cardiovascular", "ANATOMY", 6, 20], ["cardiovascular aging", "DISEASE", 6, 26], ["COVID-19", "CHEMICAL", 77, 85], ["cardiovascular", "ANATOMICAL_SYSTEM", 6, 20], ["COVID", "TEST", 77, 82]]]], "b857a5ba64d9d8282d2703f1292a79ee0bf69ea2": [["IntroductionA virus [1] is micro/nano meter in size which is reproduced inside the living cell of an organism.IntroductionPresently coronavirus is created a health emergency to the world population and became a pandemic [2] , [3] , [4] .", [["cell", "ANATOMY", 90, 94], ["coronavirus", "DISEASE", 132, 143], ["cell", "CELL", 90, 94], ["coronavirus", "ORGANISM", 132, 143], ["IntroductionA virus", "PROBLEM", 0, 19], ["micro/nano meter in size", "TREATMENT", 27, 51], ["size", "OBSERVATION_MODIFIER", 47, 51], ["living cell", "OBSERVATION", 83, 94]]], ["Initially, this virus is transferred from the bat animal to the human [5] .IntroductionFurther this virus shows the human to human transmission [6] .", [["bat", "ORGANISM", 46, 49], ["human", "ORGANISM", 64, 69], ["human", "ORGANISM", 116, 121], ["human", "ORGANISM", 125, 130], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 125, 130], ["this virus", "PROBLEM", 11, 21]]], ["COVID 19 virus is spreading to the people by the respiratory droplets and contact mode [7] .", [["respiratory droplets", "ANATOMY", 49, 69], ["COVID 19 virus", "ORGANISM", 0, 14], ["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41], ["COVID 19 virus", "SPECIES", 0, 14], ["COVID 19 virus", "PROBLEM", 0, 14], ["the respiratory droplets", "TEST", 45, 69], ["virus", "OBSERVATION", 9, 14], ["respiratory droplets", "OBSERVATION", 49, 69]]], ["The SIR model is simple and effective model which can give the prediction of different pandemic situation [9] .IntroductionHere, we are studying the spreading effects of the COVID19 to the Maharashtra state.", [["COVID19", "GENE_OR_GENE_PRODUCT", 174, 181], ["COVID19", "PROTEIN", 174, 181], ["simple", "OBSERVATION_MODIFIER", 17, 23]]], ["This state has a total population of 11.42 crore which is ~8.5 % of the overall population of India.", [["a total population", "TEST", 15, 33], ["total", "OBSERVATION_MODIFIER", 17, 22], ["population", "OBSERVATION_MODIFIER", 23, 33], ["8.5 %", "OBSERVATION_MODIFIER", 59, 64], ["overall", "OBSERVATION_MODIFIER", 72, 79], ["population", "OBSERVATION_MODIFIER", 80, 90]]], ["At 12 march, world health organization (WHO) announce that COVID 19 is outbreak of pandemic where the term used by disease experts when epidemics are growing in multiple countries and continents at the same time [12] .", [["epidemics", "PROBLEM", 136, 145]]], ["In current situation, after 12 march corona virus cases are rapidly increase in India and there are several cases also observed in the Maharashtra.", [["march corona virus", "ORGANISM", 31, 49], ["12 march corona virus cases", "PROBLEM", 28, 55], ["rapidly", "OBSERVATION_MODIFIER", 60, 67], ["increase", "OBSERVATION_MODIFIER", 68, 76]]], ["This study explains the epidemic growth by using SIR Model for this state which helps to control this epidemic.Introduction.", [["This study", "TEST", 0, 10], ["the epidemic growth", "PROBLEM", 20, 39], ["SIR Model", "TREATMENT", 49, 58]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["The ratio of the infected ratio and recovery ration is known as reproduction ratio (R) .Results and DiscussionsIn the results and discussion section, the present rate of the virus infection is studied.", [["infection", "DISEASE", 180, 189], ["The ratio", "TEST", 0, 9], ["the infected ratio", "PROBLEM", 13, 31], ["discussion section", "TREATMENT", 130, 148], ["the virus infection", "PROBLEM", 170, 189], ["infected", "OBSERVATION_MODIFIER", 17, 25], ["virus infection", "OBSERVATION", 174, 189]]], ["The infected population is also predicted by the SIR model.", [["The infected population", "PROBLEM", 0, 23], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["population", "OBSERVATION", 13, 23]]], ["The reproduction ratio parameter also explained for the spreading rate of the virus.", [["The reproduction ratio parameter", "TEST", 0, 32], ["the virus", "PROBLEM", 74, 83]]], ["Where I represent the infected people and t represents the days.Results and DiscussionsThe undercover area is covered by the black line which follows the equation 1.", [["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37], ["the black line", "TREATMENT", 121, 135], ["infected", "OBSERVATION", 22, 30], ["black line", "OBSERVATION", 125, 135]]], ["This predication is followed a similar tend when there is no recovery and death of the population.", [["death", "DISEASE", 74, 79], ["no", "UNCERTAINTY", 58, 60]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Results and Discussionsis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.10.20056697 doi: medRxiv preprint certain peak.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 214, 234], ["this preprint", "TREATMENT", 239, 252], ["medRxiv", "TREATMENT", 304, 311], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["After certain period, the infected population are decreases.", [["the infected population", "PROBLEM", 22, 45], ["infected", "OBSERVATION_MODIFIER", 26, 34], ["population", "OBSERVATION", 35, 45], ["decreases", "OBSERVATION_MODIFIER", 50, 59]]], ["The blue line shows the recovery or death of the population which is increasing by time.", [["death", "DISEASE", 36, 41], ["blue line", "CELL", 4, 13], ["The blue line", "TREATMENT", 0, 13], ["blue line", "OBSERVATION", 4, 13], ["recovery", "OBSERVATION_MODIFIER", 24, 32], ["population", "OBSERVATION_MODIFIER", 49, 59], ["increasing", "OBSERVATION_MODIFIER", 69, 79]]], ["Image 4 (b) shows the reproduction ratio (R) effects to the infected people.", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["Image", "TEST", 0, 5], ["infected", "OBSERVATION", 60, 68]]], ["The reproduction ratio is varied from 1.33 to 5 where infected population was increased in the high reproductive ratio.", [["The reproduction ratio", "TEST", 0, 22], ["infected population", "PROBLEM", 54, 73], ["varied", "OBSERVATION_MODIFIER", 26, 32], ["infected", "OBSERVATION_MODIFIER", 54, 62], ["population", "OBSERVATION", 63, 73], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["high", "OBSERVATION_MODIFIER", 95, 99], ["reproductive ratio", "OBSERVATION", 100, 118]]], ["When susceptible are high than infected people will be more as shown in Figure 4 (c)-(d) and corresponding infected people at different reproduction ratio.", [["people", "ORGANISM", 40, 46], ["people", "ORGANISM", 116, 122], ["people", "SPECIES", 40, 46], ["people", "SPECIES", 116, 122], ["high", "OBSERVATION_MODIFIER", 21, 25], ["infected", "OBSERVATION_MODIFIER", 107, 115]]], ["During the lockdown, people will make the proper social distancing which will reduce the spreading of infection.ConclusionThe study explains the spreading of COVID 19 in the Maharashtra region which is part of India.", [["infection", "DISEASE", 102, 111], ["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27], ["infection", "PROBLEM", 102, 111], ["The study", "TEST", 122, 131], ["infection", "OBSERVATION", 102, 111]]], ["In this particular region, the effect of the virus is studied by the SIR model.", [["the virus", "PROBLEM", 41, 50], ["virus", "OBSERVATION", 45, 50]]], ["The model predicted that the maximum infected population will be almost ~ 3000 after 40 days at the peak point.", [["the maximum infected population", "PROBLEM", 25, 56], ["maximum", "OBSERVATION_MODIFIER", 29, 36], ["infected", "OBSERVATION_MODIFIER", 37, 45], ["population", "OBSERVATION", 46, 56]]], ["After reaching the peak point the recovery will be more and the virus infection will be high for R ~ 2.66.", [["infection", "DISEASE", 70, 79], ["the virus infection", "PROBLEM", 60, 79]]], ["This study is considered only 7000 population are migrating in the state which can be affected in the lockdown condition.", [["This study", "TEST", 0, 10]]], ["If the migrated population will increase which causes the increment of infection and infect the population more.", [["infection", "DISEASE", 71, 80], ["the migrated population", "PROBLEM", 3, 26], ["infection", "PROBLEM", 71, 80], ["migrated", "OBSERVATION_MODIFIER", 7, 15], ["population", "OBSERVATION", 16, 26], ["infection", "OBSERVATION", 71, 80]]], ["This can control by the lockdown situation only which is presently imposed by the Governments to the people.", [["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107]]], ["There should be a global health community that unites to urgently avoid the pandemic issues.Conclusion.", [["the pandemic issues", "PROBLEM", 72, 91]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conclusionis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["this preprint", "TREATMENT", 226, 239], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]]]}